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Glossary
Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from 
the context but a glossary is provided for the non-specialist reader. In some cases usage differs in the
literature but the term has a constant meaning throughout this review. 
Acute renal failure  The usually sudden and
potentially reversible loss of renal function.
Allocative efficiency  This type of efficiency is
addressed by cost–benefit analysis. It is about
achieving the optimal allocation of resources
across all possible uses of such resources.
Therefore, if an intervention is shown to 
be more effective and more costly than an
alternative, a decision has to be taken as to
whether the extra cost is justified in terms of
improved effectiveness; that is, will the input
of more resources to that particular area of
care enhance allocative efficiency?
Automated cycler machine  A device used to
administer peritoneal dialysis for a defined
period usually at night time. The patient
usually needs to make only one connection
and the automated cycler machine carries out
the prescribed dialysis exchanges. A variety of
automated cycler machines are available.
Automated peritoneal dialysis
* There are 
a number of new technologies which are
adaptations of continuous ambulatory peri-
toneal dialysis and which have the potential 
to improve quality of life for some patients.
These include intermittent peritoneal dialysis,
continuous cyclic peritoneal dialysis and night-
time intermittent peritoneal dialysis. These
new technologies require more expensive
dialysis fluids or dialysis machines or both.
Blinding (synonym: masking)
* Keeping 
secret group assignment (e.g. to treatment or
control) from the study participants or inves-
tigators. Blinding is used to protect against the
possibility that knowledge of assignment may
affect patient response to treatment, provider
behaviours (performance bias) or outcome
assessment (detection bias). Blinding is not
always practical (e.g. when comparing surgery
to drug treatment).
The importance of blinding depends on how
objective the outcome measure is; blinding is
more important for less objective outcome
measures such as pain or quality of life.
Chronic renal failure* Kidneys slowly destroy-
ed over months or years. To begin with there 
is little to see or find, which means that many
patients present for medical help very late in
their disease, or even in the terminal stages.
Cochrane Collaboration
* An international
organisation that aims to help people make
well-informed decisions about health by pre-
paring, maintaining and ensuring the accessi-
bility of systematic reviews of the benefits and
risks of healthcare interventions.
Cochrane Library
* A collection of databases,
published on disk and CD-ROM and updated
quarterly, containing the Cochrane Database of
Systematic Reviews, the Cochrane Controlled
Trials Register, the Database of Abstracts of
Reviews of Effectiveness, the Cochrane Review
Methodology Database and information about
the Cochrane Collaboration.
Cochrane review
* A Cochrane review is a
systematic, up-to-date summary of reliable
evidence of healthcare benefits and risks.
Cochrane reviews are intended to help people
make practical decisions. For a review to be
called a ‘Cochrane review’, it must be in the
parent database maintained by the Cochrane
Collaboration. This composed of modules of
reviews submitted by Collaborative Review
Groups (CRGs) registered with the Cochrane
Collaboration. The reviews contributed to one
of the modules making up the parent database
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are refereed by the editorial team of the CRG,
as described in the CRG module. Reviewers
adhere to guidelines published in the Cochrane
Handbook. The specific methods used in a
review are described in the text of the review.
Cochrane reviews are prepared using Review
Manager software provided by the Collabo-
ration and adhere to a structured format that 
is described in the Handbook.
Concealment of allocation
* The process used
to prevent foreknowledge of group assignment
in an RCT, which should be seen as distinct
from blinding. The allocation process should
be impervious to any influence by the indi-
vidual making the allocation by having the
randomisation process administered by some-
one who is not responsible for recruiting par-
ticipants: for example, a hospital pharmacy 
or a central office.
Methods of assignment such as date of 
birth and case record numbers (see quasi-
random allocation) are open to manipulation.
Adequate methods of allocation concealment
include: centralised randomisation schemes;
randomisation schemes controlled by a phar-
macy; numbered or coded containers in which
capsules from identical-looking, numbered
bottles are administered sequentially; on-site
computer systems, where allocations are in 
a locked unreadable file; and sequentially
numbered opaque, sealed envelopes.
Confidence interval* The range within which
the ‘true’ value (e.g. size of effect of an inter-
vention) is expected to lie with a given degree
of certainty (e.g. 95% or 99%). Note: Con-
fidence intervals represent the probability of
random errors but not systematic errors (bias).
Continuous ambulatory peritoneal dialysis*
In this technique, dialysis fluid is introduced
into and withdrawn from the peritoneal cavity
(which is around the bowel) via a silastic tube
(catheter). Waste products are removed from
the blood across the peritoneal membrane. The
fluid is chemically composed to draw or ‘attract’
excess salts and water from the blood to cross
the membrane without the blood itself being in
contact with the fluid. Dialysis fluid is withdrawn
from the peritoneal cavity after a dwell of 
4–5 hours during the day and about 8 hours
overnight and fresh fluid introduced. This
procedure, which takes about 20 minutes, is
called an exchange and occurs four times daily.
Continuous cyclic peritoneal dialysis This 
is a form of peritoneal dialysis in which all
connections and preparation of equipment
usually takes place at bedtime in the privacy 
of the home. To administer it a peritoneal
cycler is required and the process is usually
carried out at night when the patient is asleep.
It is called continuous because fluid is usually 
left in the abdomen during the day. If no
dialysis fluid is left in the abdomen during 
the day, it is called nocturnal intermittent
peritoneal dialysis.
Continuous data
* Data with a potentially
infinite number of possible values along 
a continuum. Height, weight and blood
pressure are examples of continuous variables.
Cost-effectiveness analysis* An economic
analysis used to compare effectiveness and cost
of health interventions in which either:
• effects of the interventions are known to be
equal and so the option to be recommended
is that which is least (or less) costly (some
times known as ‘cost-minimisation analysis’); 
or
• effects and costs differ across interventions;
hence, the option to be recommended is
that with the lowest (or lower) ratio of cost
per unit of health gain, as implementation
of this option will lead to the most (or
more) effective use of a fixed budget.
Creatinine* A natural waste product of muscle
metabolism which is normally excreted by the
kidney. When renal function is reduced the
level of creatinine in the blood rises and the
amount cleared from the kidneys (creatinine
clearance) falls. These measures are used as 
a broad approximation of the prevailing level
of renal function.
Crossover trial
* A type of clinical trial com-
paring two or more interventions in which the
participants, upon completion of the course of
one treatment, are switched to another. For
example, for a comparison of treatments A
and B, half the participants are randomly
allocated to receive them in the order A, B
and half to receive them in the order B, A.
A problem with this study design is that the
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effects of the first treatment may carry over
into the period when the second is given.
Data abstraction  The systematic procedure of
transcribing data from included studies. Data
abstracted typically include a description of the
intervention, population and setting together
with outcomes data.
Decision analysis
* A technique used to aid
decision-making under conditions of uncer-
tainty by systematically representing and exam-
ining all of the relevant information for a deci-
sion and the uncertainty around that informa-
tion. The available choices are plotted on a
decision tree. At each branch, or decision node,
the probabilities of each outcome that can be
predicted are estimated. The relative worth or
preferences of decision-makers for the various
possible outcomes for a decision can also be esti-
mated and incorporated in a decision analysis.
Dichotomous data (synonym: binary data)*
Observations with two possible categories, 
such as dead/alive, smoker/non-smoker,
present/non-present.
End-stage renal disease  End-stage renal
disease is defined as the last stage in the course
of renal failure which cannot be controlled by
conservative management and when the
patient requires either dialysis or a kidney
transplant in order to maintain life.
Exchange  Used in continuous ambulatory
peritoneal dialysis, this term refers to the
process of draining fluid out of the peritoneal
cavity and instilling a fresh bag of dialysate into
the peritoneal cavity.
Exit site  That site on the skin surface where
the peritoneal dialysis catheter exits.
Fixed-effect model* A statistical model that
stipulates that the units under analysis (e.g.
people in a trial or study in a meta-analysis) are
the ones of interest, and thus constitute the
entire population of units. Only within-study
variation is taken to influence the uncertainty of
results (as reflected in the confidence interval)
of a meta-analysis using a fixed-effect model.
Variation between the estimates of effect from
each study (heterogeneity) does not affect the
confidence interval in a fixed-effect model.
Grey literature  Refers to literature that is not
widely published such as dissertations, theses
and government reports.
Haemodialysis  Removal of waste products
from the blood by allowing these products to
diffuse across a thin membrane into dialysis
fluid which is then discarded along with the
toxic waste products. The fluid is chemically
composed to draw or ‘attract’ excess salts and
water from the blood to cross the membrane,
without the blood itself being in contact with
the fluid. The patient’s circulation is attached
to a machine through which fluid is passed
and exchange can take place.
Heterogeneity
* In systematic reviews
heterogeneity refers to variability or differ-
ences between studies in the estimates of
effects. A distinction is sometimes made
between ‘statistical heterogeneity’ (differences
in the reported effects), ‘methodological het-
erogeneity (differences in study design) and
‘clinical heterogeneity’ (differences between
studies in key characteristics of the participants
interventions or outcome measures).
Statistical tests of heterogeneity are used 
to assess whether the observed variability 
in study results (effect sizes) is greater than
that expected to occur by chance. However,
these tests have low statistical power (see 
also homogeneity).
Homogeneity* In systematic reviews homo-
geneity refers to the degree to which the
results of studies included in a review are
similar. ‘Clinical homogeneity’ means that, 
in trials included in a review, the participants
interventions and outcome measures are
similar or comparable. Studies are considered
‘statistically homogeneous’ if their results vary
no more than might be expected by the play of
chance (see also heterogeneity).
Hyperkalaemia  An abnormally high level of
potassium in the blood usually defined as
greater than 5.0 mmol/l (the ranges may vary
from laboratory to laboratory).
Intention-to-treat
* An intention-to-treat
analysis is one in which all the participants 
in a trial are analysed according to the inter-
vention to which they were allocated, whether
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they received it or not. Intention-to-treat
analyses are favoured in assessments of effect-
iveness as they mirror the non-compliance 
and treatment changes that are likely to occur
when the intervention is used in practice, and
because of the risk of attrition bias when
participants are excluded from the analysis.
Intermittent peritoneal dialysis
* An older but
still useful technique of peritoneal dialysis in
which fluid is instilled into the peritoneal
cavity at regular intervals but for a limited
period. The process may be repeated.
Kt/V  Measure of dialysis adequacy.
Markov model  A Markov process is a tech-
nique used in decision analysis (see Decision
analysis). In a standard decision tree analysis 
a patient moves through states, for example,
from not treated to treated to final outcome;
however, in a Markov process a patient would
move between states, for example, backwards
and forwards between continuous ambulatory
peritoneal dialysis and haemodialysis. There
are some states, however, that once entered
cannot be left. These are defined as ‘absorbing
states’ (in models of medical interventions
such states are normally defined as death).
Membranes* The material used as a filtering
agent in dialysers. Many are formed from a
cellulose base, others from synthetic materials
constructed in an attempt to adjust the mol-
ecular weight of the substances filtered and to
reduce any reaction in the patient which may
result from the contact of blood with the
membrane surface.
MeSH (medical subject headings)
* A standard
set of keyboarding terms used by the US
National Library of Medicine to index articles
in Index Medicus and Medline. Designed to
reduce problems that arise from, for example,
differences in British and American spelling,
the MeSH system has a tree structure in which
broad subject terms branch into a series of
progressively narrower subject terms.
Meta-analysis
* The use of statistical
techniques in a systematic review to integrate
the results of the included studies. Also used
to refer to systematic reviews that use 
meta-analysis.
Methodological quality* (synonyms: validity,
internal validity)  The extent to which the
design and conduct of a trial are likely to have
prevented systematic errors (bias). Variation 
in quality can explain variation on the results
of trials included in a systematic review. More
rigorously designed (better ‘quality’) trials are
more likely to yield results that are closer to
the ‘truth’.
Odds ratio
* The ratio of the odds of an event
in the experimental (intervention) group to
the odds of an event in the control group.
Odds are the ratio of the number of people in
a group with an event to the number without
an event. Thus, if a group of 100 people had
an event rate of 0.20, the event happened to
20 people and did not happen to 80, and the
odds would be 20/80 or 0.25.
An odds ratio of one indicates no difference
between comparison groups. For undesirable
outcomes an odds ratio of less than one indi-
cates that the intervention was effective in
reducing the risk of that outcome. When the
event rate is small, odds ratios are very similar
to relative risks.
Peritoneal catheter  This is a length of 
straight or curled silicon rubber or poly-
urethane tubing with numerous side holes 
at the distal end. Usually one or two Dacron®
cuffs are present on the catheter to provoke 
a local inflammatory response to anchor the
catheter firmly into a subcutaneous tunnel.
The catheter itself is placed in the peritoneal
catheter by a surgeon or a nephrologist.
Peritoneal dialysis  A modality of renal replace-
ment therapy in which dialysis is carried out 
by instilling fluid into the potential peritoneal
cavity through a catheter. The fluid is then
allowed to remain in the peritoneal cavity for 
a time and dialysis occurs by diffusion and by
ultrafiltration. The fluid is then drained out
and fresh dialysate is instilled into the
peritoneal cavity to continue the process.
Peritoneal membrane  A mesothelial
membrane which lines the inner wall of the
abdominal cavity (perietal peritoneum) and
also covers the abdominal viscera (visceral
peritoneum). The membrane is actually a
heterogeneous series of tissue barriers
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between blood and the peritoneal space 
which normally contains no free fluid. It 
can be used for purposes of dialysis as
described above under peritoneal dialysis.
Permuted index  Allows exploration in
Medline of every MeSH term which contains a
particular word, for example, all MeSH terms
containing the word ‘dialysis’ such as
peritoneal dialysis.
Peto’s method
* A way of combining odds
ratios that has become widely used in meta-
analysis. The calculations are straightforward
and understandable but the method produces
biased results in some circumstances. It is a
fixed-effect model.
Protein catabolic rate  The rate at which
protein is catabolised by the body. In patients
who are in a steady state, protein catabolic rate
equals the dietary in take of protein.
Protocol* The plan or set of steps to be
followed in a study. A protocol for a systematic
review should describe the rationale for the
review, the objectives and the methods that
will be used to locate, select and critically
appraise studies, and to collect and analyse
data from the included studies.
Pruritus  Skin itch.
Quality assessment  The extent to which the
design and conduct of a trial are likely to have
prevented systematic errors (bias). Variation in
quality can explain variation in the results of
trials included in a systematic review. More rig-
orously designed (better ‘quality’) trials are
more likely to yield results that are closer to
the ‘truth’.
Quasi-random allocation
* A method of
allocating participants to different forms 
of care that is not truly random, for example,
allocation by date of birth, day of the week,
medical record number, month of the year, or
the order in which participants are included in
the study (e.g. alternation).
Quasi-randomised trials
* A trial using a quasi-
random method of allocating participants to
different forms of care. There is a greater risk
of selection bias in quasi-random trials in
which allocation is not adequately concealed
compared with randomised controlled trials
with adequate allocation concealment.
Random allocation
* A method that uses 
the play of chance to assign participants to
comparison groups in a trial, for example, by
using a random numbers table or a computer-
generated random sequence. Random allo-
cation implies that each individual or unit
being entered into a trial has the same chance
of receiving each of the possible interventions.
It also implies that the probability that an indi-
vidual will receive a particular intervention is
independent of the probability that any other
individual will receive the same intervention.
Random effects
* A statistical model some-
times used in meta-analysis, in which both
within-study sampling error (variance) and
between-studies variation are included in the
assessment of the uncertainty (or confidence
interval) of the results of a meta-analysis (see
Fixed-effect model). If there is significant
heterogeneity among the results of the
included studies, random-effects models 
will give wider confidence intervals than 
fixed-effect models.
Randomisation* Method used to generate 
a random allocation sequence, such as using
tables of random numbers or computer-
generated random sequences. The method 
of randomisation should be distinguished
from concealment of allocation because 
of the risk of selection bias, despite the use 
of randomisation, if there is not adequate
allocation concealment.
For instance, a list of random numbers may 
be used to randomise participants but, if the
list is open to the individuals responsible for
recruiting and allocating participants, those
individuals can influence the allocation
process, either knowingly or unknowingly.
Randomised controlled trial (synonym:
randomised clinical trial)
* An experiment in
which investigators randomly allocate eligible
people into groups (e.g. treatment and con-
trol) to receive or not to receive one or more
interventions that are being compared. The
results are assessed by comparing outcomes 
in the treatment and control groups.
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Reference Manager
* A software package
designed to manage bibliographic references.
Sometimes confusingly referred to as RefMan
(see RevMan). Examples of other similar
packages are Papyrus and ProCite.
Review Manager* Software developed for the
Cochrane Collaboration to assist reviewers in
preparing Cochrane reviews. Reviewers enter
their protocols and reviews into RevMan, from
which they can be imported into ModMan by
a Collaborative Review Group coordinator for
inclusion in the parent database and the
Cochrane Database of Systematic Reviews 
as part of the Group’s edited module.
Review protocol  see Protocol.
Search strategy
*
(1) The methods used by a Collaborative
Review Group registered with the Cochrane
Collaboration to identify trials within the
Group’s scope. This includes handsearching
relevant journals, searching electronic data-
bases, contacting drug companies, other
forms of personal contact and checking refer-
ence lists. Groups must describe their search
strategy in detail in their module. Reviewers
can refer to the Group’s search strategy when
preparing a Cochrane Review and, if neces-
sary, supplement this with a description of
their own additional searches.
(2) The methods used by a reviewer to locate
relevant studies, including the use of a
Collaborative Review Group’s trials register.
(3) The combination of terms used to identify
studies on an electronic database such as
Medline.
Serum urea  Urea has a molecular weight of
67 and is a product of metabolism of amino
acid. The normal serum concentration of 
urea is 4–6.6 mmol/l. A high serum urea
concentration is seen in patients with renal
failure but may also be seen in patients 
with gastrointestinal haemorrhage 
and dehydration.
Systematic review (Synonym: systematic
overview)
* A review of a clearly formulated
question that uses systematic and explicit
methods to identify, select and critically
appraise relevant research, and to collect 
and analyse data from the studies that are
included in the review. Statistical methods
(meta-analysis) may or may not be used to
analyse and summarise the results of the
included studies (see also Cochrane review).
Technical efficiency  Whereas an allocative
efficiency perspective addresses the question
of whether to carry out or expand an activity,
technical efficiency addresses the issue of how
best to undertake an activity once a decision
has been made to carry it out. Strictly, tech-
nical efficiency is ensuring the production 
of a given output with less of one input and
no more of other inputs. Cost-effectiveness,
which is about minimising the costs of a given
output, implies technical efficiency.
Transfer sets  In continuous ambulatory
peritoneal dialysis, a solution container is
connected to the patient’s peritoneal dialysis
catheter by a length of plastic tubing called 
a transfer set. There are two types of transfer
sets, each requiring a different method of
performing the exchange. These can be
classified into straight transfer sets and the 
Y-transfer set.
Tunnel infections  Those which occur in the
tunnel portion of catheters. In peritoneal
dialysis catheters, tunnel infections usually
require removal and replacement of catheter.
Weighted mean difference (in meta-analysis)
*
A method of meta-analysis used to combine
measures on continuous scales (such as
height), where the mean, standard deviation
and sample size in each group are known. 
The weight given to each study (e.g. how
much influence each study has on the overall
results of the meta-analysis) is determined by
the precision of its estimate of effect and, in
the statistical software in RevMan and the
Cochrane Database of Systematic Reviews, 
is equal to the inverse of the variance. This
method assumes that all of the trials have
measure the outcome on the same scale.
* Reproduced with permission from The Cochrane
Collaboration Handbook, v. 3.0, December 1996, 
and the Renal Purchasing Guidelines, NHS
Executive, May 1996.
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List of abbreviations
ACE angiotensin converting enzyme
BCM biocompatible*
BICM bio-incompatible
*
BPH benign prostatic hyperplasia
BUN blood urea nitrogen
*
CAPD continuous ambulatory 
peritoneal dialysis
CCPD continuous cyclic peritoneal dialysis
CCT controlled clinical trial
CI confidence interval
EPO erythropoietin
ESRD end-stage renal disease
HDL high-density lipoprotein
LDL low-density lipoprotein
NNT numbers-needed-to-treat
OR odds ratio
PCR protein catabolic rate
PKD polycystic kidney disease
PMMA polymethylmethacrylate
RCT randomised controlled 
(clinical) trial
RRT renal replacement therapy
SD standard deviation*
SEM standard error of the mean
UFc ultrafiltration coefficient
URR urea reduction ratio
WMD weighted mean difference
* Used in figures and tablesHealth Technology Assessment 1998; Vol. 2: No.5
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Objectives
• To review systematically the literature on six
major topics in dialysis therapy for patients 
with end-stage renal disease (ESRD).
• To link clinical effectiveness with cost (resource
use) in an economic analysis to assess efficiency.
• To suggest implications for clinical practice and
policy needs.
• To indicate areas for further research.
Methods
Cochrane Collaboration methods were adopted
and are described in detail in the full report.
Results
About 16,000 abstracts were considered and about
2300 possible randomised controlled trials (RCTs)
relevant to ESRD (excluding transplantation)
identified; 537 were relevant to the six topics and
only 47 actually met the eligibility criteria and were
included in the review. A total of 820 papers were
used for the economic evaluation.
1.Synthetic compared with cellulose-
based membranes in haemodialysis
treatment for ESRD
The inclusion criteria were met by 22 studies. The
incidence of nausea and vomiting was significantly
less with synthetic than with cellulose membranes.
Predialysis b2 microglobulin concentrations were
significantly lower with high-flux synthetic mem-
branes. In a 6-year study, the incidence of amyloid
disease was less with high-flux synthetic membranes.
Plasma triglyceride was lower with synthetic high-
flux membranes (one study) and serum albumin
was higher. Whether the differences were attri-
butable to the membrane material or to the flux is
unclear. There was no other significant difference.
When compared with modified cellulose mem-
branes, the incidence of pruritus was less with
synthetic membranes. The additional benefits 
of synthetic membranes were achieved at 
additional cost.
2.Bicarbonate-buffered compared 
with acetate-buffered dialysate in
haemodialysis treatment for ESRD
The inclusion criteria were met by 18 studies.
There was a significant reduction with bicarbonate
dialysis in the number of haemodialysis treatments
complicated by headaches, nausea/vomiting,
symptomatic hypotension and non-specific intoler-
ance. There was no clear evidence of improved
cardiovascular stability, lipid profile or biochemical
indicators of renal bone disease. Economic evalu-
ation showed the cost of the self-mix bicarbonate
buffer to be similar to that of acetate.
3.Short-duration compared with
standard-duration haemodialysis 
for ESRD
One study with 165 patients was identified. It com-
pared ≤ 3.5 hours dialysis with > 3.5 hours dialysis
three times a week. There was no significant differ-
ence in mortality. Hospitalisation rates were greater
in the short-duration group. There was no conclusive
difference in the incidence of intradialytic adverse
symptoms between the groups. Blood pressure con-
trol was worse in the short-duration group. There was
insufficient evidence to judge relative efficiency.
4.Continuous ambulatory peritoneal
dialysis (CAPD) delivery systems:
Y-set/modified Y-set versus standard
spike as treatment for ESRD
Six studies met the inclusion criteria. The number
of patients with at least one episode of peritonitis
was significantly lower in patients using Y-set
delivery systems. All but one study demonstrated 
a significant increase in the number of months per
episode of peritonitis with the Y-set delivery systems.
All studies showed a significant increase in the time
to first episode of peritonitis with the Y-set system.
There was no significant reduction in the number
of patients who suffered exit-site infections or
tunnel infections with the Y-set system. No study
addressed technique failure. Benefits are
achievable at extra cost.
5.Continuous cycler-assisted peritoneal
dialysis (CCPD) compared with CAPD
as treatment for ESRD
One study of 82 patients met the inclusion criteria.
There were no significant differences in the num-
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ber of patients with peritonitis, catheter exit-site
infections or catheter tunnel infections. The mean
number of peritonitis episodes per patient per year
was significantly lower with CCPD. There was no
significant difference in Kt/V, six-monthly serum
creatinine, urea or phosphate. Fewer patients on
CCPD needed to change dialysis technique but this
was not statistically significant. Patient preference
could not be adequately assessed because of the
parallel group trial design. The estimated cost per
episode of peritonitis avoided is considerable.
6.Haemodialysis compared with CAPD 
as treatment for ESRD
No relevant RCTs were identified. Because of the
poor quality of the study designs used to obtain
primary data for economic analyses, it is not possi-
ble to judge whether any assumed extra benefits
provided by haemodialysis are worth any extra 
costs that may be incurred.
Conclusions
Implications for policy
• The moderate benefits of high-flux synthetic
membranes are currently achieved at additional
cost. For general use, cellulose (particularly
modified cellulose) membranes are appropriate.
Synthetic membranes may be appropriate for
patients experiencing persistent nausea and
vomiting and for patients likely to be treated by
haemodialysis for many years. The price of high-
flux synthetic membranes is likely to fall in the
future and policy recommendations should be
kept under review.
• Bicarbonate dialysis is preferable to acetate dialysis
for the haemodialysis of patients with ESRD,
producing fewer unwanted effects at a similar cost.
• There is no evidence that reduced dialysis
duration (≤ 3.5 hours three times per week)
decreases mortality and it may increase
morbidity. If reduced dialysis duration regimens
are implemented on the basis of patient pre-
ference or assumed lower cost, their unproven
safety should be explicitly acknowledged.
• Y-set delivery systems significantly reduce the
incidence of peritonitis. Given that recurrent
peritonitis is a major cause of technique failure,
the additional cost is likely to be justified.
• CCPD showed benefit in one patient outcome but
is more expensive than CAPD. It is suggested that
CCPD should only be offered as an alternative to
CAPD, at present, to patients for whom there is a
specific indication.
• Data are not available to allow reliable
conclusions to be drawn about the relative
effectiveness and efficiency of haemodialysis 
and CAPD.
• Dialysis for ESRD intrudes greatly into people’s
daily lives. Informed patient preference, based on
evidence of effectiveness and efficiency, should be
taken into account when policy is decided.
Recommendations for research
• Further multicentre pragmatic RCTs with
economic evaluations concentrating on primary
outcomes of major importance to patients are
required to compare the different dialysis mem-
branes available. These should take into account
membrane reuse, their properties, including flux
and material, and should include modified cellu-
lose and low-flux synthetic membranes which
may be less expensive than their high-flux
counterparts. The trials should include older
patients and those with comorbid illnesses.
• A large multicentre pragmatic RCT comparing
haemodialysis treatment duration policies is
required. Such a trial should include the longer
duration haemodialysis practised in other parts
of Europe, have minimum exclusion criteria, 
a long follow-up period and minimum data
collection, concentrating primarily on patient
morbidity and mortality.
• More evidence of the effect on patient outcomes
and costs of technique failure would further
inform the decision about the use of Y-set systems.
• Further RCTs with economic evaluations are
required comparing CCPD with CAPD, with
particular reference to peritonitis, technique
failure rates and patient preference. Studies are
also required to compare CCPD with haemo-
dialysis to determine whether it is efficient to
provide CCPD for those patients who have a
relative contraindication to CAPD and who
would otherwise be treated by haemodialysis.
• The issue facing the health services is not
whether to have CAPD or haemodialysis but
rather the balance of provision between the two
modalities. International variations in usage
show that a large proportion of patients requir-
ing dialysis for ESRD could be managed initially
with either CAPD or haemodialysis. Information
is required about the relative costs, benefits and
risks of policies of starting with one or other
modality. Information on benefits, risks and costs
should come from a pragmatic RCT of policies
based on starting with CAPD or haemodialysis.
• Further systematic reviews are required in 
other aspects of dialysis where there are 
practice options. 
• The results of the on-going large American study
(HEMO) should be taken into account when the
research agenda is decided.
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T
he authors were commissioned under the 
NHS Executive Research and Development
Programme to undertake a systematic literature
review of the effectiveness of dialysis therapy for
end-stage renal disease (ESRD). There are many
points in the management of patients on dialysis
where choices require to be made. Using a dialysis
decision tree, six of them were selected in which
there were known variations in practice and in
which there were likely to be significant resource
implications. Six reviews were undertaken by a
multidisciplinary team of clinicians, health services
researchers experienced in carrying out literature
reviews and health economists using the standard-
ised format of the Cochrane Collaboration. There
is currently no agreed arrangement for incorpor-
ating economic analyses into Cochrane reviews;
however, these have been added to each review and
their findings included in the overall conclusions
and summaries. A summary of the results of all
reviews is given in chapter 4 and the full reviews,
including the economic analyses, are included 
as appendices 4–9.
Background
When people with irreversible loss of kidney
function reach that point in the course of their
illness when their kidneys fail to support life, they
are said to have ESRD. The only way in which they
can then be kept alive is by renal replacement
therapy (RRT). There are two types of RRT, dialysis
and transplantation. Those needing RRT are likely
to move between the various modalities of treat-
ment; for example, they may begin with haemo-
dialysis, move to continuous ambulatory peritoneal
dialysis (CAPD), receive a renal transplant, and
then return to haemodialysis if transplantation fails.
Although transplantation is the treatment of
choice, the number of donor kidneys is limited 
and hence many patients require long-term or 
even life-long dialysis. Such therapy is not only
associated with considerable morbidity and a
significantly impaired quality of life but also
imposes a major economic burden on the health
service. In recent years, the number of patients
accepted for dialysis in the UK has increased. In 
the UK in 1982, an average of 20 patients per
million of the population started dialysis.1 This
figure is now about 80 patients per million and 
will almost certainly rise further, particularly in
areas where ethnic minorities comprise a high
proportion of the population.2–4 As the number of
patients receiving RRT increases, there is increased
pressure to spend more on renal services and this
is, quite rightly, raising concerns about the effect-
iveness and efficiency of current provision.
Methods of dialysis
Dialysis removes fluid, electrolytes and toxins 
that the failed kidney cannot excrete. It also allows
buffering of the blood with alkali as the kidney can
no longer correct the body’s tendency to acidity. A
fuller explanation is given in appendix 1. There are
two principal modes of dialysis for patients with
ESRD – haemodialysis and CAPD.
Haemodialysis
The artificial kidney (dialyser) used in haemo-
dialysis contains a semi-permeable membrane;
dialysis relies on the fact that small molecules such
as urea and creatinine, which are usually excreted
by the kidney, can pass across this membrane down
a concentration gradient. Removal of fluid from
blood is achieved by applying hydrostatic pressure
across the membrane and acidosis is corrected by
acetate or bicarbonate in the dialysis fluid (dialy-
sate) that flows on the other side of the membrane.
This procedure requires permanent easy access to
the patient’s circulation which is usually obtained
by creating an arteriovenous fistula in the arm.
Several types of dialysers, dialysates and ‘dialysis
machines’ which monitor the procedure are
commercially available, and the frequency and
duration of dialysis sessions, dialyser membranes,
dialysate composition and dialysis schedules vary
from centre to centre. Haemodialysis can be
carried out in the patient’s home or in a satellite
unit run by nursing staff, as well as in a large
hospital dialysis unit.
CAPD and CCPD
The human peritoneal membrane is semi-
permeable and, hence, can be used as a dialysis
membrane. In CAPD, using the peritoneal mem-
brane in this way requires a permanent catheter 
to be inserted in the abdomen through which 
the dialysing fluid (dialysate) is passed into the
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peritoneal cavity. The small molecules normally
excreted by the kidney, such as urea and creatinine,
pass across the peritoneal membrane down a con-
centration gradient. Removal of fluid relies on an
osmotic gradient across the membrane and this is
created by using varying concentrations of glucose
or carbohydrate polymer (Icodextrin) in the
dialysis fluid. The dialysate is left in the peritoneal
cavity for 6–8 hours to allow equilibration and then
drained out and replaced with fresh fluid. Thus,
peritoneal dialysis does not require a machine and
can be carried out by patients in their own homes.
Several types of catheter and dialysis fluid are avail-
able commercially and a range of management
regimens have been advocated. Continuous cyclic
peritoneal dialysis (CCPD) is a modification of
CAPD in which the exchanges are performed
overnight by a machine. Recently it has been
proposed as an alternative to CAPD.
Variation in dialysis practice
Despite the marked differences between haemo-
dialysis and CAPD there are surprisingly wide inter-
and intra-national variations in the use of the two
approaches. In part, this seems to reflect differing
perceptions of the role of CAPD as an alternative to
haemodialysis. In the 1980s, the criteria for accept-
ing patients for dialysis in the UK were broadened,
and older patients and those with co-morbid
illnesses, such as heart disease and diabetes, were
accepted for treatment. This coincided with the
introduction of CAPD. In the UK, CAPD was seen
as a way of allowing the treatment of an increasing
number of patients without the need to create
more haemodialysis facilities, purchase expensive
machines and employ large numbers of highly
trained staff. Currently in the UK, about 50% 
of new patients beginning dialysis are treated by
CAPD; this contrasts with other countries, such 
as France, Germany, Italy and the USA, where
CAPD is used in less than 20% of patients.
In certain patients it may not be possible to offer
both types of dialysis therapy; those who have had
extensive abdominal surgery, for example, may only
be suitable for haemodialysis and those in whom
the creation of vascular access has become impos-
sible may be restricted to CAPD. Such medical
issues, however, apply to a relatively small number
of patients and, in the majority of cases, the choice
of dialysis modality made by health personnel and/
or the patient is based on non-medical factors.
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Outside the UK, the strongest determinant may 
be the higher levels of reimbursement associated
with haemodialysis enjoyed by both the physician
and dialysis facility.6 In the UK, factors which may
influence the choice include the distance of 
a patient’s home from the renal unit and the
presence of co-morbid illnesses.
Once these factors have been taken into account, 
it is generally considered by nephrologists in the
UK that informed patient choice should be the
major factor in influencing the selection of treat-
ment modality, although, in fact, the decision is
often influenced by the current availability of local
facilities. Furthermore, the wide variation in dialy-
sis practice is not limited to the choice between
haemodialysis and CAPD. Once the decision to use
haemodialysis has been made, selection of mem-
branes, dialysis fluids and treatment protocols also
vary, as do the choice of catheters, fluids and
schedules for CAPD.
These variations may hide important differences
within the range of approaches used for dialysis. All
approaches to dialysis are associated with consider-
able morbidity and impose major restrictions on the
lifestyles of those being treated. Dietary and fluid
restrictions, dependence on dialysis technology for
survival, and limits on ability to work and to travel,
cause major stresses affecting the quality of life of
both patients and their families, and it is important
to assess, in as unbiased a way as possible, how such
effects vary across dialysis approaches.
Costs of dialysis therapy
Dialysis therapy already consumes considerable
health service resources and, as indicated above, 
as the number of patients likely to be treated each
year increases, the stock of patients will rise, result-
ing in increasing pressure to spend more on renal
services. The number of people on RRT (dialysis
and transplantation) will increase until there is equi-
librium between the numbers being accepted for
treatment and the numbers dying. The number on
dialysis will increase as a proportion of those treated
if there is a shortage of kidney donors or if older
people on RRT, especially those with co-morbid ill-
nesses, are thought unsuitable for a renal transplant.
Differences in costs between alternative approaches
may therefore be very important. It has been
estimated that when the rising number of dialysis
patients reaches a plateau, 0.08% of the total num-
ber of patients will be consuming between 2% and
4% of the health budget.
7 A recent review, however,
highlighted the variation in estimated costs of dialy-
sis in the UK. The authors of one of the reports
cited estimated the annual cost per patient to be
£18,000 for hospital haemodialysis and £13,000 for
CAPD whereas, in another report, these costs were
estimated to be £10,500 and £11,000, respectively.
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cost variations may have occurred because of local
differences in policies for administering and deliv-
ering dialysis services and differences in method-
ology used in assessing cost; for example, in some
units the cost of CAPD fluids and expensive drugs
such as erythropoietin (EPO) may be charged to
general practitioners’ budgets.
The systematic review
It was against this background of increasing
pressure on resources and wide variations in
practice that this systematic review of dialysis for
ESRD was commissioned. We chose to address the
issue in two complementary ways. Firstly, the aim
was to review evidence of clinical effectiveness in
terms of benefits and risks. Secondly, it was planned
to link effectiveness with costs (resource use) in an
economic analysis to assess efficiency. From the
outset it was recognised that the choices were often
not simply between one approach and another but
rather between different policies, reflecting the fact
that it may be good management in some circum-
stances to change from one technique to another.
Thus, for example, the choice between haemo-
dialysis and CAPD is a planning decision about
which technique to use first, while recognising 
that it may be appropriate to switch to the
alternative later.
The choice of questions addressed
To ensure that the review focused on the most
important questions in dialysis, a ‘dialysis decision
tree’ was developed (Figure 1).
Six points in the management of patients on
dialysis were selected when major choices were
made, at which there were known to be variations
in practice and for which there were likely to be
significant resource implications (Table 1).
The topics for systematic reviews were chosen by two
clinical nephrologists, based on recommendations
from the NHS Executive, for two main reasons.
• There is wide variation in clinical practice in
each of the six areas selected both in the UK 
and internationally.
• These areas all have important health 
economic implications.
In view of the resources available for this systematic
review, both in terms of staffing and time, it was
considered that only these six areas could be
addressed in this project. There are, of course,
many other areas in the management of ESRD by
dialysis for which there are considerable resource
implications and variations in practice. These topics
could be considered for future systematic reviews.
Choice of literature to assess
effectiveness and efficiency
The study concentrated on the evidence from
randomised controlled trials (RCTs), even though
it was suspected that there were likely to be
relatively few such reports in the literature. Our
concern was that observational studies, even well-
conducted cohort studies, might be subject to
selection biases of the same order of magnitude 
as the likely treatment differences.
It is now widely accepted that the only way to 
avoid such biases is by secure random allocation 
of the alternative approaches to care. The groups
generated then only differ by chance in respect of
Do we treat at all?
How do 
we treat?
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FIGURE 1  Dialysis decision tree (HD,haemodialysis;PD,peritoneal dialysis; ,topics selected for this series of reviews)Introduction
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baseline prognostic variables. However, even when
well-designed, the results of RCTs may still be of
only limited value, because few are sufficiently 
large for precise enough estimates of treatment
differences to be generated so that chance may be
ruled out as an explanation. To overcome this, our
plan was to consider the data from all similar trials
in statistical meta-analysis, wherever possible.
Clearly, potential bias also needed to be minimised
in the process by which data from comparable trials
were brought together and synthesised. Systematic
approaches to the identification of relevant studies
and the abstraction of data from relevant reports
were therefore used. These are discussed in 
detail later.
Although information on costs was sought in the
reports of RCTs, the systematic literature search 
for the economic analysis within each review was
extended to identify previously conducted eco-
nomic evaluations. The use of these data are
described in detail later.
Choice of outcome measures
The main body of this report has been kept
succinct by limiting it to a summary of activities 
and findings; individual topics are supported by
appendices in which more detailed information 
is presented on the methods used in, and results 
of, each review topic. After the description of
research methods and the products of the liter-
ature searches, summaries of the six reviews are
reported with conclusions and recommendations.
The report finishes with a discussion of the study.
This has resulted in some degree of duplication 
of text but with the aim of ensuring an appropriate
level of detail throughout.
TABLE 1  Subjects addressed in the systematic reviews
1 Comparison of synthetic with cellulose-based membranes in haemodialysis treatment for patients with ESRD
2 Comparison of bicarbonate-buffered dialysate with acetate-buffered dialysate in haemodialysis treatment for patients 
with ESRD
3 Comparison of short-duration with standard duration dialysis treatments in haemodialysis treatment for patients 
with ESRD
4 Comparison of CAPD delivery systems – Y-set/modified Y-set versus standard spike in treatment for patients with ESRD
5 Comparison of CCPD with CAPD in treatment for patients with ESRD
6 Comparison of haemodialysis with CAPD as treatment for patients with ESRDHealth Technology Assessment 1998; Vol. 2: No.5
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The methods of the review were based on those
used by the Cochrane Collaboration9 and the
Centre for Reviews and Dissemination.10 For
identification, synthesis and presentation of the
data on clinical effectiveness, the format of the
Cochrane Collaboration was chosen. The prin-
cipal reason for this decision was that the reviews
were based on RCTs, and customised software
(Review Manager) was available for the preparation
and analysis of systematic reviews which incorp-
orated statistical programs for meta-analysis, 
when appropriate.
Development of protocols
A review protocol was formulated for each of the
six topics under review. The protocol structure
followed that recommended by the Cochrane
Collaboration.
11 Each protocol explicitly described:
• the objectives of the review
• the clinical and methodological criteria required
of studies for inclusion
• the outcome measures of importance
• the search strategy to be used for identification
of trials
• the methods of quality assessment, data
abstraction and qualitative and quantitative
synthesis of results.
Protocols were then lodged with the Centre for
Reviews and Dissemination in York and entered
into Review Manager. Completed protocols for the
six topics form the background, objectives, and
materials and methods sections of the reviews
presented in appendices 4–9.
Search strategy for the
identification of studies for
inclusion in the systematic review
For the reasons outlined in chapter 1, the
systematic search for studies of effectiveness was
limited to finding RCTs. A broad search strategy
was adopted in order to identify as many RCTs as
possible relevant to the management of patients
with ESRD, and not only those relevant to the 
six review topics. This broad search served 
two purposes.
1. It avoided potential duplication of work which
would have followed if separate searches had
been performed for each selected topic.
2. It allowed the establishment of a register of RCTs
relevant to the management of ESRD which we
and/or others can use when performing future
systematic reviews in this area. (A Cochrane
Renal Review Group has recently been estab-
lished and the register will contribute to the
work of that Group.)
Systematic electronic bibliographic
database searching
Five electronic databases were searched
systematically:
• Medline (National Library of Medicine, USA:
the electronic version of Index Medicus) using the
search software Ovid, CD Plus
• Embase (Elsevier Science Publishers BV, The
Netherlands: the electronic version of Excerpta
Medica) using BIDS (on-line)
• CINAHL (CINAHL Information Systems, USA –
Citation Index of the Nursing and Allied Health
Literature) using the search software Ovid, 
CD Plus
• Biosis (Biological Abstracts Inc., USA: the
electronic version of Biological Abstracts) using
the search software SilverPlatter
• Cochrane Library (Cochrane Collaboration, UK:
Update Software, April 1996; Issue 1, CD-ROM
version – available from BMJ Publishing 
Group, London).
Medline was the first electronic bibliographic
database to be searched. At this time, most search
strategy development work by the UK Cochrane
Centre had been carried out on Medline using
SilverPlatter search software.
12 We modified this
strategy for use on Medline (on Ovid, CD Plus) to
allow for the different syntax used by the different
search software.
The Cochrane search strategy has three compon-
ents, each succeeding part being less specific but
more sensitive than the one previous; the first is
Chapter 2
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relatively specific but insensitive, the last most
sensitive but least specific. Pilot searches indicated
that the third component did little to improve the
number of relevant trials identified but generated
very large numbers of abstracts describing studies
using other types of research design; for this
reason, we limited the search to the two initial com-
ponents plus the textword search term ‘volunteer$’
in title and abstract (as now recommended by the
UK Cochrane Centre; ‘volunteer$’ was the only
term in the third part of the Cochrane search strat-
egy that increased the number of RCTs identified
without producing a large number of irrelevant
abstracts). The Cochrane search strategy was com-
bined with additional search terms describing the
management of ESRD (see appendix 2). These
were developed by a nephrologist and a research
fellow experienced in literature searching, in line
with the decision to perform a broad search cover-
ing all aspects of ESRD rather than perform indi-
vidual searches for each of the review topics. These
ESRD search terms were built up by investigating
the MeSH terms, using the MeSH tree with scope 
notes and permuted index, as well as by textword
searching (searching for terms in the title 
and abstract).
As new search terms were added to the search
strategy, the first 50 references were scanned to
assess their relevance to ESRD and dialysis; terms
that retrieved only irrelevant articles were further
modified or rejected. The final search strategy
adopted for the Medline search is presented in
appendix 2.
This search strategy was modified for searching
other databases by changing the syntax to suit that
of the relevant search software and interrogating
the thesaurus or indices of each database to iden-
tify equivalents of the MeSH terms (i.e. the data-
base controlled language). The definitive search
strategies which were used to search Embase,
CINAHL, Biosis and the Cochrane Library are 
also presented in appendix 2.
Other databases searched
The following databases were also searched. The
search strategies are presented in appendix 2.
• Chemabs (Chemical Abstracts Service, USA: 
the electronic version of Chemical Abstracts) using
STN. An on-line search, performed by a librarian
experienced in use of this database, was focused
on one of the review topics, acetate versus
bicarbonate dialysate buffer.
• SIGLE (System for Information on Grey Liter-
ature in Europe, compiled by EAGLE) using
SilverPlatter, CD-ROM version. SIGLE was search-
ed, in an attempt to identify RCTs in the grey
literature in this field, by an experienced infor-
mation officer at the Grampian Health Board.
• CRIB (Current Research in Britain, 10th edition,
1995; published by Cartermill Publications,
London). This was searched in order to identify
on-going trials in the field of dialysis and ESRD.
Authors of on-going trials relevant to the six
chosen topics were contacted to ascertain if 
the study was an RCT.
• NRR (National Research Register, 14th
consolidation, September 1996). The aim was 
to identify on-going trials in the field of dialysis
and ESRD. Authors of on-going trials relevant 
to the six topics were contacted to ascertain if
the study was randomised.
Handsearching of specific journals
Experience of systematic reviews in other areas of
health care has shown that despite rigorous search-
ing of electronic bibliographic databases as in this
review, a significant proportion of relevant RCTs
are missed because of poor indexing.
11 Hence, 
a large number of journals are currently being
handsearched as part of the Cochrane Collabora-
tion’s effort. The products of these searches are
being made available through retrospective tagging
in Medline and in the Cochrane Register of RCTs
in the Cochrane Library. Any trials relevant to
those reviews already found in this way by the Coch-
rane Collaboration should have been identified
through the searches described above. Current
handsearching, however, within the Cochrane
Collaboration does not cover the majority of
journals, particularly those in specialised areas.
According to the Baltimore Cochrane Center,
which coordinates handsearching activities world-
wide, as of 6 May 1997, Clinical Nephrology and
Hellenic Nephrology are the only nephrology journals
currently being handsearched outside Aberdeen.
Only limited handsearching was possible within 
the resources available. Kidney International was
chosen as the nephrology journal most likely to
contain relevant RCTs; it is one of the main inter-
national nephrology journals and one of the most
widely cited of all medical journals, and is held in
the local medical school library. Full-text searching
of Kidney International (including supplements)
from January 1988 to December 1995 was 
therefore undertaken.
Each issue of Kidney International was fully searched
and each original article found was read to the
point where it was possible to make a definite classi-
fication of the study design. Conference abstracts,Health Technology Assessment 1998; Vol. 2: No.5
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with the exception of those listed in appendix 3)
were not searched. This decision was taken after
handsearching the conference proceedings for 
1 year and extrapolating the figures over 15 years
(approximately 9000 abstracts). For those abstracts
relevant to the six topics, confirmation of subse-
quent publication and/or contacting authors for
further details would have been required and it 
was decided that time and resources did not allow
for this. Handsearching was performed by two
members of the team, one a nephrologist and 
the other a methodologist.
A quality assurance control was implemented 
and a ‘gold-standard’ search was devised. The 
1990 and 1995 volumes of Kidney International were
searched by both handsearchers separately. After
discussion an agreed attribution of all studies was
made – this was the gold standard. A sensitivity and
precision of greater than 90% was required of 
each searcher.
In keeping with the philosophy and practice of 
the Cochrane Collaboration, the aim of this hand-
searching was to identify all possible RCTs and
controlled clinical trials (CCTs) regardless of
subject content. Details of all such trials identified
will be sent to the Cochrane Renal Review Group
and to the Baltimore Cochrane Center, which is
responsible for the Cochrane register of RCTs and
for liaising with the National Library of Medicine 
for retrospective indexing on Medline.
Other methods of ascertainment 
of RCTs
Reference lists of selected articles
The reference lists of other reviews (expert/
narrative), of identified RCTs and of relevant book
chapters on the topics of interest were checked for
possible RCTs. These searches were limited to ‘first
generation’ references only; in other words, the
reference lists of reports of studies originally
identified from a previous reference list search
were not searched (appendix 3).
Other experts in the field
The authors of trials included in each systematic
review and those from whom clarification of
methodology had been sought were contacted to
ascertain if they knew of any other possibly relevant
RCTs. An example of the letter and associated
forms sent to authors is presented in appendix 10.
Biomedical companies 
Where relevant, biomedical companies were
contacted for details of any other relevant 
possible RCTs, published or unpublished.
Identification of possible RCTs
All possible RCTs were electronically imported or
manually entered into the reference managing
software package, Reference Manager (v. 6.01N,
Research Information Systems, Carlsbad, CA, USA).
Subject keywords and source of article were added.
Register of possible RCTs
All electronically derived abstracts and study titles
were read by a team of three nephrologists to assess
subject relevance. Initially, all abstracts were read by
both a nephrologist and a methodologist; however,
because of the high degree of concurrence, the
greater speed at which the abstract could be assessed
by the nephrologists and the large number of
abstracts to be read (about 12,000), it was decided
that the nephrologists alone should assess the
abstracts. Each of three nephrologists was given up
to 800 abstracts at a time and used a standard form
(see appendix 10) to identify those abstracts judged
to be possible RCTs or quasi-RCTs related to the
management of ESRD. All possible RCTs or quasi-
RCTs relevant to the six selected topics were
assigned specific topic keywords on Reference
Manager and the full published paper was obtained.
Quality assessment of studies
Full copies of studies were independently assessed
for subject relevance, eligibility and methodological
quality by a nephrologist and a methodologist using
a standard form (see appendix 10). The quality of
random allocation was recorded, including conceal-
ment of allocation, blinding, withdrawals, drop-outs,
numbers lost to follow-up and whether intention-to-
treat analysis was possible. The assessors were not
blinded to author, institution or journal. Recent
evidence suggests that blinding of assessors has a
relatively small impact, if any, on the results of a
meta-analysis.
13 Any differences of opinion were
resolved by discussion. If agreement could not be
reached, a second double-assessor team, aware of
the previous team’s deliberations, reassessed the
study and reached a final decision.
Data abstraction
A data abstraction form was generated for each
review prior to the actual abstraction of the data
from each published paper (see appendix 10).
Only comparisons and outcomes that had been
identified a priori in the protocols were included.Review methods for assessing effectiveness
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For each review, the data were abstracted by a
single, medically qualified assessor and then
entered into Review Manager.
Data analysis
Where results from studies could be quantitatively
combined, a statistical meta-analysis of the data 
was undertaken to determine the typical effect 
size of the intervention. For dichotomous data, 
a ‘typical’ odds ratio (OR) was derived using Peto’s
method14 and, for continuous data, a weighted
mean difference (WMD) was calculated (weighted
by the inverse of the variance). Analyses for both
dichotomous and continuous data adopted a 
fixed effects approach.15 Results from the limited
number of included crossover trials were treated 
in the same fashion as parallel group trials.9
All comparisons were framed in terms of unfavour-
able events, such as adverse symptoms rather than
freedom from adverse symptoms. As such, an OR 
of less than one would favour the experimental
treatment, and an OR greater than one would
favour the control treatment. The 95% confidence
intervals (CIs) were derived for all comparisons.
Meta-analysis graphs have been presented when
possible. An annotated example of such graphs is
shown in Figure 2.
Evidence of heterogeneity16 across studies was
explored using the chi-squared test for hetero-
geneity; if evidence of significant heterogeneity 
was identified, potential sources of heterogeneity
were sought. If data could not be combined
quantitatively they were assessed qualitatively.
Reporting
The reviews are reported in a modified form of the
standard format of the Cochrane Collaboration
(see appendices 4–9). The full reviews were then
summarised for the purposes of this report 
(see chapter 4).
Experimental
n/N
Study
Sessions with symptomatic hypotension
Cellulose membrane
Aakhus, 1995
Bergamo, 1991
Collins, 1993
Danielson, 1986
Levin, 1993
Locatelli, 1996
Quereda, 1988
Skroeder, 1994
Subtotal (95% CI)
Chi-square 13.49 (df = 6) Z = 1.86
1/8
39/214
187/1260
1/12
143/645
0/0
71/192
5/80
447/2411
Modified cellulose membrane
Levin, 1993
Skroeder, 1994
Subtotal (95% CI)
Chi-square 0.34 (df = 1) Z = 2.19
143/645
3/77
146/722
Total (95% CI)
Chi-square 14.91 (df = 8) Z = 2.68
593/3133
Control
n/N
Peto OR
(95% CI fixed)
1/8
32/214
180/1260
1/6
137/422
0/0
82/192
3/77
436/2179
118/428
6/77
124/505
560/2684
Weight
(%)
0.2
6.8
36.0
0.2
22.7
0.0
10.6
0.9
77.3
21.7
1.0
22.7
100.0
Peto OR
(95% CI fixed)
1.00 (0.06, 17.62)
1.27 (0.76, 2.11)
1.05 (0.84, 1.30)
0.45 (0.02, 9.33)
0.59 (0.44, 0.78)
Not estimable
0.79 (0.52, 1.18)
1.62 (0.39, 6.70)
0.87 (0.74, 1.01)
0.75 (0.56, 0.99)
0.49 (0.13, 1.89)
0.73 (0.55, 0.97)
0.83 (0.73, 0.95)
0.1 0.2 1 5 10
Favours treatment Favours control
Indicates subgroup analysis Estimates which lie to the
left of the ‘line of no effect’
indicate that the result favours
the experimental treatment
Line of no effect
The horizontal lines 
are 95% CIs around 
the estimate
Not estimable because
there are no events
‘Diamond’ indicates pooled estimate. If it crosses 
the ‘line of no effect’, the estimate is not statistically 
significant (the result is compatible with no effect)
FIGURE 2  Example of meta-analysis graph (Comparison:synthetic vs.cellulose/modified cellulose haemodialysis membranes)Health Technology Assessment 1998; Vol. 2: No.5
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Introduction
Economic evaluation is the comparative analysis 
of alternative courses of action in terms of both
their costs (resource use) and effectiveness (health
effects). In this study, the term ‘alternative courses
of action’ can be equated to different ways of
treating people with ESRD. Economic evaluation 
is useful for addressing both questions of technical
efficiency and questions of allocative efficiency.
Cost-effectiveness analysis deals with technical
efficiency and has been defined by Mooney17 as 
the technique used to address the question of 
how to meet a given objective at least cost. Con-
sideration of allocative efficiency means address-
ing the issue of how many resources to allocate 
to competing healthcare programmes. This
involves making judgements about the relative 
sizes of different healthcare programmes and,
therefore, about the relative worth of proposed
expansions of such programmes. Such questions
are addressed by cost–benefit analysis.
It may be possible to examine technical and
allocative efficiency through cost–utility analysis
(which has the advantage of focusing on the trade-
off between cost and quality of life). However, we
have used the more general frameworks of cost-
effectiveness and cost–benefit analysis in decision-
making because the nature of the evidence does
not lend itself to estimating quality adjusted 
life-years – the main outcome measure used 
in cost–utility analysis.
The aim of the project was to address questions 
of efficiency as well as effectiveness of alternative
approaches to dialysis. By deriving and linking
estimates of the relative costs and effectiveness 
of the procedures under consideration, it 
should be possible to determine whether one 
procedure is:
(i) less costly as well as being at least as effective 
as its comparator, in which case it would be
judged, unequivocally, to be a better use of
healthcare resources (i.e. more technically
efficient), or
(ii) more costly, as well as more effective, than 
its comparator, in which case a judgement
would have to be made about whether the
extra cost is worth incurring in terms of the
gains in health achieved (an allocative
efficiency question).
The manner in which costs and outcome were
related in this study is further developed as an
economic framework.
The economic framework
The manner in which data on costs and clinical
effectiveness can be brought together to aid in the
judgement about whether one procedure should
be preferred to a comparator is illustrated in more
detail in Table 2. These theoretical permutations of
cost and clinical effectiveness are brought together
in a matrix in Figure 3.
For any procedure the optimum position on 
the matrix shown in Figure 3 is the square A1, 
where an experimental treatment would both 
save costs and be more effective relative to a com-
parator. In squares A1, A2 and B1 the procedure 
is more efficient than a comparator and receives 
a positive response to the question of whether the
experimental treatment is to be preferred. In
squares B3, C2, and C3 the procedure is less
Chapter 3
Methods of economic evaluation
TABLE 2  Categories of evidence on effectiveness and cost
Cost Effectiveness
A  Evidence of cost savings 1  Evidence of greater effectiveness
B  Evidence of no difference in costs 2  Evidence of no difference in effectiveness
C  Evidence of greater costs 3  Evidence of less effectiveness
D  Insufficient evidence to judge difference in costs 4  Insufficient evidence to judge difference in effectivenessMethods of economic evaluation
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efficient than the comparator and this receives a
‘negative response. In squares A3 and C1 a judge-
ment is needed as to whether the more costly
procedure is worthwhile in terms of extra effec-
tiveness. Square B2 is neutral with no difference 
in either costs or effectiveness. In those squares
with question marks there is insufficient infor-
mation on cost or effectiveness or both to provide 
a definitive answer on relative efficiency.
Assessment of effectiveness
The methods used to assess the relative effective-
ness of the interventions being compared were
described in chapter 2.
Identification of data on resource
use and cost
Data collection
Two ways of identifying data on resource use and
costs were considered. The first was a broad search
for relevant studies conducted in parallel with the
searches for RCTs of effectiveness. The second was
a more focused search, delayed until the reviews 
of effectiveness had been completed, aimed at
supplementing economic information from the
RCTs. The former approach was chosen for two
reasons. Firstly, it was anticipated that RCTs would
probably not be the best source of information on
resource use and that each individual trial would
not have incorporated a formal economic evalu-
ation. Secondly, it was predicted that the reviews of
effectiveness would take most of the time available,
leaving insufficient time for any later searching of
the economics literature. As a result, a separate,
parallel search strategy of electronic databases was
developed which attempted to identify the maxi-
mum number of economic evaluations and studies
that considered the resources used in the manage-
ment of ESRD relevant to the six review topics. The
strategy was developed by the health economists
and a research fellow experienced in literature
searching. This strategy did not confine itself to
randomised or quasi-randomised CCTs, unlike the
search on effectiveness, but included economics
studies using other research designs.
Although the detail of each review is slightly
different, in general, data from the systematic
reviews of trials were used:
• to assess relative effectiveness
• to estimate resource use associated with the 
initial interventions
• to estimate the resource consequences, if any, 
of differential rates of adverse events (such 
as complications).
Data from additional material identified in the
review of economic studies were used:
• to estimate differential rates of adverse events
with resource consequences, when such data
were not available from the review of RCTs
• to provide estimates of the magnitude of
resources used in each option evaluated, when
such data were not available from the review of
RCTs (although if more accurate estimates could
be obtained from local, that is, UK-based,
costings, these were used instead).
Databases searched for the review of economic
studies were: 
• Medline
• Embase on BIDS
• CINAHL
• Biosis
• IBSS (British Library of Political and Economic
Science) using BIDS
• NEED (NHS Economic Evaluation Database,
NHS Centre for Reviews and Dissemination) 
on-line
• Econlit (American Economics Association) 
using the search software SilverPlatter
• The Economist (The Economist Newspaper Ltd,
London) on CD-ROM.
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FIGURE 3  Matrix linking evidence on effectiveness and cost 
(4 = yes,8 = no;84 = neutral;? = not enough evidence;
,judgement required to be made.1
1 In economic terms this judgement about which treatment to
choose in areas A3 and C1 involves the same trade-off;is the more
effective treatment worth its extra cost?However,in practice it may
be more difficult to justify the implementation of a lower cost but
less effective alternative.Health Technology Assessment 1998; Vol. 2: No.5
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Details of the years searched and the search terms
are presented in appendix 2.
The Medline search strategy was the first to be
developed using similar methodology to that 
for the electronic search for possible RCTs (see
chapter 2). The search terms to identify RCTs 
were omitted in this search strategy. These terms
were replaced by terms designed to identify eco-
nomic evaluations and studies that considered the
resources used in the management of ESRD. The
Medline search strategy was then modified for
searching other databases (see chapter 2).
Identification of potentially relevant
studies and economic evaluations from
titles,abstracts and keywords
The abstracts generated by the search for
additional papers relevant to the economic evalu-
ation were assessed by one health economist. This
followed a pilot exercise in which no differences
were found in the abstracts selected when they were
read by two health economists. All possible studies
that were potentially relevant to the economics of
the management of ESRD were identified using 
the same standard form (see appendix 10) used in
the identification of possible RCTs or quasi-RCTs.
These reports were assigned, where appropriate, 
to our six specific topic files and the complete
published paper was obtained.
Quality assessment
Using a similar methodology to that described for
the systematic review of effectiveness, the method-
ological quality of identified studies was assessed by
one health economist (see the economic quality
assessment form in appendix 10).
Data abstraction
A single investigator abstracted data on the
characteristics of participants, interventions 
and outcome measures from each economic
evaluation, study, RCT or quasi-RCT. The 
precise data abstracted depended on the topics. 
In general, information about resource use was
abstracted on the dialysis treatments described,
taking into account their duration and frequency,
incidence of complications, treatment of compli-
cations, time delay before complication occurs,
duration of complication and duration of the
treatment of complications.
When data were required on items of resource use
(i.e. labour, consumables or capital) and on the
occurrence of events with resource consequences,
they were abstracted, if possible from the included
RCTs. When this was not possible, information was
abstracted from the less rigorous studies identified
by the separate economic searches.
Data analysis
The objective of the data analysis was to combine
data on differential resource use with data on
effectiveness obtained from the systematic review 
of RCTs of effectiveness. Data were analysed in 
two stages. First, when economic evaluations were
identified which attempted to address the study
questions, their methods were evaluated and their
results synthesised. Second, the results of the sys-
tematic literature search for studies that reported
data on resource use were combined with the 
data on effectiveness obtained from the systematic
review of RCTs described above. For all reviews,
except for the comparison of CAPD and haemo-
dialysis, the information on resource use and cost
was combined to assess relative efficiency using 
a decision-analysis approach (this is described in
detail in appendices 4–9). For the comparison of
CAPD with haemodialysis, the data from formal
economic evaluations conducted by others 
was synthesised. 
All costs are presented in £UK for the financial 
year 1996/97.Health Technology Assessment 1998; Vol. 2: No.5
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Systematic literature review
Over 12,000 abstracts of published papers 
were considered for inclusion in the review 
of effectiveness. Table 3 summarises:
• where they were first identified
• how many were judged to be possible RCTs
relevant to ESRD
• how many of these were concerned with the
chosen six topics
• how many were confirmed to be RCTs suitable
for inclusion
• how many were considered in the 
economic analysis.
Full details are presented in appendix 3.
Results of searches for RCTs for
assessing effectiveness
The search identified 537 studies as possible 
RCTs relevant to the topics under review, of which
four were conducted in the UK. However, after
assessment of the full published papers of these
studies, only 47 were found to be RCTs in which
any of our predetermined outcome measures for
one or more of the reviews had been considered.
Of these, 34 were found on Medline after reading
5429 abstracts, a further five were found among the
6447 abstracts generated by the systematic searches
of the other electronic databases, and the
remaining eight were found by other means.
Results of economic searches
In the supplementary health economics electronic
searches, a total of 4168 abstracts, additional to
those from the effectiveness search were assessed.
For 820 of these, full papers were ordered as they
appeared likely to contain information. Most 
of these papers were used either to clarify the 
issues around the six questions or for reference
Chapter 4
Summary of results
TABLE 3  Sources of RCTs included in the reviews
Source Number  Number of possible  Number of possible  Number of 
of reports  RCTs relevant  RCTs relevant  RCTs included in 
identified
a to ESRD
b to topics
b,c final review
Medline 5429 1480 243 34
Embase 4764 391 81 4
CINAHL 366 25 10 0
Biosis 1317 189 4 1
Cochrane Library N/A
d N/A
d 20
Subtotal (systematic 
electronic searches) 11,876 2085 340 39
Other databases
e 269 122 9 0
Handsearching 287 133 48 0
Reference lists and experts in the field 56
f N/A
g 140 8
h
Subtotal (all other sources) 612 255 197 8
TOTAL 12,488 2340 537 47
a Some reports were identified from more than one source
b Includes controlled trials with quasi-random methods of allocation
c Relevant to the six selected topics
d A nephrologist searched this database on-screen and selected RCTs/CCTs relevant only to the six topics (for search strategy 
see appendix 2)
e Chemabs,SIGLE,CRIB,and NRR
f Numbers of reference lists checked
g Collected possible RCTs for the six topics only
h Responses from the authors of RCTs and CCTs are currently being assessed;any additional RCTs will be incorporated into later 
versions of the Cochrane systematic reviews.Five RCTs came from reference lists and three from experts in the fieldSummary of results
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when developing the methodology to address 
each question.
Discussion
Although the aim was a highly sensitive but
relatively non-specific search strategy, we were 
still surprised by the number of reports identi-
fied. In respect of RCTs alone, approximately
12,000 abstracts were assessed and this repre-
sented a major undertaking with significant
resource implications for the project group. From
our prior knowledge of the field, we did not expect
to find many RCTs. Although the dividend of only
three RCTs per 1000 abstracts assessed seems
disappointing, the total number of relevant RCTs
identified (47) is somewhat greater than was
expected. However, as described later, the RCTs
tended to be small and of variable quality.
About 70% of relevant RCTs were identified from
the Medline search, which is consistent with experi-
ence in other fields. It confirms that the decision to
search Medline first was correct. The next greatest
yield was from Embase but only about one extra
RCT was found for each 1000 abstracts checked.
The decision to carry out a broad search for
economic studies at the beginning of the review
period also resulted in the assessment of large
numbers of additional papers. However, the time
taken to complete the reviews of effectiveness was
longer than expected, and allowed no time later 
for the more focused economics searches that 
had been initially considered.
In the light of our experience, one option in future
economic evaluations would be to perform a restrict-
ed literature search at the beginning of the review
period, and supplement this by further focused
searches to address any outstanding gaps once the
effectiveness reviews have been completed.
Review 1:Comparison of 
synthetic with cellulose and
modified cellulose membranes 
in the haemodialysis of patients
with ESRD
The full systematic review is presented in 
appendix 4.
Background
The basic principle of haemodialysis is that
products of protein breakdown and water can 
be removed when blood is passed over a semi-
permeable membrane in a dialyser with dialysate
flowing on the other side. Metabolites are removed
mainly by diffusion and water by the application 
of a pressure gradient across the membrane.
Cellulose-based membranes, produced principally
from cotton, were the first membranes produced
for dialysis and, in their standard form, have a low
hydraulic permeability (low flux). Characteristic-
ally, they also have poor clearance of molecules
larger in size than urea and creatinine, and this
may be responsible for some of the clinical features
of uraemia. Because of their poor clearance of b2
microglobulin, it is thought that amyloid disease
may occur more frequently in patients treated with
these membranes. This condition is characterised
by carpal tunnel syndrome, bone and joint disease;
it rarely occurs during the first 5 years of dialysis
but by 12 years it affects 50% of patients.
In recent years standard cellulose membranes have
been modified to make both larger molecule and
water removal more efficient; that is, they can be
manufactured to have a higher flux than was possi-
ble with standard cellulose membranes; such mem-
branes are called modified cellulose, substituted
cellulose or semi-synthetic membranes. In general,
they are more expensive than standard membranes
although this may now be changing.
In the early 1970s, synthetic polymer-based mem-
branes became available. They are usually manu-
factured with high-flux characteristics but can also
be manufactured to have a low flux. They may
remove b2 microglobulin, which may cause dialysis-
related amyloid disease, more effectively, especially
those which have high-flux characteristics. It is of
particular importance to evaluate the benefits of the
synthetic membranes. Although high-flux properties
may be better, they are generally about three to four
times as expensive as cellulose or modified cellulose
membranes. Despite the economic and practical
importance of the choice of dialysis membrane, the
benefits of synthetic membranes are not clear to
nephrologists or to healthcare planners and, if
benefits do exist, can their extra costs be justified.
Objective
The objectives of the study were:
• to determine whether good evidence supports 
the view that synthetic membranes offer clinically
important advantages compared with standard
cellulose or modified cellulose membranes in the
haemodialysis of patients with ESRD
• to determine from the literature the resource-
use implications and relative efficiency analysis
of the use of synthetic membranes.Health Technology Assessment 1998; Vol. 2: No.5
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The hypotheses being tested were that using
synthetic membranes (compared with cellulose 
or modified cellulose membranes):
(i) reduces the frequency of adverse symptoms
during dialysis (symptomatic hypotension,
headaches, nausea and vomiting, pruritus 
and anaphylaxis)
(ii) reduces the number of significant infections
and hospital admissions (including length 
of stay)
(iii) improves dialysis adequacy, as measured by
Kt/V or urea reduction ratio (URR)
(iv) decreases predialysis b2 microglobulin values
and the incidence of amyloidosis
(v) improves the patient’s lipid profile
(vi) improves predialysis albumin and protein
catabolic rate (PCR)
(vii)improves quality of life and patient survival.
Methods
Search strategy, inclusion criteria and methods of
the review are described in chapters 2 and 3 and
appendices 2 and 4.
Results
The inclusion criteria were met by 22 studies; 
data from these were summated by meta-analyses –
Peto’s OR and WMD – and 22 outcome measures
were sought. For two outcome measures, number
of episodes of significant infection per year and
quality of life, no data were available and for one,
URR – a measure of dialysis adequacy – data were
not given in a form that could be analysed. For the
comparison of cellulose with synthetic membranes,
data for 10/19 outcome measures were studied 
in only a single trial. For modified cellulose and
synthetic membranes, 4/7 outcome measures were
each assessed in one trial only and for 12 of the
outcomes no trials were found.
The incidence of nausea and vomiting was signifi-
cantly less with synthetic than with cellulose mem-
branes (OR, 0.62; 95% CI, 0.49, 0.78). Predialysis
b2 microglobulin concentrations were significantly
lower at the end of the studies in patients treated
with synthetic membranes, although all studies
which showed this effect used high-flux synthetic
membranes (WMD, 14.5; 95% CI, 17.4, –11.6).
Similarly, one study showed that the incidence 
of amyloid was less in patients who were dialysed
for a period of 6 years with high-flux synthetic
membranes; no low-flux membranes were used in
this study (OR, 0.05; 95% CI, 0.01, 0.18). Plasma
triglyceride values were lower with synthetic
membranes (high-flux) in the single study that
measured this outcome (WMD, –0.660; 95% CI,
–1.181, –0.139). Serum albumin was also higher 
in patients treated with synthetic membranes
(WMD, –0.111; 95% CI, –0.210, –0.013).
It is therefore difficult to determine whether the
differences found were attributable to the materials
from which the membranes were made or to the
differences in flux. There was no significant differ-
ence between these membranes for any of the
other clinical outcomes measures.
Pruritus occurred less frequently with synthetic
membranes than modified cellulose membranes
(OR, 0.78; 95% CI, 0.66, 0.93); no other differences
were found. The differences between synthetic 
and modified cellulose appeared smaller, although
many fewer trials were carried out for this com-
parison. Economic evaluation showed that these
additional benefits for synthetic membranes 
were achieved at considerable cost.
Conclusions and implications
Policy implications
The authors are hesitant to recommend the
universal use of synthetic membranes for haemo-
dialysis in patients with ESRD on the basis of the
above results because of the small number of trials
(many with low patient numbers), the hetero-
geneity of many of the trials compared, the vari-
ations in membrane flux and the differences in
exclusion criteria, particularly co-morbidity. There
is insufficient information from this review to carry
out a satisfactory economic evaluation. Such evi-
dence as there is favours synthetic membranes over
cellulose membranes but if extra benefit is assumed
it would be at considerable cost, particularly if 
high-flux membranes were to be used. In particular,
little evidence was found of any difference between
synthetic and modified cellulose membranes.
However, the price of high-flux membranes is 
likely to change in the future; hence, policy
recommendations should be kept under review.
Future research needs
Further RCTs are required to compare the
different dialysis membranes available.
They are required to:
(i) take into account reuse of membranes and
other properties, particularly flux, as well 
as the material from which the membrane 
is made, and should include modified cellu-
lose membranes and low-flux synthetic mem-
branes which are less expensive than their
high-flux counterpartsSummary of results
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(ii) record the minimum of data concentrating 
on primary outcomes of major importance 
to patients
(iii) explicitly record whether the symptoms used 
as outcome measures are patient or staff
reported, while recognising that, in general,
patient-reported data will be more appropriate
for evaluating effectiveness but staff-reported
data may be necessary for calculating the cost
of treating complications
(iv) be multicentre (and possibly multinational) 
in order to have sufficient patients to com-
plete the study and allow for withdrawals 
and drop-outs
(v) have sufficient length of follow-up to draw
conclusions about important clinical outcome
measures and continue to follow-up patients
who have undergone transplantation
(vi) include older patients and those with 
co-morbid illnesses, and take age and 
co-morbidity into account when assessing
outcomes (possibly by stratification at 
trial entry)
(vii)carry out an economic evaluation.
Review 2:Comparison of
bicarbonate-buffered with
acetate-buffered dialysate in
haemodialysis as treatment 
for patients with ESRD
The full systematic review is presented in 
appendix 5.
Background
Bicarbonate has largely replaced acetate dialysate
in the haemodialysis of patients with ESRD in the
UK, on the assumption that it significantly reduces
intradialytic adverse symptoms and improves
haemodynamic stability.
Objective
The objective of this review was to compare
bicarbonate with acetate haemodialysis in patients
with ESRD and to assess whether there is evidence
of improved patient outcome to support its
adoption as the dialysate of choice. The cost
implications of using bicarbonate haemodialysis
instead of acetate haemodialysis were also to be
examined. The hypotheses being tested were 
that bicarbonate haemodialysis:
(i) reduces the frequency of adverse 
symptoms during dialysis compared 
with acetate haemodialysis
(ii) improves cardiovascular stability during dialysis
compared with acetate haemodialysis
(iii) improves the patient’s lipid profile compared
with acetate haemodialysis
(iv) slows the progression of renal bone disease
compared with acetate haemodialysis.
Methods
Search strategy, inclusion criteria and methods 
of the review are described in chapter 2 and in
appendices 2 and 5.
Results
The inclusion criteria were met by 18 studies and
data from these studies were synthesised using
meta-analyses. There was a significant reduction
with bicarbonate dialysis in the number of haemo-
dialysis treatments complicated by headaches (OR,
0.84; 95% CI, 0.71, 0.99), nausea/vomiting (OR,
0.42; 95% CI, 0.26, 0.66), symptomatic hypotension
(OR, 0.28; 95% CI, 0.11, 0.69) and non-specific
intolerance (OR, 0.79; 95% CI; 0.67, 0.93). There
was a lack of clear evidence of benefit from
bicarbonate dialysis in terms of improved cardio-
vascular stability, lipid profile and indicators of 
renal bone disease.
Conclusions and implications
Policy implications
1. Bicarbonate dialysis is preferable to acetate
dialysis for the haemodialysis of patients with
ESRD because of its associated reduction in
intradialytic adverse symptoms and similar cost.
2. In those countries with less well-financed 
renal replacement services, who continue to
depend on haemodialysis machines that can
only use acetate dialysate, replacement of 
their machines with those that can use either
dialysate should be encouraged as replace-
ments are required. However, the cost to 
their healthcare systems of a complete rapid
change to new dialysis machines or modifi-
cation of all their present machines would 
not be warranted on the basis of the relatively
modest benefits which bicarbonate dialysis
offers. The benefits of such changes need to 
be considered in terms of their opportunity
cost and this will vary from country to country.
The provision of information on the costs and
benefits of such a change provided in this
review should assist in the estimation of such
opportunity costs.
Future research needs
Methodologically sound clinical trials with long-
term follow-up comparing bicarbonate with acetate
haemodialysis are rare. We should continue to Health Technology Assessment 1998; Vol. 2: No.5
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be open-minded about the possible beneficial 
or adverse effects that bicarbonate dialysis may 
have on long-term outcomes such as lipid profile 
and cardiovascular disease, renal bone disease 
and morbidity.
Any further RCT at this stage is unlikely to produce
significantly different data from that which exists
already and is therefore unlikely to change 
clinical practice.
Review 3:Comparison of 
short duration with standard
duration haemodialysis as
treatment for patients 
with ESRD
The full systematic review is presented in 
appendix 6.
Background
Shortening haemodialysis treatment time is
welcomed by the patient and is seen by the health-
care purchaser as an improved use of resources.
Technological advances, coupled with patient pres-
sure and pressure on costs, led to the development
and implementation of shortened dialysis schedules,
particularly in the USA. However, the annual mor-
tality among dialysis patients in the USA began to
increase as the average dialysis treatment times
decreased. If short dialysis is at least comparable 
to standard dialysis in terms of clinical outcome, 
it should be offered to all appropriate patients. If,
however, it has significant disadvantages compared
to standard dialysis, either in the short or long term,
those patients to whom it is being offered should 
be made aware of the potential trade-off.
Objective
The objective of this review is to ascertain the 
effect of short haemodialysis treatment duration 
(> 3.5 hours) on patient morbidity and mortality,
assuming a treatment frequency of three per week.
It also attempts to assess patient preference and 
the impact of shortened treatments on healthcare
resource use.
Methods
Search strategy, inclusion criteria and methods of
the review are described in chapters 2 and 3 and 
in appendices 2 and 6.
Results
Only a single study by Lowrie and colleagues
(1983) with 165 randomised patients was identified.
There was no significant difference in mortality
(OR, 0.53; 95% CI, 0.05, 5.15). Morbidity as
reflected by hospitalisation rates was greater in 
the short-duration dialysis group (OR, 2.85; 95%
CI, 1.39, 5.85). There was no conclusive differ-
ence in the incidence of intradialytic adverse
symptoms between the groups. Blood pressure
control was worse in the short-duration dialysis
group as indicated by predialysis systolic blood
pressure (mean difference, 7.5 mmHg; 95% CI, 
3.1, 11.8), predialysis diastolic pressure (mean
difference, 2.9 mmHg; 95% CI, 0.5, 5.2), and
predialysis mean arterial blood pressure (mean
difference, 3.4 mmHg; 95% CI, 0.0, 6.9).
Conclusions and implications
Policy implications
1. Current evidence from this North American
study offers little reassurance that short-
duration dialysis (≤ 3.5 hours, three times per
week) is as effective as standard dialysis. There
is no evidence that reduced dialysis duration
improves patient outcome in terms of mor-
tality and morbidity. It may, in fact, increase
morbidity as reflected by increased hospital-
isation and poorer blood pressure control.
From this it is concluded that ‘standard’
dialysis duration (> 3.5 hours, three times 
per week) should remain the recommended
treatment. It should be noted that no study 
was found that compared the longer duration
dialysis that is the norm in Europe.
2. If a reduced dialysis duration regimen is
implemented on the basis of patient prefer-
ence or assumed lower cost, its unproven safety
should be explicitly acknowledged.
Future research needs
1. One or more large, multicentre, pragmatic
RCTs comparing haemodialysis treatment
duration policies are required. Such a trial
should include the longer duration haemo-
dialysis practised in Europe, have minimum
exclusion criteria, a long follow-up period and
minimum data collection that concentrates
primarily on patient morbidity and mortality.
The follow-up should include patients who
withdraw (for example, for renal transplant-
ation) and all patients should be followed for a
period after trial completion to assess residual
effect on mortality and morbidity. Key primary
outcomes such as mortality should be analysed
on an intention-to-treat basis. Avoidance of
collection of secondary outcome data should
reduce the complexity of such a trial. Dialysis
therapy and the overall treatment of ESRD
within such a trial should be to the highestSummary of results
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standard as recommended by the best 
available evidence.
2. If such a trial showed no advantage with stand-
ard duration dialysis, short-duration dialysis
should be the recommended treatment option.
3. The HEMO RCT, comparing high- and low-
flux membranes and the ability to achieve a
given Kt/V, is at present under way. It may
address some of the above questions. This
should be taken into account when the
research agenda is decided.
Review 4:Comparison of CAPD
delivery systems – Y-set/modified
Y-set versus standard spike as
treatment for patients with ESRD
The full systematic review is presented in 
appendix 7.
Background
CAPD is an alternative to haemodialysis for patients
with ESRD. It may be used as the first choice ther-
apy and, in a number of countries, more patients
are treated by this modality of treatment than by
haemodialysis. Catheter and transfer set types,
insertion techniques, and peri- and post-operative
management display significant variation.
There are two main types of catheter 
connecting systems:
(i) the standard or straight connecting system in
which the catheter is connected with a straight
piece of tubing, which in turn is connected to
the dialysate bag. At each exchange the bag is
drained and a new connection is made. The
empty bag is rolled up and remains attached
until the next exchange when the process 
is repeated
(ii) the Y-set in which the patient is disconnected
from bags between exchanges and, when a new
exchange is due, a Y-connection is used, with
one limb connected to an empty bag and one
to a bag containing fresh dialysate. The peri-
toneal dialysate is first drained into the empty
bag. Before introducing the new fluid, the Y-
connector is flushed with fresh dialysate into
the drained bag, which allows any bacteria to
be flushed into the spent fluid. The fresh fluid
is then introduced into the peritoneal cavity
and the connector removed from the catheter.
At present about 40% of CAPD patients in the 
UK use this connecting system (data from the
National Registry provided at the Renal 
Association meeting, 1997).
Objective
The aim of this review is to describe the best
practice for CAPD-connecting systems, insofar 
as present evidence allows, and to indicate where
future research should be concentrated.
The hypothesis being tested was that the 
Y-connector/modified Y-connector was asso-
ciated with fewer episodes of peritonitis than 
the standard connector in patients on CAPD.
Methods
Search strategy, inclusion criteria and methods of
the review are described in chapters 2 and 3 and in
appendices 2 and 7.
Results
Six studies met the inclusion criteria and results of
these studies were synthesised using meta-analysis.
The Y-set/modified Y-set significantly reduced the
incidence of CAPD-related peritonitis compared
with standard non-Y-set connection systems. There
was no difference in the incidence of exit-site
infections between the two methods.
The number of patients who experienced at 
least one episode of peritonitis in all the studies
combined was significantly lower in patients using
the Y-set delivery systems (57/194 versus 107/201;
OR, 0.30; 95% CI, 0.23, 0.53) compared with those
assigned the non-Y-set system. Only one study
(Cheng, et al., 1994 – see appendix 7) did not show
this effect, although all studies demonstrated a
significant increase in the number of months per
episode of peritonitis. No study provided standard
deviations for this statistic and, hence, a WMD
could not be obtained. All studies also showed 
that the time to first peritonitis was longer with 
the use of Y-set/modified Y-set systems.
There was no evidence of significant reduction in
the number of patients who suffered exit site infec-
tion or tunnel infections with the Y-set (39/162
versus 44/171; OR, 0.87; 95% CI, 0.51, 1.48).
Conclusions and implications
Policy implications
Peritonitis is one of the main complications of 
CAPD and is known to lead to morbidity, technique
failure and mortality. Based on the results of this
review, there is insufficient evidence to support the
continued use of non-Y-set connecting systems in
CAPD. The economic evaluation of this reviewHealth Technology Assessment 1998; Vol. 2: No.5
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reveals that the use of a Y- or modified Y-set
connector imposes an incremental cost of approxi-
mately £900 to £3900 per patient per year, based on
low and high cost estimates. Preventing one episode
of peritonitis would cost approximately £4700 per
case of peritonitis avoided. However, there was wide
variation in this estimate, which depended on the
relative probability of peritonitis episodes.
The Y-set delivery system significantly reduces 
the incidence of peritonitis. Given that recurrent
peritonitis is a major course of technique failure,
the additional cost is likely to be justified.
Future research needs
Peritonitis remains a major problem in CAPD and
further research into methods of prevention of this
complication is required.
Evidence of the effect of technique failure on
patient outcomes and costs would further inform
the evidence concerning the use of Y-set systems.
Review 5:Comparison of CCPD
with CAPD as treatment for
patients with ESRD
The full systematic review is presented in 
appendix 8.
Background
CAPD is an alternative to haemodialysis for patients
with ESRD. Dialysate fluid is drained into and then
out of (exchange) the peritoneal space using a
surgically-placed permanent catheter in the abdom-
inal wall. These exchanges are performed four times
daily. One of the major complications of the tech-
nique is peritonitis. CCPD is a modification of this
technique in which exchanges are performed over-
night by a machine and it has recently been pro-
posed as an alternative for all patients suitable for
chronic peritoneal dialysis. It has also been suggest-
ed that it may decrease the incidence of peritonitis.
Objectives
The objectives of this study were to undertake a
systematic literature review comparing CCPD with
CAPD, while testing the following hypotheses with
which CCPD is associated:
(i) reduced incidence of dialysis-associated
infections
(ii) improved adequacy of dialysis
(iii) reduced incidence of technique failure
(iv) increased patient preference for the technique
(compared with CAPD).
Methods
Search strategy, inclusion criteria and methods of
the review are described in chapters 2 and 3 and 
in appendices 2 and 8.
Results
Only a single study involving 82 patients met 
the inclusion criteria. Results are expressed 
as ORs and WMDs. There were no significant
differences in the number of patients with
peritonitis (OR, 0.56; 95% CI, 0.24, 1.33), 
catheter exit-site infections (OR, 1.13; 95% CI,
0.43, 2.94) or catheter-tunnel infections (OR,
0.5; 95% CI, 0.05, 4.99). However, when infective
complications were reported as episodes per
patient year, the study demonstrated a reduced
mean incidence per patient year of peritonitis –
CCPD, 0.51; CAPD, 0.94 (p = 0.03). There was 
no significant difference in measures of dialysis
adequacy, such as Kt/V (WMD, 0.40; 95% CI, 
–0.23, 1.03) and 6-monthly serum creatinine, 
urea and phosphate. Though fewer patients 
on CCPD needed to change dialysis technique 
this was not statistically significant (OR, 0.48; 
95% CI, 0.18, 1.26).
Because this was a parallel group trial design,
patient preference could not be adequately
assessed. We estimated that the cost per 
episode of peritonitis avoided by using CCPD 
was £21,000.
Conclusions and implications
Policy implications
The review indicated that CCPD showed benefit 
for one patient outcome but is more expensive
than CAPD. The authors suggest that, at present,
CCPD is offered to patients for whom there is a
specific indication. However, patient preference 
is likely to be important here.
Future research needs
1. Further RCTs are required which compare
CCPD with CAPD with particular reference 
to peritonitis, technique failure rates and
patient preference. If these confirm 
the reduced peritonitis rate of CCPD, 
then it may need to be considered as 
the preferred chronic peritoneal 
dialysis option.
2. More widespread use of CCPD may have
significant resource-use implications. 
Future RCTs should include a thorough
economic evaluation to provide more
information on whether any additional
benefits are worth the additional resources
that CCPD, relative to CAPD, may require.Summary of results
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RCTs and economic evaluations are required to
compare CCPD with haemodialysis to determine
whether it is efficient to provide CCPD for those
patients who have a relative contraindication 
to CAPD and would otherwise be treated 
by haemodialysis.
Review 6:Comparison of
haemodialysis with CAPD 
as treatment for patients 
with ESRD
A full systematic review is presented in appendix 9.
Background
Patients with ESRD require either dialysis 
(haemo- or peritoneal dialysis) or renal transplant-
ation to maintain life. Transplantation is normally
considered to be the preferred choice but there 
are insufficient donors to meet the demand. There-
fore, for those patients for whom transplants are
unavailable or who are unsuitable for transplant-
ation, there is the question of which mode of
dialysis should be used.
Objective
The objective was to ascertain if there is clear
evidence for the increased effectiveness of haemo-
dialysis compared with CAPD for all patients with
ESRD, or a particular subgroup of patients with
ESRD. It was also the aim to ascertain the relative
costs of haemodialysis and CAPD and to combine
this information with the information on effective-
ness to determine which of these modalities is the 
more efficient.
Methods
The methodology used to answer this question is
described in detail in chapter 3. In addition, the
systematic review of ‘economic aspects’ identified
formal economic evaluations that had tried to
assess the relative efficiency of CAPD and haemo-
dialysis. The results of these economic evaluations
were summarised to provide an overall view of the
current evidence of the relative efficiency of these
two modes of treatment.
Results
No RCTs were identified that compared CAPD 
with haemodialysis. The economic evaluations
identified made assumptions on the basis of data
from poor quality study designs that CAPD is
cheaper than haemodialysis and, in some cases,
that haemodialysis provides better patient survival.
Because of the poor quality of the study designs
used to obtain primary data, it is not possible to
judge whether the assumed extra benefits provided
by haemodialysis are worth any extra costs that 
may be incurred.
Conclusions and implications
The issue facing the health service is not whether
to have CAPD or haemodialysis but rather the
balance of provision between the two modalities.
We know from variations in uptake of these tech-
niques in different countries that a large propor-
tion of patients requiring dialysis for ESRD could
be managed with either CAPD or haemodialysis
initially. What is required is information about the
relative costs, benefits and risks of policies of start-
ing with one or other modality. In this respect, it
should be possible to develop a more detailed
model based upon observational data. Ideally,
information on benefits and risks should come
from comparisons, within a pragmatic RCT, of
policies based on starting with CAPD or
haemodialysis, as used in the UK.
Data are not available to allow reliable conclusions
to be drawn about the relative effectiveness and
efficiency of haemodialysis and CAPD.
If an assumption is made of equal effectiveness in
terms of survival then the limited data available
favour CAPD.
Although some studies have assumed that a policy
of starting with haemodialysis is more effective 
than a policy of starting with CAPD, it is not
possible to quantify reliably with current data 
this extra benefit and, hence, it is not possible 
to determine whether haemodialysis is worth any
extra cost that may be incurred. This issue would 
be resolved most reliably by a pragmatic RCT 
that includes a formal economic evaluation com-
paring the two policies. Currently, Baxter Ltd 
are attempting to undertake a RCT in this area
(Personal communication, 1997).
The implications of policies based on starting 
with haemodialysis rather than on CAPD are more
complex than described in previously reported
economic evaluations. An attempt at a more sophis-
ticated economic model is described in appendix 9.
The results obtained using this model are, however,
inconclusive, because of the poor quality of 
the data.
The development of new methods of dialysis, such
as CCPD, and the advances in renal transplantation
techniques warrant additional evaluation to investi-
gate their place alongside haemodialysis and CAPD
in the treatment of ESRD.Health Technology Assessment 1998; Vol. 2: No.5
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T
he management of ESRD was one of the first
priorities identified in the NHS R&D Health
Technology Assessment Programme. The original
1994 commissioning brief, which led to the work
reported here, called for a systematic review of
ESRD, “concentrating on the effectiveness and 
cost-effectiveness of alternative schedules of con-
ventional haemodialysis and CAPD”. Given the
complexity of the issues involved, and the limited
time and resources available, we chose to concen-
trate on what were judged to be key ‘decision
points’ in the management of ESRD. The choice
was made after developing a dialysis decision tree
(see Figure 1) and six topics were selected. There
are, therefore, many aspects of the management 
of ESRD which are not addressed directly in this
study (although an attempt was made to consider
some of these, such as co-morbidity, indirectly).
This is not then a comprehensive systematic 
review of the management of ESRD.
The reviews were performed systematically in the
sense that there were explicit search strategies,
explicit selection criteria for the studies considered,
explicit data extraction protocols and explicit
methods for data synthesis. In other words, it would
be expected that repetition of this study would be
likely to lead to similar findings. The reviews were
not, however, comprehensive in the sense that all
types of evidence were considered. It was judged that
protection from the distorting effects of selection
and other biases was likely to be most secure if our
reviews were limited to RCTs and so other study
designs were not considered systematically (other
than in the review of economic analysis of haemo-
dialysis compared with CAPD). When this decision
was taken, we were aware of the argument that some
well-conducted non-randomised cohort studies may
be less prone to bias that poor quality RCTs. Never-
theless, it was decided that it was important to iden-
tify and assess all RCTs first; also, we realised that we
did not have the resources to identify studies using
other research designs systematically, partly because
of the work involved in finding the RCTs and partly
because the methods for finding well-conducted
observational studies are not well developed.
In an attempt to avoid duplication of effort, a
broad search for RCTs related to the management
of ESRD in general was undertaken rather than
searches restricted to just the six topic areas form-
ally covered. We were fortunate to be able to draw
on the search strategy developed for this purpose
by the Cochrane Collaboration, although this did
need extensive adaptation for use on databases
other that Medline. The aim was for a sensitive
search to identify as complete a register of relevant
trials as possible. In retrospect, the size of this task
was underestimated, particularly in respect of the
relatively poor specificity that this decision implied.
In the event, about 12,500 abstracts were assessed
(see Table 3) in order to identify the 47 RCTs
considered in the six reviews.
Despite these efforts, it is possible that a few
relevant RCTs have not been included: non-English
language databases were not searched; ‘grey
literature’ has been covered to only a limited
extent; Science Citation Index has not been fully
used; the Internet has not been fully explored, and
hand-searching has been limited. It is difficult to
estimate how many relevant RCTs may have been
published in non-English language journals or are
non-European based RCTs missed in the searches;
no language limits were used when searching the
electronic databases and, where possible, non-
English papers were translated to clarify, first, if
they were RCTs and, second, if they were relevant
to the six topics (so far only nine possible RCTs
identified from the searches have not been trans-
lated; 22 papers were translated). It has not been
possible to estimate the size of the renal literature
in, for example, Japan (where the Cochrane 
Stroke Group found 25% of its RCTs); a search 
of Medline (1993–November 1997) found almost
3000 possible RCTs related to ESRD and dialysis, 
of which 47 were in Japanese and a further 149, 
in languages other than Japanese, were by authors
based in Japan. Contact with the authors of the 
one Japanese study included in the reviews and
with other authors based outside Europe did not
identify any new relevant RCTs in any language.
Also, responses are still being received from
authors of abstracts and articles clarifying their
study methodologies and suggesting other possible
RCTs; hence, it has not been possible to consider
these here. It was partly for this reason that the
reviews were written using the Cochrane format.
This will allow them to be updated easily as and
when further RCTs are identified.
Chapter 5
DiscussionDiscussion
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We were fortunate to be given access to all the
resources of the Cochrane Collaboration at a time
when there was no formal Cochrane Renal Group.
(This was subsequently established in 1997 with one
of us, Alison MacLeod, as an editor.) The use of the
customised software, Review Manager, made the
task much easier, with the one limitation that some
forms of data, such as medians, cannot yet be
combined statistically using its meta-analysis
program, Meta-view.
In contrast to some areas of clinical practice, such
as cancer, heart disease, and prenatal medicine, the
management of ESRD has not been characterised
by large collaborative RCTs. The 47 relevant RCTs
found were, therefore, as large a number as we had
originally hoped for. Nevertheless, their value is
limited. One reason is that they did not cover the
six topics uniformly (see appendix 3, Table 5).
Whereas 22 studies compared alternative haemo-
dialysis membranes, none addressed what is argu-
ably the most important question, the comparison
of haemodialysis with CAPD (topic 6). Another
reason for their limited value is that the 47 trials
were of variable but generally poor quality. Many
were poorly reported making it difficult to judge
the methods used. Details of attempts to avoid 
bias, such as methods of randomisation or analyses,
were often not available. When it was possible to
judge, the methods were often sub-optimal. Drop-
outs were common following changes in clinical
management and yet intention-to-treat analyses
were the exception rather than the rule. Also, 
the issue of appropriate censoring of data after
transplantation was often not considered.
Most trials included small numbers of participants,
so that estimates of effects were often imprecise,
particularly for dichotomous variables. Even after
combining data, where possible, from more than
one trial, the CIs for these estimates were often so
wide that it was frequently not possible to rule out 
a clinically important difference, even when the
point estimate suggested that there was none. (To
put this another way, lack of statistical significance
could not be taken as ‘no clinically significant
difference’ in many comparisons.)
Another concern when reviewing small trials 
such as those included in these reviews is the pos-
sibility that selective publication of the results of
small trials which showed ‘statistically significant
differences’, combined with the failure to report
less promising results of other small trials, may 
lead to important publication bias. Contact with 
the authors of the included RCTs and with manu-
facturers did not uncover unpublished RCTs. This
may mean that these data do not exist or that con-
tacts were unwilling to release details or were not
aware of the importance of unpublished results to
the systematic review process. For the majority of
outcomes, there were too few trials to explore the
impact of publication bias formally, for example,
using a funnel plot. For a small number of out-
comes, however, the construction of a funnel plot
was possible. For example, within the comparison 
of bicarbonate with acetate dialysate, funnel 
plots could be constructed for the outcomes of
patients experiencing headaches and nausea/
vomiting. These are presented in Figures 4 and 5. 
A publication bias effect is suggested because 
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FIGURE 4  Funnel plot for bicarbonate versus acetate dialysate – patients experiencing headachesHealth Technology Assessment 1998; Vol. 2: No.5
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there are no small trials reporting in favour of the
control treatment. The interpretation of the results
of small trials for the comparison of bicarbonate
versus acetate dialysate should, therefore, be treated
with caution. A similar effect is seen in the funnel
plot for peritonitis episodes for the comparison 
of Y-set versus standard spike delivery systems in
CAPD (Figure 6). For the comparison of synthetic
versus cellulose membranes for symptomatic/
treatment requiring hypotension, however, 
there was no evidence to suggest publication 
bias, with comparable representation of both
positive and negative results among the small trials
(Figure 7).
A related concern is selective reporting within 
the 47 RCTs of outcome data that are statistically
significant. It is not reassuring in this respect that
data are available from only a minority of relevant
trials for many comparisons in the reviews.
The generalisability of the trials is also limited.
Their eligibility criteria were usually restrictive
(aiming to study a tightly defined group of patients)
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FIGURE 6  Funnel plot for Y-set versus standard spike delivery system – patients experiencing peritonitisDiscussion
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and they were mostly conducted at single centres.
They also tended to concentrate on short-term
surrogate measures of outcome, such as bio-
chemical measures of dialysis adequacy, rather than
parameters directly relevant to patients, such as
quality of life, treatment complications and survival.
This latter consideration applied, in particular, to
crossover design trials. In a chronic condition such
as ESRD, randomised crossover designs appear
attractive but their value is limited because they
cannot be used to assess the longer-term conse-
quences of alternative approaches to care.
The style of the trials was therefore explanatory
rather than pragmatic. They tended to test specific
hypotheses about efficacy, rather than compare the
effectiveness of alternative policies for dialysis, which
incorporate changes in management when clinically
indicated. Whereas explanatory trials are useful for
exploring new developments in dialysis in an ‘ideal’
setting, they are of limited value for assessing alterna-
tive approaches to dialysis that might be used within
the NHS in terms of outcomes, including costs, that
are most important to patients, providers and
purchasers. Pragmatic designs are needed for this.
An important point to consider in an economic
evaluation is that costs are subject to economies 
of scale. Generally speaking, the more units of 
a product that are purchased the cheaper the 
unit price becomes. In the economics analyses
contained in this report, this has been taken into
account by using, where possible, average selling
prices which tend to be less than manufacturers’
quoted ‘list’ prices. However, this provides only 
an indication of possible economies of scale. For
any local situation, information on resource use
contained in each of the economic evaluations 
can be combined with local data on prices. One
can then judge whether the local costs are worth
the benefits that they provide.
Reflecting our wish to inform patient care within
the NHS, the systematic reviews have incorporated
economic evaluations. Although it is important to
determine which interventions are most effective, 
it is increasingly widely recognised that this must 
be balanced against the relative costs and cost con-
sequences of alternative interventions. An economic
evaluation relates cost to effectiveness. The RCTs
appropriate to our topics, although providing 
some information on effectiveness, were found 
not to provide adequate costing data to allow a 
full evaluation to be made. In our economic eval-
uations, data from the reviews of randomised trials
were used, where possible, to estimate resource 
use associated with the initial interventions and
differential rates of measures of effectiveness with
resource consequences (expressed as adverse
events, such as complications). When such data
were not available, use was made of cost data from
the less methodologically rigorous studies identified
by our separate ‘economics literature search’.
These studies were also used to obtain estimates 
of the magnitude of resources used in each option
evaluated (unless more accurate data could be
obtained from UK-based costings). Reflecting 
the lack of pragmatic trials of different starting
therapies, neither long-term cost data nor 
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FIGURE 7  Funnel plot for synthetic versus cellulose membranes – patients experiencing symptomatic or treatment-requiring hypotensionHealth Technology Assessment 1998; Vol. 2: No.5
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long-term estimates of probabilities of switching
between modes of treatment were available.
The results of the economic evaluations have 
been constructed around a ‘standard’ patient. 
It is possible that there are definable subgroups 
of patients for whom the costs and benefits may
vary substantially from the standard. Although 
this is a recognised issue in economic terms8 there
are insufficient data available to perform reliable
subgroup analyses. The framework developed 
and the information presented currently provide,
therefore, the best available evidence on which 
to base judgements about treatments in 
definable subgroups.
In certain of the economic evaluations, the analysis
is constrained because the ‘lifetime’ costs of treat-
ment have not been identified. The economic
evaluation of alternative forms of CAPD delivery
systems was the principal evaluation where this type
of cost data would have been useful. Unfortunately,
the necessary data on, for example, the prob-
abilities of patients dying or switching modalities
were not available, and it was considered that 
this information could not be abstracted in a
sufficiently robust form from a non-randomised
study to make extending the analysis in this way
worthwhile. However, when reliable data were
obtainable and the type of analysis was appropriate,
for example, for the comparison of CAPD and
CCPD, patient lifetime costs were calculated.
For all the reasons outlined above, the value 
of this work is limited by the material available 
to us from relevant previous primary research.
Nevertheless, the reviews do provide clear guid-
ance for patients, providers and purchasers on
some of the six key decisions:
• choice of dialysate for haemodialysis
• duration of haemodialysis
• choice of catheter in CAPD
and provide a basis for an informed decision 
where a judgement has to be made between
possible greater effectiveness and greater cost:
• choice of membrane for haemodialysis
• use of CCPD.
They also demonstrate to those who commission
and perform research where further research 
is needed:
• choice of membrane for haemodialysis
• duration of haemodialysis
• further evaluation of CCPD
• choice between haemodialysis and CAPD as the
initial modality for patients starting dialysis.
As indicated earlier, information about effective-
ness and efficiency is necessary but not sufficient
when making decisions about health care. We have
already alluded to the changing health needs of the
population served by the NHS and the particular
requirements and preferences of some of the
patients with ESRD. Data from renal registries
describing those currently receiving long-term
dialysis and their management will clarify the
applicability of our findings and the potential for
change. For example, bicarbonate as a buffer in
haemodialysis is already used in most renal units.
There may be criticisms that much time and effort
has been used in some of these reviews to confirm
what clinicians have felt about some aspects of
treatment for some time; again, the use of bicar-
bonate is an example. A formal systematic review,
however, can give that argument conviction, set it
in the context of cost and prevent further expen-
sive unnecessary studies being carried out. When
the review began, scarcely any similar work had
been carried out in the subject area of renal
disease, particularly ESRD. Our group was truly
multidisciplinary including nephrologists, health
services researchers, health economists and
librarians and information officers. The whole
group met weekly and we consider that this
successful integration of the various types of
expertise and skills is manifest in this report.
Despite the involvement of experienced health
service researchers, nephrologists and health
economists, it took time to define the best search
strategy and we were surprised that our search
yielded as many as 12,000 abstracts. This sort of
exercise will, however, be significantly easier in 
the future. The Cochrane Collaboration will be
performing broad searches of all the principal
electronic databases for all RCTs, irrespective 
of subject area. Possible RCTs identified in this 
way will contribute to a new register (CENTRAL)
within the Cochrane Library and so, in the future,
it will only be necessary for groups of researchers 
to search the CENTRAL register for trials relevant
to a particular subject area. We do plan to dis-
seminate our findings actively. The reviews are
likely to have the greatest influence on 
professional groups.
Nephrologists have The Renal Association 
as a platform for dissemination and discussion, 
and the Department of Health and its equivalents Discussion
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at the Scottish and Northern Ireland Offices 
also have wide-ranging information 
dissemination systems.
The Renal Association (in conjunction with the
Royal College of Physicians of London) has pro-
duced a document, Treatment of adult patients with
renal failure – recommended standards and outcome
measures.18 The results of systematic reviews such 
as this should, after discussion with all interested
groups, inform these standards. Similarly, we hope
that our findings will influence any later versions 
of the recently published Review of renal services 
in England by the Department of Health19 and
appear in peer-reviewed journals. In this way the
evidence gathered is more likely to be put into
practice, and the process will be seen not as a
threat but as an opportunity to provide optimum
care for patients with ESRD.
This work is not seen as a ‘once-and-for-all’
exercise. The six reviews will be submitted for
publication in the Cochrane Database of Systematic
Reviews, and regularly updated thereafter as new
evidence becomes available. Also, the other RCTs
that have been identified in the broad searches 
will be contributed to the Cochrane Collaboration,
thus facilitating the systematic review of RCTs 
of other aspects of dialysis.
The project has highlighted the paucity of RCTs
that usefully inform the key issues on the effective-
ness and, hence, provision of NHS dialysis services
for ESRD that were identified in the original com-
missioning brief. Ideally, the NHS needs evidence
from large pragmatic trials comparing the manage-
ment policies used in many renal units over a range
of types of patient. This will require a culture shift
away from the current explanatory style of research,
investigating underlying mechanisms of dialysis in
small groups of patients in single centres, to simply
designed collaborative trials evaluating the longer-
term impact of alternative dialysis policies on
patients and the health service.Health Technology Assessment 1998; Vol. 2: No.5
27
T
hose reviews were supported by the 
NHS R&D Executive’s Health Technology
Assessment Programme.
The authors would like to acknowledge the
considerable help of staff in the Medical School
Library of the University of Aberdeen.
We would also like to thank Dr Iain Chalmers and
the staff of the UK Cochrane Centre for their
advice prior to the formation of the Cochrane
Renal Review Group.
The authors also acknowledge the contribution of
Ms Elizabeth Kirby, who performed the Markov
modelling presented in appendix 9.
Finally, we also owe our thanks to the referees for
their perseverance in reading the report and the
quality of their comments.
AcknowledgementsHealth Technology Assessment 1998; Vol. 2: No.5
29
1. Kramer P, Broyer M, Brunner FP, Brynger H,
Donckerwolcke RA, Jacobs C, et al. Combined
report on regular dialysis and transplantation in
Europe, 1983. In: Proceedings of European Dialysis
and Transplantation Association, XIV, 1984:2–68.
2. Khan IH, Catto GRD, Edward N, MacLeod 
AM. Chronic renal failure: factors influencing
nephrology referral. QJM 1994;87:559–64.
3. Feest TG, Mistry CD, Grimes DS, Mallick NP.
Incidence of advanced chronic renal failure 
and the need for end-stage renal replacement
treatment. BMJ 1990;301:897–900.
4. Roderick PJ, Jones I, Raleish V, McGeown M,
Mallick NP. Population need for RRT in Thames
regions: ethnic discussion. BMJ 1994;309:1111–14.
5. Knolph KD, Henderson LW. Editorial. 
Kidney Int 1993;43 (suppl 40):S1–3.
6. Nissenson AR, Prichard SS, Cheng IK, et al. Non-
medical factors that impact on ESRD modality
selection. Kidney Int 1993;43 (suppl 40):S120–7.
7. Mallick NP. What do we learn from the European
Registry: what will be the underlying problems in
the year 2000? Nephrol Dial Transplant 1995;10
(suppl 7):S2–6.
8. Beech R, Mandalia S, Melia J, Mays N, Swan A.
Purchasing services for end stage renal failure: the
potential and limitations of existing information
sources. Health Trends 1993;25:60–4.
9. Mulrow CD, Oxman AD (editors). Cochrane
Collaboration handbook [updated 1 March 1997].
In: The Cochrane library [database on disk and 
CD-ROM]. Oxford: Cochrane Collaboration: 
update software; 1996–97.
10. Deeks J, Glanville J, Sheldon T. Undertaking
systematic reviews of effectiveness: guidelines for
those carrying out or commissioning reviews. York:
CRD Publications, 1996.
11. Mulrow CD, Oxman AD (editors). Developing 
a protocol. Cochrane Collaboration handbook
[updated 1 March 1997]: Section 3. In: The
Cochrane library [database on disk and 
CD-ROM]. Oxford: Cochrane Collaboration: 
update software; 1996–97.
12. Dickersin K, Scherer R, Lefebvre C. Identifying
relevant studies for systematic reviews. BMJ
1994;309:1286–91.
13. Berlin JA (on behalf of the University of
Pennsylvania Meta-analysis Blinding Study Group).
Does blinding of readers affect results of meta-
analysis? Lancet 1997;350:185.
14. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta
blockade during and after myocardial infarction: 
an overview of the randomized trials. Prog Cardiovasc
Dis 1994;27:335–71.
15. Berlin, JA, Laird NM, Sacks HS, Chalmers TC. 
A comparison of statistical methods for combining
event rates from clinical trials. Stat Med
1989;8:141–51.
16. Thompson SG. Why sources of heterogeneity 
in meta-analysis should be investigated. 
BMJ 1994;309:1351–5.
17. Mooney G., Economics, medicine and health 
care. 2nd edition. New Jersey: Harvester
Wheatsheaf, 1992.
18. Renal Association/Royal College of Physicians 
of London. Treatment of adult patients with 
renal failure – recommended standards 
and audit measures. London: RCP 
Publications, 1995.
19. NHS Executive. Review of renal services and renal
purchasing guidelines. London: NHS Executive,
1996. EL96/35.
ReferencesHealth Technology Assessment 1998; Vol. 2: No.5
31
T
his appendix provides background
information on renal failure and describes 
the services available for its treatment. It has 
been adapted from Renal purchasing guidelines 
EL 96/35, published by the NHS Executive in 
May 1996, and is reproduced with permission.
Renal disease
Diseases of the kidney are not as common as 
other important diseases such as cardiovascular
conditions or cancers but are much more 
common than some well-known disorders such 
as multiple sclerosis or muscular dystrophy. Renal
conditions account for about 7000 deaths per
annum (Registrar General’s figures) not includ-
ing cancers of the kidney and associated organs 
of the urinary tract such as bladder and prostate.
However, around one-third of deaths of people
with renal failure are not recorded as such in 
the death data, and in many cases – especially 
the elderly – there are associated illnesses which
preclude the institution of RRT.
Over 100 different diseases affect the kidneys. 
These diseases may present early with features 
such as pain, blood or protein in the urine or 
peripheral oedema (swelling in the legs), or 
may remain undiagnosed until the patient 
recovers or the symptoms of renal failure develop.
Much renal disease is self-limiting and often 
occurs and heals with few, if any, symptoms 
or sequelae.
Renal failure may be acute and reversible, which
occurs in previously normal kidneys after major
injury such as crush injuries or major surgery, 
in the presence of overwhelming infection, or 
if the blood supply to the kidneys is compromised
by failure of the heart’s pumping action, or 
losses of blood, salt or water so that the blood
pressure drops and the kidneys are no longer
supplied with blood. In this case, renal support 
is needed only for days or weeks before renal
function returns. However, about half such 
patients die during the illness because of 
other conditions.
More common is chronic irreversible renal failure
in which the kidneys are slowly destroyed over
months or years. Chronic irreversible renal failure
slowly erodes kidney function. To begin with there
is little to see or find, and many patients present 
for medical help late in their disease, or even in 
the terminal stages. Tiredness, anaemia, a feeling
of being ‘run down’ are often the only symptoms,
plus headache, breathlessness and perhaps angina
if high blood pressure is present – as happens 
often as the kidneys fail, or as the prime cause 
of the renal disease (ESRD). Ankle swelling 
may occur if the loss of protein in the urine 
is particularly great.
The stages of chronic irreversible renal failure are
often given different terms: chronic renal insuffi-
ciency for the early stages, chronic renal failure
when it has become obvious, and end-stage renal
failure when it reaches its terminal stages. At this
point if nothing is done the patient will die.
Two forms of treatment are available, however,
which are complementary to each other and may
both be needed if end-stage renal failure is to be
treated – dialysis and renal transplantation.
Ethnicity and age are considered to be the key
socio-demographic determinants of ESRD. There 
is cogent evidence that the incidence of ESRD
increases significantly with age. While not achiev-
ing European levels, the trend in the UK has been
for older patients to be accepted, resulting in the
rising age-profile of new patients in recent years.
Evidence from the USA suggests that the relative
risk of ESRD in the black population (predomi-
nantly of African origin) is two to four times higher
than for whites.
1 Data collected during the Review
of Renal Specialist Services in London suggest that
there is a similar increased risk of renal failure in
the ethnic populations (Asian and Afro-Caribbean)
in the Thames Regions compared with whites.
2
People from both of these groups have a higher
prevalence of non-insulin-dependent diabetes and
patients in these groups with diabetes are more
likely to develop renal failure than whites. This
partly explains the higher acceptance rate of 
Asians on to RRT programmes.
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Categories of renal disease
Most renal diseases that cause renal failure fall into
a few categories, including the following.
Autoimmune disease
‘Glomerulonephritis’ describes a group of diseases
in which the glomeruli (the filters which start the
process of urine formation) are damaged by the
body’s immunological response to tissue changes 
or infections elsewhere. Together, all forms of
nephritis account for about 30% of renal failure 
in Britain. The most severe forms are therefore
treated with medications that suppress the immune
response; however, treatment makes only a small
impact on the progress of this group of patients
into ESRD.
Systemic disease
Although many generalised diseases such as
systemic lupus, vasculitis, amyloidosis and myelo-
matosis can cause kidney failure, by far the most
important cause is diabetes mellitus (about 20% 
of all renal disease in many countries). In some
patients, progressive kidney damage begins after
some years of diabetes, particularly if blood sugar
and high blood pressure have been poorly con-
trolled. This is a particularly common and severe
problem in patients from the Indian subcontinent.
Careful lifelong supervision has a major impact 
in preventing kidney damage.
High blood pressure
Severe (accelerated) hypertension damages the
kidneys but the damage can be prevented, and to
some extent reversed, by early detection and early
treatment of high blood pressure. In patients of Afro-
Caribbean origin, hypertension is frequently the only
presumptive causative factor of renal failure. The
relationship between high blood pressure and the
kidney is being studied to see to what extent treat-
ment to bring blood pressure to normal levels might
reduce the incidence of ESRD in such target groups.
It is possible that other factors are also involved.
Obstruction
Anything which obstructs the free flow of urine can
cause back-pressure on the kidneys. Much the com-
monest cause is enlargement of the prostate in eld-
erly men; although only a small proportion of them
develop kidney failure, benign prostatic hyperplasia
(BPH) is so common that it becomes a major cause
of renal failure over the age of 70 years.
Infection of the urine
Cystitis is a very common condition affecting about
half of all women at some time in their life and
rarely has serious consequences. Infection of the
urine in young children or patients with obstruc-
tion and other abnormalities of the urinary tract 
or kidney stones may result in scarring of the
kidney and eventual kidney failure.
Genetic disease
One common disease – polycystic kidney disease
(PKD) – and many rare inherited diseases affecting
the kidneys account for about 8% of all kidney
failure in Britain. Although present from birth,
PKD often causes no symptoms until middle age or 
later. Understanding of its genetic basis is rapidly
advancing and may lead to the development of
effective treatment.
Prevention of renal failure
Prevention of chronic irreversible renal failure is
not often possible, but better control of diabetes
and high blood pressure and relief of obstruction
have much to offer, provided that the condition
can be recognised early in the course of the
disease, before much renal damage has occurred.
Screening for renal diseases has not been practised,
because of the relatively low incidence of cases.
Urine tests for protein or blood, or blood tests for
the level of some substances normally excreted by
the kidney such as creatinine and urea, are poten-
tially useful methods for screening if populations 
at risk of renal failure can be identified.
The earliest possible assessment of patients likely to
need RRT provides the greatest cost-effectiveness.
This is reinforced by the growing awareness that
medical and other complications frequently arise
caused by factors which could have been detected 
and modified if there had been time for assess-
ment. The surveillance of at-risk groups in general
practice might assist by bringing patients who will
require RRT to the attention of nephrologists as
early as possible. Hospital doctors in all specialities
should be aware that mild renal failure requires
prompt assessment by a nephrologist.
Renal failure is often accompanied by other disease
processes. Some of these are due to the primary
disease; for example, diabetes causes renal failure,
blindness and diseases of the nerves and blood
vessels. Others, such as anaemia, bone disease 
and heart failure are consequences of the renal
failure. Coincidental diseases such as cardiovascular
diseases, peripheral vascular disease, chronic
bronchitis and arthritis are particularly common 
in older patients with renal failure. All theseHealth Technology Assessment 1998; Vol. 2: No.5
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conditions (called collectively ‘co-morbidity’) can
influence the choice of treatment for renal failure
and may reduce its benefits. Expert assessment of
the patient before ESRD can reduce co-morbidity
and increase the benefit and cost-effectiveness 
of treatment. Thus early detection and referral 
of patients at risk of renal failure is important.
Evidence from the USA showed that the mortality
rate among patients aged over 55 years at the 
start of regular dialysis increased dramatically if
dialysis was started late in the illness.3 Studies of
patients in the UK confirm this.
Renal replacement therapy
The term RRT is used to describe those treatments
for ESRD where, in the absence of kidney function,
the removal of waste product from the body is
achieved by dialysis and other kidney functions 
are supplemented by drugs. It is also the term
which covers the complete replacement of all
kidney functions by transplantation. Patients 
with ESRD usually change treatment modalities
during their time on RRT. They may begin with 
one form of dialysis, change to another and 
then receive a transplant; if the transplant fails 
they return again to dialysis. The modalities 
of treatment can therefore be seen as
complementary.
Dialysis
Dialysis involves the cleansing or washing of the
blood by the use of fluids which allow the toxic
substances to leave the body by a route other than
the kidneys; in addition it is possible to regulate 
the composition of the body fluids and the amount
of water and salts in the body by altering the com-
position of the fluids used, and by pressure or 
other forms of filtration.
The method used first to achieve dialysis was 
the artificial kidney, or haemodialysis. This 
involves the attachment of the patient’s circu-
lation to a machine through which fluid is passed
and exchanged can take place. The disadvantage 
of this method is that some form of permanent
access to the circulation must be produced 
which can be needled at every treatment. Each
session lasts 4–6 hours and is needed three 
times a week.
The alternative is peritoneal dialysis, often carried
out in the form of CAPD. In this technique, fluid is
infused and withdrawn from the peritoneal cavity
which lies around the bowel; the washing fluid
must be sterile, and peritonitis (infection and
inflammation of the peritoneum) is a frequent
complication. A silastic tube must be implanted
into the peritoneum, and this may become kinked
or malpositioned. The fluid is exchanged four
times daily and hence remains in the abdominal
cavity for about 4–5 hours during the day and 
for 8 hours overnight. More recently automated
peritoneal dialysis has been introduced in 
which exchanges are carried out overnight 
by a machine and no exchanges are required 
during the day.
Neither form of dialysis corrects the loss of
hormones secreted by the kidney and replace-
ment with synthetic EPO and vitamin D is 
often necessary.
Renal transplantation
Renal transplantation replaces all the functions 
of the kidney, making EPO and vitamin D unneces-
sary. A single kidney is placed usually in the pelvis
close to the bladder, and attached to a nearby
artery and vein. The immediate problem is the
body’s acute rejection of the foreign graft, which
has largely been overcome during the first months
using drugs such as steroids and cyclosporin. 
These drugs and other which can be used have
many undesirable side-effects, including the
acceleration of vascular disease so that myocardial
infarcts and strokes are commoner in transplant
patients than in age-matched controls. During
subsequent years also, there is a steady loss of
transplanted kidneys from a process of chronic
rejection; treatment of this is unsatisfactory and
many patients require a second or even third 
graft over several decades, and have to rely 
on dialysis in the meantime.
The main bar to expanding transplantation is 
the shortage of suitable kidneys to transplant.
Although the situation could be improved, it 
is now clear that whatever social and medical
structures are present or legislation is adopted,
there will be inevitably be a significant shortage 
of kidneys from humans. This remains the case
even if kidneys from the newly dead (cadaver
kidneys) are retrieved with maximum efficiency,
and living donors (usually, but not always, from
close blood-relatives of the recipient) are used
wherever appropriate. Experiments using 
animal kidneys are under way but are still in 
the early stages. It will be some time before 
we know whether xenotransplantation, as thisAppendix 1
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procedure is known, will contribute to the
transplant programme.
The nature of renal services
The nature of the work in renal medicine is
extremely varied. The work of a nephrologist
includes the early detection and diagnosis of renal
disease and the long-term management of its com-
plications such as high blood pressure, anaemia,
and bone disease. The nephrologist may share the
management with the general practitioner or local
hospital physician, and relies on them to refer a
patient early for initial diagnosis and treatment.
Inpatient work accounts for perhaps 5% of patients
under care at any one time but is complex, and
experienced medical advice must be available on a
24-hour basis. About 95% of renal work is sustained
on an outpatient basis; this includes most RRT by
dialysis and the care of transplant patients. There
are four major components to renal medicine.
Renal replacement therapy
The most significant element of work is in relation
to the preparation of patients in ESRD for RRT.
Once accepted there is a requirement for medical
supervision for the remainder of the patient’s life.
There is demographic evidence that the patient
population will present increasing challenges for
renal staffing as more elderly and diabetic patients
are accepted for treatment.
Emergency work
The emergency work associated with the specialist
consists of the following.
• The treatment of acute renal failure, often
involving multi-organ failure, and acute-on-
chronic renal failure. Close cooperation with
other medical specialities including intensive
care is therefore a vital component of this 
aspect of the service.
• There is a significant workload of medical
emergencies arising from an ESRD programme
which is bound to increase in proportion to the
demands on the main programme.
Routine nephrology
There is a significant workload associated with 
the immunological and metabolic nature of renal
disease which requires investigative procedures 
in an inpatient setting.
Investigation and management of fluid
and electrolyte disorders
This is variable proportion of the nephrologist’s
work, depending on the other expertise available 
in the hospital.
Outpatient work
The outpatient work in renal medicine consists 
of the majority of general nephrology, together
with clinics attended by dialysis and renal
transplant patients.
Acute uraemic emergencies
Up to 40% of patients requiring RRT present at the
time when dialysis is needed; this constitutes an acute
uraemic emergency, since only immediate therapy
will save life. Any such patient should receive appro-
priate assessment and treatment, and renal units
must have the facilities to deal with them. However,
other patients with potentially reversible renal failure
who present in this way eventually recover renal
function and do not require long-term RRT. It is
impossible to distinguish immediately between cases
in which recovery will occur and those in which it will
not, and clinicians need time to assess this. Even if
renal function cannot be recovered, there may be
other reasons for not proceeding to long-term RRT,
and time is required for this to be determined.
Research
Renal disease has become a defined sub-speciality
only within the last 30 years but the kidney has
stimulated academic interest for much longer due 
to its central role on metabolism, hypertension and
immunological disease. The MRC, Wellcome Trust
and the National Kidney Research Fund spend annu-
ally over £3 million in departments with an interest in
renal medicine, renal physiology and transplantation.
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General search strategies used in 
main electronic databases
The following general search strategies for the
identification of RCTs or quasi-RCTs in the
management of ESRD were used.
Medline
Medline (National Library of Medicine, electronic
version of Index Medicus, USA) on OVID, CD plus,
was searched from 1966 to June 1996 using the
following strategy.a
001 renal replacement therapy/
002 exp hemodialysis/
003 exp hemofiltration/
004 kidney, artificial/
005 exp peritoneal dialysis/
006 ultrafiltration/
007 dialysis/
008 kidney failure, chronic/ 
009 kidney failure, acute/
010 uremia/
011 (hemodia$ or haemodia$ or hemofilt$ or 
haemofiltrat$ or diafilt$).tw.
012 (ultrafilt$ or dialy$ or biofilt$).tw.
013 ((kidney$ or renal) adj2 (replac$ or artificial 
or extracorporeal)).tw.
014 ((kidney$ or renal) adj2 (disease$ or failure$ 
or sufficien$ or insufficien$)).tw.
015 esrd.tw.
016 ur?emi$.tw.
017 or/1–16
018 controlled clinical trial.pt.
019 randomised controlled trial.pt.
020 randomised controlled trials/
021 random allocation/
022 double blind method/
023 single blind method/
024 clinical trial.pt.
025 exp clinical trials/
026 (clin$ adj4 trial$).tw.
027 ((singl$ or doubl$ or trebl$ or tripl$) 
adj4 (blind$ or mask$)).tw.
028 placebos/
029 placebo$.tw.
030 random$.tw.
031 research design/
032 volunteer$.tw.
033 animal/
034 human/
035 33 not (33 and 34)
036 or/18–32
037 36 not 35
038 37 and 17
The search strategy 018–037 is a translation from
SilverPlatter syntax of the first two (plus the term
volunteer$) of the three stages of an optimised
strategy recommended by the Cochrane Collabor-
ation for the identification of RCTs (Dickersin,
1994).
12 Pilot searches combining the whole
Cochrane strategy with the disease/intervention
search terms resulted in too many irrelevant hits: 
to increase precision (specificity), but with the
possible loss of some sensitivity, only the first two
parts plus the term volunteer$ were used. 
Embase
Embase (Elsevier Science Publishers BV, electronic
version of Excerpta Medica, Amsterdam) was
searched from 1981 to June 1996 using the
following strategy.
b
(((controlled study)@KMAJOR,KMINOR,
(randomised controlled trial)@KMAJOR,
KMINOR,(clinical study)@KMAJOR,KMINOR,
(clinical trial)@KMAJOR,KMINOR,(major 
clinical study)@KMAJOR,KMINOR,(prospective
study)@KMAJOR,KMINOR,(multicenter
study)@KMAJOR,KMINOR,(randomization)
@KMAJOR,KMINOR,(double blind procedure)
@KMAJOR,KMINOR,(single blind procedure)
@KMAJOR,KMINOR,(crossover procedure)
@KMAJOR,KMINOR,(placebo)@KMAJOR,
KMINOR)+((kidney failure)@EX,(hemodialysis)
@EX,(hemofiltration)@EX,(artificialkidney)
@KMAJOR,KMINOR,(ultrafiltration)@KMAJOR,
KMINOR,(dialysis)@EX)))-((nonhuman)
@KW-((human)@KW+(nonhuman)@KW)))
Appendix 2
Literature search strategies
a
Key: / = MeSH term; exp = exploded MeSH term; $ = wildcard; adj(n) = adjacent, within n words either side of the
other term; ? = a letter may or may not be present; pt = publication type; tw = textword, searches in title and abstract.
b Key: @KMAJOR,KMINOR = term present in either major or minor EMBASE keywords; comma ‘,’ = Boolean operator
‘or’; + = Boolean operator ‘and’; @EX = exploded keyword search; minus sign ‘-’ = Boolean operator ‘not’.Appendix 2
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Textword searching of Embase resulted in too
many irrelevant hits. It was decided that, in view 
of time constraints, a more focused keyword 
search would optimise RCT identification.
Biosis
Biosis (Biological Abstracts Inc, electronic version
of Biological Abstracts, USA) on SilverPlatter was
searched from 1989 to June 1995 using the follow-
ing strategy (searching in title, abstract and
descriptor fields).c
#1: HEMODIA*
#2: HAEMODIA*
#3: HEMOFILT*
#4: HAEMOFILT*
#5: DIAFILT*
#6: ULTRAFILT*
#7: DIALY*
#8: KIDNEY* near ARTIFICIAL
#9: (KIDNEY* or RENAL) near (REPLAC* or 
ARTIFICIAL or  EXTRACORPOREAL)
#10: (RENAL or KIDNEY*) near (DISEASE* 
or FAILURE* or SUFFICIEN* 
or INSUFFICIEN*)
#11: ESRD
#12: UREMI* or URAEMI*
#13: #1or #2 or #3 or #4 or #5 or #6 or #7 or #8 or 
#9 or #10 or #11 or #12
#14: BC86215
#15: CLIN* near TRIAL*
#16: (SINGL* or DOUBL* or TREBL* or TRIPL*) 
near (BLIND* or MASK*)
#17: PLACEBO*
#18: RANDOM*
#19: VOLUNTEER*
#20: #15 or #16 or #17 or #18 or #19
#21: #13 and #14 and #20
CINAHL
CINAHL (CINAHL Information Systems,
Cumulative Index of the Nursing and Allied 
Health Literature, USA) on OVID, CD plus, was
searched from 1982 to March 1996 using the
following strategy.
d
001 exp Clinical trials/
002 exp clinical research/
003 research/
004 random assignment/
005 research.pt.
006 (clin$ adj25 trial$).tw.
007 ((singl$ or doubl$ or trebl$ or tripl$) adj25 
(blind$ or mask$)).tw.
008 placebos/
009 placebo$.tw.
010 random$.tw.
011 exp Study Design (Non-CINAHL)/
012 volunteer$.tw.
013 or/1–12
014 dialysis centers/
015 dialysis/
016 exp hemodialysis/
017 dialysis patients/
018 dialysis solutions/
019 Peritoneal Dialysis Therapy (Iowa NIC)/
020 renal osteodystrophy/
021 kidney artificial/
022 catheters dialysis/
023 nephrology nursing/
024 exp kidney failure acute/
025 kidney failure chronic/
026 exp uremia/
027 exp renal replacement therapy/
028 hemodia$.tw.
029 haemodia$.tw.
030 hemofilt$.tw.
031 haemofilt$.tw.
032 diafilt$.tw.
033 ultrafilt$.tw.
034 dialy$.tw.
035 ((kidney$ or renal) adj25 (replac$ or 
artificial or extracorporeal)).tw.
036 ((renal or kidney$) adj25 (disease$ 
or failure$ or sufficien$ or 
insufficient$)).tw.
037 esrd.tw.
038 ur?emi$.tw.
039 or/14–38
040 13 and 39
Cochrane Library
The following databases, available through 
the Cochrane Library (Cochrane Collaboration,
Oxford: update software, April 1996; Issue 1, 
on CD-ROM: available from BMJ Publishing 
Group, London) were systematically searched.
• The Cochrane database of systematic reviews
• Database of abstracts of reviews of 
effectiveness (DARE)
• The Cochrane controlled trials register.
c Key: * = wildcard; near = in the same sentence; BC86215 = human.
d Key: / = MeSH term; exp = exploded MeSH term; $ = wildcard; adj(n) = adjacent, within n words either side 
of the other term; ? = a letter may or may not be present; pt = publication type; tw = textword, searches in title 
and abstract.Health Technology Assessment 1998; Vol. 2: No.5
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The following search terms were used.e
Renal replacement
Haemodia*
Hemodia*
Dial*
CAPD
Peritoneal dialysis
Artificial kidney
Renal failure
Kidney failure
Uraemia
Uremia
CRF
End-stage renal disease
End-stage renal failure
ESRD
ESRF
The search strategy used was a modified version 
of the search strategy used with Medline (OVID)
(01–17) as outlined above. No methodology search
terms were used. The first version of the Cochrane
Library was used for this search and, because of
difficulties experienced using multiple search terms
and saving search strategies, each of the search
terms had to be individually entered. The search
was performed with a nephrologist assessing the
trials identified on screen, printing out only those
hits relevant to the six review topics.
Search strategies in 
other databases
Specific strategies were developed for searching the
following specialist databases.
Chemabs (Chemical Abstracts Service, Columbus,
Ohio, USA; electronic version of Chemical Abstracts)
on STN. Years searched: 1967–1 July 1995 (for
acetate versus bicarbonate only). 
The following three sets of search terms were used,
combined with the Boolean operator AND:
f
• renal terms – hemodia*, haemodia*,
hemofiltrat*, haemofiltrat*, dialy*, (kidney# or
renal)(2A)(artificial or replac? or extracorporeal)
• buffer terms – 144-55-8 or bicarbonate or
carbonic(w)acid(w)monosodium(w)salt, acetate
or 127-09-3, acid(w)base(w)(imbalance# or
balanc# or equilibri?) or acidosis, buffer?
• RCT terms – control?(2A)clinical(w)trial? or
random?, (singl# or doubl# or trebl# or
tripl#)(A)(blind? or mask?), placebo#.
SIGLE (System for Information on Grey Literature
in Europe, compiled by EAGLE) on SilverPlatter.
Years searched: 1980–June 1996. Search term: renal.
CRIB (Current Research in Britain, 10th edition,
1995. Book format, published by Cartermill
Publications, London). Search term: nephrology.
NRR (National Research Register, NHS Executive;
14th consolidation, September 1996) (version
prepared by NHS Executive, Anglia and Oxford). 
It includes all 6678 records in the 14th
consolidation (on Idealist).
Textword search
g of all fields: renal, haemodialy*,
haemofilt*, dialy*, kidney*
Economic search strategies
The following supplementary searches 
were performed for studies relevant to the 
economic evaluation. 
Medline economics search terms
Medline was searched from 1966 to August 1996
using the following strategy.
h
• MeSH terms – workload, health resources,
length of stay, hospitalization, explode costs 
and cost analysis, economics
• terms in title or abstract – cost$, economic$,
resource$, efficien$ (limited to economics
subheading), marginal analy$, utility, QALY,
quality adjusted life year$, HYE, healthy years
equivalent$, estimat$ adj2 (benefit or harm$).
These terms were combined using the Boolean
operator OR and then combined with line 17 
(see general Medline strategy above) using the
Boolean operator AND.
e Key: * = wildcard.
f Key: * = wildcard; # = one or zero characters; (n)A = adjacent, in any order, within n words either side of other term; 
? = truncation, any number of characters ; w = adjacent, in same order, to other term.
g Key: * = wildcard.
h Key: / = MeSH term; exp = exploded MeSH term; $ = wildcard; adj(n) = adjacent, within n words either side of the
other term; ? = a letter may or may not be present; pt = publication type; tw = textword, searches in title and abstract.Appendix 2
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Embase economics search terms
The database was searched from 1981 to August
1996 using the following strategy.i
• Terms in title, abstract or keywords – medical
economics, health resource*, hospital care,
hospitalization, cost, economic aspect, economic
value of life, resource* allocation, resource
management, efficiency, health care, quality 
of life.
These terms were combined using the Embase
Boolean operator equivalent of OR (a comma) 
and then combined with the ESRD terms for use 
in Embase (see general Embase search strategy
above) using the Embase Boolean operator
equivalent of AND (+ sign).
Biosis economics search terms 
The database was searched from 1989 to April 1996
using the following strategy (searching in title,
abstract and descriptor fields).
j
• Terms in title, abstract or descriptor –
economic*, workload, health resources, length
of stay, hospitalization, hospitalisation, QALY,
HYE, quality adjusted life year*, marginal
analys*, cost*, resource*, utility, efficient*,
estimat* near (benefit* or harm*).
These terms were combined using the Boolean
operator OR and then combined with line 13 
(see general Biosis search strategy above) using 
the Boolean operator AND.
CINAHL economics search terms
The database was searched from 1982 to March
1996 using the following strategy.
• CINAHL subject headings – economics, explode
costs and cost analysis, hospitalization, health
resource allocation, economic value of life,
productivity, explode quality of life.
These terms were combined using the Boolean
operator OR and then combined with line 39 
(see general CINAHL search strategy above) 
using the Boolean operator AND.
Other economics search terms
NHS economic evaluation database (NHS Centre
for Reviews and Dissemination) – on-line. Date of
search: 15 August 1996.k
• Search terms – hemodia$, haemodia$,
hemofilt$, haemofilt$, diafilt$, ultrafilt$, dialy$,
kidney$, renal, ESRD, uraemia, uremia.
IBSS (British Library of Political and Economic
Science) – on BIDS. Years searched: 1980–
15 January 1997.
l
• Search terms – hemofilt*, haemofilt*, diafilt*,
esrd, ultrafilt*, uremi*, uraemi*, hemodia*,
haemodia*, ultrafilt*, kidney*, renal, dialy*.
Econlit (American Economics Association) – 
on SilverPlatter. Years searched: 1969–June 1996.
m
• Search terms – hemofilt*, haemofilt*, diafilt*,
esrd, ultrafilt*, uremi*, uraemi*, hemodia*,
haemodia*, ultrafilt*, kidney*, renal, dialy*,
nephrologists.
The Economist (The Economist Newspaper Ltd,
London) – on CD-ROM. Years searched: 
1991–94.
n
• Search terms – hemofilt*, haemofilt*, diafilt*,
esrd, ultrafilt*, uremi*, uraemi*, hemodia*,
haemodia*, ultrafilt*, kidney*, renal, dialy*.
i Key: * = wildcard.
j Key: * = wildcard; near = in the same sentence.
k Key: $ = wildcard.
l Key: * = wildcard.
m Key: * = wildcard.
n Key: * = wildcard.Health Technology Assessment 1998; Vol. 2: No.5
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Introduction
Over 16,000 abstracts of published articles were
considered for inclusion in both the reviews of
effectiveness and the economic evaluation. In 
this appendix the authors describe:
• how they were first identified
• how many were judged to be possible RCTs
relevant to RCTs relevant to ESRD
• how many of these were concerned with the 
six specific topics chosen for review
• how many were confirmed as RCTs suitable 
for inclusion
• how many were considered in the 
economic analyses.
Since no previous work whatsoever has been
undertaken in the area of ESRD, it was considered
that a broad search was appropriate and would be
useful for the Cochrane Renal Review Group’s
register of trials.
Results of searches for RCTs for
assessing effectiveness
The number of abstracts of possibly relevant studies
generated by the systematic searches of the five
electronic databases are shown in Figure 8. In total,
of nearly 12,000 abstracts assessed, 2085 were
thought to be possible RCTs or quasi-RCTs and, of
these, 340 were later judged on review of the full
report to be RCTs or quasi-RCTs related to the
management of ESRD. A total of 39 were relevant
to one or more of the six topics. The dividend from
each of the five databases is shown in Table 4. Of 
the 39 RCTs found, 34 (87%) were identified on
Medline. The next largest number came from
Embase but the dividend expressed as a proportion
of abstracts identified was low (about 1/1000).
The number of trials relevant to individual reviews
varied (Table 5). The largest number were com-
parisons of haemodialysis membranes. No RCTs
were found for what is arguably the most import-
ant review, the comparison of haemodialysis 
with CAPD.
The sources of the eight additional RCTs included
in the reviews are summarised in Table 6.
Although trials related to the management of
ESRD were found in other databases and during
hand-searching of Kidney International, none of
these were included in any of the six reviews as 
they did not fit the eligibility criteria. All eight
Appendix 3
Results of literature searches
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FIGURE 8  Number of possible RCTs or quasi-RCTs as screening process progresses (electronic searches only)Appendix 3
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additional RCTs were found from searching the
reference lists of known RCTs or were made 
known to the authors by experts in this field.
The results of the handsearching of Kidney
International from 1988 to 1995 inclusive are shown
in Table 7. Of a total of 223 possible RCTs or CCTs,
107 were relevant to ESRD, 68 were not identified
in the electronic searches and 33 were thought to
be relevant to one or more of the six topics.
However, none of these were RCTs which reported
data relevant to any of the predetermined outcome
measures and therefore none of these studies were
included in the reviews.
The results of the handsearching of the confer-
ence proceedings in Kidney International for the
year 1994 are presented in Table 8. Although 
15 possible RCTs were relevant to the six topics,
none were included in the final reviews. However,
the handsearching will contribute to the inter-
national Cochrane Collaboration work and help
identify all RCTs and quasi-RCTs. Of the articles 
in Medline, 129 were incorrectly tagged and will 
be re-tagged by the National Library of Medicine
(USA) as RCTs or CCTs. In addition, the 64 RCTs
and CCTs identified in the conference proceed-
ings, which are not normally indexed in Medline,
will be included on a new auxiliary Medline
database currently under development.
Table 9 is a summary of where the 47 RCTs included
in the reviews were identified; 34 (72%) were
identified from Medline.
Most of the studies identified in the supplementary
economics searches were found in Medline and
Embase (Table 10). In contrast to the findings for
RCTs, the largest number were relevant to the
comparison of haemodialysis and CAPD 
(Table 11).
TABLE 4  Number of studies identified at each stage of the systematic electronic search according to database search
Source Number of  Number of possible Number of  Number of 
studies identified  RCTs/quasi-RCTs  possible RCTs  RCTs included in 
by electronic relevant to ESRD or quasi-RCTs  final review
searches (includes  identified by reading  relevant to six 
duplication) retrieved citations/ selected topics
abstracts
Medline 5429 1480 243 34
Embase 4764 391 81 4
CINAHL 366 25 10 0
Biosis 1317 189 4 1
Cochrane Library N/A1 N/A1 20
TOTAL 11,876 2085 340 39
1A nephrologist searched this database on screen and selected RCTs/CCTs relevant only to the six topics.For search strategy see
appendix 2
TABLE 5  Number of potential RCTs or quasi-RCTs identified
from the systematic electronic search for each selected topic at
each stage of the assessment process 
Topic Number of  Number 
possible RCTs/ of RCTs 
quasi RCTs  included in 
after abstract  final review
assessment
Haemodialysis membranes 145 20
Acetate vs.bicarbonate 85 12
Haemodialysis duration 39 1
CAPD catheters 53 5
CCPD vs.CAPD 13 1
CAPD vs.haemodialysis 33 0
TOTAL 368
1 39
1 Some studies cover more than one topicHealth Technology Assessment 1998; Vol. 2: No.5
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TABLE 6  Numbers of possible RCTs from sources other than systematic searches of electronic databases
Source Number  Number of  Number of possible  Number of 
of studies  possible RCTs  RCTs relevant  RCTs included in 
identified1 relevant to ESRD2 to topics2,3 final review
Other databases4 269 122 9 0
Hand-searching 287 133 48 0
Reference lists and experts in the field 565 N/A6 140 8
Subtotal (all other sources) 612 255 197 8
1 Some reports were identified from more than one source
2 Included controlled trials with quasi-random methods of allocation
3 Relevant to the six selected topics
4 Chemabs,SIGLE,CRIB and NRR
5 Number of reference lists checked
6 Collected possible RCTs for the six topics only
TABLE 7  Results of hand-searching Kidney International (excluding conference proceedings)
Year Number  CCTs
1 RCTs
2 Total Number  Number Number Number  Number 
searched  of articles number  of RCTs  of RCTs and  of RCTs  to be  of RCTs 
(vol) of RCTs  and CCTs  CCTs not  and CCTs  amended  included 
and  relevant  identified in relevant to  in Medline  in final 
CCTs to ESRD electronic the six topics  because  reviews
search not identified  possible 
in electronic  RCT or 
search CCT
1995 (47,48)
3 466 7 15 + 2  22 7 4 1 12 0
meta-analysis
1994 (45,46) 533 15 27 42 14 4 3 17 0
1993 (43,44) 477 9 19 28 15 14 9 19 0
1992 (42,41) 432 13 21 34 19 10 1 18 0
1991 (40,39) 369 8 7 15 9 3 3 9 0
1990 (38,37)
3 311 10 11 21 16 8 7 14 0
1989 (36,35) 335 8 21 29 6 4 1 12 0
1988 (33,34) 310 26 6 32 21 21 8 28 0
Total 3233 96 127 223 107 68 33 129 0
1 CCT.If an eligible trial has not been explicitly described as ‘randomised’,CCT is used as a collective term to distinguish possible RCTs and quasi-RCTs
from ‘definite’RCTs.Possible RCTs include trials that do not state the method of allocation but have treatment and control groups derived from a single
group of participants.Examples of quasi-random processes for assigning treatments are coin flips,odd-even numbers,patients’social security numbers,
days of the week,and patient record numbers.This conforms with the National Library of Medicine (USA) definition of an RCT.
2 RCT.If the trial meets the four eligibility criteria (given below) and the author(s) state explicitly (usually by using some variant of the term ‘random’to
describe the allocation procedure used) that the groups compared in the study were established by random allocation.This conforms with the National
Library of Medicine (USA) definition of an RCT.Eligibility criteria:the study compares treatment in human beings;the study is prospective in nature,i.e.
the interventions are planned prior to the experiment taking place,and exposure to each intervention is under the control of the study investigators;
two or more treatments or interventions are compared with one another (one may be a no-treatment control group);and the most important aspect is
that assignment to a particular intervention is intended to be random,i.e.not deliberately selected in any way.Units of randomisation may be
individuals,groups (communities,schools,or hospitals),organs or other parts of the body (such as teeth).
3The years used to obtain the ‘gold standard’.
(Footnotes 1 and 2 are based on material taken,with permission,from the Cochrane Handbook (1997),(Mulrow CD,Oxman AD (editors) – see
reference 9,main report).Appendix 3
42
TABLE 8  Results of hand-searching conference proceedings for 1994 in Kidney International
Kidney  Organisation Number CCTs RCTs Total  Number  Number  of  Number 
Int of  number  of RCTs  RCTs & CCTs  of RCTs 
abstracts of CCTs  & CCTs  relevant  included 
& RCTs1 relevant  to the six  in final 
to ESRD topics review
vol 45 Portuguese Society 
of Nephrology 48 2 1 3 3 1 0
Australian & New Zealand 
Society of Nephrology 112 2 4 6 2 0 0
Swiss Society of Nephrology 46 3 1 4 4 2 0
vol 46  Spanish Society of 
Nephrology 152 19 4 23 9 6 0
Australia & New Zealand 
Society of Nephrology 97 5 5 10 3 3 0
Societé de Nephrologie 24 1 1 2 1 1 0
Dutch Society of Nephrology 50 7 2 9 2 1 0
Brazilian Society of 
Nephrology 75 5 2 7 2 1 0
Total 604 44 20 64 26 15 0
1 Conference proceedings are not indexed on Medline.National Library of Medicine (USA) plans to have an auxiliary database which
will include proceedings and journals not normally indexed on Medline
TABLE 9  All sources of RCTs included in the six reviews
Number Medline Embase CINAHL Biosis Cochrane  Authors  Reference  Hand-
of included  Library & other  lists searching
RCTs experts
Haemodialysis 
membranes 22 16 3 0 1 0 2
1 00
Acetate vs.
bicarbonate 182 12 0 0 0 0 13 50
Haemodialysis 
duration 1 1 0 0 0 0 0 0 0
CAPD catheters 5
4 50 0 000 0 0
CCPD vs.CAPD 1 0 1 0 0 0 0 0 0
CAPD vs.
haemodialysis 0 0 0 0 0 0 0 0 0
TOTAL 47 34 4 0 1 0 3 5 0
1 Found by two of the authors of this report during the course of their personal literature update
2 More than one relevant RCT appeared in some of the published reports
3 Kindly given by a colleague
4 Six RCTs altogether but two reports were of the same trial,therefore counted as five included RCTsHealth Technology Assessment 1998; Vol. 2: No.5
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TABLE 10  Systematic electronic search for studies covering the
economic aspects of the six topics by source
Source Number of  Number of 
studies identified  possible studies 
by electronic  relevant to the 
searches economic aspects 
of the six topics
Medline 2225 467
Embase 1849 338
Biosis 3 0
Econlit 21 7
IBSS 18 0
CINAHL 30 7
Other:
The Economist 16 0
NHS Economic 
Evaluations Database 6 1
Total 4168 820
TABLE 11  Numbers of studies,organised by topic,from the
systematic electronic search covering the economic aspects of 
the six topics
Topic Number of 
studies potentially 
relevant to 
the economic 
aspects of each 
of the six topics
Haemodialysis membranes 85
Acetate vs.bicarbonate dialysate 41
Haemodialysis duration  109
CAPD catheters 34
CCPD vs.CAPD 22
CAPD vs.haemodialysis 529
Total 820Health Technology Assessment 1998; Vol. 2: No.5
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Background
When the kidney fails, the blood-borne metabolites
of protein breakdown and water cannot be excret-
ed. The principle of haemodialysis is that such sub-
stances can be removed when blood is passed over
a semi-permeable membrane with dialysate flowing
on the other side. Metabolites are removed mainly
by diffusion and water by applying a pressure
gradient across the membrane.
Cellulose-based membranes are produced 
principally from cotton. They were the first
membranes produced for dialysis and in their
standard form have a low hydraulic permeability 
(< 10 ml/h/m
2/mmHg) and are commonly 
known as low-flux membranes. They character-
istically also have poor clearance of molecules
larger in size than urea and creatinine, which 
may be responsible for some of the clinical 
features of uraemia. In recent years, standard
cellulose membranes have been modified to 
make both larger molecule and water removal
more efficient; such membranes are called
modified cellulose, substituted cellulose or 
semi-synthetic membranes and can more readily 
be made to have a higher flux than cellulose
membranes. They are generally more expensive
than standard membranes.
In the early 1970s, synthetic polymer-based
membranes became available which could be
manufactured to have either high- or low-flux
characteristics. They may remove b2 micro-
globulin, a middle molecule which may cause
dialysis-related amyloid disease, more effectively,
particularly those which have a high flux. Such
membranes have been used by those wishing to
reduce the number of hours in a dialysis session.
Synthetic membranes are also regarded as more
‘biocompatible’, in that they incite less of an
immune response than cellulose-based membranes.
Dialysis membranes can be cleaned or ‘repro-
cessed’ after use and reused for the same patient.
This practice is more common for the more
expensive synthetic membranes.
The greater stimulation of the immune system by
the cellulose membranes may increase patients’
susceptibility to infection and malnutrition, and
may also, through production of cytokines and
stimulation of the complement system, be partially
responsible for the adverse symptoms experienced
during haemodialysis. It is of particular import-
ance to evaluate the benefits of synthetic mem-
branes, since they are generally about three to 
four times more expensive than cellulose or modi-
fied cellulose membranes. Despite the economic
and practical importance of the choice of dialysis
membrane, it is not clear to nephrologists or
healthcare purchasers what the benefits of synthetic
membranes are and, if benefits do exist, whether
their extra cost can be justified.
Objectives
The objectives of this review are:
• to determine whether synthetic membranes offer
clinically important advantages compared with
standard or modified cellulose membranes in
the haemodialysis of patients with ESRD
• to determine from the literature the resource-
use implications of biocompatible membranes
and to relate this to measures of effectiveness 
in an economic analysis.
Materials and methods
Criteria for considering studies for 
this review
Types of studies  An attempt was made to identify
all trials which compared synthetic haemodialysis
membranes with those made with cellulose or
modified cellulose.
Types of participants  Any patient maintained on
or commencing haemodialysis for ESRD.
Types of intervention  Any RCT or quasi-RCT
comparing any (or several) synthetic haemodialysis
Appendix 4
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membranes with any (or several) cellulose or
modified cellulose haemodialysis membranes.
Types of outcome measures
1.  Symptomatic hypotension or hypotension
requiring intervention, headaches, nausea 
and vomiting, pruritis, anaphylaxis occurring
during haemodialysis treatment session
(recorded as the number of treatment sessions 
on which the event occurred).
2.  Number of haemodialysis treatments associ-
ated with ‘any adverse symptoms’ if they 
were not specified with the publication.
3.  Number of episodes of significant infection
either per patient or per year (diagnosis of 
and significance of infection as determined 
by each individual study).
4.  Number of hospital admissions and length 
of stay (as indicator of morbidity and 
resource use).
5.  Adequacy of dialysis measured either by 
Kt/V or URR.
6. Pre-dialysis  b2 microglobulin concentration.
7.  Number of patients with dialysis-associated
amyloidosis.
8.  Indices of nutritional status: fasting predialysis
total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol and triglyceride values, 
pre-dialysis albumen and PCR.
9.  Quality of life.
10. Mortality.
Search strategy for identification 
of studies
The search strategy used was one developed for 
the identification of all possible RCTs or quasi-
RCTs relating to the management of ESRD, and is
described in detail in chapter 2 and appendices 2
and 3.
Methods of the review
All possible RCTs identified on this topic were
evaluated using a study evaluation form and those
which met the eligibility criteria (included studies)
were then considered in detail. Data were extracted
using a data abstraction form designed for this
review (see appendix 10). Review Manager v. 3.0
was used for the analysis. A full description of the
methods used is given in chapter 2.
Description of studies
A total of 21 studies were identified that met the
eligibility criteria of being RCTs or quasi-RCTs
(Table 12). The descriptions of method of allocation
published were accepted, and author confirmation
was not sought. All studies included have been
published in complete form. Clarification from the
authors (Schaefer et al., 1993) of the number of
dialysis treatments with each type of membrane 
was sought and obtained, so that the number of
episodes of anaphylaxis per dialysis session could
be calculated and entered into Meta-view. A total 
of 23 trials were excluded because the outcomes
were not relevant to this review, and four were
excluded because the comparison was not between
cellulose and synthetic membranes.
Methodological quality of studies included
Of the 21 studies included (Table 12), ten were
parallel group randomised trials and 12 were
randomised or quasi-randomised crossover studies.
Potential for selection bias at trial entry
The reports of all 21 studies stated that the order 
of treatment had been randomly allocated. In 16 
of these, the method of random allocation used 
was not described. A secure method of random
allocation concealment prior to final trial entry
(third party or computer randomisation) was used
in three trials (Aakhus et al., 1995; Grooteman 
et al., 1995; Locatelli et al., 1996); three others
(Bergamo Collaboration, 1991; Parker et al., 1996)
had potentially insecure methods of random
allocation concealment (coin toss with no stated
third party involvement and alternation).
Potential for bias in trial analysis
The numbers and reasons for any withdrawals 
or drop-outs were described in six of the trials
(Caramelo et al., 1994; Collins et al., 1993; Hakim 
et al., 1996; Locatelli et al., 1995; Parker et al., 
1996; Schiffl et al., 1995); three (Levin et al., 1993;
Skroeder et al., 1994; Ward et al., 1993) mentioned
the number of withdrawals and drop-outs but did
not give the reasons. The remaining 12 trials did
not mention withdrawals or drop-outs.
One trial (Parker et al., 1996) was carried out on an
intention-to-treat basis and four (Caramelo et al.,
1994; Collins et al., 1993; Hakim et al., 1996; Ward
et al., 1993) were not. In the remaining 16 trials, it
was not possible to determine whether analysis had
been performed on an intention-to-treat basis.
Potential for bias at time of treatment or
outcome assessment
In three trials, blinding was mentioned; in one
(Aakhus et al., 1995), the membranes were hidden
by a covering from the patient and investigator 
and, in another (Danielson et al., 1986), the
patients and healthcare workers were blinded 
but the method of blinding was not given. There
was no blinding in the trial by Gardinali andHealth Technology Assessment 1998; Vol. 2: No.5
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TABLE 12  Characteristics of included studies
Study Method Participants Interventions Outcomes Notes
Aakhus,et al.,1995 Randomised crossover; Eight chronic dialysis  One dialysis session – Symptomatic  URR expressed as 
randomisation by third  patients;age range, 1 hour haemodialysis, hypotension;URR; mean (standard deviation 
party allocation;with- 24–73 years;M:F 1:1; 2 hours ultrafiltration – echo-cardiographic  (SD)).
drawals and drop-outs  inclusion and exclusion  with each membrane; data.
not mentioned;possibly  criteria not stated;co- membranes used:cupro- 
intention-to-treat  morbidity:two patients, phane (AM-65H-SD;
analysis;blinded effectively coronary artery disease; Asahi);Filtral 12 (AN69 
for patients and  one patient,diabetes; HF,Hospal);flux not 
outcomes assessors. none,ejection fraction  stated;surface area,not 
< 40%. stated;blood flow rate 
and dialysis flow rate not 
stated but kept constant;
buffer,bicarbonate;EPO,
not stated;ACE inhibitor,
one patient.
Bergamo  Randomised study with  428 patients from six  One dialysis with each  Hypotension requiring  Headaches,nausea,
Collaboration,1991 an attempt at conceal- dialysis units who had  membrane,duration as  treatment;interdialytic  vomiting,pruritis 
ment (tossing coin); undergone haemodialysis  usual for each patient  headache;interdialytic  recorded as improved,
withdrawals and drop- for ESRD for at least  (243 ± 22 minutes, nausea and vomiting; unchanged or worse 
outs not mentioned; 1 month;mean age, cellulose;243 ± 19, interdialytic pruritus; (post- compared with 
patients and healthcare  56.9 years,range  synthetic);vascular  interdialytic muscle  predialysis).No significant 
providers well blinded to  17–79 years (synthetic); access,not stated;blood  cramps;b2 difference  between 
treatment;no mention  55.9 years,range  flow rate,as usual for  microglobulin. membranes but data not 
of blinding for outcomes  19–80 years,cellulose; patient (mean,324 ± 33, suitable for meta-analysis.
assessors;intention-to- M:F 93:71,synthetic; synthetic;328 ± 33, b2 microglobulin was 
treat not clear. M:F,102:62,cellulose; cellulose);dialysate flow  measured before and 
inclusion criteria –  rate,as usual for patient  after test dialysis;hence,
dialysed for at least  (mean,500 ml/min);buffer, long-term effect could 
1 month;exclusion  acetate or bicarbonate, not be judged.
criteria – acute illness, as usual for patient (bicar- 
co-morbidity,diabetes  bonate – 28 cellulose,
7 (synthetic); 20 synthetic);membrane 
11 (cellulose). type – polysulphone 
(Bellco SPA,Italy),
cuprophan (Bellco SPA,
Italy),both custom-made 
with opaque housing,
surface area approx.
1 m
2,similar urea and 
creatinine clearance.
Blankestijn,et al.,1995 Two studies included  28 patients stable on  Duration,6 weeks with  Predialysis albumin; Main focus was high 
in paper,but only one  haemodialysis,14 on  either cuprophane or  predialysis trigly-  versus low flux;the 
relevant;randomised  cuprophane membranes, synthetic membrane;two cerides,cholesterol, second study compared 
study,states random  14 on synthetic;median  patients dialysed twice  lipoprotein A, the fall in lipids during 
allocation but no  age 63 years,range  weekly,and 26 patients  LDL,HDL. dialysis and,as this was 
description;withdrawals  22–80 years;M:F,10:18; three times weekly; not one of our outcome 
and drop-outs not  co-morbidity not stated; mean time on dialysis, measures,it was not 
mentioned;analysis  inclusion criteria – on  11 ± 1.4 hours;blood  included.
possibly on intention-to- chronic haemodialysis  flow rate and dialysate 
treat basis but not clear; for 6 months;exclusion  flow rate not stated – 
no mention of blinding  criteria – diabetes or  same as usual for each 
of patients,healthcare  on lipid-lowering drugs. patient;buffer type,
providers or outcomes  bicarbonate;membranes:
assessors. cuprophane – Asahi 
AM 140 and 160 Nova,
low flux;synthetic – 
F60S polysulphone high 
flux (Fresenius);EPO and 
ACE inhibitor use not 
mentioned;no reuse.
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Bosch,et al.,1986 Randomised crossover  Ten chronic  Three membranes  Symptomatic 
study;randomisation not  haemodialysis patients; used,each for 2 weeks; hypotension inter- 
described;withdrawals  mean age,54.7 years, duration and frequency  dialytic – any adverse 
and drop-outs not  range,38–69 years; of dialysis and vascular  symptoms;general 
mentioned;possibly  M:F,4:1;co-morbidity, access not stated;blood  well-being;adequacy –
intention-to-treat  inclusion and  flow,200 ml/min;dialy-  clearances in ml/minute 
analysis;no mention of  exclusion criteria  sate flow,5000 ml/min; of urea,creatinine,
blinding for patients, not mentioned. buffer,all acetate;mem-  phosphate but not URR 
healthcare providers or  branes – regenerated or Kt/V;component 
assessors. cellulose GF120 1.2 m
2 of complement,C3a;
(Gambro) hemophan  white blood cells,
1.2 m
2 (ENKA AG Wuper- platelets,elastase a-1 
tal,FRG) cellulose ace-  proteinase inhibitor,
tate CDAK 4000,1.0 m
2 platelet consumption.
(Cordis Dow);EPO and 
ACE inhibitor use not 
stated;reuse not stated.
Caramelo,et al.,1994 Randomised trial;gives  22 patients with ESRD; Trial duration,9 months; Any adverse symptoms, No numerical data 
random allocation but no  none had had transplant; duration and frequency  creatinine clearance, suitable for Meta-view.
description;drop-outs –  mean age:cellulose, of dialysis,vascular  urine volumes.
four from each group, 54 ± 15 years;synthetic, access,blood and 
four transplants,four  46 ± 16 years;M:F 13:9; dialysate flow rate not 
deaths;analysis not  exclusions – diabetes, stated;buffer type:cellu-
intention-to-treat;no  active rapidly-progressing  lose – nine acetate,four 
mention of blinding of  glomerulo nephritis,urine  bicarbonate;synthetic 
patients,healthcare  vol < 500 ml/24 hours  – five acetate,four 
providers or outcomes  at start of dialysis, bicarbonate;membranes:
assessors. major co-morbid illness  cuprophane,PAN,also 
(congestive cardiac failure, polysulphone;EPO or 
recent myocardial infarc- ACE inhibitors use not 
tion,chronic obstructive  stated;reuse not stated.
airways disease).
Collins,et al.,1993 Randomised,crossover  35 patients;mean age, 3 months with each  Hypotension,intra-  No numerical data given 
study;random allocation  cuprophane,55 years; dialysate three times  dialytic headaches, for hospital admissions 
not described;number  PAN,50 years;M:F,6:14  weekly (time not stated); vomiting,pruritus, – states no significant 
and reasons for drop-  cuprophane,7:10 PAN; blood flow rate: other symptoms –  differences were found;
outs given – five with-  co-morbidity – nine  300–400 ml/min;dialysate  angina,cramp,broncho- episodes of vomiting 
drawals excluded,i.e.not  diabetes,cuprophane: flow rate:500 ml/min; spasm,episodes of  reported as similar for 
intention-to-treat;no  eight diabetes,PAN; membranes;cuprophane, infection,hospital  both membranes using 
mention of blinding of  inclusion/exclusion  surface area 1.6 m
2, admission. Bonferroni’s test,but 
patients,healthcare  criteria not stated. UFc 8 ml/mmHg/hour; p < 0.05 using t test;this 
providers or outcomes  PAN (AN69),surface  significant on Meta-view,
assessors. area 1.55 m
2,UFc  so authors contacted.
44 ml/mmHg/hour;EPO 
and ACE inhibitor use not 
stated;reuse not stated.
Danielson,et al.,1986 Withdrawals and drop- Seven patients,sex  Synthetic – polycarbonate Hypotensive episodes; * Not clear if patients 
outs not mentioned; not stated,on regular  (Gambrane);cellulose  intradialytic headaches; were asked to report 
randomised,double-blind  haemodialysis;mean  (Gambro-Lundia), intradialytic nausea  these symptoms or if 
crossover study;method  age (SD),51 (16) years, parallel plate;duration  and vomiting;intra-  they were volunteered 
of allocation not  age range,30–65 years; of study:polycarbonate, dialytic pruritus;rise  spontaneously.
described;patients and  co-morbidity not stated; 2 weeks,cuprophane, in blood pressure,
staff responsible for  inclusion and exclusion  4 weeks;duration and  tachycardia,arrhythmia,
dialysis treatment both  criteria not stated. frequency of dialysis, chest pain,sweating 
blinded but methods  4 hours three times  dyspnoea,muscle 
not stated – possibly  weekly;flux,surface area, cramps,back pain,
intention-to-treat but  dialysate flow rate,blood  other pain,anxiety,
not clear. flow rate,type of buffer, fever,shivering
*;
use of ACE inhibitor,and  anaphylaxis.
reuse all not stated.
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Gardinali,et al.,1994 Randomised study,states  36 patients (16  Duration of trial, b2 microglobulin  Patients on mix of 
random allocation but no  cuprophane,10 PAN, 3 months;duration and  levels;components  membranes before study 
description;withdrawals  10 polysulphone);age  frequency,vascular access, of complement,C3a, began;at start,patients 
and drop-outs not stated; range,27–72 years;M:F, blood flow rate and dialy-  C5a;interleukin-1,2; on haemodialysis using 
possibly carried out on  23:13;co-morbidity and  sate flow rate not stated; tumour necrosing  cuprophane had higher 
basis of intention-to-treat, inclusion criteria not  buffer type,bicarbonate; factor;s/L-2r;CD3/ b2 microglobulin levels 
but not clear;no blinding  stated;exclusion criteria, membrane types: HLA-DR positive  than those using 
of patients,healthcare  recurrent bacterial  cellulose – cuprophane  cells + lymphocytes. synthetic membranes;at 
workers or outcomes  infections,diabetes, (Nephross Andante 1.0, end of study,predialysis 
assessors. autoimmune disease  Organon);polysulphone  levels were 49.7 ± 12.5 
and/or myeloma. (BL 627,Bellco,Mirandola, (cuprophane),32.7 ± 9.3 
Italy);polyacrylonitrile (polysulphone),35.3  ± 9.4 
(Filtral AN69,Hospal, (PAN),but these not 
Meyzieu,France). significantly different from 
those at start of study.
Grooteman,et al., Randomised crossover  31 patients on  3 weeks with each  Kt/V;extraction  Significant improvement 
1995a,b trial with good attempt at  haemodialysis for at least  membrane;duration of  ratio (1 – Ct180/Ct0)  in Kt/V and extraction 
concealment (computer- 6 months;median age, dialysis:3 or 4 hours, for urea,creatinine, ratios for urea,creatinine 
ised);withdrawals and  67 years,range, depending on patients’  phosphate;b2 micro-  and phosphate became 
drop-outs not mentioned; 27–84 years;M:F,15:16; previous prescription; globulin predialysis (at  non-significant when 
possibly intention-to-treat co-morbidity – one  vascular access,not  end of study);leuco-  correction made for 
but not clear;no mention  patient with diabetes; stated;blood flow, cytes,lymphocytes, surface area of 
of blinding. inclusion criteria – on  200–250 ml/min;buffer, complement and  membrane.
haemodialysis for at least  bicarbonate;membrane  cytokines.
6 months;exclusion  types:substituted 
criteria – acute infection, cellulose-CT 150 G 
autoimmune disease, cellulose triacetate 
malignancy,immuno- (Baxter,Osaka,Japan),flux 
suppressive drugs, – UFc,35,surface area,
non-steroidal anti- 1.5 m
2;synthetic F60 S 
inflammatory drugs. (Fresenius,Bad Homburg,
Germany),flux – UFc,
40,surface area,1.3 m
2;
EPO and ACE inhibitor 
use not stated;dialysers 
not reused.
Hakim,et al.,1996 Multicentre,randomised  159 patients on chronic  Duration,18 months; b2 microglobulin  High drop-out rate on 
trial;states random  haemodialysis;79 BCM, duration and frequency, (mg/l) predialysis  basis of inadequate Kt/V,
allocation but not  mean age 51 ± 14 years, vascular access,blood  measured at baseline, particularly in BCM 
described;numbers and  80 BICM,mean age  flow rate,dialysate flow  and at 3,6,7,12 and  group;very imbalanced.
reasons for withdrawals  54 ± 15 years;co-  rate,and buffer type not  18 months.
and drop-outs given – 37  morbidity – no patients  stated;membranes:
bioincompatible (BICM)  excluded on basis of  polymethylmethacrylate 
(46%),56 biocompatible  aetiology of renal failure  (PMMA) Toray 32–1.5 H,
(BCM) (71%);high  or any other medical  flux – UFc,5.0,surface 
drop-out rate – 13  condition;inclusion  area,1.7 m
2;cellulose 
(6 BICM:7 BCM) trans-  criteria – all patients over T175,flux – UFc,6.0,
ferred to another centre, 18 years,new to dialysis  surface area,1.5 m
2;EPO 
12 (9:3) transplants,10  between 1/3/91 and  and ACE inhibitor use 
(4:6) non-compliant,29  31/12/92;exclusion cri- not stated;re-used,but 
(4:25) did not achieve  teria,16 inadequate Kt/V  number of times not 
Kt/V (includes 16 exclud- values in first 2 weeks  specified.
ed),8 (3:5) CAPD,1 BCM  and data not used.
recovered,16 (4:4) died,
4 (3:1) other reasons;
analysis not on intention-
to-treat basis;no 
mention of blinding 
of patients,healthcare 
workers or outcomes 
assessors.
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Hosokawa &  Randomised trial,states  200 patients on  Duration of trial,1 year; Serum Si,Al,and b2  It is assumed that ‘before’ 
Yoshida,1991 randomisation but no  haemodialysis,100 per  duration and frequency, microglobulin levels. and ‘after’ treatment 
description;withdrawals  membrane;mean age, 5 hours three times per  refers to the beginning 
and drop-outs not  52.4 years (PMMA), week;membranes: and end of the study 
mentioned;analysis  53.8 years (cuprophane); PMMA,cuprophane; period,and not pre- and 
possibly on intention-to- M:F,101:99;co-morbidity  EPO,ACE inhibitor use  postdialysis.
treat basis;no mention  and inclusion criteria  and reuse not stated.
of blinding of patients, not stated;exclusion cri- 
healthcare providers or  teria,blood transfusions 
outcomes assessors. or vitamin supplements 
during the study period.
Levin,et al.,1993a;b Randomised crossover  37 patients at five centres 2 weeks with each of  Symptomatic hypo-  Stated Kt/V measured 
trial;random allocation  in four countries;mean  seven dialysers;time on  tension,headaches, but results not given;
stated but not described; age 54 years,range  dialysis,three times  nausea,vomiting, marked variations 
three withdrawals but  22–78 years;M:F,23:13; weekly,as follows:Chi-  pruritus,anaphylaxis, between centres;used 
timing and reasons not  co-morbidity not stated; cago,3.3.hours,Detroit, chest pain,back pain, symptoms as reported 
given;possibly on  inclusion criteria,on  3.1,Osaka,4.6,Stock-  dyspnoea,muscle  by staff but not patients.
intention-to-treat basis  dialysis for miniumum  holm,3.9;vascular access, cramps,chills,and 
but not clear;no mention  6 months,stable and  blood flow rate and dialy-  fever.
of blinding of patients, compliant,midweek  sate flow rate not stated;
healthcare providers, blood urea nitrogen  buffer,acetate;membranes:
outcomes assessors. (BUN),25–32 mmol/l; G10-3N,cuprammonium 
exclusion criteria, cellulose,plate 0.8 m2 – 
diabetes,no imminent  cellulose;G120 M cupram- 
medical problems. monium cellulose,hollow 
fibre,1.2 m
2 – cellulose;
CD4000 cellulose acetate,
hollow fibre,1.4 m
2 – 
modified cellulose; Duo- 
flux cellulose acetate,
hollow fibre,1.4 m
2 – 
modified cellulose;T150 
PMMA,hollow fibre,
1.4 m
2 – synthetic;F60 
polysulphone,hollow 
fibre,1.25 m
2 – synthetic;
Filtral copolymer of 
acrylonitrile and sodium
methallyl sulphonate 
(AN69S),hollow fibre,
1.15 m
2 – synthetic;EPO,
ACE inhibitor use and 
reuse not stated.
Locatelli,et al.,1996 RCT;good attempt at  279 patients;mean age  Duration of trial, Symptomatic hypo-  Very high drop-out rate,
concealment,third-party  54.4 (12.8) years,syn-  24 months;frequency  tension,treatment  especially for ‘technical 
blocked;number and  thetic,53.16 (12.7) years, of dialysis,three times  requiring hypotension  reasons’;two studies 
reasons for drop-outs –  cellulose;M:F,60.5% M, weekly;duration,vascular  plus any hypotension  included in this paper;
164 patients withdrew  synthetic,63.6% M,cellu-  access,blood flow rate, all taken together; ‘hypotension’ included 
during 2-year follow-up, lose;co-morbidity,6.1%  and dialysate flow rate  predialysis albumen; those with asymptomatic 
20 died,22 transplants; with diabetes,synthetic, not stated;buffer, PCR;adequacy (Kt/V); hypotension.
two acute clinical reasons, 4.5% with diabetes,cellu-  bicarbonate;membranes  mortality;no hospital 
four fistula problems, lose;inclusion criteria, – low flux polysulphone admissions and length 
29 because of treatment  age range 18–80 years, cuprophane;EPO, ACE  of stay;predialysis b2 
inadequacy,89 for tech- very stable clinically,RRT  inhibitor use and reuse  microglobulin;lipids;
nical reasons;possible  ³ 2 months,haemodialy-  not stated. transferrin;body 
intention-to-treat;no  sis three times per week, weight;skin fold 
mention of blinding of  PCR ³ 1.0 g/kg/day;exclu-  thickness,mid-arm 
patients,healthcare sion  criteria,malignant  circumference.
providers,outcome disease,no  myocardial 
assessors. infarction in last 12 months,
no stroke or transient 
ischaemic event in 
6 months,New York 
Heart Association 3 or 4.
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Parker,et al.,1996 Prospective randomised  159 new haemodialysis  Duration of trial, Pre-dialysis albumin; Drop-out because of 
design;randomisation not  patients,80 BICM,79  18 months;duration, PCR;Kt/V;mortality; inadequate Kt/V in high 
concealed – alternation; BCM;age,54 ± 15 years  frequency,vascular access, estimated dry weight; number on BCM,yet 
no mention of blinding  (BICM),51 ± 14 years  blood flow rate,dialy-  pre-albumin;insulin- Kt/V was one of the 
for patients,healthcare  (BCM);M:F,50:50; sate flow rate and buffer  like growth factor 1. outcomes;overall drop- 
workers or outcomes  inclusion criteria – over  type not stated,left to  out rate very high;
assessors;withdrawals  18 years,new patients; individual physician; SDs only given for 
and drop-outs:BICM, exclusion criteria – none  membranes,BCM –  significantly different 
37/80,BCM,56/79; but note many drop-outs; PMMA Toray B2-1.5  albumin values;the value 
reasons for drop-outs: co-morbidity:BICM,49%  (Filtryzer Toray Industries), we considered was at 
13 (6 BICM,7 BCM)  with diabetes,15% with  low-level complement  10 months,and at 
transferred to other facili- hypertension as aetiology; activation,low flux; 18 months (end of the 
ties,12 (9 BICM,3 BCM)  BCM,43% with diabetes, BICM – T175 (Terumo  study) there was no 
received transplants,ten  24% with hypertension  Corporation),high-level  significant difference.
(4 BICM,6 BCM) non- as aetiology. complement activation,
compliant or asked to  cellulose;EPO and use 
stop,29 (4 BICM,25 BCM)  of ACE inhibitors not 
inadequate Kt/V,eight  stated;reuse,10 ± 3.
(3 BICM,5 BCM) 
changed to peritoneal 
dialysis,one (BCM) 
recovered renal function,
16 (8 BICM,8 BCM) died,
four (3 BICM,1 BCM) 
dropped out for 
other reasons.
Quereda,et al.,1988 Randomised crossover  Eight patients;mean age, Eight phases of  Symptomatic hypo- Symptomatic hypotension 
study;random allocation  58 ± 9 years;M:F,2:6; 48 sessions each,four  tension;volume of  may reflect dialysate 
stated but no description; co-morbidity – no  sessions of cuprophane  infused saline. sodium concentration 
withdrawals and drop- diabetes or systemic  and four of PAN; and temperature rather 
outs not mentioned; disease;inclusion and  duration and frequency, than membrane type;
analysis possibly on  exclusion criteria  blood flow rate and  ‘symptomatic hypo- 
intention-to-treat basis; not stated. dialysate flow rate not  tension’ seemed to be 
no mention of blinding  stated;buffer – acetate; defined as blood pressure 
of patients,healthcare  membranes,cuprophane  < 90 mmHg systolic.
providers or outcomes  – hollow fibre,surface 
assessors. area,0.9 m
2,PAN – flat 
plate,surface area,0.7 m
2;
EPO use,ACE inhibitor 
use and reuse 
not stated.
Schaefer,et al.,1993 Randomised crossover  Ten patients on  Duration of trial,three  Anaphylaxis; There was one 
study;random allocation  haemodialysis;mean  dialyses with each dialy-  plasma bradykinin. anaphalactoid reaction 
stated but no description; age,57 years,range, ser;duration,frequency, in a patient treated with 
withdrawals and drop- 21–68 years;M:F,7:3; vascular access,blood  AN69;not possible to 
outs not mentioned; co-morbidity not stated; flow rate,dialysate flow  add the data as number 
analysis possibly on  inclusion criteria,long- rate and buffer type not  of dialysis sessions not 
intention-to-treat basis; term dialysis patients  stated;membranes,cellu- stated;when authors 
no mention of blinding  treated either with  lose – cuprophane GFE 12 contacted they stated 
of patients,healthcare  cuprophane or poly-  Gambro,1.3 m
2;synthetic  there were three dialysis 
providers or outcomes  sulphone dialysers; – AN69 Filtral 12 Hospal, treatments with each 
assessors. exclusion criteria, 1.3 m
2,and polysulphone  membrane with sample 
patients using ACE  F 60 Fresenius,1.2 m
2; collection at third 
inhibitors or with a  membrane fluxes not  treatment.
history of hyper-  stated;EPO use not 
sensitivity reactions. stated;no patients using 
ACE inhibitors;reuse 
not stated.
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Schiffl,et al.,1995a;b Study B appears to be a  24 patients but four  Duration of trial, Predialysis b2 Checking  randomisation
(also in:Mrowka  randomised trial;claims  drop-outs,two from each  72+ months;duration  microglobulin;carpal  with authors.
& Schiffl,1993) random allocation but also  group,makes total of 20; and frequency,4 hours  tunnel syndrome.
that ‘patients grouped  age range,28–69 years  three times weekly;blood 
according to their demo- (no mean given);co- flow rate,dialysis flow 
graphic data;definitely not morbidity and inclusion  rate and buffer not stated;
concealed;withdrawals and criteria not stated; membranes:cellulose – 
drop-outs,two transplants  exclusion criteria,no  Disscap 140,hollow fibre,
and two deaths;possibly  infection,autoimmune  surface area 1 m2,low- 
on intention-to-treat basis  disease,cancer. flux;synthetic – F60 
but not clear;no mention  polysulphone,surface 
of blinding of patients, area 1.25 m2,high-flux;
healthcare providers or  EPO use, ACE inhibitor 
outcomes assessors. use and reuse not stated.
Skroeder,et al.,1993 Randomised crossover  20 patients;mean age  Three types of membrane  Drop in b2 micro- 
study;randomisation  59(3) years,range 40–  used:Cuprophan GF120H globulin concentration 
method not stated;four  79 years;M:F,4:1;co-  (Gambro),surface area, per dialysis.
withdrawals;not clear if  morbidity – no patients  1.2 m
2;Hemophan GF120,
on intention-to-treat  had inflammatory,liver  surface area,1.2 m
2;poly-
basis;no mention of  or myelo-proliferative  amide polyflux,surface 
blinding of patients, disorders;inclusion  area,1 or 1.6 m
2;80–88 
healthcare providers  criteria – stable for at  dialysis sessions per mem-
or outcomes assessors. least 3 months on dialy-  brane,2 or 4 hours 
sis;exclusion criteria –  equally distributed;blood 
immuno-suppressed or  flow rate,200–400 ml/min,
malignancy,diabetes, equally distributed;buffer 
acute infection or on  type,bicarbonate;EPO 
anticoagulants. or ACE inhibitor use not 
states;no reuse.
Skroeder,et al., Randomised crossover  20 chronic patients on  Three membranes used  Symptomatic hypo- Skroeder,et al.,1994b 
1994a;b study;randomisation  haemodialysis;mean age  – cellulose (Cuprophan  tension;intradialytic  should be excluded 
method and withdrawals  61(1) years,range  GM120H,surface area, headaches;pruritus; because the outcomes 
not stated;possibly on  40–80 years;M:F,4:1; 1.2 and 2 m
2),Hemophan subjective  symptoms  are not relevant to this 
intention-to-treat basis; co-morbidity – immuno- (GF120,surface area,1.2– during dialysis. review,although the same 
no mention of blinding  suppression,malignancy, 2 m
2),polyamide (Poly-  patients are studied;
of patients,healthcare  diabetes,anticoagulants, flux,surface area,1 and  Review Manager software 
providers or outcomes  acute infection;inclusion  0.6 m
2);flux not stated; is not capable of distin- 
assessors. criteria – 3 months stable  duration – 77–80 sessions  guishing between the 
on dialysis;exclusion  per membrane,2–4 hours  two studies.
criteria – as for  equally distributed;vascu- 
co-morbidity. lar access not mentioned;
blood flow rate,
200–400 ml/min equally 
distributed;dialysate flow 
rate,500 ml/min;buffer 
type,bicarbonate;EPO not 
used; ACE inhibitor use 
not stated;no reuse.
Vanholder,et al.,1992 Randomised crossover  15 new patients on  Duration of trial, No episodes of 
trial;states random  dialysis,seven synthetic, 12 weeks with each  significant infection;
allocation,but no  eight cellulose  dialyser;duration, metabolic response 
description;withdrawals  membrane;ages and  frequency,vascular access, to phagocyte stimulus.
and drop-outs not  sex ratio not stated; blood flow rate and 
mentioned;possibly on  inclusion criteria –  dialysate flow rate not 
intention-to-treat basis  new chronic dialysis  stated;buffer type,
but not clear;no mention  patients;exclusion  bicarbonate;membranes:
of blinding of patients, criteria not stated; cuprophane either 
healthcare providers or  Bravo 501 or Gambro 
outcomes assessors. GF20;low flux poly-
sulphone,F-6 Fresenius 
with minimal complement 
reactivity;EPO and ACE 
inhibitor use not stated;
no reuse.
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colleagues (1994). In the remaining 18 trials, 
no mention was made of blinding.
Our quality assessment tool assumes that the
avoidance of bias is best achieved by an RCT with:
• secure concealment of allocation before formal
trial entry
• adequate blinding of patients, outcomes
assessors and healthcare providers
• description of reasons and numbers of
withdrawals and drop-outs
• analysis on an intention-to-treat basis.
None of the trials fulfilled all of these criteria.
Other characteristics of included studies
All the studies were published in English; 15 were
published between 1993 and 1996, three in 1991
and 1992, and three in the late 1980s. The majority
of trials were thus relatively recent and, for the
most part, described membranes in current use. 
Ten studies commented on the co-morbid illnesses
present in the dialysis patients and eight excluded
patients on the basis of co-morbidity, although the
nature of the excluding conditions varied from
study to study.
In some studies, it was not possible to derive 
data for the outcome measure in question, either
because outcomes were not given in numerical
form at all or because they were not given in suffi-
cient detail (e.g. means given without standard
deviations or standard errors). When this occurred
it is described in the Results (below).
Results
For the purpose of this review, when cellulose
membranes were compared with synthetic mem-
branes, the cellulose membranes were regarded 
as the controls. Similarly, when modified cellulose
membranes were compared with synthetic, the
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Ward, et al.,1993 Randomised crossover  21 patients at three  Duration,2 weeks  Intradialytic pruritus  b2 microglobulin 
study;states random  centres;mean ages, (6 treatments) with each  (sessions of no dialysis  clearance measured and 
allocation but no  62 ± 12 years (centre 1), dialyser;duration and  not stated,so data  was similar in high-flux 
description;three drop- 53 ± 6 years (centre 2), frequency,three times  not in Meta-view); modified cellulose and 
outs but no reasons;no  37 ± 8 years (centre 3); weekly but time variable; three patients on EVAL synthetic but both were 
mention of blinding of  overall M:F,62:38;co- vascular access not  membrane;URR. greater than cuprophane;
patients,healthcare  morbidity not stated; stated;blood flow rate, study authors suggest 
workers or outcomes  inclusion criteria –  200 ml/min (centre 3 kept  this may reflect flux 
assessors. stable on three times  it at this level for first  rather than synthetic 
weekly dialysis,b2  hour only);dialysate flow  nature of membrane.
microglobulin > 35 mg/l; rate,500 ml/min;buffer 
exclusion criteria –  type,18 bicarbonate,
evidence of infection, three acetate;mem- 
haematocrit level  branes:cuprophane – D2 
< 18%. Fresenius,surface area,
1.1 m2,six patients;
GF180M Gambro,surface 
area,1.6 m
2,six patients;
GFS120 Gambro,surface 
area,1.1 m
2,one patient;
L10-5N Gambro,surface 
area,1.1 m
2,seven 
patients;L10-6N Gambro,
surface area,1.6 m
2,one 
patient;modified cellulose 
– Haemophan HP Nikkiso,
surface area,1.2 m
2,
21 patients;synthetic – 
AN69 (Filtral 12) Hospal,
surface area,1.15 m
2,
21 patients;EVAL 
(KF 101N) Kuraray,surface 
area,1.3 m
2,21 patients;
EPO and ACE inhibitor 
use not stated;reuse,
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modified cellulose membranes were regarded as
controls. A total of 22 outcome measures were
sought in 11 broad areas. For two outcome meas-
ures (number of episodes of significant infections
per year and quality of life) no data were available,
and for one (URR), data were not presented in a
form that could be analysed. For the comparison 
of cellulose with synthetic membranes, data on
10/19 outcome measures were available for only 
a single trial; for modified cellulose and synthetic
membranes, four outcome measures were available
in one trial, and for 12 outcomes no data were
found in any of the trials.
The results of the meta-analyses are presented in
Table 13 (A and B).
Dialysis treatment associated 
with symptomatic or treatment-
requiring hypotension
Data are available for seven trials that compare
cellulose with synthetic membranes for this
outcome measure. The number of dialysis sessions
varied from eight (Aakhus et al., 1995) to 1260
(Collins et al., 1993) and this is reflected in the 
CIs; four trials included more than 100 dialysis
sessions, and overall there is no evidence of
significant heterogeneity within this group of 
trials. One trial (Locatelli et al., 1996) reported
symptomatic hypotension, treatment-requiring 
and non-symptomatic hypotension, without
distinguishing between these three groups; these
results have not therefore been included in the
meta-analysis. The authors’ own figures show no
significant difference in hypotension between 
those on cellulose and synthetic membranes 
(both were low-flux membranes). None of the
individual studies showed a statistically significant
difference between the membranes for this out-
come. Modified cellulose and synthetic membranes
were also compared for this outcome measure in
two trials (Skroeder et al., 1994; Levin et al., 1993)
and, again, there was no statistically significant
difference between the two membranes, nor was
there significant heterogeneity between the trials.
Two of the larger trials included patients with
diabetes (Collins et al., 1993; Bergamo Collabor-
ation, 1993) and two did not (Levin et al., 1993;
Querada et al., 1988). Locatelli and colleagues
TABLE 13A Synthetic vs.cellulose/modified cellulose haemodialysis membranes:overall summary
Comparison or outcome Peto OR WMD
(95% CI) (95% CI)
Sessions with symptomatic/treatment-requiring hypotension
Sessions with headaches
Sessions with nausea/vomiting
Sessions associated with pruritus
Sessions with anaphylaxis Subgroup analysis only
Sessions with adverse symptoms
Patients with episode of infection
Infections per year on haemodialysis per patient Not estimable
Number of hospital admissions per year
Number of days in hospital Subgroup analysis only
Kt/V
URR Subgroup analysis only
Predialysis b2 microglobulin serum concentration (mg/l)
Number of patients with dialysis-associated amyloidosis
Total cholesterol concentration Subgroup analysis only
HDL cholesterol concentration Subgroup analysis only
LDL cholesterol concentration Subgroup analysis only
Triglyceride concentration Subgroup analysis only
Serum albumin concentration (g/dl) Subgroup analysis only
PCR Subgroup analysis only
General well-being/quality of life Not numerical data
Mortality
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TABLE 13B  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Number of haemodialysis treatments associated with symptomatic or treatment-requiring hypotension
Cellulose membrane
Aakhus,1995 1/8 1/8 0.3 1.00 (0.06,17.62)
Bergamo,1991 39/214 32/214 8.6 1.27 (0.76,2.11)
Collins,1993 187/1260 180/1260 45.2 1.05 (0.84,1.30)
Danielson,1986 1/12 1/6 0.2 0.45 (0.02,9.33)
Levin,1993 75/645 42/422 14.4 1.19 (0.80,1.76)
Querada,1988 71/192 82/192 13.3 0.79 (0.52,1.18)
Skroeder,1994 3/77 5/80 1.1 0.62 (0.15,2.55)
Subtotal (95% CI) 377/2411 343/2179 83.1 1.03 (0.88,1.21)
Chi-square 3.60 (df = 6) Z = 0.38
Modified cellulose membrane
Levin,1993 75/645 54/428 15.7 0.91 (0.63,1.33)
Skroeder,1994 3/77 6/77 1.2 0.49 (0.13,1.89)
Subtotal (95% CI) 78/722 60/505 16.9 0.87 (0.61,1.25)
Chi-square 0.74 (df = 1) Z = 0.75
Total (95% CI) 455/3133 403/2684 100.0 1.00 (0.86,1.16)
Chi-square 5.03 (df = 8) Z = 0.04
Number of haemodialysis treatments associated with headaches
Cellulose membrane
Collins,1993 24/1260 30/1260 11.9 0.80 (0.46,1.37)
Danielson,1986 0/6 3/12 0.5 0.18 (0.01,2.35)
Levin,1993 152/645 96/422 41.1 1.05 (0.78,1.40)
Skroeder,1994 5/77 12/80 3.4 0.42 (0.15,1.14)
Subtotal (95% CI) 181/1988 141/1774 57.0 0.92 (0.72,1.18)
Chi-square 4.96 (df = 3) Z = 0.66
Modified cellulose membrane
Levin,1993 152/645 88/428 40.3 1.19 (0.89,1.59)
Skroeder,1994 5/77 8/77 2.7 0.61 (0.20,1.88)
Subtotal (95% CI) 157/722 96/505 43.0 1.14 (0.86,1.51)
Chi-square 1.27 (df = 1) Z = 0.90
Total (95% CI) 328/3133 237/2684 100.0 1.01 (0.84,1.22)
Chi-square 7.48 (df = 5) Z = 0.09
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TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Number of haemodialysis treatments associated with nausea/vomiting
Cellulose membrane
Collins,1993 68/1260 108/1260 40.6 0.61 (0.45,0.83)
Danielson,1986 0/6 0/12 0.0 Not estimable
Levin,1993 81/645 78/422 32.1 0.63 (0.44,0.88)
Subtotal (95% CI) 149/1911 186/1694 72.7 0.62 (0.49,0.78)
Chi-square 0.01 (df = 1) Z = 4.10
Modified cellulose membrane
Levin,1993 81/645 50/428 27.3 1.09 (0.75,1.58)
Subtotal (95% CI) 81/645 50/428 27.3 1.09 (0.75,1.58)
Chi-square 0.00 (df = 0) Z = 0.43
Total (95% CI) 230/2556 236/2122 100.0 0.72 (0.59,0.88)
Chi-square 6.31 (df = 2) Z = 3.27
Number of haemodialysis treatments associated with pruritis
Cellulose membrane
Collins,1993 14/1260 10/1260 4.6 1.40 (0.63,3.13)
Danielson,1986 0/6 0/12 0.0 Not estimable
Levin,1993 205/645 154/422 44.2 0.81 (0.62,1.05)
Skroeder,1994 9/77 6/80 2.6 1.62 (0.56,4.68)
Subtotal (95% CI) 228/1988 170/1774 51.4 0.88 (0.69,1.12)
Chi-square 2.94 (df = 2) Z = 1.03
Modified cellulose membrane
Levin,1993 205/645 174/428 45.6 0.68 (0.53,0.88)
Skroeder,1994 8/77 9/77 3.0 0.88  (0.32,2.39)
Subtotal (95% CI) 213/722 183/505 48.6 0.69 (0.54,0.88)
Chi-square 0.24 (df = 1) Z = 2.95
Total (95% CI) 441/2710 353/2279 100.0 0.78 (0.66,0.93)
Chi-square 5.13 (df = 4) Z = 2.79
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TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Number of haemodialysis treatments associated with anaphylaxis
Cellulose membrane
Danielson,1986 0/12 1/12 52.9 0.14 (0.00,6.82)
Schaefer,1993 1/60 0/30 47.1 4.48 (0.07,286.51)
Subtotal (95% CI) 1/72 1/42 100.0 0.70 (0.04,12.17)
Chi-square 1.44 (df = 1) Z = 0.24
Modified cellulose membrane
Subtotal (95% CI) 0/0 0/0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Number of haemodialysis treatments associated with adverse symptoms
Cellulose membrane
Danielson,1986 3/6 1/12 4.8 9.75 (0.99,96.31)
Skroeder,1994 18/77 22/80 49.0 0.81 (0.39,1.65)
Subtotal (95% CI) 21/83 23/92 53.8 1.01 (0.51,1.99)
Chi-square 4.14 (df = 1) Z = 0.02
Modified cellulose membrane
Skroeder,1994 18/77 19/77 46.2 0.93 (0.45,1.95)
Subtotal (95% CI) 18/77 19/77 46.2 0.93 (0.45,1.95)
Chi-square 0.00 (df = 0) Z = 0.19
Total (95% CI) 39/160 42/169 100.0 0.97 (0.59,1.60)
Chi-square 4.17 (df = 2) Z = 0.12
Number of patients who had an episode of significant infection
Cellulose membrane
Vanholder,1992 0/7 3/8 100.0 0.11 (0.01,1.30)
Subtotal (95% CI) 0/7 3/8 100.0 0.11 (0.01,1.30)
Chi-square 0.00 (df = 0) Z = 1.75
Modified cellulose membrane
Subtotal (95% CI) 0/0 0/0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 0/7 3/8 100.0 0.11 (0.01,1.30)
Chi-square 0.00 (df = 2) Z = 1.75
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TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Number of hospital admissions per year
Cellulose membrane
Locatelli,1996 147 0.50 (1.20) 132 0.40 (0.80) 100.0 0.100 (–0.137,0.337)
Subtotal (95% CI) 147 132 100.0 0.100 (–0.137,0.337)
Chi-square 0.00 (df = 0) Z = 0.83
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 147 132 100.0 0.100 (–0.137,0.337)
Chi-square 0.00 (df = 0) Z = 0.83
Number of days in hospital
Cellulose membrane
Locatelli,1996 147 4.70 (11.50) 132 4.00 (10.00) 100.0 0.700 (–1.823,3.223)
Subtotal (95% CI) 147 132 100.0 0.700 (–1.823,3.223)
Chi-square 0.00 (df = 0) Z = 0.54
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 147 132 100.0 0.700 (–1.823,3.223)
Chi-square 0.00 (df = 0) Z = 0.54
Kt/V
Cellulose membrane
Locatelli,1996 59 –1.35 (0.25) 56 –1.32 (0.20) 40.5 –0.030 (–0.113,0.053)
Parker,1996 79 –1.24 (0.27) 80 –1.37 (0.29) 36.4 0.130 (0.043,0.217)
Subtotal (95% CI) 138 136 77.0 0.046 (–0.014,0.106)
Chi-square 6.83 (df = 1) Z = 1.50
Modified cellulose membrane
Grooteman,1995a 31 –0.97 (0.22) 31 –1.08 (0.22) 23.0 0.110 (0.000,0.220)
Subtotal (95% CI) 31 31 23.0 0.110 (0.000,0.220)
Chi-square 0.00 (df = 0) Z = 1.97
Total (95% CI) 169 167 100.0 0.061 (0.008,0.113)
Chi-square 7.85 (df = 2) Z = 2.26
continued
–1 0 1
Favours control Favours treatment
–10 0 –5 51 0
Favours control Favours treatment
–0.5 0 0.5
Favours control Favours treatmentHealth Technology Assessment 1998; Vol. 2: No.5
59
TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Predialysis b2 microglobulin serum concentration (mg/l)
Cellulose membrane
Gardinali,1994 10 32.70 (9.30) 16 49.70 (12.50) 9.7 –17.000 (–25.411,–8.589)
Hakim,1996 23 34.00 (10.00) 43 36.80 (13.90) 20.3 –2.800 (–8.628,3.028)
Hosokawa,1991 100 42.00 (16.00) 100 81.00 (26.00) 19.2 –39.000 (–44.984,–33.016)
Locatelli,1996 59 37.50 (19.20) 56 37.50 (11.22) 21.1 0.000 (–5.713,5.713)
Schiffl,1995 10 37.00 (14.00) 10 55.00 (7.00) 7.3 –18.000 (–27.702,–8.298)
Subtotal (95% CI) 202 225 77.6 –14.217 (–17.195,–11.239)
Chi-square 105.89 (df = 5) Z = 9.90
Modified cellulose membrane
Grooteman,1995a 31 27.00 (10.56) 31 30.00 (11.67) 22.4 –3.000 (–8.540,2.540)
Subtotal (95% CI) 31 31 22.4 –3.000 (–8.540,2.540)
Chi-square 0.00 (df = 0) Z = 1.06
Total (95% CI) 233 256 100.0 –11.703 (–14.326,–9.080)
Chi-square 117.66 (df = 5) Z = 8.74
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Number of patients with dialysis-associated amyloidosis
Cellulose membrane
Schiffl,1995 0/20 14/20 100.0 0.05 (0.01,0.18)
Subtotal (95% CI) 0/20 14/20 100.0 0.05 (0.01,0.18)
Chi-square 0.00 (df = 0) Z = 4.58
Modified cellulose membrane
Subtotal (95% CI) 0/0 0/0 0/0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 0/20 14/20 100.0 0.05 (0.01,0.18)
Chi-square 0.00 (df = 0) Z = 4.58
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TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Total cholesterol concentration
Cellulose membrane
Blankestijn,1995 14 4.71 (0.95) 14 5.20 (0.57) 100.0 –0.490 (–1.070,0.090)
Subtotal (95% CI) 14 14 100.0 –0.490 (–1.070,0.090)
Chi-square 0.00 (df = 0) Z = 1.65
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
HDL cholesterol concentration
Cellulose membrane
Blankestijn,1995 14 –0.81 (0.16) 14 –0.88 (0.19) 100.0 0.070 (–0.060,0.200)
Subtotal (95% CI) 14 14 100.0 0.070 (–0.060,0.200)
Chi-square 0.00 (df = 0) Z = 1.05
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
LDL cholesterol concentration
Cellulose membrane
Blankestijn,1995 14 2.87 (0.73) 14 2.99 (0.59) 100.0 –0.120 (–0.612,0.372)
Subtotal (95% CI) 14 14 100.0 –0.120 (–0.612,0.372)
Chi-square 0.00 (df = 0) Z = 0.48
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
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TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Triglyceride concentration
Cellulose membrane
Blankestijn,1995 14 1.82 (0.59) 14 2.48 (0.80) 100.0 –0.660 (–1.181,–0.139)
Subtotal (95% CI) 14 14 100.0 –0.660 (–1.181,–0.139)
Chi-square 0.00 (df = 0) Z = 2.48
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Serum albumin concentration (g/dl)
Cellulose membrane
Blankestijn,1995 14 –3.30 (0.33) 14 –3.50 (0.44) 11.7 0.200 (–0.088,0.488)
Locatelli,1996 59 –4.00 (1.54) 56 –4.00 (1.12) 4.0 0.000 (–0.490,0.490)
Parker,1996 79 –3.89 (0.34) 80 –3.73 (0.35) 84.3 –0.160 (–0.267,–0.053)
Subtotal (95% CI) 152 150 100.0 –0.111 (–0.210,–0.013)
Chi-square 5.47 (df = 2) Z = 2.22
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
PCR
Cellulose membrane
Locatelli,1996 59 –1.22 (0.24) 56 –1.24 (0.24) 100.0 0.020 (–0.068,0.108)
Subtotal (95% CI) 59 56 100.0 0.020 (–0.068,0.108)
Chi-square 0.00 (df = 0) Z = 0.45
Modified cellulose membrane
Subtotal (95% CI) 0 0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
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(1996) excluded patients with recent evidence 
of cardiovascular and cerebrovascular disease 
and malignant disease.
Levin and colleagues (1993) reported hypotension
as noted by the staff and as ‘problems with blood
pressure’ reported by patients; for this study, data
from staff reporting were entered into Meta-view in
line with two other trials that used this outcome
measure and which mentioned the method of
reporting. The patients reported blood pressure
problems very much more frequently (143/645
sessions on synthetic membranes and 137/422
sessions on cellulose membranes; there was no
mention of blinding of patients or staff) and if
these data had been used, the results of the study
by Levin and colleagues would have achieved
statistical significance in favour of synthetic mem-
branes, although the overall results would just have
failed to reach significance. Patients also reported
symptoms more frequently when treated with
modified cellulose membranes (118/428). Had
these results been entered, significantly fewer
episodes of symptomatic hypotension would have
been reported with synthetic membranes for this
study and for the overall meta-analysis.
Number of haemodialysis treatments
associated with headache
Four trial reports include headache as an outcome
measure. There was no evidence of significant
heterogeneity between these trials and, overall,
there was no statistically significant difference be-
tween cellulose and synthetic membranes. For this
outcome, the patient-reported data from the study
by Levin and colleagues (1993) were entered; had
the number of headaches reported by the staff
been used (25/645 synthetic and 7/422 cellulose),
there would have been no change in the overall
result. Two papers compared modified cellulose
membranes with synthetic membranes; there was
no evidence of significant heterogeneity between
the trials and no difference in the incidence 
of headaches.
Number of haemodialysis treatments
associated with nausea/vomiting
Three trials compared nausea and vomiting
between cellulose and synthetic membranes. One
very small trial (Danielson et al., 1996) showed no
episodes of nausea or vomiting with either treat-
ment, and two other trials (Collins et al., 1993;
Levin et al., 1993), using patient-reported data,
showed significantly less nausea and vomiting with
synthetic membranes. There was no evidence of
heterogeneity between the trials and reflecting 
this, the overall effect confirmed significantly less
nausea and vomiting when a synthetic membrane
was used (OR, 0.62; 95% CI, 0.49, 0.78). ‘Numbers-
needed-to-treat’ (NNT) analysis indicated that in 
31 (95% CI, 20, 78) dialysis sessions there would 
be one fewer episode of nausea or vomiting using 
a synthetic membrane.
Only one trial compared modified cellulose with
synthetic membranes (Levin et al., 1993) and no
TABLE 13B contd  Synthetic vs.cellulose/modified cellulose haemodialysis membranes:detailed meta-analysis
Study Patient Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Mortality
Cellulose membrane
Locatelli,1996 12/147 8/132 56.2 1.37 (0.55,3.40)
Parker,1996 8/79 8/80 43.8 1.01 (0.36,2.84)
Subtotal (95% CI) 20/226 16/212 100.0 1.20 (0.61,2.37)
Chi-square 0.18 (df = 1) Z = 0.53
Modified cellulose membrane
Subtotal (95% CI) 0/0 0/0 0.0 Not estimable
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 20/226 16/212 100.0 1.20 (0.61,2.37)
Chi-square 0.18 (df = 1) Z = 0.53
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significant difference was found for this outcome.
This trial included patients with diabetes, although
no other description of co-morbidity was given.
Meta-analysis of the studies showed a significantly
lower incidence of nausea and vomiting with
synthetic membranes compared with cellulose 
and modified cellulose membranes.
Number of haemodialysis treatments
associated with pruritus
Four papers considered pruritus as an outcome
measure. There was no evidence of heterogeneity
and no overall significant differences between cellu-
lose and synthetic membranes. Levin and colleagues
study (1993), using patient-reported data, just failed
to reach statistical significance in favour of synthetic
membranes. Two trials compared this outcome be-
tween modified cellulose and synthetic membranes.
There was no evidence of significant heterogeneity
and there was a significant difference in favour of
synthetic membranes in the trial by Levin and
colleagues and when the results of the two studies
were combined (NNT, 15; 95% CI, 8, 71). Although
in the trial by Levin and colleagues, staff reported
fewer cases of pruritis overall (22/645 synthetic,
19/422 modified cellulose), the estimate of risk
reduction (OR, 0.75) is similar to that derived from
patient-reported symptoms. The overall estimate for
all trials, for both cellulose and modified cellulose,
should be interpreted with caution because it is
largely dependent on a single trial (Levin et al.,
1993) and the data from the group treated with
synthetic membranes in this trial were counted twice
because it was a three group comparison.
Number of haemodialysis treatments
associated with anaphylaxis
Anaphylaxis was mentioned in the reports of only
two trials; a single case was reported among those
managed with a synthetic membrane, and a single
case after use of a synthetic membrane. Patients on
angiotensin converting enzyme (ACE) inhibitors
were excluded from the trial by Schaefer and
colleagues (1993), and were not mentioned in 
the earlier trial, carried out at a time when such
drugs were not readily available.
Number of haemodialysis treatments
associated with any adverse symptoms
Two papers commented on ‘unspecified adverse
symptoms’ in numerical form. One trial was very
small and, overall, there was no evidence of any
difference. Another paper (Caramelo et al., 1994)
commented that there were no adverse symptoms
in patients being treated with either membrane 
but did not give any numerical data.
Number of patients who had an episode
of significant infection
Relevant data on infection were available for 
only 15 patients (van Holder et al., 1992), of 
whom three were reported to have had 
significant infections.
Number of hospital admissions per 
year and number of days of hospital
admission per year
The large trial by Locatelli and colleagues (1996)
was the only one to report hospital admissions; 
no difference between cellulose and synthetic
membranes was found. The methodology of this
trial was well described but excluded many patients
with co-morbid illness, particularly cardiovascular
disease. The number of hospital admission days 
per year was also similar between the two groups.
Kt/V
Two trials showed values for Kt/V in patients
treated with cellulose or synthetic membranes;
Parker and colleagues (1996) showed a difference
between the membranes that favoured the cellulose
membrane, Locatelli and colleagues (1996) did 
not but excluded two patients with a Kt/V value 
of < 0.95 (lower than required for inclusion in 
the study). Both studies used low-flux membranes.
Meta-analysis of these studies failed to show a sig-
nificant benefit for either of these membranes for
this outcome measure. The trials did, however,
display heterogeneity, perhaps because of their
exclusion criteria, different policies for reuse, 
and duration of dialysis session (not reported).
One trial compared Kt/V for synthetic and
modified cellulose membranes (Grooteman et al.,
1995). The lower value for the synthetic group is 
of borderline statistical significance; the flux, as
measured by the ultrafiltration coefficient (UFc), 
of the two membranes was again reported by the
authors to be similar (UFc = 35, modified cellulose;
UFc = 40, synthetic). 
Meta-analysis of all three studies just reached
statistical significance in favour of cellulose and
modified cellulose membranes.
Urea reduction ratio
One trial (Ward et al., 1993), which compared
cellulose, modified cellulose and synthetic mem-
branes, measured URR. However, standard devi-
ations were not given and the WMD could not be
calculated. When cellulose membranes were com-
pared with two synthetic membranes, the URR was
slightly higher for those dialysing with cellulose
membranes (mean URR cellulose membrane, Appendix 4
64
60%; mean URRs synthetic, 55%, 54%). When a
modified cellulose membrane was compared with
synthetic membranes, the mean URR values were
52%, 55% and 54%, respectively. The authors
concluded that the cellulose membrane had a
greater clearance than the others (p = 0.013).
Predialysis b2 microglobulin 
serum concentration and amyloid
disease development
Five groups measured predialysis b2 microglobulin
serum concentrations at the beginning and 
end of their trials when comparing cellulose with
synthetic membranes; there was evidence of signifi-
cant heterogeneity between studies, probably due
to differences in flux. Overall, there was a signifi-
cant decrease in b2 microglobulin values when
synthetic membranes were used. However, two
studies (Hakim et al., 1996; Locatelli et al., 1996)
showed no significant improvement with synthetic
membranes and they are characterised by the use
of cellulose and synthetic membranes with a similar
low flux. The trials, which showed a significantly
lower concentration of b2 microglobulin with the
synthetic membrane at the end of the study period,
all compared high-flux synthetic membranes with
low-flux cellulose membranes. The trials varied in
length from 3 months (Gardinali et al., 1994) to 72
months (Schiffl et al., 1995).
In one trial (Grooteman et al., 1995), modified
cellulose membranes were compared with synthetic
membranes. There was no significant difference in
predialysis b2 microglobulin serum concentration
between these membranes, both of which had
similar high-flux characteristics.
In a further trial, Schiffl and colleagues (1993)
compared the development of amyloid disease over
a 6-year period and found significantly less amyloid
disease occurring with the synthetic membranes
(the sample size was, however, small); no cases 
of amyloid disease were seen using the synthetic
membrane. The authors point out again that the
synthetic membrane had a high UFc whereas 
that for the cellulose membrane was low.
Predialysis lipids
In one trial, Blankestijin and colleagues (1995)
measured predialysis plasma total cholesterol, LDL
cholesterol, HDL cholesterol and trigylcerides over a
6-week period. Of these, only the serum triglyceride
concentration in the group assigned a synthetic
membrane was significantly lower. The synthetic
membrane had high-flux characteristics and the
cellulose membrane low-flux characteristics. In
another study, Locatelli and colleagues (1996)
commented that there was no statistically significant
difference in plasma cholesterol or triglycerides in
patients dialysed with cellulose or synthetic mem-
branes in the 24-month follow-up period of their
trial. Both these membranes were low flux.
Serum albumin concentration
Three trials reported serum albumin concentra-
tions. In the largest, Parker and colleagues (1996)
showed a significantly higher mean level in the
group using synthetic membranes and the overall
estimate reflects this one trial. The trial by Blanken-
stijn and colleagues (1995) excluded patients with
diabetes and that of Locatelli and colleagues (1996)
patients who had had a recent myocardial infarct 
or who had a history of stroke or transient ischaemic
attack. Parker and colleagues included patients 
with diabetes in their trial. Meta-analysis of the 
three studies showed a significant difference in
serum albumin concentration in favour of 
synthetic membranes.
Protein catabolic rate
PCR was only reported in one trial and there 
was no significant difference between the
membranes used.
Mortality
The trials by Parker and colleagues (1996) and
Locatelli and colleagues (1996) both had mortality
as an outcome measure. The trial by Parker and
colleagues lasted 18 months and there were eight
deaths in each group. Locatelli and colleagues quote
deaths at their 24-month follow-up as 12/147 (18%)
in patients dialysed with low-flux synthetic mem-
branes and 8/132 (12%) in those dialysed with cellu-
lose membranes. In neither trial nor in the overall
meta-analysis was there a significant difference
between cellulose and synthetic membranes.
Discussion
Overall, this systematic review indicates that the
incidence of nausea and vomiting was less with
synthetic than with cellulose membranes, and that
the incidence of pruritis was less with synthetic
membranes than with modified cellulose mem-
branes. Predialysis b2 microglobulin concentrations
were significantly lower at the end of the studies 
in patients treated with synthetic membranes also,
although all studies which showed this effect used
high-flux synthetic membranes. Similarly, one 
study showed the incidence of amyloid disease to
be less in patients who were dialysed for 6 years
with high-flux synthetic membranes. In the one
study in which triglyceride values were measured,Health Technology Assessment 1998; Vol. 2: No.5
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there was a significant effect in favour of the
synthetic high-flux membrane. Serum albumin
concentrations were higher in patients treated with
synthetic membranes (of both high and low flux).
There was no significant difference between these
membranes for any other outcomes measures.
Many types of membranes are now manufactured;
128 ‘commonly used dialysers’ are currently listed
in the Handbook of Dialysis (2nd edition; Daugirdas
& Ing, 1994). They vary in surface area, clearance of
various molecules, UFc, and geometry (hollow fibre
or parallel plate) as well as in the material from
which they are manufactured. Biocompatibility is
generally believed to be a property of the material
of the membrane and the higher the biocompati-
bility, the fewer the blood–membrane interactions
releasing complement and activating leucocytes.
Whether such reactions lead to clinical sequelae
such as malnutrition and infection is not clear
(Bauremeister et al., 1989). Synthetic membranes
are more biocompatible and have, therefore, 
been made with a larger surface area. They are 
also generally more porous and, hence, suitable 
for more rapid removal of water and molecules
larger than urea and creatinine, particularly b2
microglobulin, persistently high concentrations 
of which are believed to result in the development
of amyloid over a period of years in dialysis patients.
This correlation, however, is still in some doubt
(Cheung, 1990). Synthetic membranes with high-
flux characteristics and also, possibly, with an ability
to absorb substances such as b2 microglobulin on
their surfaces are used to shorten dialysis time; this
is popular both with patients and with busy dialysis
units, although rapid fluid removal may result in
hypotension. However, this was not shown in this
review. The beneficial effect of synthetic mem-
branes on serum albumin levels, however, occurred
in trials using both high- and low-flux membranes. 
It is somewhat disappointing, therefore, given the
plethora of membranes and the claims made for
them, that more large well-planned RCTs which
take into account the material of the membrane
and its flux have not been undertaken. In particu-
lar, relatively few trials have been performed which
used the outcome measures of symptoms felt 
by patients.
A total of 22 RCTs were identified (Table 12) 
which had clinical outcome measures as their 
end-points, and some data from most of them have
contributed to this review. Levin and colleagues’
detailed trial (1993) shows that a given symptom 
is recorded more frequently when patients rather
than staff are asked to undertake recording. We
had to choose which results to display, although
both were calculated for the four outcome meas-
ures. For hypotension, data from staff were shown;
patient data favoured the synthetic membrane in
this study and the aggregated result almost achiev-
ed statistical significance. For the other outcomes
(headache, nausea and vomiting, pruritis) patient-
recorded data were displayed, although the rela-
tive risk reductions (ORs) were generally similar
whichever type of data were used. Most trials did
not mention the method of symptom recording.
Recording of symptoms is subjective and in future
trials should be explicit and predominantly patient-
based, with blinding of the patients and the staff to
the treatment where possible.
Significant heterogeneity between trials was 
noted for three outcome measures, most notably 
b2 microglobulin concentrations. This may have
been because both low- and high-flux membranes
were used and significant improvement was only
seen with synthetic membranes when high-flux
membranes were used. b2 microglobulin was used
as a surrogate for amyloidosis, which takes many
years to develop, and in the one 6-year study found,
the incidence of amyloidosis was less with a high-
flux synthetic membrane.
The co-morbid illnesses of patients taking part 
in the trials were mentioned in some but not all
studies. It is possible to argue that biocompatible
membranes may be more suitable for patients with
complex illnesses but also that the low-flux, long
dialysis carried out with cellulose membranes may
also be beneficial for some patients, particularly
those with cardiovascular instability. It would be
useful, given the increasing co-morbidity of dialysis
patients, to be able to address these issues in
secondary stratified analysis but data to allow this
are not currently available. It would be particularly
useful to study modified cellulose membranes
which can be made with a higher flux than stand-
ard cellulose membranes (UFc, approximately 15)
and synthetic membranes with a similar flux.
Trials in which cellulose was compared with
synthetic membranes and for which Kt/V was
reported as an outcome measure were significantly
heterogeneous. When cellulose and modified cellu-
lose membranes together were compared with
synthetic membranes, Kt/V was just significantly
lower in the latter. Duration of dialysis session,
however, was not given in all studies and this,
together with the heterogeneity, makes it difficult
to draw any conclusions. In one study, Hakim and
colleagues (1996) used inadequate Kt/V in the 
first 2 weeks of the trial as an exclusion criterion,Appendix 4
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although not as an outcome measure. Locatelli 
and colleagues (1996) excluded two patients
because the Kt/V value was < 0.95. Furthermore, 
in studies in which the methodology was described
in some detail (Hakim et al., 1996; Locatelli et al.,
1996) there was a large drop-out rate because 
of transfer of patients to another modality of
dialysis, transplantation, transfer to another 
centre, non-compliance and, in one study, not
achieving an adequate Kt/V. Variation within 
the studies is, therefore, a major limitation 
of this review.
The management of end-stage renal failure is a
high technology speciality for relatively few patients
at great cost. Therefore, trials tend to be on small
groups of patients whose numbers are further
reduced by the drop-out rates as detailed above.
Because of the high cost of dialysis, RCTs are a
valuable means of decision-making in this area.
They require, however, large numbers of patients
with prolonged follow-up, so that the longer-term
implications which are important to patients 
can be adequately measured.
Surrogate outcome measures such as complement
levels are more likely than primary outcome
measures to change significantly over the course 
of a short study, are easier to measure and, hence,
are more frequently undertaken. There is a real
need, as others in the field have already suggested
(Bauremeister et al., 1989; Daugirdas, 1994;
Churchill, 1995; Locatelli et al., 1996), for further
large multicentre studies. Such trials should state
the patients’ co-morbid illnesses and, perhaps,
stratify them before trial entry such that the most
effective membranes for all types of patient can 
be determined. The trials should be designed to
evaluate the role of flux, as well as the material
from which the membrane is made, and should
have sufficient follow-up for clinical outcomes 
to be measured. In this manner, it could be
determined whether the new membranes which 
are being rapidly developed have improved the
effectiveness over previously available membranes
for patients or sub-groups of patients 
on haemodialysis.
Economic evaluation
Introduction
The principles of economic evaluation are
described in detail in chapter 3 (page 9) including,
in an economic framework, the manner in which
costs and outcome are related (see, in particular,
Table 2 and Figure 3).
Aims
It is possible that synthetic membranes offer
additional benefits over cellulose or modified
cellulose membranes for the dialysis of patients
with ESRD. The relative efficiency of these
alternatives will be investigated using the
framework of economic evaluation outlined. 
More specifically, the aims of this economic
evaluation are:
(i)  to investigate the relative resources used and
the costs of synthetic, cellulose or modified
cellulose membranes using data extracted
from the identified RCTs and non-randomised
studies in which the three type of membranes
are compared
(ii)  to combine data on cost differences with 
data on differential effectiveness from the
systematic review of effectiveness described
above in order to assess the relative efficiency
of dialysing patients with synthetic, cellulose,
or modified cellulose membranes.
Methods
Data collection
The methods used are described in detail in
chapter 2 of the main report.
Benefits to patients
The systematic review of RCTs or quasi-RCTs
synthesised data on the effectiveness of various
membranes. The outcome measures were 
as follows.
1.  Symptomatic hypotension or hypotension
requiring intervention, headaches, nausea 
and vomiting, pruritis, anaphylaxis occurring
during haemodialysis treatment session
(recorded as the number of treatment sessions 
on which the event occurred).
2.  Number of haemodialysis treatments associ-
ated with ‘any adverse symptoms’ if they 
were not specified with the publication.
3.  Number of episodes of significant infection
either per patient or per year (diagnosis of 
and significance of infection as determined 
by each individual study).
4.  Number of hospital admissions and length 
of stay (as indicator of morbidity and 
resource use).
5.  Adequacy of dialysis measured either by 
Kt/V or URR.
6. Pre-dialysis  b2 microglobulin concentration.
7.  Number of patients with dialysis-associated
amyloidosis.
8.  Indices of nutritional status: fasting predialysis
total cholesterol, HDL cholesterol, LDLHealth Technology Assessment 1998; Vol. 2: No.5
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cholesterol and triglyceride values, predialysis
albumen and PCR.
9.  Quality of life.
10. Mortality.
Identification of resource use and costs
The overall cost of haemodialysis using the various
membranes was not given in any of the available
information. Differences in resource use (and thus
cost) between delivery of haemodialysis under
different policies for use of membranes was
therefore assessed in four stages.
1.  The definition of the process of care, so that all
relevant items of resource use could be identified.
2.  For each part of the process of care (e.g. 
the dialysis session, the treatment of compli-
cations) in which resource use was believed 
to be different, data on resource use were
abstracted from the publications of trials in 
the effectiveness review.
3.  Similar data were abstracted from non-
randomised studies obtained from the
economic search.
4.  The information on resource use (obtained
from stages 2 and 3) was then combined with
information on the unit cost of the resources 
to determine the cost differential between 
the various membranes using methodology
described below. This differential could then be
compared with the difference in effectiveness.
Model of costs
Dialysis session  The information from the 22 RCTs
included in the effectiveness review showed that the
same equipment and dialysate could be used for
both types of membranes and the sessions, where
stated, were similar in duration (see following refer-
ences in the list of studies included (page 71):
Aakhus et al., 1995; Bergamo Collaboration, 1991;
Danielson et al., 1986; Grooteman et al., 1995;
Hosokawa & Yoshida, 1991; Mrowka & Schiffl, 1993;
Skroeder et al., 1993; 1994). Therefore any differ-
ence in the cost of the dialysis is due solely to the
different cost of the membrane used.
Treatment of complications  The relative cost 
of treating complications with the different mem-
branes was also estimated using decision analysis
(Figure 9) (Lapin, 1991). It is assumed in this analysis
that when a particular complication occurs
treatment is always provided. Data on the propor-
tion of patients that had a specific complication
such as pruritus or amyloidosis were abstracted
from the identified RCTs, which provided the most
robust estimates available. These were used to esti-
mate the probability that a patient would receive
treatment for a complication in a set period (either
per session, per week or per month). The RCTs and
the non-randomised studies were used to identify
more precisely the resources used in treatment of 
a specific complication. The treatments were then
costed according to the staff, consumables, over-
heads and capital that the treatment consumed.
The estimates of staff time were taken from a study
conducted in the USA (Jones, 1992) in which a
panel of clinicians and nurses were sampled and
asked for estimates of staff time for selected clinical
vignettes of complications of haemodialysis (which
included some of the complications in which we are
interested). This paper provided upper and lower
estimates of staff time and so allowed upper and
lower estimates to be calculated for the costs of
complications. No such data were available from 
a UK source. The prices of any pharmaceuticals
consumed were taken from the BNF (1996), and
the cost of staff time was estimated by combining
information on time with that from the relevant UK
NHS salary scales (NHS, 1996a; b). An important
assumption of this type of model is that the prob-
ability of having a complication (and therefore,
receiving treatment) is independent of the prob-
ability of having any other type of complication.
Results
Benefits to patients
The systematic review of effectiveness compared:
(i) synthetic membranes as the experimental
treatment and cellulose membranes as 
the control
(ii) synthetic membranes as the experimental
treatment and modified cellulose membranes
as the control.
For these two comparisons no significant differ-
ences were found for dialysis treatments associated
with hypotension or with headache, anaphylaxis,
any adverse symptoms, hospital admissions, signifi-
cant infection, mortality, PCR or Kt/V. There were
also no significant differences in fasting pre-dialysis
serum total cholesterol concentration, LDL chol-
esterol concentration or HDL cholesterol concen-
tration (see general references to this appendix).
Fasting pre-dialysis serum triglyceride concen-
tration was significantly lower in patients dialysed
with synthetic membranes compared with cellulose
membranes, and nausea and vomiting were also
less. The results of the one available trial showed 
no significant differences between the incidence 
of nausea and vomiting in patients treated with
synthetic and modified cellulose membranes. 
A significant difference was reported favouringAppendix 4
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synthetic over modified cellulose membranes 
in respect of patients’ assessments of the number 
of treatments associated with pruritus. No such
difference was found when episodes of pruritus
were reported by staff who would initiate treatment.
There was a significant reduction in pre-dialysis 
b2 microglobulin serum concentration when
synthetic membranes were used compared with
cellulose membranes. The trials that showed a sig-
nificant difference between synthetic and cellulose
membranes were comparing high-flux synthetic
membranes with low-flux cellulose membranes. In
the two papers reporting no significant difference,
both used membranes of similar low flux. For the
comparison of synthetic with modified cellulose
membranes, no significant difference was reported.
The development of amyloidosis was significantly
less common in those managed with synthetic
membranes compared with those managed with
cellulose membranes.
Resource use and costs
Estimates of the costs of membranes were obtained
from the manufacturers (primarily from Gambro
Ltd) and from information obtained from
Aberdeen Royal Hospitals NHS Trust. A range of
costs (low, medium and high) is shown in Table 14
with upper estimates based upon companies’ price
lists and lower costs based upon estimates of the
prices paid by hospital providers.
Cost estimates for complications were obtained 
by combining the staff time estimates with the
Synthetic
Cellulose
Modified
cellulose
No 
TGC
TGC
Membrane
Amyloidosis
No amyloidosis
Pruritus
No pruritus
Pruritus
No pruritus
Amyloidosis
No amyloidosis
Pruritus
No pruritus
Pruritus
No pruritus
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
Vomiting
No vomiting
FIGURE 9  Decision model to compare the alternative forms of haemodialysis (n,decision node; l,chance node; ,terminal node;
TGC = triglyceride concentration)
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relevant pay scales and the cost of any consum-
ables (Table 15). The cost of treating pruritus has
not been calculated as there was no significant
difference in the recording of pruritus per dialysis
session by healthcare providers, although patients
assessed that there were more episodes with
cellulose than synthetic membranes. It has been
assumed that treatment would only be provided 
if the healthcare provider knew of the problem.
Amyloidosis is a long-term condition that may
require surgical interventions (possibly many 
years later) to relieve some of its symptoms. 
The cost of such interventions and the time 
delay before they occurred were not determined 
as no data were identified on which to base
estimates. Information would be required on 
the form of intervention, the time delay before 
the intervention is given and the proportion 
of patients that would require treatment. Also
required would be data on the outcome of 
any intervention.
The probabilities for the occurrence of compli-
cations described in the systematic review of
effectiveness are shown in Table 16. The higher 
the probability, the greater the chance of that
complication occurring. There was insufficient
evidence of any differences in the rate of com-
plications when synthetic membranes were
compared with modified cellulose membranes.
Using the data contained in Tables 15 and 16 the
cost of complications can be calculated using the
framework shown in Figure 9. This information 
can then be combined with that on the cost of
membranes (see Table 14). The results of this are
shown in Table 17 for cellulose compared with
synthetic membranes. When modified cellulose
and synthetic membranes were compared, no
differences were found between complications 
that would require treatment. The only cost differ-
ences remaining are those between the costs of 
the membranes themselves.
Combining costs and benefits
The combination of the information on the 
relative effectiveness and cost of haemodialysis
using synthetic versus modified cellulose or cellu-
lose membranes can provide information on the
relative efficiency of the two alternatives. Overall,
there is greater cost and insufficient evidence of
effectiveness (area C4 on matrix in Figure 3), and
thus there is insufficient evidence to recommend
managing patients with haemodialysis using syn-
thetic membranes in preference to cellulose or
substituted cellulose membranes. Such information
that is available tends to suggest that haemodialysis
using synthetic membranes provides more benefits
to patients than haemodialysis using modified
cellulose or cellulose membranes. If this is assumed
to be the case, it would be achieved at greater cost
TABLE 14  The cost of haemodialysis membranes
Cost Type of membrane
Synthetic Modified  Cellulose 
(£ per  cellulose  (£ per 
membrane) (£ per  membrane)
membrane)
Low 10 7.5 7.5
Medium 20
High 29 12 10.5
TABLE 15  Staff costs of complications per session
Complication       Staff  Consumable Cost per 
time          cost  session 
(hours) (£) (£)
Low High Low  High 
Vomiting 0.25 0.75 0.50 3.47 8.86 
TABLE 16  The probabilities of complications occurring when
there was a significant difference in outcome between synthetic
and cellulose membranes (per treatment)
Condition Cellulose Synthetic
Amyloidosis 0.7 0
Nausea and vomiting 0.075 0.047
TABLE 17  The cost per dialysis session of cellulose membranes
compared to synthetic membranes
Type of membrane
Cellulose Synthetic 
(£ per dialysis  (£ per dialysis 
session) session)
Low Price  Low  Medium  Price 
cost list cost cost list
Cost of 
membrane 7.5 10.5 10 20 29
Cost of 
complications 0.55 0.55  0.34 0.34 0.34
Total cost 8.05 11.05 10.34 20.34 29.34Appendix 4
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(area C1 on matrix, Figure 3) and a judgement
would be required as to whether the synthetic
membranes are worth the extra cost.
Additional information can be obtained from the
data by using incremental analysis, to identify the
extra resources required to achieve one additional
unit of a beneficial effect. An estimate of the extra
cost required to prevent an extra case of nausea
and vomiting can be calculated to be between 
£90 and £680 avoided. These figures do not
account for other benefits beyond the prevention
of nausea and vomiting shown for synthetic
membranes. Using the data in Table 14 and
assuming three dialysis sessions per week it can 
be calculated that the total additional annual 
cost per patient of using synthetic membranes 
lies between £390 [(£10 – £7.50) ´ 3 ´ 52] and
£3354 [(£29 – £7.50) ´ 3 ´ 52] (with the higher
value based upon manufacturers’ price lists for
synthetic membranes). These calculations exclude
the costs of complications.
For the comparison of synthetic membranes 
with modified cellulose membranes only one
outcome was significantly different – the reduction
of patient-reported episodes of pruritus. Using
incremental analysis it is possible to estimate that 
it would cost between £37.5 and £255 per case of
pruritus averted when synthetic are used in prefer-
ence to modified cellulose membranes.
Discussion
The limitations of the evidence on effectiveness
discussed in the preceding section must be borne
in mind when interpreting this review. We have
chosen to concentrate on differences that have
reached statistical significance and it should be
remembered that lack of statistical significance
does not necessarily equate with no difference.
Certainly, most confidence intervals for the
estimated effects do not rule out clinically
important differences.
The data used to estimate the relative efficiency of
the alternative membranes also have to be treated
with some caution. Costs are derived from estimates
of resource use which are taken from different
studies and which may not be generalisable to
others. A further issue is that for this review not all
potential complications were included in the calcu-
lation of costs. The cost of treating amyloidosis
remains uncertain and further work is required 
to identify whether synthetic membranes offer
some protection against the development of this
condition compared with cellulose and modified
cellulose membranes. If such differences do exist
then the costs and benefits of such treatment 
need evaluation. 
There is insufficient data available on effectiveness
for a judgement to be made on the relative effi-
ciency of the different membranes. If such data
that we have are accepted then the implication
would be that synthetic membranes are both more
effective for certain outcomes and more costly 
than either cellulose or modified cellulose
membranes. A judgement would be required as 
to whether the additional benefits are worth the
additional costs, since the additional resources 
can only be obtained by reducing potentially
beneficial services elsewhere.
One problem when making this judgement is that it
is not possible to amalgamate the many measures of
effectiveness into a single unitary value. Therefore,
ratios of incremental cost to incremental effective-
ness fail to formally take into account the many
different aspects of benefits that are provided.
Conclusions
The conclusions are drawn from both the
systematic review of effectiveness and the 
economic evaluation.
Implications for clinical practice
1. End-of-study  b2 microglobulin values and the
development of amyloid disease were less in
patients treated with synthetic membranes
compared with cellulose membranes. Plasma
triglyceride values were also lower with syn-
thetic membranes in the single study that
measured this outcome. These outcomes may
have reflected the high flux of the membrane.
Nausea and vomiting were less with synthetic
membranes (both low and high flux) and
serum albumin concentrations were higher.
Pruritus was recorded less frequently with syn-
thetic than with modified cellulose membranes.
2.  We are hesitant to recommend the universal
use of synthetic membranes for haemodialysis
in patients with ESRD on the basis of the above
results because of the small numbers of trials,
particularly for modified cellulose membranes
(many with low patient numbers); the hetero-
geneity of many of the trials compared; the
variations in membrane flux, and the differ-
ences in exclusion criteria, particularly relating
to co-morbidity. In this review we found insuffi-
cient information to perform a satisfactory eco-
nomic evaluation. Such evidence as there is
favours synthetic membranes but the extraHealth Technology Assessment 1998; Vol. 2: No.5
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benefit would currently be at considerable
cost, particularly if high-flux membranes 
were to be used.
Implications for research
Further pragmatic RCTs are required to compare
the different dialysis membranes available. They 
are required:
(i) to take into account other properties,
including flux, as well as the material from
which the membrane is manufactured, and 
to test modified cellulose membranes as 
well as standard ones
(ii) to record the minimum of data, concentrating
on primary outcomes of major importance 
to patients and on patient preference
(iii) to explicitly record whether symptoms of
patient- or staff-reported, while recognising
that, in general, patient reporting will be 
more appropriate for evaluating effectiveness
but staff reporting may be necessary for
calculating the cost of treating complications
(iv) to be multicentre (and possibly multi-
national)in order to have sufficient patients 
for the trial to be completed despite consider-
able numbers of withdrawals and drop-outs
(v) to have sufficiently long follow-up for
conclusions to be drawn on important 
clinical outcome measures; they should
continue to follow patients who withdraw
because they receive a transplant
(vi) to include older patients and those with 
co-morbid illnesses and to take these into
account when assessing outcomes (possibly 
by stratification at trial entry)
(vii)to have performed, in parallel, an economic
evaluation of the different policies being
compared in the trial.
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Background
Patients with end-stage renal failure require either
dialysis (haemodialysis or peritoneal dialysis) or 
a renal transplant to maintain life. Haemodialysis
achieves its purpose of replacing renal function 
by passing the patient’s blood through a dialyser
containing a semi-permeable membrane. Dialysate
is passed through the dialyser on the opposite side
of the membrane. This membrane allows certain
substances to pass through it by the process of
diffusion. Substances normally excreted by the
kidney, such as urea and potassium, which are in
relatively high concentrations in the blood, will
diffuse into the dialysate and be removed from 
the body.
One of the critical functions of dialysis is the
correction of the metabolic acidosis caused by the
diseased kidney’s failure to excrete non-volatile
acids and to regenerate bicarbonate. A buffer is
therefore added to the dialysate to correct the
metabolic acidosis. This buffer passes across the
semi-permeable membrane from the dialysate 
into the blood. Bicarbonate is the natural buffer
normally regenerated by the kidneys and was the
initial choice as dialysate buffer in the 1940s and
1950s. However, if sodium bicarbonate is added to 
a calcium- or magnesium-containing dialysate, their
respective carbonate salts will precipitate unless the
dialysate is maintained at a low pH level. Dialysate
concentrate containing calcium or magnesium was
therefore stored separately from bicarbonate-
containing dialysate concentrate. When both were
mixed with water to produce the final dialysate,
carbon dioxide was bubbled through the dialysate
to lower its pH level and thus avoid precipitation 
of the salts. These procedures demanded extra
storage, equiment and labour.
In 1964, Mion used acetate as an alternative buffer
(Mion, et al., 1964). Acetate is rapidly converted to
bicarbonate in the liver through the action of the
enzyme acetyl CoA synthetase. From a practical
point of view, acetate offered the major advantage
of not precipitating calcium or magnesium in the
dialysate; it quickly replaced bicarbonate as the
standard dialysate buffer and remained so for 
the next 20 years.
In the late 1970s and early 1980s, a number of
studies suggested that some of the morbidity asso-
ciated with haemodialysis could be attributed to the
acetate component of the dialysate (Novello, 1976;
Aizawa, 1977). This morbidity particularly referred
to intra- and post-haemodialysis symptoms such 
as nausea, vomiting, muscle cramps, headaches,
symptomatic hypotension, poor appetite and
cardiovascular instability. Patients on haemodialysis
have a markedly increased prevalence of athero-
matous vascular disease and it was suggested that
acetate may contribute to this by its adverse effect
on lipid metabolism (Tolchin, 1979). Renal bone
disease may be a source of significant morbidity 
for dialysis patients and, by its poorer correction 
of metabolic acidosis, acetate dialysate may
contribute to its progression.
The dialysis-associated symptoms which had 
been attributed to ‘acetate intolerance’ appear 
to have been unmasked by the introduction of
high-efficiency and short-duration dialysis using
membranes with large surface areas. This
movement towards high-efficiency dialysis 
was particularly marked in the USA.
Acetate intolerance led to the reappraisal of
bicarbonate as a dialysis buffer in the early 1980s
and, following the solving of technical difficulties,
to its reintroduction. Initially it was reintroduced
specifically for patients thought to be more prone
to the adverse effects of acetate, such as those who
had previously demonstrated acetate intolerance,
those with acute renal failure and those with 
known cardiovascular instability. It was also used 
for patients with possibly impaired acetate meta-
bolism, such as those with reduced muscle mass,
diabetes mellitus and liver disease. In addition,
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bicarbonate dialysate was used for those
undergoing high-efficiency dialysis in which 
large surface area membranes may allow a greater
mass transfer of acetate than the liver is readily 
able to metabolise.
From these early specific indications, bicarbonate
dialysate rapidly became generally used for all
haemodialysis patients in many countries.
The use of bicarbonate dialysis in preference to
acetate dialysis initially had significant cost impli-
cations. However, today, because nearly all haemo-
dialysis machines can use either acetate or bicar-
bonate dialysate with no modification, and because
of the increased use of bicarbonate, the cost differ-
ential between acetate and bicarbonate dialysis 
may no longer apply.
The purpose of this review was to identify whether
bicarbonate dialysis is to be preferred to acetate
dialysis for the haemodialysis of patients with ESRD.
Objectives
The objectives of this review were to compare
bicarbonate dialysis with acetate dialysis for the
haemodialysis of patients with ESRD by testing 
the following hypotheses:
(i) that bicarbonate haemodialysis reduces the
frequency of adverse symptoms during dialysis
compared with acetate dialysis
(ii) that bicarbonate haemodialysis improves
cardiovascular stability during dialysis
compared with acetate haemodialysis
(iii) that bicarbonate haemodialysis improves lipid
profile compared with acetate haemodialysis
(iv) that bicarbonate haemodialysis slows the
progression of renal bone disease compared
with acetate haemodialysis.
The cost implications of using bicarbonate
haemodialysis instead of acetate haemodialysis 
were also examined.
Materials and methods
Criteria for considering studies for 
this review
Types of studies  An attempt was made to identify
all trials in which bicarbonate (experimental
group) was compared with acetate (control 
group) in the haemodialysis of patients with ESRD
and in which patients were prospectively randomly
(e.g. sealed envelopes with third party involvement)
or quasi-randomly (alternate patients or alternate
treatments) allocated to either treatment. Cross-
over trials in which treatments alternated to at least
the degree A–B–A–B were also included, even if the
allocation to first treatment was neither random
nor quasi-random.
Types of participants  Patients with ESRD who 
were maintained on haemodialysis were eligible,
irrespective of age, sex, race, primary renal disease
or co-morbidity. Trials which exclusively comprised
patients with acute renal failure were excluded.
Each individual study’s definition of ESRD or
maintenance haemodialysis was accepted.
Types of intervention  In the experimental 
group haemodialysis was against a predominantly
bicarbonate-buffered dialysate, while in the control
group it was against a predominantly acetate-
buffered dialysate. Only haemodialysis was
considered and any form of haemofiltration 
was excluded.
Types of outcome measures
1. Intra- and postdialytic symptoms: frequency 
of nausea, vomiting, headaches, muscle 
cramps, symptomatic or treatment-requiring
hypotension; any assessment of patient
acceptability, well-being or quality of life.
2. Intradialytic cardiovascular stability: changes 
in blood pressure, cardiac output and 
peripheral vascular resistance.
3. Correction of metabolic acidosis: pre-, 
intra- and postdialysis pH level, PCO2 and
bicarbonate concentrations.
4. Indicators of renal bone disease: serum
calcium, phosphate and parathyroid 
hormone concentrations.
5. Lipid profile: fasting cholesterol 
and trigylcerides.
Search strategy for identification 
of studies
The search strategy used was one developed for 
the identification of all possible RCTs or quasi-
RCTs relating to the management of ESRD, and is
described in detail in chapter 2 and appendices 2
and 3.
Methods of the review
Identified studies were evaluated using a study
evaluation form and those which met the eligibility
criteria (included references) were then consider-
ed in detail. Data were extracted using a data
abstraction form designed for this review (see
appendix 10). Review Manager v. 3.0 was used Health Technology Assessment 1998; Vol. 2: No.5
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for the analysis. A full description of the methods
used is given in chapter 2.
Description of studies
A total of 18 studies were identified which met the
eligibility criteria of being RCTs or quasi-RCTs. The
Antwerp trial in 1983 was subsequently considered
as two separate trials (de Backer, et al., 1983); in
addition to being randomised to bicarbonate or
acetate dialysis, patients had also been randomised
to dialysis with a polyacrylonitryl or a cuprophane
membrane. Similarly, the Hamilton trial in 1983
was subsequently considered to be two separate
studies (Shimizu, et al., 1983) as patients had also
been randomised to high sodium or low sodium
dialysate. The descriptions of method of allocation
published were accepted and no confirmation was
sought from the authors. In cases where the same
study had been published more than once, only 
the most recent data were used. If more than one
relevant study was published in the same paper,
each study was listed and analysed separately. All
the studies included were published in full except
for the Philadelphia study in 1985 (Brezin, et al.,
1985), which was only available as an abstract. 
Only published data from the studies were used.
Seven of the studies could not be included in 
the quantitative analyses because the recorded
measures outcome differed from those specified.
This indicates the wide variation in recorded
measures of outcome for essentially similar
outcomes demonstrated across the studies. 
The studies are summarised in Table 18.
A total of 30 crossover studies which were not
randomised or quasi-randomised or did not
demonstrate alternation at least to the degree
A–B–A–B are listed as excluded studies. No 
further analyses of these studies were made.
Methodological quality of 
included studies
All 18 included studies were of crossover design,
although in the 1983 Paris study (Lefebvre, et al.,
1983b) only half of the patients entered the
crossover phase.
Potential for selection bias at trial entry
In 16 studies it was claimed that the order of
treatment had been randomly allocated but in 
14 of these the method of random allocation was
not described. Only in the Cambridge study in 
1988 (Bradley, et al., 1988) was a secure method 
of random allocation concealment prior to final
trial entry described (third-party involvement). 
In the 1979 Columbia study (van Stone & Cook,
1978; 1979) a potentially insecure method of
random allocation concealment was described
(coin toss with no stated third-party involvement).
Two studies were included on the basis of quasi-
randomisation solely because their treatments or
treatment periods alternated A–B–A–B (Brezin, 
et al., 1985: Savidie, et al., 1977). The order of
treatments was not randomly allocated. Neither 
of these studies had data which could be included
in any of the meta-analyses; hence, sensitivity
analyses to determine the influence of these less
methodologically robust studies on the summary
statistics could not be undertaken.
Potential for bias in trial analysis
In four of the 18 studies the numbers and reasons
for withdrawals and drop-outs were described. One
study mentioned that there had been withdrawals
but did not give details. A further six studies report-
ed no withdrawals or drop-outs, and seven studies
made no mention of withdrawals or drop-outs.
None of the studies from which data were included
for meta-analysis had been explicitly undertaken on
an intention-to-treat basis.
Potential for bias at time of treatment or
outcome assessment
In four studies, patients, healthcare providers 
and outcomes assessors were explicitly stated to 
have been blinded. Three studies described an
effective method of blinding; the fourth gave 
no description.
In six studies, no mention was made of blinding.
The remaining eight studies, although not always
describing the method, mentioned blinding of at
least one of three groups: patients, healthcare
providers, outcomes assessors. In some studies,
healthcare providers and outcomes assessors 
may have been the same people, and hence 
our categorisation may have underestimated 
the degree of blinding.
The quality assessment tool used in this study
assumes that the avoidance of bias is best achieved
by an RCT with:
• secure concealment of allocation before formal
trial entry
• adequate blinding of patients, outcomes
assessors and healthcare providers
• descriptions of reasons and numbers of
withdrawals and drop-outs
• analysis on an intention-to-treat basis.
None of the trials fulfilled all these criteria.Appendix 5
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TABLE 18  Characteristics of included studies:bicarbonate- versus acetate-buffered dialysate in haemodialysis of patients with ESRD
Study Method Participants Interventions Outcomes Notes
Antwerp 1983a  RCT,crossover design; Six patients with  Acetate with cuprophane  Intra- and postdialytic  Four comparisons were 
method of randomisation  terminal renal failure  membrane vs.acetate  symptoms not stated; made in this study;data 
(de Backer,et al., not described;blinding  maintained on haemo-  with polyacrylonitryl  intradialytic cardio-  for each membrane type 
1983) of patients,healthcare  dialysis;sex not stated; membrane vs.bicar-  vascular stability not  analysed separately;
providers and outcomes  age range,32–71 years; bonate with cuprophane  stated;arterial blood  cuprophane membranes 
assessors not stated; mean weight not stated; vs.bicarbonate with poly- gases and acid–base  analysed here;for poly- 
withdrawals,drop-outs co-morbidity:normal  acrylonitryl  membrane; balance,pH,PO2,P CO2, acrylonitrile membrane 
and number lost to  ventilatory function as  duration of study,single  at 0,15,30,60 and  see Antwerp 1983b.
follow-up,not stated; assessed by spirometry  treatment with each of  240 minutes from start 
possibly intention-to-treat and body plethys- four combinations; of dialysis;renal bone 
analysis but not clear. mography. duration of each dialysis, disease indicators
4 hours;blood flow rate, not stated;lipid profile 
250 ml/min;dialysate  not stated;other 
flow rate,not stated; parameters:O2
membrane type, uptake,CO2 output,
Cuprophan or PAN as  respiratory quotient,
above,surface area,1 m2; minute ventilation,
dialysate sodium and  tidal volume,inspir-
buffer concentrations  atory time and alveolar-
not stated. arterial oxygen tension 
difference.
Antwerp 1983b see Antwerp 1983a. see Antwerp 1983a. see Antwerp 1983a. see Antwerp 1983a. see Antwerp 1983a;poly- 
acrylonitryl membranes
(de Backer,et al.,1983) only analysed here.
Bologna 1989 RCT,crossover design; Five patients on haemo-  Acetate vs.bicarbonate  Intra- and postdialytic 
no description of method  dialysis;sex,mean age, dialysis (vs.acetate-free  symptoms not stated;
(Spongano,et al.,1989) of randomisation;blinding  and mean weight,not  biofiltration);duration of  intradialytic cardio- 
of patients,healthcare  stated;co-morbidity, study,one treatment per  vascular stability:
providers and outcomes  not stated. dialysate;duration of  systolic,diastolic and 
assessors,not stated; dialysis,4 hours;blood  mean arterial blood 
withdrawals,drop-outs  and dialysate flow rates  pressure,heart rate,
and number lost to  not stated;membrane  stroke volume,cardiac 
follow-up,none;analysis  type and surface area not  output and total 
on intention-to-treat basis. stated;dialysate sodium  peripheral vascular 
and buffer concentration  resistance;arterial 
not stated. blood gases and acid 
balance not stated;
renal bone disease 
indicators and lipid 
profile not stated.
Boston 1983 RCT,crossover design; Nine stable patients on  Acetate vs.bicarbonate  Intra- and postdialytic 
method of randomisation  haemodialysis;M:F,5:4; dialysis;duration of study, symptoms not stated;
(Schick,et al.,1983) not stated;blinding of  mean age,42.3 years, two dialyses,1 week  intradialytic cardio- 
patients and healthcare  range,19–57 years;mean  apart;duration of  vascular stability:pulse 
providers but method not  weight not stated;co- dialysis not stated;blood  rate,number of 
described;blinding of  morbidity:three had  and dialysate flow rates  patients experiencing 
outcomes assessors not  diabetes mellitus as  not stated;membrane  hypotension (decrease 
mentioned;withdrawals, primary renal disease, type,Gambro 11.5,paral-  in systolic blood 
drop-outs and number  otherwise only cardio- lel plate,surface area not  pressure > 15 mmHg),
lost to follow-up not  vascular status recorded; stated;dialysate sodium  ejection fraction,stroke 
stated;possibly intention- at time of study none  concentration:acetate  volume,cardiac output 
to-treat analysis but  had congestive cardiac  130 mmol/l,bicarbonate  and velocity of circum- 
not clear. failure,angina or were  139 mmol/l;dialysate  ferential fibre 
taking digoxin. buffer concentration: shortening;arterial 
acetate dialysis – acetate  blood gases and acid–
37 mmol/l,bicarbonate  base balance not stated;
nil;bicarbonate dialysis –  renal bone disease 
acetate 4 mmol/l, indicators and lipid 
bicarbonate 35 mmol/l. profile not stated.
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TABLE 18 contd  Characteristics of included studies:bicarbonate- versus acetate-buffered dialysate in haemodialysis of patients with ESRD
Study Method Participants Interventions Outcomes Notes
Cambridge 1988 RCT,crossover design; Eight patients on  Acetate vs.bicarbonate  Intra- and postdialytic 
method of random-  haemodialysis;M:F,5:3; dialysis;duration of study, symptoms not stated;intra- 
(Bradley et al., isation not stated; mean age (SD),52 years  4 weeks,one study dialy-  dialytic cardiovascular 
1988) blinding of patients  (15.6);mean weight not  sis session per week,two  stability:predialysis and 
and outcomes assessors  stated;co-morbidity:no  treatments per dialysate; change during dialysis in 
not stated;healthcare  evidence of cardio-  duration of dialysis,4 hours; mean arterial pressure,
providers not blinded; vascular disease,none  blood and dialysate flow  forearm venous tone,
withdrawals,drop-outs  on any cardiovascular  rates not stated;membrane  forearm vascular resistance 
and number lost to  drugs. type,hollow fibre,surface  and pulse rate;arterial 
follow-up not stated; area,1.3 m2;dialysate sodi-  blood gases and acid–base 
possibly intention-to-  um concentration:acetate, balance:change in 
treat analysis but  130 mmol/l,bicarbonate, bicarbonate concentration 
not clear. 138 mmol/l;dialysate buffer  during dialysis treatment;
concentration:acetate  renal bone disease 
dialysate – acetate 35 mmol/l, indicators and lipid 
bicarbonate nil;bicarbonate  profile not stated.
dialysate – acetate 3 mmol/l,
bicarbonate 32 mmol/l.
Chicago 1990a RCT,crossover design, Ten chronic patients on  L-lactate vs.acetate vs. Intra- and postdialytic  This is study A in 
method of randomisation  haemodialysis,no known  bicarbonate dialysis (only  symptoms not stated; this paper;for study 
(Dalal,et al.,1990) not stated;patients and  cardiovascular instability  acetate vs.bicarbonate  intradialytic cardio-  B see Chicago 1990b 
healthcare providers  or acetate intolerance  comparisons used here); vascular stability: below.
blinded but no descrip-  to normal efficiency  duration of study,single  systolic,diastolic and 
tion,outcomes assessors  haemodialysis;M:F,10:0; treatment with each dialysate  mean arterial blood 
blinding not stated; mean age 50 years;mean  buffer;duration of dialysis, pressure,cardiac 
withdrawals,drop-outs  weight 70 kg;no other  225 minutes;blood flow rate, output (measured by 
and number lost to  co-morbidity stated. 300–500 ml/min;dialysate  impedance plethys-
follow-up not stated; flow rate,700 ml/min; mography) and total 
possibly intention-to-treat  membrane type,Baxter  peripheral vascular 
analysis but not clear. CA 210TM,surface area not  resistance;arterial 
stated;dialysate sodium  blood gases and acid–
concentration 139 mmol/l; base balance not 
dialysate buffer concentration: stated;renal bone 
acetate dialysis – acetate  disease indicators 
39 mmol/l,bicarbonate nil; and lipid profile not 
bicarbonate dialysis – acetate  stated.
4 mmol/l,bicarbonate 
35 mmol/l.
Chicago 1990b see Chicago 1990a  12 patients on chronic  Comparisons as Chicago  Intra- and postdialytic symptoms: Preliminary results 
above. haemodialysis;M:F,at  1990a;duration of study, number of treatments with head-  published in Dalal,
(Dalal,et al.,1990) least 8 M;mean age and  2 week run-in using bicar-  aches,nausea or vomiting,weak- et al.,1989;full study 
weight not stated;co- bonate,then 3 weeks  ness or washed-out feeling, published as study B 
morbidity not stated. on each of three buffers; muscle cramps;‘dizziness/ in Dalal,et al.,1990.
three dialysis sessions  hypotension’ was symptom 
per week,duration  category in preliminary study but 
180 minutes;blood flow  change to ‘hypotension severe 
rate,body weight ´ enough to warrant a treatment 
5 ml/min;dialysate flow  intervention’;number of treatments 
rate,800 ml/min; with any of above symptoms 
membrane type,Baxter  stated;intradialytic cardiovascular 
CA 210 TM,surface area  stability,mean change in systolic,
not stated;dialysate  diastolic and mean arterial blood 
sodium concentration  pressure;arterial blood gases 
139 mmol/l;dialysate  and acid–base balance:pH,PO2,
buffer concentration: PCO2,standard bicarbonate,pre-
acetate dialysis – acetate  dialysis levels and change during 
39 mmol/l,bicarbonate  dialysis recorded for single treat- 
nil;bicarbonate dialysis –  ment only;renal bone disease 
acetate 4 mmol/l, indicators and lipid profile not 
bicarbonate 35 mmol/l. stated;other outcomes:change 
in serum phosphate during single 
treatment;measure of dialysis 
adequacy,Kt/V.
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Columbia 1979 RCT,crossover design; Nine stable haemo-  Acetate vs.bicarbonate  Intra- and postdialytic symp-  First published 
random allocation by  dialysis patients with no  dialysis;duration of study, toms,percentage of treatments  1978;1979 version 
(van Stone &  coin toss;patients, known previous acetate  six treatments on both  with any ‘untoward’ symptoms  includes extra data 
Cook,1978; healthcare providers  intolerance;M:F not  dialysates,duration of  and percentage with severe  relating to blood 
1979) and outcomes assessors  stated;mean age and  dialysis,4 hours;blood and  ‘untoward’ symptoms – specific pressure and 
all blinded and method  weight not stated; dialysate flow rates not  symptoms not stated;intra-  serum potassium.
likely to be effective; co-morbidity not  stated;membrane type: dialytic cardiovascular stability:
withdrawals,drop-outs  stated. Travenol 1500,surface  systolic and diastolic blood 
and number lost to  area 1.5 m2 – five patients; pressure predialysis (supine),
follow-up not stated; Cordis model V,surface  lowest intra- and postdialysis 
possibly intention-to- area 2.5 m2 – four patients; (supine and upright);arterial 
treat analysis but  dialysate sodium concen- blood gases and acid–base 
not clear. tration,acetate 135.4 mmol/l, balance:arterial pH,PO2,P CO2
bicarbonate 133.7 mmol/l; after 1 and 2 hours of dialysis;
dialysate buffer concen-  venous bicarbonate and anion 
tration:acetate dialysis –  gap pre-,after 1 hour,and 
acetate 37.2 mmol/l,bicar- postdialysis;renal bone 
bonate nil;bicarbonate  disease indicators and lipid 
dialysis – acetate nil, profile not stated;other para- 
bicarbonate 35.3 mmol/l. meters,serum potassium pre-,
after 1 hour,and postdialysis.
Hamilton 1983a RCT,crossover design, 34 clinically stable  Acetate with high sodium  Intra- and postdialytic  Study had four 
method of randomisation hospital haemodialysis  vs.bicarbonate with high  symptoms:percentage of  interventions;rather 
(Shimizu,et al., not described but stated  patients;age over  sodium vs.acetate with  treatments in which headaches, than combining the 
1983) to be such as to ensure  16 years;data on  low sodium vs.bicarbonate  vomiting,muscle cramps,and  high and low sodium 
each dialysate was  28 patients analysed; with low sodium;duration  non-specific intolerance  outcomes,the data 
followed by every other, M:F not stated;mean  of study,36 weeks in 2-week  occurred with any severity  are reported separ- 
including itself;patients, age and weight not  blocks,duration of dialysis, or moderate/ severe;intra-  ately as published.
healthcare providers and  stated;co-morbidity  4–6 hours;blood and  dialytic cardiovascular stability  Hamilton 1983a 
outcomes assessors all  not stated. dialysate flow rates not  not stated;arterial blood  considers only low 
blinded and method likely  stated;membrane type and  gases and acid–base balance  sodium dialysate.
to be effective;numbers  surface area not stated; not stated;renal bone disease  For high sodium 
and reasons stated for  dialysate sodium concen-  indicators and lipid profile  dialysate see 
withdrawals,drop-outs  tration:high,142 mmol/l, not stated. Hamilton 1983b.
and number lost to  low,135 mmol/l;dialysate 
follow-up – four died,one  buffer concentration:acetate 
changed dialysis modality, dialysis – acetate 40 mmol/l,
one transferred to  bicarbonate nil;bicarbonate 
another unit;no intention-  dialysis – acetate nil,
to-treat analysis. bicarbonate 35 mmol/l.
Hamilton 1983b See Hamilton 1983a  See Hamilton 1983a  See Hamilton 1983a  See Hamilton 1983a  Considers only high 
above. above. above. above. sodium dialysate;
(Shimizu,et al., for low sodium 
1983) dialysate see 
Hamilton 1983a.
Madras 1991 RCT,crossover design, 30 stable ESRD patients  Acetate vs.bicarbonate  Intra- and postdialytic symp- 
randomisation method  on haemodialysis for  dialysis;duration of study, toms – number of treatments 
(Gurudev,et al., not stated;patients, > 4 weeks;all on renal  three treatments with each  associated with and number of 
1991) healthcare providers  transplant list;M:F,25:5; dialysate buffer,duration of  patients developing headache,
and outcomes assessors  mean age (SD),35.62  dialysis 300 minutes;blood  giddiness,nausea/vomiting,
all blinded,method  (11.75);mean weight  flow rate,200 ml/min;dialy-  malaise,muscle cramps,or 
likely to be effective; not stated;co- sate flow rate,500 ml/min; symptomatic hypotension;
withdrawals,drop-outs  morbidity,all with  membrane type,cuprophane, intradialytic cardiovascular 
and number lost to  hypertension,two  surface area 0.8 m
2;dialysate  stability:supine and standing 
follow-up not stated; with diabetic  sodium concentration, mean arterial blood pressure 
possibly intention-to-  nephropathy. 138 mmol/l;dialysate buffer  before and at 30,60,120 and 
treat analysis but  concentration:acetate  300 minutes during dialysis;
not clear. dialysis – acetate 40 mmol/l, arterial blood gases and acid–
bicarbonate nil;bicarbonate  base balance:pH,PO2,P CO2,
dialysis – acetate nil, and standard bicarbonate at 
bicarbonate 39 mmol/l. 0,30,60,120,300 minutes;renal 
bone disease indicators and 
lipid profile not stated.
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Newcastle 1983 RCT,crossover design, 11 patients maintained  Acetate vs.bicarbonate  Intra- and postdialytic symp- 
randomisation method  on dialysis;M:F,6:5; dialysis;duration of study, toms not stated;intradialytic 
(Ramos,et al., not described;blinding  mean age 45.7 years, 3 weeks,buffer alternating  cardiovascular stability not 
1983) of patients,healthcare  range 31–35 years; each week,duration of  stated;arterial blood gases and 
providers and outcomes  mean weight not stated; dialysis 4 hours;blood and  acid–base balance:pH,PO2,
assessors not stated; co-morbidity not stated. dialysate flow rates not  PCO2 pre- and each hour 
withdrawals,drop-outs  stated;membrane type, during dialysis for first treat- 
and number lost to  Triex 1,surface area not  ment each week,predialysis 
follow-up not stated; stated;dialysate sodium  only for second treatment 
possibly intention-to- concentration 136 mmol/l; each week;renal bone disease 
treat analysis but not  dialysate buffer concen-  indicators:serum ionised 
clear. tration:acetate dialysis –  calcium,total calcium,inorganic 
acetate 40 mmol/l,bicar-  phosphate,parathyroid hormone,
bonate nil;bicarbonate  (c-terminal by radio-immuno 
dialysis – acetate nil, assay) pre- and hourly during 
bicarbonate 35 mmol/l. dialysis for first treatment 
each week,predialysis only 
for second treatment each 
week;lipid profile 
not stated.
Odense 1990 RCT,crossover design, 16 stable ESRD patients  Acetate vs.bicarbonate  Intra- and postdialytic symp- 
randomisation method  on regular haemo-  dialysis;duration of study  toms:subjective well-being 
(Otte,et al.,1990) not stated;patients and  dialysis,none being due  6 months,3 months on  questionnaire (included 
healthcare providers  to change dialysis mode  acetate and 3 months on  questions on sleep disturbance,
blinded,likely to be  nor were on renal  bicarbonate dialysis,duration  joint pain,dyspnoea,nausea/ 
effective;outcome  transplant waiting list; of dialysis,3–4 hours three  vomiting,headaches,tiredness,
assessors,blinding not  M:F,10:6;mean age  times weekly;blood flow rate  cramps,angina,pruritus,
stated;numbers and  52.1 years,range  200–250 ml/min;dialysate  abdominal pain – each 
reasons stated for with- 24–74 years;mean  flow rate 500 ml/min; complaint scored as 1 point);
drawals,drop-outs and  weight not stated; membrane types,Fresenius  cramp incidents per patient 
number lost to follow-up co-morbidity,no known  40,Fresenius 50 and Biospal  in 12 weeks;intradialytic 
– one patient died after  malignant disease. 2400,surface area,0.65–  cardiovascular stability:
treatment allocation but  1.0 m
2;dialysate sodium  hypotensive episodes per 
before study commenced  concentration 140 mmol/l; patient per 12 weeks 
from complications  dialysate buffer concen-  (hypotension not defined);
following fractured femur, tration:acetate dialysis –  arterial blood gases and acid– 
allocated group not  acetate 35 mmol/l, base balance:predialysis pH,
stated;analysis not on  bicarbonate nil; PO2,P CO2,standard bicarbonate 
intention-to-treat basis. bicarbonate dialysis –  and base excess at 0,4,8 and 
acetate 3.0 mmol/l, 12 weeks;renal bone disease 
bicarbonate 35 mmol/l. indicators and lipid profile 
not stated;other outcomes:
predialysis serum potassium,
urea,sodium,creatinine and 
haematocrit at 0,4,8 and 
12 weeks;anthropometric 
data:weight change (not 
clear if pre- or postdialysis),
skinfold thickness,mid-arm 
muscle circumference at 
0,12 and 24 weeks;dietary 
assessment,average energy 
intake;pre- and postdialysis 
serum albumin and transferrin 
levels;therapeutic interventions 
(hypertonic saline,analgesics,
muscle relaxants plus others 
not described) per patient per 
12 weeks.
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Ovideo 1986 RCT,crossover design; 14 patients maintained on  Acetate vs.bicarbonate dialysis; Intra- and postdialytic symp- 
randomisation method  haemodialysis,in two groups  order of dialysate type in each  toms not stated;intradialytic 
(Peces  not described;blinding  – group 1,six patients with  group randomly allocated;acetate  cardiovascular stability:mean 
Serrano, of patients,healthcare  known chronic pulmonary  dialysis with nasal oxygen also  arterial blood pressure stated 
et al.,1986) providers and outcomes  disease;group 2,eight  studied but allocation method  as stable with all treatments 
assessors not stated; patients without signs or  not stated;duration of study, but no data given;arterial 
withdrawals,drop-outs  symptoms of pulmonary  single treatment with each buffer  blood gases and acid–base 
and number lost to  disease and with normal  plus one with acetate plus nasal  balance:pH,PO2,P CO2,HCO3,
follow-up not stated; spirometry;M:F,group 1, oxygen;duration of dialysis 4 hours  at 0,15,30,60 and 120 minutes;
possibly intention-to- 3:3,group 2,6:2;mean age  three times weekly;blood flow  renal bone disease indicators
treat analysis but not  group 1,54.8 years (range  rate 250 ml/min;dialysate flow  and lipid profile not stated.
clear. 45–65 years),group 2, rate 500 ml/min;membrane type,
56.7 years (range not stated); cuprophane,surface area 1.0 m
2;
mean weight not stated; dialysate sodium concentration:
co-morbidity:groups  acetate 134 mmol/l,bicarbonate 
defined in relation to  136.5 mmol/l;dialysate buffer 
pulmonary co-morbidity, concentration:acetate dialysis – 
nothing else stated. acetate 36 mmol/l,bicarbonate 
nil;bicarbonate dialysis – acetate 
nil,bicarbonate 34.5 mmol/l.
Oxford 1991 RCT,crossover design; Ten established ESRD  Acetate vs.bicarbonate dialysis; Intra- and postdialytic symp- 
randomisation method  patients on regular haemo-  duration of study,single treatment  toms not stated;intradialytic 
(Akanji,et al., not described;blinding  dialysis for > 6 months; with each buffer 1 week apart, cardiovascular stability not 
1991) of patients,healthcare  five had diabetes with  duration of dialysis,300 minutes; stated;arterial blood gases and 
providers and outcomes  diabetic nephropathy,5 not  blood flow rate,200 ml/min; acid–base balance not stated;
assessors not stated; diabetic but with chronic  dialysate flow rate,500 ml/min; renal bone disease indicators 
numbers and reasons  glomerulo-nephritis;stable  membrane type, Allegro hollow  and lipid profile not stated;
for withdrawals,drop- glycaemic control,no hypo-  fibre,surface area not stated; other outcomes:blood glucose,
outs and numbers  glycaemia or hypotension on  dialysate sodium concentration, insulin,lactate,pyruvate,aceto-
lost to follow-up  glucose-free dialysis;M:F, 131 mmol/l;dialysate buffer  acetate,3-hydroxy-butyrate,
given:eight drop-outs  10:0;mean age (SD):diabetes concentration:acetate dialysis –  non-esterfied fatty acids,
in total but treatment  group 53.0 years (6.6);non- acetate 38 mmol/l,bicarbonate nil; glycerol and acetate measured 
group not specified; diabetes group 50.0 years  bicarbonate dialysis – acetate  before dialysis,1 hour after 
analysis not on  (13.0);mean weight – given  2 mmol/l,bicarbonate 30 mmol/l; dialysis started and during 
intention-to- treat  as body mass index – (SD): other interventions:overnight  the i.v.glucose tolerance test.
basis. diabetes group 23.0 kg/m
2 fast and intravenous glucose 
(1.3),non-diabetes group  tolerance test during dialysis 
24.5 kg/m2 (3.7);no other  treatment.
co-morbidity stated.
Paris 1983 RCT,randomisation  50 patients on outpatient  25 patients (group A) on acetate  Intra- and postdialytic 
method not described; haemodialysis with previous  dialysis throughout study, symptoms not stated;intra- 
(Lefebvre, patients randomised  reasonable tolerance of  25 patients (group B) allocated to  dialytic cardiovascular stability:
et al.,1983) either to stay on acetate  acetate dialysis;M:F,29:21; cross over to bicarbonate dialysis  predialysis supine systolic 
dialysis for duration of  mean age (SD) 43 years  after 90 days;duration of study: blood pressure,heart rate,
trial or to switch to  (13);mean weight (SD), group A,18 months,group B,ace-  pre-ejection period,left 
bicarbonate dialysis  predialysis,day 0:group A, tate dialysis 3 months,bicarbonate  ventricular ejection time,
after 90 days;the group  63.4 kg (1.0),group B  dialysis 15 months;dialysis duration  electro-mechanical interval;
that switched thus con-  63.4 kg (2.5);co-morbidity, not stated;blood and dialysate flow  arterial blood gases and acid–
stituted a separate cross- no important co-morbid  rates not stated;membrane type  base balance not stated;renal 
over trial but allocation  illness (in particular,vasculo-  and surface area not stated; bone disease indicators:
to treatment order was  pathy,coronary disease, dialysate sodium concentration, predialysis serum calcium and 
not randomised;blinding  severe hypertension and  140 mmol/l;dialysate buffer  phosphate on days 0 and 
of patients and healthcare cardiac dysrhythmia). concentration:acetate dialysis –  540 (mmol/l);lipid profile not 
providers not stated,out- acetate 38 mmol/l,bicarbonate  stated;other outcomes,
comes assessors blinded  nil;bicarbonate dialysis – acetate  predialysis serum potassium 
and method likely to be  nil,bicarbonate 35 mmol/l. on days 0 and 540.
effective;withdrawals,
drop-outs and numbers 
lost to follow-up – stated 
to be withdrawals but 
numbers and reasons not 
stated;analysis not on 
intention-to-treat basis.
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Philadelphia 1985 Crossover trial with  105 patients at an  Acetate vs.bicarbonate  Intra- and postdialytic symp-  Data from abstract 
alternation,method  outpatient haemo-  dialysis,duration of study, toms:episodes of ‘shock’  of a presentation 
(Brezin,et al., of allocation to first  dialysis unit;M:F not  8 weeks divided into four  (presumed to be symptomatic  only;authors being 
1985) treatment not stated; stated;mean age and  2-week periods (4 weeks on  hypotension),vomiting,head-  contacted to 
blinding of patients and  mean weight not  each dialysate),duration of  aches,muscle cramps;intra-  ascertain if full study 
healthcare providers  stated;co-morbidity  dialysis not stated;blood and  dialytic cardiovascular stability: subsequently 
stated but not described, not stated. dialysate flow rates not  initial,lowest and end-dialysis  published.
outcomes assessors  stated;membrane type and  systolic blood pressure;saline 
blinding not stated; surface area not stated;dialy-  requirements also recorded;
withdrawals,drop-outs  sate sodium concentration: arterial blood gases and acid– 
and number lost to  acetate 136 mmol/l,bicar-  base balance not stated;renal 
follow-up not stated; bonate 135 mmol/l;dialysate  bone disease indicators and 
analysis possibly on  buffer concentration: lipid profile not stated.
intention-to-treat basis  acetate dialysis – acetate 
but not clear. 37.75 mmol/l,bicarbonate 
nil;bicarbonate dialysis – 
acetate nil,bicarbonate 
36 mmol/l.
Seattle 1982 RCT,crossover design; 21 stable maintenance  Acetate (38 mmol/l) vs. Intra- and postdialytic symp-  Combination buffer 
randomisation method  haemodialysis patients; bicarbonate (35 mmol/l)  toms:episodes of nausea, data from this study 
(Pagel,et al., not stated;patients  M:F,9:14;mean age (SD) vs.acetate (38 mmol/l) plus  vomiting,headache;choice  is not included in 
1982) blinded but method not  54 years (14),range  bicarbonate (10 mmol/l)  reaction time (time taken to  this review.
described,no mention of  28–75 years;mean  dialysis;duration of study: make decision about flashing 
blinding of healthcare  weight (SD):sympto-  single dialysis treatment on  colour panel,used as objective 
providers and outcomes  matic group 62.1 kg  each dialysate,three treat-  measure of ability to maintain 
assessors;numbers and  (8.1),asymptomatic  ments total;dialysis duration  sustained concentration and 
reasons given for with- group 62.2 kg (1.7); 4 hours;blood flow rate  hypothesised to relate to ‘feel- 
drawals,drop-outs and  co-morbidity:no  200 ml/min;dialysate flow  ings of well-being’) measured 
numbers lost to follow- respiratory,cardiac  rate 500 ml/min;membrane  pre- and postdialysis;intra- 
up;two patients who  or diabetic history –  type C-DAK (Cordis-Low), dialytic cardiovascular stability:
participated but were on  exclusion criteria:as surface area 1.8 m
2;dialysate  predialysis and lowest 
antihypertensive therapy  for co-morbidity. sodium concentration  intradialytic systolic,diastolic 
did not have their data  140 mmol/l;dialysate buffer  and mean arterial blood 
analysed;analysis not on  concentration:acetate dialysis pressure,change in mean 
intention-to-treat basis. – 38 mmol/l,bicarbonate nil; arterial blood pressure (pre- 
bicarbonate dialysis – acetate  dialysis minus lowest level);
nil,bicarbonate 35 mmol/l; arterial blood gases and acid–
combination dialysis –  base balance:pH,plasma 
acetate 38 mmol/l, bicarbonate and serum acetate 
bicarbonate 10 mmol/l. change during dialysis;renal 
bone disease indicators and 
lipid profile not stated.
Sydney 1977 Crossover trial with  Eight patients with  Acetate vs.bicarbonate  Intra- and postdialytic symp- 
alternation;allocation  ESRD established on  dialysis;duration of study  toms not stated;intradialytic 
(Savidie,et al., to first treatment not  haemodialysis with  12–20 weeks (four periods  cardiovascular stability not 
1977) randomised;blinding of  fasting hypertri-  of 3–5 weeks),duration of  stated;arterial blood gases and 
patients,healthcare  glyceridaemia on two  dialysis 6 hours;blood flow  acid–base balance:pH and 
providers and outcomes  consecutive occasions  rate not stated;dialysate flow  standard bicarbonate;renal 
assessors not stated; (> 150 mg%);M:F,1:7; rate 500 ml/min;membrane  bone disease indicators not 
withdrawals,drop-outs  mean age 44 years, type,Cordis-Dow (seven  stated;lipid profile:total fasting 
and number lost to  range 29–55 years; patients),surface area 1.3 m
2; predialysis plasma cholesterol 
follow-up not stated, mean weight (SD)  Gambro optima – one  and triglyceride concentrations;
but all eight patients in  60.7 kg (4.7) at first  patient;dialysate sodium  other indicators:mean 
results section;analysis  acetate dialysis;co-  concentration not stated; predialysis urea,relative 
on intention-to-treat  morbidity:no diabetic  dialysate buffer concen-  weight and calorie intake.
basis. or nephrotic patients; tration:acetate dialysate 
no patient had medical  – acetate 40 mmol/l,
or technical compli-  bicarbonate nil;bicarbonate 
cations likely to affect  dialysate – acetate nil,
health or dialysis within  bicarbonate 40 mmol/l.
the ensuing 3 months.
continuedAppendix 5
84
Results
The meta-analyses of the results of these studies are
presented in Table 19 (A and B).
Intradialytic symptoms
Five symptom categories were considered.
Headaches
Five studies compared the number of haemodialysis
treatments during which headaches were reported.
In the 1983 Hamilton trial (Shimizu, et al., 1983),
buffers were compared at two levels of dialysate
sodium concentrations (high and low) and, hence,
was considered as two separate studies in subse-
quent analyses. The incidence of headaches on
bicarbonate dialysis was lower in four of the five
trials with an overall estimate favouring bicarbonate
dialysis (OR, 0.84; 95% CI, 0.71, 0.99; NNT, 33).
Although there was evidence of heterogeneity
across the trials (chi-squared test, 2p < 0.05), 
over 90% of the data came from the 1983 
Hamilton trial and the summary OR is largely
determined by this trial.
The 1985 Philadelphia trial reported the incidence
of headaches (Brezin, et al., 1985) but in relation 
to episodes over a period and, hence, could not be
included in this meta-analysis. There was a non-
significant tendency favouring bicarbonate dialysate.
Nausea and vomiting
In five studies the number of haemodialysis treat-
ments were compared for which nausea and/or
vomiting were reported. The estimate of the overall
effect favoured the use of bicarbonate (OR, 0.42;
95% CI, 0.26, 0.66; NNT, 49). The results of the
trials were significantly heterogeneous (chi squared
test, 2p < 0.01). The incidence rates of nausea and
vomiting in the acetate groups were higher in the
three smaller studies, in which there were fewer
episodes during bicarbonate dialysis, than in the
1983 Hamilton trial (Shimizu, et al., 1983a; b) in
which there was no difference between the groups.
In the 1985 Philadelphia trial (Brezin, et al., 1985),
which was not included in the meta-analysis (see
above), there were fewer episodes of vomiting in
the bicarbonate group (6 versus 30; p < 0.005).
Muscle cramps
Data describing muscle cramps were available for
only the two parts of the Hamilton trial (Shimizu, 
et al., 1983a; b) and the smaller Chicago trial
(Dalal, et al., 1990b; c). The comparison is there-
fore dominated by the data from the Hamilton
trial, which suggested there was no difference.
The 1991 Madras trial (Gurudev, et al., 1991) was
not included in the meta-analysis because no
muscle cramps were reported with either dialysate
(0/90 treatments with bicarbonate; 0/90
treatments with acetate); hence, no OR could be
calculated.
Symptomatic or treatment-requiring
hypotension
Two studies with a total of 396 haemodialysis
treatments were included in the meta-analysis. 
The suggestion of a significant reduction in
symptomatic hypotension with bicarbonate
dialysate (OR, 0.28; 95% CI, 0.11, 0.69; NNT, 17)
reflects the findings of the 1979 Chicago trial
(Dalal, et al., 1979b; c).
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Torrance 1981 RCT,crossover design, Seven routine  Acetate vs.bicarbonate  Intra- and postdialytic symp- 
method of random  haemodialysis patients; dialysis;duration of study, toms not stated;intradialytic 
(Dolan,et al., allocation not described; M:F,3:4;mean age  one treatment with each  cardiovascular stability not 
1981;Davidson, patients blinded but  44.7 years,range  dialysate,duration of dialysis, stated;arterial blood gases and 
et al.,1982) method not given; 22–55 years;mean  4 hours;blood flow rate  acid–base balance:PO2,P CO2;
blinding of healthcare  weight 61.2 kg,range  200 ± 20 ml/min;dialysate  renal bone disease indicators
providers and outcomes  41.0–92.8 kg;co-  flow rate 500 ± 50 ml/min; and lipid profile not stated;
assessors not stated; morbidity:free of  membrane type,Travenol  other parameters:VO2 (oxygen 
withdrawals,drop-outs  cardiovascular and  CF 1500,surface area  uptake),VCO2 (CO2 excretion),
and number lost to  pulmonary disease  1.5 m
2;dialysate sodium  VCO2/VO2 (respiratory gas 
follow-up not stated; apart from mild  concentration;acetate  exchange ratio).
analysis possibly on  controlled hyper-  130 mmol/l,bicarbonate 
intention-to-treat basis  tension;two patients  130 mmol/l;dialysate buffer 
but not clear. with diabetes mellitus  concentration:acetate 
as cause of renal dialysate – acetate 35 mmol/l,
failure. bicarbonate nil;bicarbonate 
dialysate – acetate nil,
bicarbonate 35 mmol/l.Data from a number of the included studies could
not be included in this meta-analysis. In the Odense
trial (Otte, et al., 1990), the number of hypotensive
episodes (not further defined) per patient over 12
weeks were given. There was no significant differ-
ence between the dialysates: bicarbonate, 3.0
(standard deviation, 4.26); acetate, 1.5 (standard
deviation, 2.71). Episodes of shock (not further
defined) were reported in the Philadelphia study
(Brezin, et al., 1985); however, there was no signifi-
cant difference in the results: bicarbonate, 8; ace-
tate, 19. There was no significant difference in the
TABLE 19A  Bicarbonate versus acetate-buffered haemodialysis:overall summary
Comparison or outcome Peto OR WMD 
(95% CI) (95% CI)
Treatments associated with headaches
Treatments associated with nausea/vomiting
Treatments with muscle cramps
Treatments with symptomatic hypotension
Treatments with non-specific intolerance
Patients with any adverse symptoms
Treatments with any adverse symptoms
Fasting predialysis serum cholesterol Not estimable
Fasting predialysis serum triglyceride Not estimable
Fasting predialysis HDL cholesterol Not estimable
Fasting predialysis LDL cholesterol Not estimable
Predialysis serum calcium (mmol/l) Not estimable
Predialysis serum phosphate (mmol/l) Not estimable
Predialysis serum alkaline phosphatase Not estimable
Predialysis parathyroid hormone Not estimable
Predialysis pH
Postdialysis pH
Predialysis bicarbonate
Postdialysis arterial bicarbonate
Postdialysis arterial PO2 (kPa)
Greatest fall in intradialytic PO2 Not estimable
Lowest recorded intradialytic PO2 Not estimable
Postdialysis PCO2 (kPa)
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TABLE 19B Bicarbonate versus acetate-buffered haemodialysis:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Treatments associated with headaches
Chicago,1990b 3/108 12/108 2.6 0.28 (0.10,0.79)
Hamilton,1983a 178/672 178/672 48.7 1.00 (0.78,1.27)
Hamilton,1983b 141/672 172/672 44.7 0.77 (0.60,0.99)
Madras,1991 2/90 9/90 1.9 0.26 (0.08,0.88)
Seattle,1982 11/21 11/21 2.0 1.00 (0.30,03.31)
Total (95% CI) 335/1563 382/1563 100.0 0.84 (0.71,0.99)
Chi-square 10.38 (df = 4) Z = 2.03
continued
0.1 0.2 1 5 10 –10 –5 0 5 10
0.1 1 0.2 51 0
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TABLE 19B contd  Bicarbonate versus acetate-buffered haemodialysis:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Treatments with nausea/vomiting
Chicago,1990b 1/108 17/108 22.7 0.15 (0.06,0.38)
Hamilton,1983a 9/672 11/672 27.0 0.82 (0.34,1.97)
Hamilton,1983b 10/672 8/672 24.3 1.25 (0.49,3.17)
Madras,1991 2/90 8/90 13.0 0.28 (0.08,1.01)
Seattle,1982 2/21 12/21 13.1 0.12 (0.03,0.44)
Total (95% CI) 24/1563 56/1563 100.0 0.42 (0.26,0.66)
Chi-square 16.12 (df = 4) Z = 3.74
Treatments with muscle cramps
Chicago,1990b 5/108 16/108 6.5 0.32 (0.13,0.77)
Hamilton,1983a 108/672 88/672 57.6 1.27 (0.94,1.72)
Hamilton,1983b 50/672 64/672 35.9 0.76 (0.52,1.12)
Total (95% CI) 163/1452 168/1452 100.0 0.97 (0.77,1.22)
Chi-square 10.53 (df = 2) Z = 0.29
Treatments with symptomatic hypotension
Chicago,1990b 2/108 15/108 84.1 0.19 (0.07,0.51)
Madras,1991 2/90 1/90 15.9 1.96 (0.20,19.11)
Total (95% CI) 4/198 16/198 100.0 0.28 (0.11,0.69)
Chi-square 3.38 (df = 1) Z = 2.77
Treatments with non-specific intolerance
Chicago,1990b 2/108 30/108 4.6 0.13 (0.06,0.27)
Hamilton,1983a 199/672 211/672 47.9 0.92 (0.73,1.16)
Hamilton,1983b 175/672 190/672 44.7 0.89 (0.70,1.14)
Madras,1991 2/90 17/90 2.9 0.17 (0.07,0.45)
Total (95% CI) 378/1542 448/1542 100.0 0.79 (0.67,0.93)
Chi-square 34.92 (df = 3) Z = 2.87
continued
0.1 1 0.2 51 0
Favours control Favours treatment
0.1 1 0.2 51 0
Favours control Favours treatment
0.01 1 0.1 10 100
Favours control Favours treatment
0.1 1 0.2 51 0
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TABLE 19B contd  Bicarbonate versus acetate-buffered haemodialysis:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Patients with any adverse symptoms
Madras,1991 3/30 9/30 100.0 0.29 (0.08,1.03)
Total (95% CI) 3/30 9/30 100.0 0.29 (0.08,1.03)
Chi-square 0.00 (df = 0) Z = 1.92
Treatments with any adverse symptoms
Chicago,1990b 9/108 63/108 6.4 0.11 (0.06,0.19)
Columbia,1979a 12/54 24/54 3.2 0.37 (0.17,0.82)
Hamilton,1983a 307/672 322/672 44.6 0.91 (0.74,1.13)
Hamilton,1983b 255/672 293/672 43.3 0.79 (0.64,0.98)
Madras,1991 5/90 15/90 2.4 0.33 (0.13,0.83)
Total (95% CI) 588/1596 717/1596 100.0 0.71 (0.61,0.82)
Chi-square 54.94 (df = 4) Z = 4.71
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Predialysis pH
Chicago,1990b 12 –7.39 (0.03) 12 –7.38 (0.03) 73.1 –0.010 (–0.034,0.014)
Odense,1990 15 –7.34 (0.06) 15 –7.33 (0.05) 26.9 –0.010 (–0.050,0.030)
Total (95% CI) 27 27 100.0 –0.010 (–0.031,0.011)
Chi-square 0.00 (df = 1) Z = 0.96
Postdialysis pH
Madras,1991 90 –7.45 (0.03) 90 –7.45 (0.03) 100.0 0.000 (–0.009,0.009)
Total (95% CI) 90 90 100.0 0.000 (–0.009,0.009)
Chi-square 0.00 (df = 0) Z = 0.00
continued
0.01 1 0.1 10 100
Favours control Favours treatment
0.1 1 0.2 51 0
Favours control Favours treatment
–0.5 0 0.5
Favours control Favours treatment
–0.5 0 0.5
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number of patients who experienced ‘transient
hypotension’ (a drop in systolic blood pressure of 
> 15 mmHg), as reported in the 1983 Boston trial
(Schick, et al., 1983): bicarbonate, 2; acetate, 6.
Non-specific intolerance
In four studies (3084 haemodialysis treatments)
there were reports of non-specific intolerance. All
four studies found that it was less common with
TABLE 19B contd  Bicarbonate versus acetate-buffered haemodialysis:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI (%) (95% CI  fixed)
Predialysis bicarbonate
fixed)
Chicago,1990b 12 –20.40 (2.22) 12 –18.90 (2.07) 40.4 –1.500 (–3.217,0.217)
Columbia,1979a 54 –19.00 (7.35) 54 –18.00 (2.94) 26.8 –1.000 (–3.111,1.111)
Odense,1990 15 –20.30 (2.97) 15 –18.70 (2.32) 32.8 –1.600 (–3.507,0.307)
Total (95% CI) 81 81 100.0 –1.399 (–2.491,–0.307)
Chi-square 0.19 (df = 2) Z = 2.51
Postdialysis arterial bicarbonate
Columbia,1979a 54 –23.10 (7.35) 54 –18.30 (6.61) 9.6 –4.800 (–7.437,–2.163)
Madras,1991 90 –26.75 (2.57) 90 –25.90 (3.28) 90.4 –0.850 (–1.711,0.011)
Total (95% CI) 144 144 100.0 –1.231 (–2.049,–0.412)
Chi-square 7.79 (df = 1) Z = 2.95
Postdialysis arterial PO2 (kPa)
Antwerp,1983a 6 –12.60 (1.10) 6 –9.60 (1.80) 5.5 –3.000 (–4.688,–1.312)
Antwerp,1983b 6 –12.10 (1.20) 6 –11.00 (0.80) 11.9 –1.100 (–2.254,0.054)
Madras,1991 90 –12.85 (1.44) 90 –11.99 (1.55) 82.6 –0.860 (–1.297,–0.423)
Total (95% CI) 102 102 100.0 –1.007 (–1.404,–0.610)
Chi-square 5.82 (df = 2) Z = 4.97
Postdialysis PCO2 (kPa)
Madras,1991 90 –5.04 (0.38) 90 –4.88 (0.42) 100.0 –0.160 (–0.277,–0.043)
Total (95% CI) 90 90 100.0 –0.160 (–0.277,–0.043)
Chi-square 5.82 (df = 2) Z = 4.97
–10 0 –5 51 0
Favours control Favours treatment
–10 0 –5 51 0
Favours control Favours treatment
–4 0 –2 24
Favours control Favours treatment
–1 0 1
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bicarbonate dialysate (NNT, 22). Again there was
marked heterogeneity between the results of the
Hamilton trial (Shimizu, et al., 1983a; b), which
suggested a modest 10% reduction in the OR, 
and the two smaller trials, which suggested about
an 85% reduction in the OR.
Any adverse symptoms
In five studies (3192 haemodialysis treatments) 
any adverse symptoms were recorded. The overall
estimate favoured bicarbonate (OR, 0.71; 95% 
CI, 0.61, 0.82; chi-squared test for heterogeneity, 
p < 0.001). The pattern was similar to that for non-
specific intolerance: all suggested fewer symptoms
associated with bicarbonate, but the estimate of
effect was much more modest in the larger
Hamilton trial (Shimizu, et al., 1983a; b).
General well-being and 
patient acceptability
Only two studies reported on general well-being
and/or patient acceptability. However, different
measurement tools were used in these trials, hence
the results could not be combined.
In the 1982 Seattle trial (Pagel, et al., 1982), the
‘choice reaction time’ immediately postdialysis was
used as an indicator of well-being. A significant
difference favouring bicarbonate was noted
(bicarbonate, 9.1 ms, standard error of the mean
(SEM), 37.1; acetate, 29.3 ms, SEM, 38.1; p < 0.05).
A ‘state of well-being index’ was used in the 1979
Columbia trial (van Stone & Cook, 1979a; b) in
which patients described how they felt both pre-
and postdialysis. Although there was no significant
difference predialysis, patients using bicarbonate
felt significantly better postdialysis that patients
using acetate.
Meta-analyses of the included studies indicated a
significant reduction in all adverse symptoms, both
collectively and individually (apart from muscle
cramps) with bicarbonate dialysis.
Any data from the included studies which were
relevant to these outcomes but not possible to
include in the meta-analysis either supported the
use of bicarbonate or failed to find a significant
difference between the dialysates.
Cardiovascular stability
The frequency of symptomatic or treatment-
requiring hypotension was the only indicator 
of cardiovascular stability subjected to meta-
analysis. The results are recorded above under
intradialytic symptoms.
In other studies, parameters were recorded which
were relevant to cardiovascular stability but which
were not encompassed by our comparisons. In the
Columbia trial (van Stone & Cook, 1979a; b), no
significant differences in the means of predialysis,
postdialysis and lowest intradialytic supine and
upright systolic and diastolic blood pressures were
found between the dialysates. In the Seattle trial
(Pagel, et al., 1982), the change in mean arterial
intradialytic pressure was reported as significantly
less and the lowest intradialytic systolic, diastolic
and mean arterial blood pressures were reported as
significantly greater with bicarbonate dialysis. A
significantly decreased rate of fall in mean arterial
pressure but no difference in change of venous
tone during bicarbonate dialysis was reported in
the Cambridge trial (Bradley, et al., 1988).
Although a significant increase in heart rate with
acetate as opposed to bicarbonate dialysis was
reported in the Paris trial (Lefebvre, et al., 1983b),
there was no significant difference in the fall of
systolic blood pressure with bicarbonate compared
with acetate dialysis. A significant increase in heart
rate was reported with acetate but not with bicar-
bonate dialysis in the Boston trial; however, Schick
and colleagues (1983) found no significant differ-
ence between the two dialysates in changes in
systolic, diastolic and mean arterial blood pressure,
ejection fraction and cardiac output. Only one of
the two studies included in the meta-analysis
indicated a reduction in symptomatic hypotension
with bicarbonate dialysis. In the studies which
assessed cardiovascular stability with parameters
other than those used in this comparison, no
significant differences were usually found between
the dialysates. If any significant difference was
found, it always favoured bicarbonate dialysis.
Therefore, no conclusive evidence was found 
that bicarbonate dialysis improves cardiovascular
stability in the haemodialysis of patients with ESRD.
Correction of metabolic acidosis
Postdialysis arterial (from arteriovenous fistula) 
pH and bicarbonate levels indicate how well 
a particular dialysate buffer has corrected the
metabolic acidosis over the course of treatment.
Predialysis pH and bicarbonate levels reflect 
the chronic acid–base status of the patient, 
which is likely to have greater long-term
pathophysiological significance.
Predialysis pH level (after at least one dialysis 
on specific dialysate)
Two studies were included in the meta-analysis.
There was no significant difference between the
dialysates (WMD, 0.01; 95% CI, –0.01, 0.03).Appendix 5
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Predialysis bicarbonate level (after at least one
dialysis on specific dialysate)
Three studies were included in the meta-analysis. 
A significant difference was found which favoured
bicarbonate (WMD, 1.4; 95% CI, 0.31, 2.49).
Postdialysis pH level
Only one study reported postdialysis pH levels
(Gurudev, et al., 1991). There was no difference
between the dialysates.
Postdialysis bicarbonate level
Two studies were included in this meta-analysis.
Bicarbonate dialysate resulted in higher postdialysis
bicarbonate levels (WMD, 1.23; 95% CI, 0.41, 2.05).
However, a larger difference was observed in one
trial than in the other (chi-squared test, p < 0.01).
Summary
Bicarbonate dialysis was associated with only a
marginally higher pre- and postdialysis blood
bicarbonate level compared with acetate dialysis.
There was no difference between the dialysates in
relation to arterial pH level.
Arterial blood gases
Some of the adverse symptoms and cardiovascular
instability experienced on haemodialysis have been
attributed to hypoxia. It has been suggested that
acetate dialysate may be associated with more
severe hypoxia because of loss of respiratory drive
caused by hypocarbia (a consequence of greater
loss of carbon dioxide into the dialysate).
Postdialysis PO2
Three studies were included in the meta-analysis.
End-dialysis PO2 was higher with bicarbonate dialysis
in all three studies (WMD, 1.01; 95% CI, 0.61,
1.40), although the size of the difference varied
between them (chi-squared test, p < 0.05).
Lowest intradialytic PO2
None of the studies reported this outcome.
Postdialysis PCO2
Only the 1991 Madras study (Gurudev, et al., 
1991) reported postdialysis PCO2; it was signifi-
cantly higher at the end of bicarbonate dialysis
compared with acetate dialysis (WMD, 0.16; 
95% CI, 0.04, 0.28).
Not all data relevant to the stated outcomes from
the included trials could be included in the meta-
analyses, because of the various time points used 
by the different studies when reporting acid–base
and blood gas data. These data may be summarised
as follows.
• In the Chicago trial (Dalal, et al., 1989; 1990b), 
a significant decrease in PO2 and PCO2 during
acetate but not bicarbonate dialysis was reported,
together with a significantly faster correction of
pH and bicarbonate levels with bicarbonate dialy-
sis. However, by 1 hour postdialysis there were no
significant differences in these parameters.
• The 1979 Columbia trial (van Stone & Cook,
1978; 1979) reported significantly higher levels
of PO2, PCO2, and pH after a 3-hour dialysis with
bicarbonate compared with acetate.
• The data from the 1983 Newcastle trial (Ramos,
et al., 1983) showed a significant fall in PO2 dur-
ing acetate dialysis but not during bicarbonate
dialysis. The PO2 had returned to predialysis
values by the last hour of dialysis, the pH level
was raised more rapidly during bicarbonate
dialysis, and PCO2 and bicarbonate level were
significantly increased during bicarbonate but
not during acetate dialysis.
• A significant fall in PO2 during acetate dialysis
(still present at end of dialysis) but not during
bicarbonate dialysis was reported in the 1981
Torrance trial (Dolan, et al., 1981; Davidson, 
et al., 1982).
• The results of the 1983 Antwerp trial (de Backer,
et al., 1983) demonstrated a significant fall in 
PO2 with both acetate and bicarbonate dialysate
when using cuprophane dialysis membranes 
but only with acetate dialysate when using
polyacrylonitryl membranes.
• In the 1982 Seattle trial (Pagel, et al., 1982),
significantly higher bicarbonate and pH levels
after 1 hour of dialysis, which persisted through-
out the dialysis treatment, were reported during
bicarbonate dialysis compared with 
acetate dialysis.
Overview
The meta-analysis and other data from the
included studies indicate that bicarbonate dialysis is
more likely to avoid dialysis-associated hypoxia than
acetate dialysis. However, there was no evidence
that this improved either morbidity or mortality.
Fasting lipids
Only the 1977 Sydney trial (Savidie, et al., 1977)
reported on fasting lipids. A mean difference could
not be calculated, however, because the relevant
standard deviation could not be derived from the
data published. No significant difference in fasting
predialysis lipids between bicarbonate and acetate
dialysis was noted.
Indicators of renal bone disease
The 1983 Newcastle trial (Ramos, et al., 1983) 
was the only one in which data relevant to renalHealth Technology Assessment 1998; Vol. 2: No.5
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bone disease was presented but, because these data
were only presented graphically, they could not be
included in a meta-analysis. However, there was no
significant difference between bicarbonate and
acetate dialysis relative to predialysis calcium,
phosphate and parathyroid hormone levels.
Discussion
Bicarbonate has largely supplanted acetate as the
most frequently used dialysate buffer in haemo-
dialysis/haemofiltration. In general, bicarbonate-
buffered dialysate is used for 78% of patients on
haemodialysis/haemofiltration in the UK and for
76% of patients in Europe (Vallerrabano, et al.,
1996). However, some countries such as Bulgaria
and Romania have lagged behind this general
switch to bicarbonate dialysis. The switch from
acetate to bicarbonate haemodialysis was based 
on perceived advantages in reducing intradialytic
symptoms (Leenan, et al., 1980; Heneghan, 1982),
improved cardiovascular stability (Okusa, et al.,
1982), better correction of metabolic acidosis,
superior lipid profile and, possibly, a slowing 
of the progression of renal bone disease.
This systematic review of the literature has
attempted to define whether this switch to
bicarbonate-buffered haemodialysis is supported 
by evidence from good clinical trials, which specific
putative benefits are so supported and what the
economic outcomes of the change have been.
Meta-analyses of the included studies indicated a
significant reduction in all adverse symptoms apart
from muscle cramps, both collectively and individ-
ually, with bicarbonate dialysis. The NNT (for
example, 33 bicarbonate haemodialysis treatments
would, on average, need to be undertaken in order
to produce one extra treatment without headaches)
should be considered in the contest of the number
of treatments each patient requires each year
(approximately 150). However, there was consider-
able heterogeneity across the studies, although this
was related predominantly to magnitude rather than
direction of effect. It is difficult to identify precisely
the explanation for this heterogeneity across trials;
however, much is a consequence of the difference 
in size of effect favouring bicarbonate noted
between the 1983 Hamilton studies (Shimizu, et al.,
1983) and the 1991 Madras (Gurudev, et al., 1991)
and 1990 Chicago studies (Dalal, et al., 1989; 1990).
This may be attributable to differences in the dur-
tion of the study (number of treatments per patient)
and in the method of symptom reporting. The 1983
Hamilton study assessed approximately 96 dialysis
treatments per patient while the 1991 Madras study
assessed six treatments per patient and the 1990
Chicago study only two per patient. The method of
adverse symptom reporting in the 1983 Hamilton
study (and in the 1982 Seattle study (Pagel, et al.,
1982)) was explicitly by patient questionnaire, while
the 1991 Madras and 1990 Chicago studies appear 
to have been recorded by dialysis staff. The report-
ing of symptoms by dialysis staff might under-
record adverse symptoms compared with a 
patient questionnaire.
The review has generated evidence in support of the
use of bicarbonate-buffered haemodialysis in the
treatment of all patients with ESRD. However, the
evidence only conclusively favours bicarbonate
haemodialysis in relation to a reduction in intra-
dialytic symptoms, particularly headaches, nausea
and vomiting, and symptomatic hypotension. There
is no clear evidence that bicarbonate dialysis has 
any effect on the frequency of intradialytic muscle
cramps, leads to a more favourable lipid profile or
slows the progression of renal bone disease; how-
ever, there are few data available for these outcomes.
The evidence of improved cardiovascular stability is
inconclusive. This may be a consequence of our
inability to summate various cardiovascular para-
meters from the different studies. There is evidence
of a modest improvement in control of metabolic
acidosis with bicarbonate, although the clinical and
pathophysiological relevance of this is uncertain.
Early studies suggested that the improvement in
outcomes associated with switching to bicarbonate
haemodialysis may be particularly marked in certain
patient groups, such as those with acute renal
failure, cardiovascular instability or known acetate
intolerance. None of the studies included exclusively
examined these patient groups; indeed, in general,
patient groups were composed of chronic stable
patients with limited associated co-morbidity. The
results of this review may therefore underestimate
the beneficial effect of bicarbonate-buffered
haemodialysis in respect to these sub-groups.
In the UK at least, bicarbonate haemodialysis is no
longer significantly more expensive than acetate
haemodialysis. This is a dramatic change from the
situation some 5–10 years ago. The initially greater
cost of bicarbonate haemodialysis certainly 
slowed its uptake, even by those convinced of the
clinical benefits. The health economics history of
bicarbonate haemodialysis may be illustrative of the
implementation of high technology advances in
general. Initial studies suggested that it had at least
a modest superiority over acetate dialysis, which
seemed to be most marked in relation to relativelyAppendix 5
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small patient groups, such as those with cardiac
disease or with known acetate intolerance. If
bicarbonate dialysis had been restricted to these
groups, it is likely that its cost would have remained
significantly higher than acetate dialysis. However,
its general use in the stable dialysis population has
led to a significant fall in cost.
When undertaking this review, a number of
methodological problems were encountered which
may be relevant to future reviews in this area. The
management of ESRD is a low patient volume and
high technology speciality; hence, trials have tended
to be of small populations. The very high drop-out
rates from medium or long duration studies, which
are an inevitable consequence of dialysis technique
failure, renal transplantation and high morbidity
and mortality in this population, may also have
encouraged trials of short duration. Studies assessing
important, unequivocal primary outcome measures
such as death are rare because they require relatively
prolonged follow-up. Moreover, primary outcomes
such as death cannot be assessed satisfactorily using
a crossover study design. Secondary outcome
measures are more likely than primary ones to
change significantly over the course of a short study.
The routine management of dialysis patients pro-
duces a vast array of secondary outcome measures,
such as blood pressure recordings and biochemical
data. These two factors may have influenced, and are
likely to continue to influence, the predominance of
surrogate endpoints in studies of dialysis treatment.
Essentially similar surrogate endpoints may be
recorded differently by different studies; reported
bicarbonate may, for example, be pre- or post-
dialysis, while cardiovascular stability may be assessed
by many different parameters, from mean arterial
blood pressure to changes in systolic blood pressure.
This variation in recording of similar outcomes
presented significant difficulties in this review, 
as data from various trials could often not 
be combined.
Economic evaluation
Introduction
The principles of economic evaluation are
described in detail in chapter 3 (page 9) 
including, in an economic framework, the manner
in which costs and outcome are related (see, in
particular, Table 2 and Figure 3).
Aims
Bicarbonate can be used as a buffer in haemo-
dialysis and has been suggested as an alternative 
to acetate-buffered haemodialysis in the belief that
patients dialysed with bicarbonate suffer fewer
complications. The relative efficiency of these two
alternatives will be investigated using the frame-
work of economic evaluation outlined in chapter 3.
More specifically, the aims of this economic
evaluation are:
(i) to investigate the relative resources used 
and the cost of acetate and bicarbonate
haemodialysis fluids using data extracted from
the identified RCTs and non-randomised
studies which compared acetate and
bicarbonate buffers in haemodialysis
(ii) to combine data on differences in costs with
data on differential benefits to patients from
the systematic review of effectiveness above 
in order to assess the relative efficiency of
haemodialysing patients with bicarbonate 
or acetate buffer.
Methods
Data collection and extraction
The methods used are described in detail in
chapter 3 of the main report.
Benefits to patients
The systematic review of RCTs or quasi-RCTs
described above had as its main objective the syn-
thesis of data on the effectiveness of haemodialysis
with acetate compared with bicarbonate as a buffer
from the RCTs. Information was extracted from the
RCTs on the following outcomes:
(i) the frequency of adverse symptoms 
during dialysis
(ii) cardiovascular stability during dialysis
(iii) the patient’s lipid profile
(iv) the progression of renal bone disease.
Identification of resource use and costs
The identification of the relative resources used
when dialysing patients with either bicarbonate 
or acetate haemodialysis involved four steps. 
1. The process of care was defined so that all
items of resource use could be identified; for
example, resources could potentially be con-
sumed during three main stages: preparation
of the dialysate; the dialysis session itself; and
in the treatment of any complications which
may occur.
2. All the relevant information was extracted
from the RCTs.
3. The data on resource use contained in the
non-randomised studies was assessed.
4. The information on resource use was then
combined with information on the unit cost Health Technology Assessment 1998; Vol. 2: No.5
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of the resources to determine the cost differ-
ential between bicarbonate and acetate
haemodialysis using methodology described
below. This differential could then be com-
pared with data on differential benefits to
patients obtained from the systematic 
review of effectiveness.
Model of costs
1.  Dialysate preparation  The bicarbonate
dialysate can be prepared in three ways. First, 
it can be mixed by hand from a pre-prepared
powder. Second, the dialysate powder can be
automatically mixed by the dialysis machine.
Finally, the dialysate solution can be obtained
as a premixed concentrate. Acetate dialysate 
is normally only provided as a pre-mixed
concentrate (G Anderson, Gambro: personal
communication, 1996). The resources (and
costs) required for each of the three bicar-
bonate options are different; the additional
cost of bicarbonate dialysate is, therefore,
dependent on the method of preparation 
of the dialysate. The prices of the alternative
forms of preparation of the dialysate were
obtained from the manufacturers. Staff costs
were estimated from the relevant UK NHS
salary scales (NHS, 1996a; b) together with
estimates of time required.
2. The dialysis session  The information
extracted from the RCTs indicates that the
resources required to perform the dialysis 
were independent of the nature of the buffer
used. The same equipment was used for both
dialysates and the sessions were of the same
length (de Backer, et al., 1983; Spongono, 
et al., 1989; Schick, et al., 1983; Bradley, et al.,
1988; Dalal, et al., 1989; 1990; van Stone &
Cook, 1979; Shimizu, et al., 1983; Gurudev, 
et al., 1991; Ramos, et al., 1983; Otte, et al.,
1990; Peces Serrano, et al., 1986; Akanji &
Sacks, 1991; Lefebvre, et al., 1983; Brezin, et al.,
1985; Pagel, et al., 1982; Savidie, et al., 1977;
Dolan, et al., 1981). Therefore, any difference
in the cost of the dialysis is due solely to the
different cost of the dialysate used.
3. Treatment of complications  The cost of
treating complications was also calculated. 
In order to calculate the relative cost of
complications associated with the different
methods of delivering bicarbonate compared
with acetate haemodialysis, the model depicted
in Figure 10 was used. In this analysis it has
been assumed that when a particular compli-
cation occurs then treatment is always pro-
vided. Data from the identified RCTs, which
provided the best quality information avail-
able, were extracted on the proportion of
patients who had a specific complication such
as headache, nausea or muscle cramps. This
provided information on the probability that 
a patient would receive treatment for a com-
plication in a set period (either per session,
per week or per month). The review of the
economic aspects of the RCTs and non-
randomised studies attempted to identify 
the precise treatment provided for a 
specific complication.
The treatments were then costed according 
to the staff time, consumables, overheads and
capital that the treatment consumed. The
estimates of staff time come from an American
paper by Jones and colleagues (1995) which
asked a panel of clinicians and nurses to esti-
mate staff time for selected clinical vignettes 
of complications of haemodialysis (including
some of the complications of interest here). 
It provided upper and lower estimates of staff
time, thus allowing calculation of upper and
lower estimates of the cost of complications.
The price of any pharmaceuticals consumed
was taken from the BNF (BMA, 1996); the cost
of staff time was estimated by combining infor-
mation on time with that from the relevant UK
NHS salary scales (NHS, 1996a; b). An import-
ant assumption in this type of model is that 
the probability of having a complication (and
therefore, receiving treatment) is independent
of the probability of having any other type 
of complication.
Results
Benefits to patients
The results of the systematic review of effective-
ness were reported earlier. In brief, the review
studied five symptom categories: headaches,
nausea/vomiting, muscle cramps, symptomatic 
or treatment-requiring hypotension and non-
specific intolerance. The meta-analysis showed 
an overall estimate of the frequency of occurrence
of headaches favouring bicarbonate haemodialysis
(OR, 0.84; 95% CI, 0.71, 0.99). For nausea and
vomiting, the estimate of overall effect favoured 
the use of bicarbonate haemodialysis (OR, 0.42;
95% CI, 0.26, 0.66). There was no significant
difference for muscle cramps (OR, 0.97; 95% 
CI, 0.77, 1.22). There was a significant reduction 
in symptomatic hypotension with bicarbonate
haemodialysis (OR, 0.28; 95% CI, 0.11, 0.69). 
For non-specific intolerance, the overall estimate
favoured bicarbonate haemodialysis (OR, 0.79;
95% CI, 0.67, 0.93).Appendix 5
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Two RCTs assessed general well-being and patient
satisfaction; they found that patients felt significantly
better with bicarbonate dialysis compared with ace-
tate dialysis. No significant differences were found
between acetate haemodialysis and bicarbonate
haemodialysis when cardiovascular stability, correc-
tion of metabolic acidosis, postdialysis pH and bicar-
bonate, predialysis pH (after at least one dialysis on
a specific dialysate) and bicarbonate (after at least
one dialysis on a specific dialysate), arterial blood
gases, postdialysis PO2, fasting lipids and indicators 
of renal bone disease were measured.
The meta-analyses and the other data from the
included studies indicate that dialysis-associated
hypoxia occurs less frequently when bicarbonate is
used as the dialysis buffer. There was no evidence
that this improved either morbidity or mortality.
Resource use and costs
None of the studies identified by this review
involved any form of economic or cost analysis 
of bicarbonate haemodialysis compared with
acetate haemodialysis. The principle cost differ-
ences between the two modes of treatment result
from differences in the method of preparation, the
cost of the dialysate used and the cost of treatment 
of complications.
Resources used before and during the 
dialysis session
The RCTs provided information on the nature of
the dialysates available. To find the cost of prepar-
ation of these dialysates, manufacturers were con-
tacted to provide information on the costs of alter-
native preparations. The differences in cost between
acetate and bicarbonate are shown in Table 20 and
were estimated for the following three scenarios:
(a) each dialysate is in a prepacked solution
(b) the bicarbonate is mixed from commercially
available powder by hand, while the acetate 
is a prepacked solution that is ready for use
(c) the bicarbonate comes in a container of dry
powder which the dialysis machine apportions
and, again, the acetate comes as a 
prepacked solution.
Complications
Cost estimates for complications were obtained 
by combining the staff time estimates with the
relevant salary scales and the cost of any consum-
Acetate
Dry powder
Self mix
Solution
Bicarbonate
Dialysate
Muscle cramps
No muscle cramps
Hypotension
No hypotension
Vomiting
No vomiting
Vomiting
No vomiting
Hypotension
No hypotension
Vomiting
No vomiting
Vomiting
No vomiting
FIGURE 10  Decision model to compare the alternative forms of haemodialysis (n,decision node; l,chance node; ,terminal node)
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ables (Table 21). The probabilities for the compli-
cations which are obtained from the systematic
review of effectiveness are shown in Table 22. The
higher the probability, the more chance there is 
of that complication occurring. It was not possible
to obtain cost estimates for the treatment of head-
aches or for non-specific intolerance. The
significance of this is discussed below.
Using the data contained in Tables 21 and 22, 
the cost of complications can be calculated. This
information can then be combined with the cost 
of dialysates shown in Table 20. The results are
presented in Table 23.
The costs for each of three methods of preparation
of bicarbonate buffer and the cost of acetate sup-
plied in pre-mixed solution are shown in Table 23.
High, medium and low estimates are provided 
for the methods of preparation of each form of
dialysate. The cost of preparation depends upon
estimates of the cost of the buffer, the costs of 
acid for the bicarbonate and an estimation of the
cost of mixing the bicarbonate for the self-mixed
bicarbonate. The information on the price of
bicarbonate obtained from the manufacturers
suggests that bicarbonate is, on average, sold at 
a substantial discount from the list price. Acetate,
however, is sold on average, at a price roughly 
similar to the list price (G Anderson, Gambro;
personal communication, 1996). Therefore, the 
costs of bicarbonate would tend to be at the lower
values while the acetate would tend to be the 
higher. Likewise, the cost of complications is also 
split into a high and low estimate. The values high-
lighted in the two final columns represent the likely
cost per session of acetate and bicarbonate. (Note
that only those areas where resource use is likely 
to differ between acetate and bicarbonate have 
been costed. For example, the same dialysis
machines can be used for both dialysates and 
dialysis sessions take the same time. Therefore, 
the cost of the dialysis machines is not included 
in the evaluation).
TABLE 20  The cost per patient per session of the alternative forms of dialysate and the different methods available for 
their preparation
Dialysate Type Cost Preparation Acid Total
(£ per session) (£ per session) (£ per session) (£ per session)
Low High Low High Low High
Bicarbonate Self mixa,b,c 1.90 2.10 1.05 2.45 3.15 5.40 6.30
Bicarbonate Dry concentratea,b 4.00 5.95 2.45 3.15 6.45 9.10
Bicarbonate Solutiona,b 4.90 6.30 2.45 3.15 7.35 9.45
Acetate Solution
a,b 4.90 6.30 4.90 6.30
aThe same dialysis machine can be used for both acetate and bicarbonate haemodialysis
b 8 litres of dialysate solution is required per patient
c Mixing of dry powder takes one grade C nurse 1.5 hours to prepare a batch of 100 litres
TABLE 21  The staff costs of complications
Complication Staff time (hours) Consumable Combined costs (£)
Low High 
cost (£)
Low High
Muscle cramp 0.083 0.5 0 0.99 3.94 
Hypotension 0.083 1.167 2.00 2.99 3.94 
Vomiting 0.25 0.75 0.50 3.47 8.86 
TABLE 22  The probabilities of complications for both acetate
and bicarbonate per patient per session
Complication Acetate Bicarbonate
Muscle cramps No significant difference
Hypotension 0.08 0.02
Vomiting 0.035 0.0154Appendix 5
96
The cost of acetate and bicarbonate haemodialysis
is heavily influenced by the cost of the dialysates
themselves. The results presented above show 
that the episodes of hypotension, nausea and
vomiting, and hypotension do decrease when
bicarbonate buffer is used in preference to acetate
buffer. The overall level of complications with
acetate, however, is not high and the reduction 
in complications due to the use of bicarbonate
dialysate is not great. Therefore, even when it 
is assumed that all episodes of any complication
require active treatment, the reduction in cost
caused by the reduction in complications requiring
treatment is small and does not greatly affect the
overall results.
Combining costs and benefits
The combination of the information on the relative
effectiveness and cost of acetate and bicarbonate
haemodialysis can provide information on the
relative efficiency of the two alternatives. The avail-
able information suggests that bicarbonate haemo-
dialysis provides more benefits to patients than
acetate haemodialysis at the same or lower cost. 
In terms of the cost–benefit framework described
in Figure 3, the results suggest that we are in squares
A1 or B2, marked ‘Yes’. In both these areas the
available evidence suggests that bicarbonate-
buffered haemodialysis is more efficient than
acetate-buffered haemodialysis.
Discussion
Bicarbonate haemodialysis is no longer significantly
more expensive than acetate haemodialysis, at least
in the UK. This is a dramatic change from the
situation of 5–10 years ago. The greater initial
expense of bicarbonate haemodialysis certainly
slowed its uptake, even by those convinced of its
clinical benefits. There have been no published
economic evaluations comparing the use of
bicarbonate and acetate buffers. Given the 
real but apparently quite small benefits of
bicarbonate over acetate, an earlier economic
evaluation would have found that bicarbonate
would have been more expensive but more
beneficial. The effect on cost is illustrated by 
the results presented in Table 23, which indicates
that these costs are very sensitive to the costs of the
dialysates. Over the last 5 years, use of bicarbonate
has increased and the price has fallen, whereas the
use of acetate has fallen and its price has remained
virtually unchanged. Initial studies suggested that
bicarbonate haemodialysis had a modest superiority
over acetate dialysis in terms of effectiveness. This
superiority seemed to be most marked in relation
to relatively small patient groups, such as those 
with cardiac disease or with known acetate intoler-
ance. If bicarbonate dialysis had been restricted to
these groups, it is likely that the cost would have
remained significantly higher than those for 
acetate haemodialysis and, in terms of Figure 3,
bicarbonate haemodialysis relative to acetate
haemodialysis would fall in the shaded area C1. 
A judgement was implicitly made that the extra
benefits provided by bicarbonate haemodialysis
relative to acetate haemodialysis were worth the
extra cost of bicarbonate. However, its general 
use in the stable dialysis population has led to a
significant drop in its cost, which has changed the
relative efficiency and moved bicarbonate haemo-
dialysis to areas A1 or B2, thus indicating that it is
more efficient than acetate haemodialysis.
Costs are derived from the estimates of resource 
use taken from different studies. There are ques-
tions as to how generalisable such data could be.
The quantity of resources consumed in any given
setting are influenced by their prices, which can 
and do vary between settings. One assumption
made, on the evidence from studies from different
countries (and, hence, facing very different unit
prices) was that the cost of the dialysis session was
the same. Thus, any unit price differences in this
situation are not relevant. One area, however,
where such differences are potentially relevant 
is in the determination of the cost of treating
TABLE 23  The cost per patient per session of using alternative types of dialysate (assuming the same dialysis machine can be used for
both types of dialysate)
Dialysate Type Preparation  Cost of complications  Total cost 
(£ per patient per session) (£ per patient per session) (£ per patient per session)
Low High Low High Low High
Bicarbonate Self mix 5.40 6.30 0.11 0.22 5.51  6.51 
Dry concentrate 6.45 9.10 0.11 0.22 6.67  9.32 
Pre-prepared 7.35 9.45 0.11 0.22 7.46 9.67 
Acetate Pre-prepared 4.90 6.30 0.36 0.62 5.26 6.92Health Technology Assessment 1998; Vol. 2: No.5
97
complications. Staff time estimates were obtained
from one American study. It is conceivable that the
time estimates could vary between countries. In the
context of this study such variations are unimport-
ant because of the small overall probability of
complications requiring treatment per session. A
further issue is that it was not possible to gain cost
estimates for the treatment of all complications.
The incidence of headaches and non-specific
intolerance differed between acetate and
bicarbonate haemodialysis with the difference
favouring bicarbonate. It was not possible to cost
the treatment of either headaches or non-specific
intolerance but, given the results presented, it is
likely that this only strengthens the case for
bicarbonate haemodialysis.
Conclusions and implication
Policy implications
1. Bicarbonate dialysis is preferable to acetate
dialysis for the haemodialysis of patients with
ESRD because of the associated reduction in
intra-dialytic adverse symptoms and similar cost.
2. In countries with less well-financed renal
replacement services, who continue to depend
on haemodialysis machines that can only use
acetate-buffered dialysate, replacement of these
machines as replacements are required with
those that can use either dialysate should be
encouraged. However, the cost to a healthcare
system of a complete rapid change to new dialy-
sis machines or modification of all their present
machines would not be warranted on the basis of
the relatively modest benefits which bicarbonate
dialysis offers. The benefits of such changes need
to be considered in terms of their opportunity
cost and this will vary from country to country.
The provision of information on the costs and
benefits of such a change provided in this study
should assist in the estimation of such
opportunity costs.
Future research needs
1. Methodologically sound clinical trials with long-
term follow-up comparing bicarbonate with ace-
tate haemodialysis are rare. We should continue
to be open-minded about the possible beneficial
or adverse effects that bicarbonate dialysis may
have on long-term outcomes such as lipid profile
and cardiovascular disease, renal bone disease
and morbidity.
2. A further RCT at this stage is unlikely to produce
significantly different data from that which we
have already and is therefore unlikely to change
clinical practice.
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Background
Shortening of haemodialysis treatment time is
welcomed by the patient and is seen by the health-
care purchaser as an improved use of resources.
Technological advances coupled with patient
pressure and pressure on costs led to the develop-
ment and implementation of shortened dialysis
schedules, particularly in USA, during the late
1970s and early 1980s. However, during the 
1980s, the annual mortality rate in patients in 
the USA began to increase as the average dialysis
treatment times decreased (Berger et al., 1991;
Held et al., 1990). The trend towards shorter
dialysis time was never as pronounced in Europe 
or Japan, both countries having a significantly
lower annual mortality rate in dialysis patients 
than the USA.
If short dialysis is at least comparable to standard
dialysis in terms of clinical outcome, it should be
offered to all appropriate patients. If, however,
there are significant disadvantages compared with
standard dialysis in either the short or long term,
then patients to whom it is offered should be made
aware of the potential trade-off.
Objectives
The objective of this review is to ascertain 
whether shortened rather than standard
haemodialysis treatment times affect the short- 
or long-term mortality, morbidity or quality of 
life of patients with ESRD. It also attempts to 
assess patient preference and to estimate any
impact shortened dialysis times may have on
healthcare resource use. The hypotheses being
tested are that shortened treatment times are
associated with:
(i) no increase in mortality
(ii) no increase in morbidity (both intra- 
and interdialytic)
(iii) increased patient preference
(iv) improved quality of life for patients.
Materials and methods
Criteria for considering studies for 
this review
Types of studies  An attempt was made to identify
all trials comparing short duration (3.5 hours or
less) haemodialysis treatment sessions (experi-
mental group) with standard duration (more than
3.5 hours) sessions (control group) in patients 
with ESRD maintained on haemodialysis, in which
patients were prospectively randomly (for example,
sealed envelopes with third party involvement) or
quasi-randomly (for example, alternate patients or
alternate treatments) allocated to either treatment.
Crossover trials in which treatments alternated at
least to the degree of A–B–A–B were also included,
even if the allocation to first treatment was neither
random nor quasi-random.
Types of participants  Patients with ESRD main-
tained on haemodialysis irrespective of age, sex,
race, primary renal disease, vascular access or co-
morbidity. Trials which were exclusively comprised
of patients with acute renal failure were excluded.
The definition of ESRD by each individual study
was accepted.
Types of intervention  Patients in the experimental
group received short duration haemodialysis treat-
ment sessions of less than 3.5 hours per session
while patients in the control group received stand-
ard duration haemodialysis treatment sessions of
more than 3.5 hours per session. Dialysis was under-
taken three times per week in both groups. Within
these parameters, the definition of short and
standard dialysis time for each individual study was
accepted. Any variation in dialysis technique, such
as bicarbonate dialysis, high-flux or high-efficiency
dialysis membranes, dialysate-sodium modelling
and high blood flow rates, were acceptable.
However, studies that included haemofiltration or
haemodiafiltration treatments were excluded.
Types of outcome measures
1. Mortality (all causes).
2. Intradialytic morbidity – nausea or vomiting,
Appendix 6
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headache, muscle cramps, hypotension, 
non-specific intolerance.
3. Interdialytic morbidity – predialysis hyper-
tension, hospital admission rate for all causes,
duration of hospitalisation.
4.  ‘Dialysis adequacy’ as indicated by Kt/V, URR,
predialysis blood urea, creatinine, potassium,
phosphate and acid–base balance.
5.  Patient acceptability (any scale or 
measurement accepted).
6.  Quality-of-life assessment (any scale or
measurement accepted).
Search strategy for identification 
of studies
The search strategy used was one developed for 
the identification of all possible RCTs or quasi-
RCTs relating to the management of ESRD, and is
described in detail in chapter 2 and appendices 2
and 3.
Methods of the review
Identified studies were evaluated using a study
evaluation form and those which met the eligibility
criteria (included references) were then consid-
ered in detail. Data were extracted using a data
abstraction form designed for this review (see
appendix 10). Review Manager v. 3.0 was used for
the analysis. A full description of the methods 
used is given in chapter 2.
Description of studies
Only a single study, the National Cooperative
Dialysis Study (Lowrie et al., 1983) met the inclusion
criteria for this review. The full study was published
as a number of separate papers in a single volume 
of Kidney International in 1983. Each individual paper
is listed in this review. A preliminary report of the
study was published in New England Journal of Medi-
cine in 1981 and is also listed although, apart from
data on hospitalisation rates, it contains no addi-
tional information. The study covered the period
1974–76. A total of 165 patients were randomised,
and there were 85 withdrawals during the random-
ised phase. Patients were randomised to four groups,
each determined by its dialysis time (short versus
standard) and its dialysis ‘adequacy’ (as defined by
its ‘prescribed’ time-averaged concentration of urea
– high versus low). A summary of the main features
of the study is presented in Table 24.
Methodological quality of the 
included study
The single study was a relatively large, partially
balanced, randomised controlled, open, parallel
(during randomised phase), multicentre trial
undertaken in the USA. Random allocation was 
by third party (the data coordinator at the lead
centre) using sequentially numbered sealed
envelopes. The sequence was generated before
initiating the study with the intention of producing
a partially balanced randomisation. There is a
detailed description of withdrawals and drop-outs
from the start of the study to completion of the
protocol. This included all drop-outs and exclu-
sions that occurred during the pre-randomisation
phases. Data on mortality, first hospitalisations and
withdrawals for medical reasons were calculated on
an intention-to-treat basis; other data were not.
There were relatively rigorous inclusion criteria
both before trial entry and before entry to the
randomised phase.
Results
The results are derived from a single trial (Lowrie,
et al., 1983). They are grouped according to the
pre-stated outcome measures of this review:
(i) mortality
(ii)  intra- and interdialytic morbidity
(iii) measures of dialysis adequacy
(iv) patient quality of life and patient acceptability.
Data are presented as a comparison of short with
standard duration dialysis, subgrouped according
to the prescribed dialysis of the allocated groups,
standard or low dialysis urea clearance. Dichoto-
mous data are presented as ORs and continuous
data as WMDs (see Table 25, A and B).
Mortality
One patient from the experimental (short 
duration dialysis) and two patients from the 
control group (standard duration) died during 
the study (OR, 0.53; 95% CI, 0.05, 5.15). Over 
the study period and follow-up, seven patients 
in the experimental group and nine in the 
control group died (OR, 0.79; 95% CI, 0.28, 
2.21). Although there was no significant differ-
ence in mortality between the two treatment
durations, a clinically important difference 
cannot be ruled out.
Intradialytic morbidity
No data relevant to intradialytic morbidity 
could be used quantitatively in this review. 
The single study noted “statistically significant
deviations only sporadically during the
experimental phase” relative to a symptom
questionnaire which attempted to assess the 
severity of adverse symptoms “commonly 
associated with dialysis”.Health Technology Assessment 1998; Vol. 2: No.5
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TABLE 24  Characteristics of included studies:short versus standard duration treatments in haemodialysis of patients with ESRD
Study Method Participants Interventions Outcomes Notes
Lowrie,et al., Partially-balanced  165 patients with  Patients randomly  Mortality;intradialytic  Study divided into 
1983 parallel (randomised  ESRD;M:F,59.6:40.4; allocated to four  morbidity;general  several phases;final 
phase) RCT with  mean age (SD), groups:Group I –  morbidity – withdrawals  phase (experimental) 
adequate concealment  49.0 (12.7) years; standard dialysis time  for medical reasons  was only phase with 
of allocation.Open  duration on dialysis  (4.5–5.0 hours),low  (excluding renal trans-  randomly allocated 
study,although “clinical  (mean,SD),4.2 (2.3) years; BUN with time-averaged  plant),cardiovascular treatments;initiation 
investigators were  residual renal function: concentration of urea, morbidity,hospitalisation  phase – 1 month,
blinded to group  creatinine clearance  50 mg/dl;Group II –  rate,blood pressure  262 patients;control 
outcomes throughout  < 3 ml/min;inclusion  standard dialysis time  control,symptom  (plus induction) phase 
the study”;detailed  criteria – age 18–70 years, (4.5–5.0 hours),high  questionnaire,EEG and  – 12–20 weeks,
desciption of with-  RRT > 4 months, BUN with time-averaged  choice reaction time, 224 patients;experi- 
drawals and drop-outs; creatinine clearance  concentration of urea, effect on haematopoietic  mental phase – 165 
some data (mortality  < 3 ml/min on centre  100 mg/dl;Group III –  system;measures of  patients;withdrawals,
and withdrawals for  dialysis;no more than  short dialysis time  dialysis adequacy –  drop-outs and failure 
medical reasons)  one missed dialysis  (2.5–3.5 hours),low  time-averaged urea  to reach inclusion 
analysed on an  treatment per month  BUN with time-averaged  concentration,midweek  criteria from initiation 
intention-to-treat  over previous 3 months, concentration of urea, pre-dialysis BUN, of study described 
basis. average intradialytic  50 mg/dl;Group IV –  pre-dialysis phosphate, in detail.
weight gain < 3.5 kg  short dialysis time  serum electrolytes, BUN 50 mg/dl 
over previous 3 months, (2.5–3.5 hours),high  arterial blood gases  » BUN 20 mmol/l;
average predialysis  BUN with time-  and pH. BUN 100 mg/dl 
serum phosphate level  averaged concentration  Quality of life, » BUN 40 mmol/l.
< 8.0 mg/dl;exclusion  of urea,100 mg/dl. general well-being and 
criteria – diabetes  Duration of study, psychosocial measures
*
mellitus,‘unstable’  approx.2.5 years,data  – MMPI,SSIAM,SAS-SR,
cerebrovascular or  collected for 48 weeks  WAIS,LES,I-E,MAACL,
coronary vascular  after randomisation; symptom questionnaire.
disease,severe or  dialysis frequency,three  Nutritional status,PCR.
‘unstable’ hypertension, times weekly (2.96,
significant hepatic or  SD,0.18);dialyser 
pulmonary dysfunction, type – selected before 
‘collagen vascular  randomisation – 
disease’;in addition  regenerated cellulose 
to these criteria,to  membrane (C-DAK,
transfer from the  Cordis Dow),surface 
control phase to the  areas,1.3 m
2,1.8 m
2,or 
experimental,randomised 2.5  m2,or cuprophane 
phase,the following  membrane (CF,
criteria had to be met  Travenol),surface 
during the control  areas,1.2 m
2,1.5 m
2,
phase – 7/10 most  or 2.3 m
2;dialysate 
recent midweek BUN  sodium,132–140 mmol/l;
concentrations within  buffer,all used acetate 
10 mg/dl of target, dialysis (33–40 mmol/l);
no more than two  dialysate flow rate 
treatments missed  varied for each patient 
in 4 weeks,average  to achieve specified 
intradialytic weight  time-averaged urea 
gain < 3.5 kg,average  concentration;blood 
PCR 0.8–1.4 g/kg/day; flow rate varied for 
co-morbidity – no  each patient (as 
significant difference  above);dialyser reuse 
between groups in  not mentioned.
terms of age,history 
of heart disease,
hypertension,peripheral 
vascular disease,
pulmonary or 
gastro-intestinal 
disease or hospitalisation 
pre-randomisation.
* MMPI,Minnesota Muliphasic Inventory;SSIAM,Structured and Scaled Interview to Assess Maladjustment;SAS-SR,Social Adjustment Scale Self Report;WAIS,Wechsler
Adult Intelligence,vocabulary subscale;LES,Life Events Scale;I-E,Locus of Control Scale;MAACL,Multiple Affect Adjective Check List.Appendix 6
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Interdialytic morbidity
The number of patients hospitalised was signifi-
cantly greater in the short duration dialysis group
(33/78 versus 15/73; OR, 2.85; 95% CI, 1.39, 5.85).
More patients were withdrawn from the study for
medical reasons from the short duration group;
however, this did not reach statistical significance
(21/81 versus 14/84; OR, 1.92; 95% CI, 0.85, 4.35).
There was a modest, although significant difference
in dialysis treatment duration in predialysis blood
pressure control, favouring better control in the
TABLE 25A  Short versus standard duration dialysis:overall summary
Comparison or outcome Peto OR WMD
(95% CI) (95% CI)
Mortality during study
Mortality during study and follow-up
Number of patients hospitalised during stay
Withdrawals for medical reasons
Number of treatments with headaches Not estimable
Number of treatments with nausea/vomiting Not estimable
Number of treatments with muscle cramp Not estimable
Treatments with symptomatic hypotension Not estimable
Treatments with non-specific intolerance Not estimable
Predialysis systolic blood pressure
Predialysis diastolic blood pressure
Predialysis mean arterial blood pressure
Kt/V Not estimable
Predialysis urea Subgroup analysis only
Quality of life/general well-being No numerical data
TABLE 25B  Short versus standard duration dialysis:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Mortality during study
Standard/high urea clearance dialysis
Lowrie,1983 0/44 2/46 66.4 0.14 (0.01,2.25)
Subtotal (95% CI) 0/44 2/46 66.4 0.14 (0.01,2.25)
Chi-square 0.00 (df = 0) Z = 1.39
Low urea clearance dialysis
Lowrie,1983 1/37 0/38 33.6 7.59 (0.15,382.75)
Subtotal (95% CI) 1/37 0/38 33.6 7.59 (0.15,382.75)
Chi-square 0.00 (df = 0) Z = 1.01
Total (95% CI) 1/81 2/84 100.0 0.53 (0.05,5.15)
Chi-square 2.66 (df = 1) Z = 0.55
continued
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TABLE 25B contd  Short versus standard duration dialysis:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Mortality during study and follow-up
Standard/high urea clearance dialysis
Lowrie,1983 2/44 4/46 39.2 0.52 (0.10,2.69)
Subtotal (95% CI) 2/44 4/46 39.2 0.52 (0.10,2.69)
Chi-square 0.00 (df = 0) Z = 0.78
Low urea clearance dialysis
Lowrie,1983 5/37 5/38 60.8 1.03 (0.27,3.87)
Subtotal (95% CI) 5/37 5/38 60.8 1.03 (0.27,3.87)
Chi-square 0.00 (df = 0) Z = 0.04
Total (95% CI) 7/81 9/84 100.0 0.79 (0.28,2.21)
Chi-square 0.41 (df = 1) Z = 0.46
Number of patients hospitalised during study
Standard/high urea clearance dialysis
Lowrie,1983 11/41 4/41 41.7 3.09 (1.02,9.40)
Subtotal (95% CI) 11/41 4/41 41.7 3.09 (1.02,9.40)
Chi-square 0.00 (df = 0) Z = 1.99
Low urea clearance dialysis
Lowrie,1983 22/37 11/32 58.3 2.69 (1.05,6.90)
Subtotal (95% CI) 22/37 11/32 58.3 2.69 (1.05,6.90)
Chi-square 0.00 (df = 0) Z = 2.07
Total (95% CI) 33/78 15/73 100.0 2.85 (1.39,5.85)
Chi-square 0.03 (df = 1) Z = 2.86
Withdrawals for medical reasons
Standard/high urea clearance dialysis
Lowrie,1983 3/44 2/46 20.7 1.59 (0.26,9.58)
Subtotal (95% CI) 3/44 2/46 20.7 1.59 (0.26,9.58)
Chi-square 0.00 (df = 0) Z = 0.51
Low urea clearance dialysis
Lowrie,1983 18/37 12/38 79.3 2.02 (0.81,5.05)
Subtotal (95% CI) 18/37 12/38 79.3 2.02 (0.81,5.05)
Chi-square 0.00 (df = 0) Z = 1.50
Total (95% CI) 21/81 14/84 100.0 1.92 (0.85,4.35)
Chi-square 0.05 (df = 1) Z = 1.57
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TABLE 25B contd  Short versus standard duration dialysis:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Predialysis systolic blood pressure
Standard/high urea clearance dialysis
Lowrie,1983 42 151.00 (13.00) 41 142.00 (12.80) 61.9 9.000 (3.449,14.551)
Subtotal (95% CI) 42 41 61.9 9.000 (3.449,14.551)
Chi-square 0.00 (df = 0) Z = 3.18
Low urea clearance dialysis
Lowrie,1983 23 150.00 (14.40) 27 145.00 (10.40) 38.1 5.000 (–2.073,12.073)
Subtotal (95% CI) 23 27 38.1 5.000 (–2.073,12.073)
Chi-square 0.00 (df = 0) Z = 1.39
Total (95% CI) 65 68 100.0 7.475 (3.109,11.842)
Chi-square 0.76 (df = 1) Z = 3.36
Predialysis diastolic blood pressure
Standard/high urea clearance dialysis
Lowrie,1983 42 83.00 (6.50) 41 79.00 (6.40) 71.4 4.000 (1.225,6.775)
Subtotal (95% CI) 42 41 71.4 4.000 (1.225,6.775)
Chi-square 0.00 (df = 0) Z = 2.82
Low urea clearance dialysis
Lowrie,1983 23 84.00 (9.60) 27 84.00 (5.20) 28.6 0.000 (–4.386,4.386)
Subtotal (95% CI) 23 27 28.6 0.000 (–4.386,4.386)
Chi-square 0.00 (df = 0) Z = 0.00
Total (95% CI) 65 68 100.0 2.856 (0.511,5.202)
Chi-square 2.28 (df = 1) Z = 2.39
Predialysis mean arterial blood pressure
Standard/high urea clearance dialysis
Lowrie,1983 42 106.00 (6.50) 41 101.00 (12.80) 61.6 5.000 (0.616,9.384)
Subtotal (95% CI) 42 41 61.6 5.000 (0.616,9.384)
Chi-square 0.00 (df = 0) Z = 2.24
Low urea clearance dialysis
Lowrie,1983 23 106.00 (9.60) 27 105.00 (10.40) 38.4 1.000 (–4.548,6.548)
Subtotal (95% CI) 23 27 38.4 1.000 (–4.548,6.548)
Chi-square 0.00 (df = 0) Z = 0.35
Total (95% CI) 65 68 100.0 3.463 (0.023,6.902)
Chi-square 1.23 (df = 1) Z = 1.97
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standard duration group: systolic blood pressure –
mean difference 7.5 mmHg (95% CI, 3.1, 11.8);
diastolic blood pressure – mean difference 
2.9 mmHg (95% CI, 0.5, 5.2); mean arterial 
blood pressure – mean difference 3.5 mmHg 
(95% CI, 0.0, 6.9).
Quality of life and general well-being
There were no data on quality of life or general
well-being which could be used quantitatively. The
authors of the included study concluded that “no
important changes in psychosocial measures can be
attributed to the different treatment prescriptions”.
Measures of dialysis adequacy
Midweek predialysis blood urea concentration 
and time-averaged concentration of urea were 
used in the study as measures of dialysis adequacy.
However, because dialysis treatments were manipu-
lated to achieve a certain dialysis adequacy for each
group, these measures were not used as outcome
data in this review.
Discussion
The results of this review show that significantly
more patients receiving short-duration dialysis were
hospitalised. This group also had more withdrawals
for medical reasons, although this did not reach
statistical significance, and there was also a modest
deterioration in blood pressure control. There 
was no clear difference between the groups in 
any of the other outcome measures considered.
Dialysis adequacy could not be used as an outcome
measure because of the structure of the included
study. However, a significantly greater number of
withdrawals for medical reasons were reported
from the low urea clearance groups and, as a result,
the short-duration dialysis, low urea clearance
group was discontinued early.
Despite the extensive search strategy, only one study
was identified in which the inclusion criteria of this
review were satisfied (Lowrie, et al., 1983). Although
the study was multicentre and relatively large, it
comprised a highly selected population with
relatively strict inclusion criteria to enter the initial
phase. Further criteria needed to be met for a
patient to pass forward to the randomised phase 
of the study. The data may, therefore, be relevant
only to this highly selected group who were main-
tained on dialysis in a particular healthcare system
at a particular time (mid-1970s). The composition
of the population on dialysis, the dialysis technology
and the treatment options for patients with ESRD
have all changed since then. For example, older
patients with greater co-morbidity are now accepted
on dialysis programmes (Port, 1994), bicarbonate
has become the standard dialysate buffer (Vallerra-
bano, et al., 1996), and the treatment of anaemia
has been revolutionised by the introduction of EPO
(Winearls, et al., 1986; Eschbach, et al., 1987). The
generalisability of the results from this study to
patients presently on dialysis and being managed 
by the presently accepted optimal treatment of
ESRD may be questionable.
The obvious significant methodological and
organisational difficulties encountered and over-
come during the included study may, in part,
explain the lack of more recent RCTs in this area.
Dialysis clinical research has its own specific
problems. The relatively low prevalence of ESRD
means that most reasonably sized trials need to be
multicentred. The high withdrawal and drop-out
rate demonstrated by this study is likely to be an
inevitable consequence of the morbidity of this
population and the potential for withdrawal
because of renal transplantation. This may have
encouraged other researchers to attempt to 
predict long-term clinical outcomes from data 
on surrogate outcomes derived from short-term
studies. However, the ability of these secondary
outcome measures to predict long-term clinical
outcomes remains open to question.
Dialysis adequacy and duration are interlinked.
Changes in dialysis adequacy can be achieved by
altering other dialysis technique parameters, such
as blood flow rate, dialysis membrane size and
membrane flux. Reduced dialysis adequacy appears
to have a definite adverse effect on outcome;
however, whether reduced dialysis time alone 
has an adverse effect is less clear.
A large, multicentre, 2 ´ 2 factorial RCT, which
compares the effect of dialysis dose and membrane
flux on survival of patients with ESRD, is currently
being conducted in the USA and is due to be
completed in 2001. The principal investigator 
of the study is Dr John Kusek of the National
Institutes of Health. The aim is to recruit 1700
patients to the study; to date, more than 1000
patients have been recruited. Although the results
of the study may answer the questions of how 
much dialysis is needed and how that amount 
of dialysis may be delivered, the specific aim is 
to study the effect of different levels of dialysis
adequacy as measured by Kt/V (equilibrated Kt/V
of 1.05 versus 1.45) rather than dialysis duration 
per se. Preliminary baseline data has already been
reported (Eknoyan, 1997; Levey, 1997; Maroni,
1997; Meyer, 1997a; b). It may be that changes inAppendix 6
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the management of patients with ESRD, such as
EPO, bicarbonate dialysis and high-flux membranes
may have altered the influence of dialysis duration
on clinical outcome.
Dialysis duration must seem a very fundamental
concept to patients, their relatives and purchasers
of renal services. If dialysis time can be shortened
safely then this should be done. However, good
evidence of such safety does not yet exist and, 
until it becomes available, the standard duration
regimen should be continued. If short-duration
dialysis is used, patients should be made aware 
that its effects on morbidity and mortality 
remain unknown.
Given the interest in shortening the length of
haemodialysis sessions, it is disappointing that only
one RCT was identified that addressed this question.
An economic evaluation was attempted but there
was insufficient information to enable judgements 
to be made about the relative efficiency of short-
compared to standard-duration haemodialysis. 
In particular, the RCT was not performed on an
intention-to-treat basis, which meant that important
information on patient outcomes was not collected
when patients were withdrawn from the trial.
Conclusions and implications
Policy implications
1. Current evidence is not reassuring that short-
duration dialysis is as effective as standard-
duration dialysis. There is no evidence that
reduced dialysis duration improves patient
outcome in terms of mortality and morbidity,
and it may in fact increase morbidity as
reflected by increased hospitalisation and
poorer blood pressure control. Standard-
duration dialysis should remain the
recommended treatment.
2. If reduced dialysis duration regimens are
implemented on the basis of patient preference
or cost, the fact that its safety is not proven
should be explicitly acknowledged.
Future research needs
1. A large, multicentre, pragmatic RCT(s) that
compares haemodialysis treatment duration
policies is required. Such a trial should have
minimum exclusion criteria, a long follow-up
period and minimum data collection, concen-
trating primarily on patient morbidity and
mortality. Follow-up should include patients
who withdraw (for example, for renal trans-
plantation) and all patients should be followed
for a period after trial completion to assess the
residual effect on mortality and morbidity. Key
primary outcomes such as mortality should be
analysed on an intention-to-treat basis. Avoid-
ance of collection of secondary outcome data
should reduce the complexity of such a trial.
Dialysis therapy and the overall treatment of
ESRD within such a trial should be to the
highest standard, as recommended by the 
best available evidence.
2. If such a trial showed no advantage with
standard-duration dialysis, short-duration
dialysis should become the recommended
treatment option.
3. The HEMO RCT, comparing high- and low-flux
membranes and the ability to achieve a given
Kt/V, is under way at present. It may address
many of the above questions. This should be
taken into account when the research agenda 
is decided.
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Background
CAPD is an alternative to haemodialysis for 
patients with ESRD. It may be used as the first
choice therapy, and in a number of countries 
more patients are treated by CAPD than by haemo-
dialysis. There is significant variation in catheter
and transfer set types, insertion techniques, and
peri- and postoperative management of patients.
Rates of complications (exit-site leak, exit-site
infection, subcutaneous tunnel infection, catheter
cuff erosion or prolapse, catheter malfunction,
pericatheter hernia/pseudohernia, posterior
peritoneal perforation, postoperative bleeding,
hollow viscus perforation) and catheter survival
also vary between centres,
There are two main types of catheter 
connecting systems.
1.  The standard or straight connecting system in
which the catheter is connected with a straight
piece of tubing which is, in turn, connected to
the dialysate bag. At each exchange the bag is
drained and a new connection is made. The
empty bag is rolled up and remains attached
until the next exchange when the process 
is repeated.
2.  The Y-set in which, between exchanges, the
patient is disconnected from dialysate bags and,
when a new exchange is due, a Y-connection
with one limb connected to an empty bag and
one to a bag containing fresh dialysate is used.
The peritoneal dialysate is first drained into the
empty bag. Before introducing the new fluid,
the Y-connector is flushed with fresh dialysate
into the drained bag. This allows any bacteria to
be flushed into the spent fluid. The fresh fluid is
then introduced into the peritoneal cavity and
the connector is removed from the catheter.
At present, about 40% of CAPD patients in the UK
use the standard system (data from Renal Registry,
presented at Renal Association meeting, 1997).
The aim of this review is to describe the best
practice for CAPD connecting systems, insofar as
present evidence allows, and to indicate areas for
future research.
Objective
The objective of  this review is to compare 
Y-transfer set systems or their modification with
standard non-Y systems in CAPD.
Materials and methods
Criteria for considering studies for 
this review
Types of studies  All RCTs or quasi-RCTs addressing
the objective.
Types of participants  All CAPD patients newly
commenced on this modality of RRT were included
in the studies considered.
Types of intervention  The use of Y-set (or
modifications thereof) using flush-before-fill 
and either hypochlorite or povidone iodine
disinfectant compared with standard non-Y-set
connection systems for the delivery of CAPD 
to patients starting on this modality of RRT.
Types of outcome measures  The following
outcome measures were considered:
(i) peritonitis
(ii) exit-site  infections.
Search strategy for identification 
of studies
The search strategy used was one developed for 
the identification of all possible RCTs or quasi-
RCTs relating to the management of ESRD, and is
described in detail in chapter 2 and appendices 2
and 3.
Appendix 7
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Methods of the review
All included studies were evaluated using a study
evaluation form and those which met the eligibility
criteria (included references) were then con-
sidered in detail. Data were extracted using a data
abstraction form designed for this review (see
appendix 10). Review Manager v. 3.0 was used for
the analysis. A full description of the methods used
is given in chapter 2.
Description of studies
A total of six studies met the inclusion criteria for
this review. Two reports were of the same study
(Maiorca, et al., 1983a; b); hence the data were
considered only once. All six studies were either
RCTs or quasi-RCTs in which Y-transfer sets were
compared with standard non-Y-set systems. A
summary of the included studies is presented 
in Table 26.
Methodological quality of 
included studies
All studies claimed to have random allocation and
owing to the nature of the intervention, blinding
was not possible. The methods of randomisation
were adequately described in three studies (Cheng,
et al., 1994 (random number tables); Maiorca, et al.,
1983a; b (envelopes); Canadian CAPD Clinical
Trials Group, 1989 (variable blocking factor)). 
All studies provided numbers and reasons for
patient withdrawals and drop-outs.
Results
Peritonitis rates
The number of patients who experienced at 
least one episode of peritonitis in all the studies
combined was significantly lower in patients using
the Y-set delivery systems (57/194; OR, 0.30; 95%
CI, 0.23, 0.53) compared with those assigned to 
the non-Y-set systems (107/201; OR, 0.87; 95% CI,
0.51, 1.48). Only one study (Cheng, et al., 1994) 
did not show this effect although all the studies
demonstrated a significant increase in the number
of months per episode of peritonitis using Kaplan-
Meier survival analysis. None of the studies pro-
vided standard deviations for this statistic and,
hence, no WMD could be obtained. All studies
showed that time to first peritonitis was longer 
with use of Y-set/modified Y-set systems.
Exit-site infections
There was no evidence of significant reductions 
in the number of patients who suffered exit-site 
or tunnel infections with the Y-set (39/162 in the
treatment group and 44/171 in the control group;
OR, 0.87; 95% CI, 0.51, 1.48). The meta-analysis of
the results is presented in Table 27 (A and B).
Discussion
This review shows that use of the Y-set delivery
systems in CAPD significantly reduces the incidence
of CAPD-related peritonitis. The flush-before-fill
technique, combined with the use of a disinfectant
(hypochlorite or povidone iodine) is considered to
lead to this improvement. CAPD-related peritonitis
is the Achilles heel of this modality of RRT and
repeated infections of the peritoneum and/or
intractable episodes of peritonitis are the major
causes of morbidity, technique failure and, often,
mortality in such patients. This review clearly
demonstrates the benefit of Y-set delivery systems
over non-Y-set systems in preventing this major
complication of CAPD. The incidence of exit-site
infections was not affected by the delivery system.
This suggests that the reduction in peritonitis seen
with the Y-set systems is not consequent upon a
reduction of exit-site infections but is probably
caused by the ‘washing’ of organisms in the tubing
by the flush-before-fill technique.
Economic evaluation
The principles of economic evaluation are
described in detail in chapter 3 (page 9) including,
in an economic framework, the manner in which
costs and outcome are related (see, in particular,
Table 2 and Figure 3).
Aims
CAPD is an alternative to haemodialysis in which
various alternative techniques are used. One way 
in which techniques can vary is in the transfer set
types that are used. The aim of this economic
evaluation is to assess the relative efficiency, using
the framework of economic evaluation outlined 
in chapter 3, of Y-set systems or their modifications
compared with standard non-Y-set systems for
delivering CAPD. More specifically, the aims 
of this economic evaluation are:
(i) to investigate the relative resources used and
the cost of Y-set systems or their modifications
compared with standard non-Y-set systems for
delivering CAPD, using data extracted from the
identified RCTs and non-randomised studies in
which the two delivery systems are compared
(ii)  to combine data on cost with those on 
benefits to patients, from the systematic 
review of effectiveness described above, Health Technology Assessment 1998; Vol. 2: No.5
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TABLE 26  Characteristics of included studies:comparison of CAPD delivery systems – Y-set/modified Y-set versus standard spike
Study Method Participants Interventions Outcomes Notes
Canadian CAPD  RCT;numbers and  124 new CAPD patients  Y-connector  Peritonitis;exit-site  Hypochlorite 
Clinical Trials  reasons for withdrawals  – from 159 consenting  (Amuchina) vs. infections;technique  disinfectant in Y-set.
Group,1989 stated;no mention of  patients eligible for inclusion, standard spike  survival (Kaplan-Meier).
blinding;analysis on  61 in study group,63 in  (Baxter II and III).
intention-to-treat  control group;M:F,not stated;
basis. exclusion criteria:age 
< 18 years,likely to die 
within 6 months,previous 
complications on CAPD.
Cheng,et al., RCT;numbers and  All 100 patients starting  Y-set (O-set) vs. Peritonitis;exit-site  Hypochlorite 
1994 reasons for withdrawal  CAPD over 2 years at  conventional spike vs. infections;costs. disinfectant used.
stated;not clear if  a tertiary referral and  ultraviolet irradiation 
analysis on intention-  satellite center;38 in  (excluded from 
to-treat basis;no  treatment group,31 in  this review).
mention of blinding. control group;M:F,20:18 
in treatment group,
17:14 in control group;
diabetes,one in treatment 
group,three in control 
group;exclusion criteria:
age < 10 or > 70 years,
renal transplant within 
6 months of treatment,
inability to afford Y-set.
Dryden,et al., Prospective RCT; 80 patients,40 in  Y-set (Freeline Solo)  Peritonitis. Hypochlorite not used 
1992 numbers and reasons  treatment group,40 in  vs.standard spike  in this system;
for withdrawals stated; control group;57% M in  (Baxter II). povidone iodine cap 
analyses on intention-  treatment group,65% M  protectors used.
to-treat basis;no  in control group;diabetes,
mention of patient  five in treatment group,
or investigator  seven in control group;
blinding. study period,3–36 months 
(mean,14.1);age range,
20–67 years (mean 49).
Maiorca,et al., RCT;numbers and  62 new CAPD patients,32 in  Y-connector with  Peritonitis episodes. Hypochlorite used;
1983a;b reasons for withdrawals  treatment group,30 in control  disinfectant (Travenol, Kaplan-Meier analysis 
stated;no mention of  group;mean age (SD),55.1 years  Lessines) vs.standard  for time to peritonitis 
patient or investigator  (14.3) in treatment group, spike (Travenol). showed improvement 
blinding. 55.5 years (17.5) in control  with Y-set.
group;M:F,15:17 in treatment 
group,11:19 in control group; Second reference 
inclusion and exclusion  is to exactly the 
criteria not mentioned; same study.
co-morbidity and renal 
diagnoses not mentioned.
Owen,et al.,1992 Prospective RCT; 60 consecutive CAPD patients  Flush-disconnect  Peritonitis;exit-site  Povidone iodine caps 
states random  from 83 commencing,30 in  (O-system,Baxter)  infection;costing. used;Kaplan-Meier 
allocation but no  treatment group,30 in control  vs.standard spike  analysis also performed.
description;numbers  group,followed for minimum  (Baxter II).
and reasons for  of 12 months;median age,
withdrawals stated. treatment group 54 years 
(range,11–79 years),
control group 56 years 
(range,16–75 years);
M:F,16:14 in treatment 
group,15:15 in control 
group;inclusion criteria,
starting CAPD after 
May 1987;exclusion 
criteria,blind or severely 
physically disabled.Appendix 7
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to assess the relative efficiency of Y-set 
systems or their modifications compared 
to standard non-Y-set systems for 
delivering CAPD.
Methods
Data collection and extraction
The methods used are described in detail in
chapter 3 of the main report.
Benefits to patients
The systematic review of RCTs or quasi-RCTs de-
scribed above had as its main objective the synthesis
of the effectiveness data from the RCTs. Information
was extracted from the RCTs on the following:
(i)  the frequency of peritoneal dialysis-
associated peritonitis
(ii)  the frequency of exit-site and tunnel infections.
TABLE 27A  Y-set/modified Y-set versus standard spike delivery system:overall summary
Comparison or outcome Peto OR WMD
(95% CI) (95% CI)
Peritonitis episodes (number of patients)
Peritonitis episodes (months per episode) Not estimable
Exit-site infections (patient numbers)
Exit-site infections (months per episode) Not estimable
TABLE 27B  Y-set/modified Y-set versus standard spike delivery system:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Peritonitis episodes (number of patients)
Canadian,1989 15/61 30/63 31.7 0.37 (0.18,0.77)
Cheng,1994 9/31 12/38 16.1 0.89 (0.32,2.47)
Dryden,1992 9/40 21/40 20.8 0.28 (0.11,0.69)
Maiorca,1983a;b 10/32 17/30 17.0 0.36 (0.13,0.98)
Owen,1992 14/30 27/30 14.5 0.14 (0.05,0.41)
Total (95% CI) 57/194 107/201 100.0 0.35 (0.23,0.53)
Chi-square 6.22 (df = 4) Z = 5.03
Exit-site infections (number of patients)
Canadian,1989 21/61 23/63 52.2 0.91 (0.44,1.90)
Cheng,1994 1/31 4/38 8.5 0.34 (0.06,2.11)
Dryden,1992 3/40 4/40 11.8 0.73 (0.16,3.43)
Owen,1992 14/30 13/30 27.5 1.14 (0.42,3.13)
Total (95% CI) 39/162 44/171 100.0 0.87 (0.51,1.48)
Chi-square 1.35 (df = 3) Z = 0.51
0.1 0.2 1 5 10 –10 –5 0 5 10
0.1 1 0.2 51 0
Favours control Favours treatment
0.1 1 0.2 51 0
Favours control Favours treatmentHealth Technology Assessment 1998; Vol. 2: No.5
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Identification of resource use and costs
The overall costs of CAPD using the two forms 
of delivery system were not elicited. Only in those
areas where there was likely to be some difference
in resource use were costs identified. When 
patients were dialysed using either of the two
delivery systems, the identification of the relative
resources used involved the following.
1. Defining the process of care so that all 
aspects of care in which resources were
consumed could be identified and compared.
The process of care comprises dialysis access
and training, dialysis exchanges, dialysis main-
tenance including routine outpatient visits,
treatment of complications and changes in
modality of treatment.
2. All relevant information on resource use was
abstracted from the RCTs on what resources
were used when utilisation differed between the
two modes of delivery. The process was repeated
for those studies that were not randomised and
the information combined with estimates of the
unit cost of the resources to determine the cost
differential between Y-set systems and standard
non-Y-set systems for delivering CAPD using the
methodology described below. This differential
could then be compared with data on benefits 
to patients obtained from the systematic review
of effectiveness.
Model of costs
Five main areas of resource use can be costed.
These reflect the sequence of the treatment process
outlined above.
1.  Catheter insertion  Peritoneal dialysis requires a
catheter to be inserted to provide access to the
peritoneum. Haemodialysis may be required
until peritoneal dialysis can be performed. For
peritoneal dialysis using either delivery system
the process of inserting the catheter would be
the same; hence, the resources which would be
consumed would also be the same.
2.  Training  Once the catheter has been inserted 
a patient requires to be trained in the use of
peritoneal dialysis. This training takes several
weeks and can be performed as either an in- 
or outpatient procedure. While undergoing
training, patients may require haemodialysis
until they are trained in peritoneal dialysis. 
For simplicity it has been assumed that the
resources required for training are the same
although the training may differ for each 
mode of delivery of CAPD.
3. The dialysis process  Costs of capital items, any
consumables used and any staff inputs for the
process of dialysis were calculated. Patients also
required routine outpatient visits which were
not costed as they were assumed to be identical
for both Y-set and standard non-Y-set systems.
4. Treatment of complications  The cost of
treating complications was also calculated by
using the model depicted in Figure 11. Data
were abstracted from the RCTs on the relative
probability of the complications. The review 
of RCTs and non-randomised studies attempted
to identify the precise treatment that was pro-
vided for a specific complication. The treat-
ments were then costed according to the staff,
consumables, overheads and capital that the
treatment consumed. The price of any pharma-
ceuticals consumed was taken from the BNF
(BMA, 1996), and the cost of staff time was
estimated by combining information on time
with that from the relevant UK NHS salary
scales (NHS, 1996a; b).
5. Changes in modality and death  Costs (and out-
comes) would be determined by the probability
of technique failure and transplantation over 
a given period (e.g. a month or year). The
probability of technique failure can be divided
into the probability of transferring to another
mode of treatment, for example, transplant-
ation, or dying, so allowing the inclusion, if
necessary, of the cost of managing patients 
after they had switched modality.
A simplified version of how these costs and
probabilities can be modelled is shown in 
Figure 11. For any given period a patient would
incur the cost of treatment (the CAPD exchanges)
and the cost of a complication (based on the 
cost of treating that complication once it has
occurred and the probability of the complication
occurring). At the end of that time, a patient 
would have the chance of ‘dropping-out’ of treat-
ment by either dying or receiving a renal transplant
or transferring to another mode of dialysis (where
appropriate the costs would be estimated). If the
patient does not drop out then they return to
another period of CAPD (indicated in Figure 11 
by the movement from ‘A1’ back to ‘A’ or ‘B1’ 
back to ‘B’).
Results
Benefits to patients
The number of patients who experienced one
episode of peritonitis was significantly lower in
patients using the Y-set delivery system (57/194)
compared with the standard non-Y-set system
(107/201). There was no significant increase 
in the number of patients who suffered exit-site 
or tunnel infections.Appendix 7
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Resource use and costs
The principle cost differences between the Y-set
and standard non-Y-set systems for delivering 
CAPD result from differences in the cost of the 
two processes of dialysis and the cost of treatment
of complications.
Resources used before and during the 
dialysis session
It has been assumed that the resources used and
the costs of the initial insertion of the catheter 
and of training the patient to use their designated
mode of peritoneal dialysis are the same for both
methods of delivery.
Cost of peritoneal dialysis
The cost per patient per month of Y-set and
standard non-Y-set systems for delivering CAPD 
are shown in Tables 28 and 29. It includes the
capital costs and the cost of consumables used in
the dialysis process. The cost of routine check-ups
have, however, not been included as these have
been assumed to be the same for patients treated
by either the Y-set or the standard non-Y-set system.
All exchanges are assumed to be performed by the
patient or the patient’s carer. The time that the
patient or carer spends in performing exchanges
has not been estimated but may differ between the
two modalities.
Cost of complications
The evidence presented in the ‘benefits to patients’
section above suggests that the rate of peritonitis
differed between patients dialysed with either Y-set
or standard non-Y-set systems. Insufficient data were
reported in the systematic review of effectiveness
for an economic analysis to be undertaken. The
only outcome measure for peritonitis suitable for
meta-analysis did not provide any information on
the period over which data was collected on
peritonitis or the number of peritonitis episodes
that occurred within that period. In order to obtain
Which mode of delivery?
Peritonitis
B
A
A1
A1
B1
B1
Y-set
Standard
No peritonitis
Drop-out
Not drop-out
Drop-out
Not drop-out
Peritonitis
No peritonitis
Drop-out
Not drop-out
Drop-out
Not drop-out
FIGURE 11  Decision model to compare the alternative forms of dialysis (n,decision node; l,chance node; ,terminal node)
s
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estimates of the probabilities and periods required,
the included studies from the systematic review of
effectiveness were further analysed.
There was insufficient evidence in the included
RCTs to suggest that the probability of death, trans-
fer to haemodialysis, or renal transplant differed
between patients starting CAPD using either the 
Y-set or the standard non-Y-set system. There was
also insufficient evidence to suggest that the prob-
ability of technique failure is different (analogous
to ‘drop-out’ in Figure 11). Of the three studies that
reported technique failure, the Canadian CAPD
Clinical Trials Group (1989) found no statistically
significant differences in technique survival
between patients started on CAPD with the Y-set
compared with the standard non-Y-set systems.
Cheng and colleagues (1994) reported that the
technique survival was comparable and Dryden and
colleagues (1992) reported technique failure to be
greater in patients receiving CAPD with the stand-
ard non-Y-set system than with the Y-set system. This
result, however, was not statistically tested.
The estimates for the relative probability of
developing peritonitis for patients who started 
on CAPD with Y-set system and the standard 
non-Y set systems are shown in Table 30. As no
single estimate could be obtained from meta-
analysis, high, medium and low estimates of cost
have been calculated from data in the literature.
These estimates are based upon the number of
patient-months of care, on average, before one
episode of peritonitis occurred.
The cost per episode of peritonitis is shown in 
Table 31.
Using the model depicted in Figure 11, the data
included in Tables 28–31 can be used to calculate the
relative cost per patient of CAPD using either the Y-
set or standard non-Y-set system. A summary of the
sensitivity analysis of the incremental cost of patients
treated on the Y-set and standard non-Y-set system is
shown in Table 32. The high and low estimates are
based on the assumptions that are most favourable
and least favourable to the Y-set system. For example,
for the low estimate presented in Table 32, the calcu-
lation of cost is based upon the low cost of CAPD
using the Y-set system (see Table 28) minus the cost of
the non-Y-set system (see Table 29) plus the high cost
of peritonitis treatment (Table 31) which has been
TABLE 28  The cost per month per patient of CAPD using the 
Y-set system
Item Number  Cost per  Cost per 
of items  item     month 
per day (£) (£)
Low High Low High
2 litre fluid 4 4.7 5.3 571.83 644.83
Cap 4 0.45 0.45 54.75 54.75
Shield 4 0.45 0.45 54.75 54.75
Total 681 754
TABLE 29  The cost per patient per month of CAPD using the
non-Y-set system
Item Number  Cost per  Cost per 
of items  item  month 
per day (£) (£)
2 litre fluid 4 3.5 425.83
Transfer set  9.3 0.77
(one per year)
Total 427
TABLE 30  The extra probability of an episode of peritonitis 
per month for patients who started CAPD with the standard 
non-Y-set system compared with patients who started CAPD 
with the Y-set system
Relative Data  source
probability 
per month
Low 0.014 Cheng,et al.,1994
Medium  0.054 Canadian CAPD Clinical 
Trials Group,1989;
Maiorca,et al.,1983b
High 0.129 Owen,et al.,1992
TABLE 31  Cost per episode of peritonitis
Item of resource use Cost per episode (£)
Low High
10-day course of antibiotics
Vancomycin (10 vials 250 mg 
plus 2 ´ 500 mg injections) 65 65
Serum concentration 
(1 per day) 300 300
Syringe 12 12
Hospitalisation 
(0 for ‘Low’,5 days for ‘High’) 0 996
Total 377 1373Appendix 7
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multiplied by the high probability of avoiding a
peritonitis episode by using the Y-set system (see
figures from Owen et al., 1992, in Table 30).
Combining costs and benefits
The combination of the information on the relative
effectiveness and cost of the Y-set and standard non-
Y-set systems for CAPD can provide information on
the relative efficiency of the alternatives. The avail-
able information on benefits suggests that the Y-set
system provides more benefits to patients than the
standard non-Y-set system. Crucial information
required to estimate the cost was not available in a
sufficiently robust form to allow a definitive calcu-
lation of cost. Therefore, in terms of the framework
described in Figure 3 (page 10), the results suggest
there is insufficient evidence on costs to make a
judgement on the relative efficiency of the two deliv-
ery systems (area D1 on the matrix linking effective-
ness and cost). If the available information is used,
then the Y-set systems are both more effective and
more costly than the non-Y-set systems (area C1 of
the matrix). In this area a judgement is required on
whether the extra benefits are worth this additional
cost. Additional information can be obtained from
the data by using incremental analysis, that is, by
identifying the extra resources required to achieve
one more of a beneficial effect. This allows a more
explicit consideration of the opportunity cost of Y-set
systems in preference to the non-Y-set systems. An
opportunity cost is defined in terms of the benefits
that could have been obtained if the resources were
used in their next best alternative use. The conse-
quence of using limited resources in one way is that
the opportunities to use them in other desirable
ways are forfeited. The cost of that decision is the
benefit that could have been obtained by using the
resources in other desirable ways.
Using the data shown in Tables 30 and 32, the
additional cost of preventing one case of peritonitis
when patients are started on CAPD using the Y-set
rather than the non-Y-set system can be calculated
(Table 33). In this table, it is important to note that
the higher the probability of avoiding a case of
peritonitis then the lower the cost of the more
effective Y-set at preventing peritonitis.
The low and high cost-effectiveness ratios shown in
Table 33 are based upon the very best and the very
worst assumptions considered when comparing 
Y-set with non-Y-set systems.
Discussion
It was not possible to definitively estimate the rela-
tive costs of the two delivery systems and, hence, it
was not possible to estimate relative efficiency.
Available data suggested that the Y-set system was
more effective but more costly than the non-Y-set
system. A judgement is therefore required as to
whether the additional costs of starting a patient on
CAPD using the Y-set system are worth the addition-
al benefits it provided compared with starting a
patient on CAPD using the non-Y-set system.
It has been assumed that technique survival is the
same with both delivery systems. The two studies that
explicitly report technique survival (Canadian CAPD
Clinical Trials Group, 1989; Dryden et al., 1992)
reported that survival was greater with the Y-set
system but that the difference failed to reach statis-
tical significance and that it was not possible to per-
form a meta-analysis of this data. If patients using
the non-Y-set method have more chance of switching
to haemodialysis because of technique failure, then
this would tend to improve the relative efficiency of
the Y-set system compared to the non-Y-set system.
With respect to this economic evaluation a number
of comments can be made. Costs are derived from
estimates of resource use and probabilities which are
directly taken from studies conducted in different
settings. There are questions as to how generalisable
TABLE 32  The incremental cost of CAPD per patient per month
of the Y-set and standard non-Y-set systems
Additional cost of Y-set  Cost per patient 
over non-Y-set per month (£)
Low 77
Medium 254
High 322
TABLE 33  The additional cost per patient on CAPD with the Y-set system for episodes of peritonitis avoided
Additional cost per  Reduction in probability of  The extra cost (£) per patient 
patient per month (£) peritonitis with Y-set system per case of peritonitis avoided
Low 77 High 0.129 597
Medium 254 Medium 0.054 4704
High 322 Low 0.014 23,000Health Technology Assessment 1998; Vol. 2: No.5
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such data could be. The quantity of resources con-
sumed in any given setting are influenced by their
prices which can, and do, vary between settings.
Further work is required to establish differences 
in the long-term costs and outcomes of the two
methods of CAPD delivery. It may be possible, using
sensitivity analysis, to gain robust estimates of long-
term costs and outcomes by identifying data from
well-designed prospective observational studies.
Conclusions and implications
Policy implications
Peritonitis is one of the main complications of
CAPD and is known to lead to morbidity, technique
failure and mortality. Based on the results of this
review, there is insufficient evidence to support the
continued use of non-Y-set connecting systems in
CAPD. The economic evaluation of this review re-
veals that the use of a Y- or modified Y-set connector
imposes an incremental cost of £77–322, based on
low and high cost estimates. The additional cost of
the Y-set system is £327 compared with the standard
system (Baxter Ltd, personal communication). In
order to prevent one episode of peritonitis, how-
ever, wide variations in cost for Y-set or modified 
Y-set systems were estimated depending on the
relative probability of peritonitis per month.
If it is assumed that there is a higher incidence of
technique failure with standard set systems, then
the use of the Y-set or modified Y-set system is 
cost efficient.
Future research needs
Peritonitis remains a major problem in CAPD and
further research into methods of prevention of this
complication is required.
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Background
CAPD has been used as an alternative to
haemodialysis for patients with ESRD since 
1976 (Popovich, et al., 1976). CCPD, in which 
most of the dialysis exchanges are performed
during the night with the aid of an automated
cycler machine is a modification of CAPD. In
CAPD, at least four 1.5–3.0 litre exchanges are
required daily; each exchange must be performed
by the patient (or carer). However, in CCPD 
only one connection/disconnection procedure 
is required; all the exchanges (variable number 
and variable volume) are performed auto-
matically by the automate cycler machine. 
CCPD was initially introduced as an alternative 
to CAPD for those patients who experienced
difficulty with CAPD or in whom it could be
predicted that difficulty with CAPD might be
encountered. For example, parents of young
children with ESRD could be freed from per-
forming daytime exchanges and older children
would no longer have to perform exchanges 
at school, away from the privacy and controlled
environment of their homes. Patients who had
difficulty performing CAPD exchanges because 
of a disability, such as a neurological deficit 
or reduced vision, could benefit either from 
the reduced number of procedures or the
possibility that a relative or partner could 
perform the connection/disconnection 
procedures (Diaz-Buxo, 1985). Patients who 
have a rapid rate of solute transfer across 
their peritoneal membranes (high transporters)
were also considered to be likely to benefit 
from CCPD, because of the ability to perform 
rapid frequent exchanges with short 
dwell-times.
More recently, CCPD has been proposed as 
an alternative to CAPD for all patients in whom
peritoneal dialysis is appropriate (Diaz-Buxo,
1985). In patients with a strong medical or 
social indication for the adoption of CCPD, the
benefits may be so convincing that waiting for
supporting evidence from CCTs may not be
justified. However, the adoption of this new
treatment modality as an option for patients 
who could be adequately managed by the 
standard treatment (CAPD) does need to be
justified by evidence of clinical benefit from 
clinical trials. If the benefits are mainly social,
relating to patient preference, patients and 
healthcare purchasers need to know if CCPD 
has any extra cost in terms of morbidity/
mortality or resource use (Woodrow, et al., 
1994) in order to make informed decisions.
However, CCPD may actually have clinical 
as well as psychosocial benefits; some authors 
have reported a reduced incidence of 
peritonitis with CCPD compared with 
CAPD (Dias-Buxo, 1985; Brunkhorst, 
et al., 1994).
Objective
The objective of this review is to compare CCPD
with CAPD in the management of patients with
ESRD. The hypotheses being tested are that,
compared with patients on CAPD, those on 
CCPD have:
(a) a reduced frequency of peritoneal 
dialysis-associated peritonitis
(b) a reduced frequency of exit-site and 
tunnel infections
(c) a reduced frequency of peritoneal dialysis
catheter changes
(d) a reduced incidence of abdominal hernias,
hydrothoraces and exit-site leaks
(e) a reduced incidence of technique failure 
(the need to change to other dialysis 
methods, such as haemodialysis)
(f) improved blood pressure control
(g) improved control of hyperkalaemia 
(a measure of dialysis adequacy)
(h) improved adequacy of dialysis as 
measured by serum urea, creatinine, 
Kt/V and PCR
(i) reduced rate of hospitalisation
(j) improved patient survival
(k) improved nutritional status (as reflected 
by serum albumin levels)
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(l) improved quality of life and general 
well-being
(m) a preference for CCPD
(n) similar resource use demands.
Materials and methods
Criteria for considering studies for 
this review
Types of studies  An attempt was made to identify
all trials comparing CCPD (experimental group)
with CAPD (control group) in the management 
of patients with ESRD in which the patients 
were prospectively randomly (for example, using
sealed envelopes with third party involvement) 
or quasi-randomly (alternate patients or alternate
treatments) allocated to either treatment. Cross-
over trials in which treatments alternated at least 
to the degree A–B–A–B were also to be included,
even if the allocation to first treatment was neither
random nor quasi-random.
Types of participants  Patients with ESRD who 
were suitable for both CCPD or CAPD, irrespec-
tive of age, sex, race, primary renal disease or co-
morbidity. Trials which were exclusively comprised
of patients with acute renal failure were excluded.
Each individual study’s definition of ESRD 
was accepted.
Types of intervention  The experimental treatment
(CCPD) comprised night-time exchanges perform-
ed by an automated cycler machine in the patient’s
home. Patients may have also performed one or
more daytime cycles (manually or otherwise). The
control treatment (CAPD) comprised a variable
number of manual peritoneal dialysis exchanges
performed during the day by either the patient 
or an assistant. An overnight in-dwelling exchange
may also have been performed. None of the con-
trol exchanges were performed by an automated 
cycle machine. Studies which included patients 
on intermittent peritoneal dialysis (peritoneal
dialysis performed by an automated cycler machine
for a prolonged period two or three times per week
either in hospital or in the patient’s home) 
were excluded.
Types of outcome measures
1.  Number of episodes of peritoneal 
dialysis-associated peritonitis
2.  Number of exit-site infections
3.  Number of peritoneal dialysis catheter 
tunnel infections
4.  Number of abdominal hernias
5.  Number of hydrothoraces
6.  Number of episodes of exit-site leaks
7.  Technique failure (the need to switch 
to another mode of dialysis such 
as haemodialysis)
8.  Serum potassium (mmol/l)
9.  Serum urea (mmol/l)
10. Serum creatinine (µmol/l)
11. Kt/V
12. PCR
13. Serum albumin (g/l)
14. Systolic blood pressure
15. Diastolic blood pressure
16. Mean arterial blood pressure
17. Hospitalisation (days per patient 
per year)
18. Measurement of quality of life
19. Patient preference (if crossover trial)
20. Employment status
21. Mortality.
Search strategy for identification 
of studies
The search strategy used was one developed for 
the identification of all possible RCTs or quasi-
RCTs relating to the management of ESRD, and is
described in detail in chapter 2 and appendices 2
and 3.
Methods of the review
Identified studies were evaluated using a 
study evaluation form and those which met the
eligibility criteria (included references) were 
then considered in detail. Data were extracted
using a data abstraction form designed for this
review (see appendix 10). Review Manager v. 
3.0 was used for the analysis). For a full 
description of the methods used, see 
chapter 2.
Description of studies
Only one study met the inclusion criteria (de 
Fijter, et al., 1994); 97 unselected patients with
ESRD were randomised, 47 to CCPD and 50 to
CAPD. However, following withdrawals and drop-
outs before commencing dialysis, only 41 patients
received CCPD and 41 patients received CAPD.
The study was conducted at a single centre in a
university hospital setting (otherwise patients 
were unselected) in Amsterdam, The Netherlands.
The main characteristics of the study are
summarised in Table 34.
Methodological quality of 
included studies
The single study found was a randomised parallel
open trial with a clear description of withdrawals
and drop-outs (see Table 34).Health Technology Assessment 1998; Vol. 2: No.5
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Results
The meta-analysis of the results from the 
included study (de Fijter, et al., 1994) are 
shown in Table 35 (A and B).
Infective complications
There were no significant differences in the
numbers of patients who had one or more 
episodes of:
• peritonitis (OR, 0.56; 95% CI, 0.24, 1.33)
• exit-site infection (OR, 1.13; 95% CI, 0.43, 2.94)
• tunnel infection (OR, 0.5; 95% CI, 0.05, 4.99).
Infective complications were also reported as
episodes per patient-year. There was a significantly
decreased mean incidence per patient-year of
peritonitis – 0.51 (CCPD) compared with 0.94
(CAPD) (p = 0.03) – but no difference in the 
mean incidence of exit-site infection – 0.38 
(CCPD) and 0.38 (CAPD).
Technique survival
Fewer patients allocated to CCPD changed mode 
of dialysis (excluding real transplants and recovery
of renal function but including change between 
the two methods of peritoneal dialysis under assess-
ment). The OR was 0.48 but the difference was not
statistically significant (95% CI, 0.18, 1.26). Simi-
larly, fewer patients in the CCPD group switched 
to haemodialysis but again the difference was 
not statistically significant (OR, 0.46; 95% CI, 
0.14, 1.56).
Seven patients on CCPD compared with 11 patients
on CAPD required peritoneal dialysis catheter
removal (OR, 0.57; 95% CI, 0.20, 1.61). The
difference was reported as being related to 
infective complications.
Mechanical complications
There were equal numbers of abdominal hernias
(OR, 1.0; 95% CI, 0.19, 5.22) and hydrothoraces
(OR, 1.0; 95% CI, 0.06, 16.27) in both groups. 
Exit-site leaks were not reported.
Dialysis adequacy
There was no significant difference in Kt/V at 
6 months (WMD, 0.40; 95% CI, –0.23, 1.03). this
study also reported no significant difference in 
6-monthly serum creatinine, urea and phosphate.
Blood pressure control
No data were presented which could be used in the
meta-analyses; however, there were no significant
differences in reported 6-monthly mean arterial
blood pressure measurements.
Quality of life and general well-being
Patients’ performance status was recorded at 
6-monthly intervals using a Karnofsky score. 
There was no significant difference between 
the two groups.
Hospitalisation
Fewer patients allocated to CCPD were judged 
to require hospitalisation, although this was not
TABLE 34  Characteristics of included studies:CCPD versus CAPD in treatment of patients with ESRD
Study Method Participants Interventions Outcomes Notes
de Fijter,et al., Parallel RCT; 97 consecutive unselected  Randomised to CCPD  Infective complications:
1994 randomisation  new patients with  or CAPD;duration of  episodes of peritonitis,
method not  ESRD;drop-outs after  study:CCPD follow-up, exit-site and tunnel 
described;blinding  randomisation but before  723 patient months, infections;removal of 
not mentioned; dialysis commenced  CAPD follow-up, catheter;technique 
numbers and reasons  resulted in 41 patients in  688 patient months; survival;number of 
for withdrawals and  each group;median age –  CCPD prescription: abdominal hernias,
drop-outs given; CCPD,54 years (range, PAC-X cycler,4–5  hydrothoraces;dialysis 
analysis not on  21–76 years),CAPD, nocturnal cycles, adequacy,serum 
intention-to-treat  56 years (18–86 years); 1 diurnal cycle, creatinine,Kt/V;
basis. M:F,52:45;no previous  2-litre fill volume; hospitalisation rate;
RRT or renal transplant; CAPD prescription: quality of life,general 
duration on RRT,first  Y-set disconnect  well-being – Karnofsky 
dialysis;inclusion criteria  system (no disinfectant), score;blood pressure 
– new patients with  2–5 2-litre exchanges  control,mean arterial 
ESRD;exclusion criteria –  daily;partner  blood pressure.
absolute contraindication  assistance not 
to peritoneal dialysis;co- mentioned.
morbidity – “co-morbid 
conditions distributed 
equally between 
the two groups”.Appendix 8
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statistically significant (OR, 0.5; 95% CI, 0.21, 1.20).
However, there was a statistically significant differ-
ence in the number of hospital admissions per
patient-year of treatment (data which could not 
be converted into an OR) – 0.6 (CCPD) and 
1.0 (CAPD) (p = 0.02).
Nutritional status
Data for 6-monthly serum albumin were 
only presented graphically and a reliable 
OR could not therefore be estimated. There 
was no significant difference between 
the groups.
TABLE 35A  CCPD versus CAPD:overall summary
Comparison or outcome Peto OR WMD
(95% CI) (95% CI)
Patients with peritonitis
Rate of peritonitis (per patient year) Not estimable
Patients with exit-site infection
Rate of exit-site infection (per patient year) Not estimable
Patients with tunnel infection
Rate of tunnel infection (per patient year) Not estimable
Patients with catheters removed
Catheter removal (per patient year) Not estimable
Patients developing abdominal hernias
Patients who developed hydrothoraces
Patients who developed exit-site leaks Not estimable
Serum potassium (mmol/l) Not estimable
Serum urea (mmol/l) Not estimable
Serum creatinine (µmol/l) Not estimable
Weekly Kt/V after 6 months’ dialysis
Serum albumin (g/l) Not estimable
Systolic blood pressure (mmHg) Not estimable
Diastolic blood pressure (mmHg) Not estimable
Mean arterial blood pressure (mmHg) Not estimable
Number of patients who required hospitalisation
Hospitalisation rate (days per patient year) Not estimable
Mortality
Patients in whom dialysis mode changed
Patients changed to haemodialysis
Quality of life/general well-being Not estimable
TABLE 35B  CCPD versus CAPD:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Patients with peritonitis
de Fijter,1994 19/41 25/41 100.0 0.56 (0.24,1.33)
Total (95% CI) 19/41 25/41 100.0 0.56 (0.24,1.33)
Chi-square 0.00 (df = 0) Z = 1.32
continued
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TABLE 35B contd  CCPD versus CAPD:detailed meta-analysis
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Patients with exit-site infection
de Fijter,1994 12/41 11/41 100.0 1.13 (0.43,2.94)
Total (95% CI) 12/41 11/41 100.0 1.13 (0.43,2.94)
Chi-square 0.00 (df = 0) Z = 0.24
Patients with tunnel infection
de Fijter,1994 1/41 2/41 100.0 0.50 (0.05,4.99)
Total (95% CI) 1/41 2/41 100.0 0.50 (0.05,4.99)
Chi-square 0.00 (df = 0) Z = 0.58
Patients with catheters removed
de Fijter,1994 7/41 11/41 100.0 0.57 (0.20,1.61)
Total (95% CI) 7/41 11/41 100.0 0.57 (0.20,1.61)
Chi-square 0.00 (df = 0) Z = 1.06
Patients developing abdominal hernias
de Fijter,1994 3/41 3/41 100.0 1.00 (0.19,5.22)
Total (95% CI) 3/41 3/41 100.0 1.00 (0.19,5.22)
Chi-square 0.00 (df = 0) Z = 0.00
Patients who developed hydrothoraces
de Fijter,1994 1/41 1/41 100.0 1.00 (0.06,16.27)
Total (95% CI) 1/41 1/41 100.0 1.00 (0.06,16.27)
Chi-square 0.00 (df = 0) Z = 0.00
continued
0.1 1 0.2 51 0
Favours control Favours treatment
0.01 1 0.1 10 100
Favours control Favours treatment
0.1 1 0.2 51 0
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TABLE 35B contd  CCPD versus CAPD:detailed meta-analysis
Study Experimental Control WMD Weight WMD
n mean (SD) n mean (SD)
(95% CI fixed) (%) (95% CI fixed)
Weekly Kt/V after 6 months’dialysis
de Fijter,1994 39 –3.40 (1.60) 39 –3.00 (1.20) 100.0 –0.400 (–1.028,0.228)
Total (95% CI) 39 39 100.0 –0.400 (–1.028,0.228)
Chi-square 0.00 (df = 0) Z = 1.25
Study Experimental Control Peto OR Weight Peto OR
n/N n/N (95% CI fixed) (%) (95% CI fixed)
Number of patients who required hospitalisation
de Fijter,1994 20/41 27/41 100.0 0.50 (0.21,1.20)
Total (95% CI) 20/41 27/41 100.0 0.50 (0.21,1.20)
Chi-square 0.00 (df = 0) Z = 1.55
Mortality
de Fijter,1994 4/41 2/41 100.0 2.04 (0.39,10.62)
Total (95% CI) 4/41 2/41 100.0 2.04 (0.39,10.62)
Chi-square 0.00 (df = 0) Z = 0.84
Patients in whom dialysis mode changed
de Fijter,1994 8/41 14/41 100.0 0.48 (0.18,1.26)
Total (95% CI) 8/41 14/41 100.0 0.48 (0.18,1.26)
Chi-square 0.00 (df = 0) Z = 1.49
Patients changed to haemodialysis
de Fijter,1994 4/41 8/41 100.0 0.46 (0.14,1.56)
Total (95% CI) 4/41 8/41 100.0 0.46 (0.14,1.56)
Chi-square 0.00 (df = 0) Z = 1.24
–4 0 –2 24
Favours control Favours treatment
0.1 1 0.2 51 0
Favours control Favours treatment
0.01 1 0.1 10 100
Favours control Favours treatment
0.1 1 0.2 51 0
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Mortality
Four patients in the CCPD group died 
compared with two patients in the CAPD group
(OR, 2.04; 95% CI, 0.39, 10.62); this was not
statistically significant.
Discussion
Only one study from the 13,000 abstracts con-
sidered met the eligibility criteria for inclusion 
(de Fijter, et al., 1994). Although this study
appeared to be well conducted, its value is limited
by its small sample size (82 patients in total). The
results tended to favour CCPD in respect of a
reduction in infective complications, reduced
technique failure and reduced need for hospital-
isation but none of the differences in these pre-
stated measures reached conventional levels 
of statistical significance. When expressed as
episodes per patient-year, there were statistically
significantly fewer episodes of peritonitis and
hospital admission. These findings increase the
likelihood that the other findings reflect true
differences between the techniques. Because 
it was a parallel study and all the patients were 
new to dialysis at its commencement, patient
preference was not reported.
The use of CCPD as an alternative to CAPD
therefore receives some support from this study. 
It suggests that where the option of CCPD is being
offered on the basis of patient preference, conveni-
ence is not being paid for by increased morbidity
and mortality. However, the capital outlay for the
extra machines and the larger volume of peritoneal
dialysate used makes CCPD significantly more
expensive than CAPD. While controversy persists
about the size of any benefits, a general change
towards CCPD from CAPD for patients on chronic
peritoneal dialysis is not yet warranted.
The generalisability of this review is obviously 
also hampered by its dependence on a single 
study. This was a single centre study and, 
although 97 patients were randomised, the
predictable attrition rate from drop-outs resulted 
in there being only 24 patients in the final 
24-month review. Further studies, preferably
multicentre studies, are needed to produce 
more precise estimates of the differences between
CCPD and CAPD suggested by this study. Peri-
tonitis is the most frequent major complication 
of all forms of peritoneal dialysis. It results in
significant morbidity, mortality and dialysis
technique failure. If future studies confirm 
a significant reduction in its frequency with 
CCPD, then CCPD should become the preferred
option in chronic peritoneal dialysis.
Future RCTs on this topic should, like this study,
concentrate on primary outcomes of major clinical
importance, such as peritonitis, technique failure
and mortality. The fact that none of 98 new patients
with ESRD had an absolute contraindication to peri-
toneal dialysis counters the argument that patient
numbers in RCTs comparing different modes of
dialysis would be significantly limited by exclusion
criteria dictated by contraindications to specific
dialysis modes. CCPD should not be viewed solely as
an alternative to CAPD. Although more expensive
than CAPD, it may have less resource demands than
hospital haemodialysis and may be a viable alter-
native, even when there is a relative contraindication
to CAPD (for example, when significant input from
a partner or assistant is required).
Economic evaluation
Introduction
The principles of economic evaluation are
described in detail in chapter 3 (page 9) including,
in an economic framework, the manner in which
costs and outcome are related (see, in particular,
Table 2 and Figure 3).
Aims
CCPD is a modification of CAPD in which dialysate
exchanges are automatically performed by an
automated cycler machine. It is considered that
CCPD offers additional benefits over CAPD in that
it provides a more acceptable lifestyle for patients
and a reduced risk of peritonitis. The relative
efficiency of these alternatives will be investigated
using the framework of economic evaluation
outlined in chapter 3. More specifically, the 
aims of this economic evaluation are:
(i)  to investigate the relative resources used 
and the cost of CCPD and CAPD using data
extracted from the identified RCTs and non-
randomised studies in which CCPD and 
CAPD are compared
(ii)  to combine data on the difference in costs with
data on differential benefits to patients from
the systematic review of effectiveness described
above in order to assess the relative efficiency
of dialysis with CCPD or CAPD.
Methods
Data collection
The methods used are described in detail in
chapter 3 of the main report.Appendix 8
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Benefits to patients
The systematic review of RCTs or quasi-RCTs
described above had as its main objective the
synthesis of the effectiveness data from the RCTs.
Information was extracted from the RCTs on 
the following:
(a)  the frequency of peritoneal dialysis-
associated peritonitis
(b) the frequency of exit-site and 
tunnel infections
(c) the frequency of peritoneal dialysis 
catheter changes
(d) the incidence of abdominal hernias,
hydrothoraces and exit-site leaks
(e) the dialysis technique survival
(f) blood pressure control
(g) the control of hyperkalaemia
(h) the adequacy of dialysis as measured by 
serum urea, creatinine and Kt/V
(i) the hospitalisation rate
(j) patient survival
(k) patient nutritional status
(l) patient quality of life and general 
well-being 
(m) patient preference for modality type.
Identification of resource use and costs
The comparison of the resources used by the two
forms of peritoneal dialysis focused only on those
areas where there was likely to be some difference
in resource use. The identification of the relative
resources used when treating patients with either
CCPD or CAPD involved four steps.
1.  The definition of the process of care so that 
all items of resource use could be identified.
Different quantities of resources could poten-
tially be consumed during the initial catheter
insertion, the training process, the dialysis pro-
cess (which would involve routine checks on
the patients’ status) and the treatment of any
complications that might occur.
2.  The extraction of all relevant information 
from the RCTs.
3.  The assessment of the data on resource 
use contained in the studies that were 
not randomised.
4.  The information on resource use (obtained 
in steps 2 and 3) could then be combined with
information on the unit cost of the resources 
to determine the cost differential between
CCPD and CAPD using the methodology
described below. This differential could then 
be compared with data on differential benefits
to patients obtained from the systematic 
review of effectiveness.
Model of costs
1.  Catheter insertion  Peritoneal dialysis requires a
catheter to be inserted to provide access to the
peritoneum. Haemodialysis may be required
until peritoneal dialysis can be performed. 
For both types of peritoneal dialysis the process
of catheter insertion is the same. Thus the
resources consumed would also be the same.
2. Training  Once the catheter is inserted 
a patient is trained to carry out peritoneal
dialysis. This training takes several weeks and
can be performed on an in- or outpatient basis.
Patients may require haemodialysis during the
training period. For simplicity, it has been
assumed that the resources required for
training are the same. This assumption is
discussed below.
3.  The dialysis process  This includes the costs 
of capital items, consumables used, any staff
inputs for the process of dialysis and the
resources used during routine outpatient visits.
The capital resources and consumables used
were identified from de Fijter and colleagues
(1994) and combined with information on
prices obtained from manufacturers to obtain
the cost of these items for a 1-year period.
Although patients also require routine out-
patient visits (information on the resources
consumed and the frequency of these out-
patient visits can be obtained from Coyte and
colleagues (1996)), these visits were not costed
as they were assumed to be identical for both
CCPD and CAPD.
4.  Treatment of complications  The relative cost
of treating complications associated with the
different methods of peritoneal dialysis was 
also calculated, using the model depicted in
Figure 12 was used. If the patient does not 
drop out, then they return to another period 
of peritoneal dialysis (indicated in Figure 12 
by the movement from ‘A1’ back to ‘A’ or ‘B1’
back to ‘B’). From the report by de Fijter and
colleagues (1994), data were extracted on the
proportion of patients who were treated for 
a specific complication, such as peritonitis,
catheter infection or hernia, within a 1-year
period. The review of the RCTs and non-
randomised studies attempted to identify the
precise treatment that was provided for a
specific complication. These were then costed
according to the staff times, consumables used,
overhead costs and capital costs of the treat-
ment. The price of any pharmaceuticals con-
sumed was taken from the BNF (BMA, 1996)
and the cost of staff time was estimated by com-
bining information on time with that from the
relevant UK NHS salary scales (NHS, 1996a; b).Health Technology Assessment 1998; Vol. 2: No.5
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The analysis in this paper is based on intention-to-
treat. The RCTs were thus reviewed in order to
identify information on the proportion of patients
who suffered technique failure or had renal trans-
plants. Also recorded was the time delay to any
switch in treatment.
Results
Benefits to patients
The results of the systematic review of effectiveness
data were reported earlier. In brief, the systematic
review identified only one RCT that met the inclu-
sion criteria for the study (de Fijter, et al., 1994).
There was no significant difference in the numbers
of patients receiving CAPD or CCPD who had one
or more episodes of: peritonitis (OR, 0.56; 95% CI,
0.24, 1.33), exit-site infection (OR, 1.13; 95% CI,
0.43, 2.94) or tunnel infection (OR, 0.5; 95% CI,
0.05, 4.99). Infectious complications, when report-
ed as episodes of peritonitis per patient per year,
were significantly decreased (CCPD, 0.51; CAPD,
0.94; p = 0.03) but there was no difference in the
number of exit-site infections (CCPD, 0.38; CAPD,
0.38). There was no significant difference in the
number of patients who changed mode of dialysis.
There was also no differences in the numbers of
abdominal hernias and hydrothoraces. The inci-
dence of exit-site leaks, however, was not reported.
No significant differences were found between
CCPD and CAPD for dialysis adequacy, blood
pressure control, quality of life/general well-being,
nutritional status or mortality.
There was no significant difference in the number
of patients hospitalised (OR, 0.5; 95% CI, 0.21,
1.20). There was, however, a significant difference
in the hospital admissions per patient-year of
treatment – data which could not be calculated 
as an OR (CCPD, 0.6; CAPD, 1.0; p = 0.02).
Which form of 
peritoneal dialysis?
Peritonitis
A
B
A1
A1
B1
B1
CAPD
CCPD
No peritonitis
Drop-out
Not drop-out
Drop-out
Not drop-out
Peritonitis
No peritonitis
Drop-out
Not drop-out
Drop-out
Not drop-out
FIGURE 12  Decision model to compare the alternative forms of haemodialysis (n,decision node; l,chance node; ,terminal node)
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Resource use and costs
The principle cost differences between CCPD 
and CAPD result from differences in the costs 
of the two processes of dialysis and the costs of
treatment for complications.
Resources used before and during the 
dialysis session
It has been assumed that the resources used and
the costs of the initial insertion of the catheter and
of training the patient to use the designated mode
of peritoneal dialysis are the same for both CCPD
and CAPD.
Cost of peritoneal dialysis
The costs per patient per year for both CAPD 
and CCPD are shown in Table 36. They include 
the capital outlay and the consumables used in the
dialysis process. The cost of routine outpatient visits
has not been included as these have been assumed
to be the same for patients treated by either method.
The costs are made up from the cost of the consum-
ables used, for example, the dialysates and equip-
ment required for exchanges, and the capital cost
of the cycler for CCPD. The current purchase price
of all equipment was obtained from the manufac-
turers and converted into an equivalent annual cost
using a 6% discount rate and assuming a life-span of
3 years. All exchanges are assumed to be performed
by the patient or the patient’s carer. The time that
the patient or their carer spends in performing
exchanges has not been estimated but is likely to
differ between the two treatment modalities.
Cost of complications
The evidence presented above suggests that only
the rates of peritonitis and number of hospital
admissions per patient per year are significantly
different. The rates of drop-out and the reasons 
for drop-out for both treatment modalities are not
significantly different (de Fijter, et al., 1994). The
cost per episode of both hospitalisation and peri-
tonitis are shown in Table 37, and the probabilities
that such a complication will occur are shown in
Table 38.
Based on the model depicted in Figure 12, the 
data included in Tables 36–38 can be used to
calculate the relative cost per patient of using
CCPD or CAPD for the duration that a patient 
can be expected to be on each treatment modality.
Costs incurred after the initial year on dialysis are
discounted at an annual rate of 6%.
The results using the model show that it would cost
on average £22,670 to manage a patient on CCPD
until treatment failure and it would cost £17,000 to
manage a patient on CAPD until treatment failure
(Table 39).
TABLE 36  Relative costs of CCPD and CAPD
Exchanges Item of resource use Cost per item of CCPD CAPD
resource use (£)
Cost per patient  Cost per patient 
per year (£) per year (£)
Capital Cycler 7800 2918 N/A
Consumables  Tubing set (reusable as drainage bag) 12.5 4563 N/A
Y connector 2.1 3066 3066
Nightly exchanges 16 5840 N/A
Daily exchanges                                      3.5 or 5.3 1277 7738
Cap 0.45 164 657
Shield 0.45 657
Labour Time spent performing exchanges not estimated
Total 17,828 12,118
N/A,not applicable
TABLE 37  Cost per episode of peritonitis and hospitalisation
Condition Item of resource use Cost per 
episode 
(£)
Peritonitis 10-day course of antibiotics:
Vancomycin (10 vials 250 mg 
plus 2 ´ 500 mg injection) 65
Serum concentration 
(one per day) 300
Syringe 12
Total 377
Hospitalisation 10 days per year 1993Health Technology Assessment 1998; Vol. 2: No.5
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Combining costs and benefits
The combination of the information on the 
relative effectiveness and cost of CCPD and CAPD
can provide information on their relative efficien-
cies. The available information on benefits suggests
that CCPD provides more benefits to patients than
CAPD but at greater cost. (Area C1 on the frame-
work described in Figure 3). Here a judgement is
required about whether the extra benefits are
worth this additional cost, which requires consider-
ation of the opportunity cost of providing CCPD
instead of CAPD. (An opportunity cost is defined 
in terms of the benefits that could have been
obtained if the resources were used in their 
next best alternative use.) The consequence 
of using limited resources in one way is that 
the opportunities to use them in other desirable
ways are given up.  The cost of that decision is the
benefit that could have been obtained by using 
the resources in other desirable ways.
The RCT identified in this systematic review 
(de Fijter, et al., 1994) can be used to provide
additional information to aid in the judgement
between CCPD and CAPD. Using data from the
RCT on the rate per patient of technique failure,
peritonitis and hospitalisation, the average inci-
dence per patient of peritonitis and hospitalisation
can be calculated; the peritonitis and hospitalis-
ation rates per patient are shown in Table 40.
Using the data on the additional cost of CCPD
relative to CAPD (Table 38) and the additional bene-
fits of CCPD (Table 40), it is possible to calculate the
additional cost per patient per case of peritonitis 
or hospitalisation avoided with CCPD relative to
CAPD. As shown in Table 41, CCPD prevents an
additional case of peritonitis per patient relative 
to CAPD at a cost of £20,100 or CCPD prevents 
an additional case of hospitalisation per patient 
at a cost of £11,570. The issue is whether the extra
TABLE 38  The probabilities of different events for CAPD and CCPD
Probabilities per year Note
CCPD CAPD
Training 1 1 Not included
Catheter insertion 1 1 Not included
Catheter removal 0 0 Not included
Hospital admissions per year 0.6 1 de Fijter,et al.,1994
Peritonitis 0.51 0.94 de  Fijter,et al.,1994
Drop-out (first year) 0.73 0.73 de Fijter,et al.,1994
Drop-out (subsequent) 0.4 0.4 de Fijter,et al.,1994
Transfer to CAPD from CCPD 0 Simplification
Transfer to CCPD from CAPD 0 Simplification
TABLE 39  Relative cost of CCPD and CAPD per patient up to
technique failure
Modality Cost per  Extra cost per  Average 
patient  patient of  period before 
(£) CCPD over  technique 
CAPD (£) failure (years)
CCPD 22,670 5670 1.22
CAPD 17,000 – 1.22
TABLE 40  Peritonitis and hospitalisation rates per patient up to technique failure
Modality  Peritonitis rates  Additional rate of  Hospitalisation Additional rate of 
per patient  peritonitis of CAPD over  hospitalisation of CAPD 
CCPD per patient over CCPD per patient
CCPD 0.62 0 0.73 0
CAPD 0.89 0.27 1.22 0.49Appendix 8
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benefits of a case of peritonitis or the avoidance 
of an episode of hospitalisation are worth the
additional cost, given that the additional resources
could be used to achieve benefit elsewhere.
Discussion
The only study identified which met the eligibility
for inclusion criteria (de Fijter, et al., 1994) demon-
strated significant reductions in episodes of peri-
tonitis and hospital admissions per patient-year
with CCPD compared with CAPD, and no publish-
ed economic evaluations were found on this study
question. There were, however, no differences in
other infective complications, technique survival,
mechanical complications, dialysis adequacy, blood
pressure control, nutritional status, general well-
being or mortality. Because it was a parallel study
and all patients were new to dialysis when it started,
patient preference was not reported.
The study shows that the modest additional
benefits of CCPD of over CAPD are achieved at
much greater cost. The question is whether these
modest clinical benefits and unmeasured benefits,
such as patient preference, are worth these extra
resources. It is unlikely that these modest benefits
would support a general change to CCPD, given
that the extra resources are likely to provide much
greater benefit if used elsewhere.
The strength and generalisability of this review is
obviously hampered by its dependence on a single
study. This was a single centre study and, although
97 patients were randomised, the predictable attri-
tion rate from drop-outs resulted in there being
only 24 patients at the final 24-month review. The
incidence of many of the complications and the
technique failure recorded did not significantly
differ between treatments. This may have been
because there was no difference or it may have
been because the study was too small to detect
differences. Further studies, preferably multicentre
studies, are needed to confirm and statistically
strengthen the comparability of CCPD and CAPD
indicated by this study. Peritonitis is the most fre-
quent major complication of all forms of peritoneal
dialysis. It can result in significant morbidity, mor-
tality and dialysis technique failure. If future studies
confirm a significant reduction in its frequency
with CCPD, the extra benefits may outweigh the
extra cost.
In this economic evaluation, costs are derived from
estimates of resource use and probabilities which
are directly taken from studies conducted in differ-
ent settings; hence, the results may not be general-
isable. The quantity of resources consumed in any
given setting is influenced by their prices, and
prices can, and do, vary between settings.
Also, the total costs of treatment with CCPD 
or CAPD have not been calculated. Only those
areas in which there are differences in resource
utilisation have been investigated. Assumptions
have been made about the aspects of care that 
are the same for both modalities of treatment. 
For example, it has been assumed that the same
process of care was followed for the insertion of 
the peritoneal catheter for both treatments.
In this situation there is no reason to believe that
the process of care would be different and, hence,
the assumptions that the resources used and the
outcomes of insertion are the same are probably
valid. Patients require training for peritoneal
dialysis and this has also been assumed to be the
same. In reality, patients on CCPD are likely to
require training in both techniques (in case of
emergencies), which patients solely on CAPD do
not. However, the duration of training is unlikely 
to differ. The cost of training CCPD patients is
likely to be slightly greater than CAPD patients 
and, other things being equal, this would tend to
reduce the efficiency of CCPD relative to CAPD.
Future RCTs on this topic should concentrate 
on primary outcomes of major clinical importance
such as peritonitis, technique failure, mortality and,
also, strength of patient preference. The evaluation
of strength of patient preference for a particular
modality may highlight significant benefits of
treatment not elicited through primary outcomes.
CCPD should not be viewed solely as an alternative
to CAPD. Although more expensive than CAPD 
it may have less resource demands than hospital
haemodialysis and may be a viable alternative 
TABLE 41  Additional cost per patient on CCPD of hospitalisation
or episodes of peritonitis avoided
1 Additional cost of CCPD over CAPD £5670
2 Number of cases of peritonitis avoided 
per patient on CCPD relative to CAPD 0.27
3 Extra cost per patient per case of 
peritonitis avoided (Row 1/ Row 2) £21,000
4 Number of episodes of hospitalisation 
avoided per patient on CCPD relative 
to CAPD 0.49
5 Extra cost per patient per episode of 
hospitalisation avoided (Row 1/ Row 4) £11,570Health Technology Assessment 1998; Vol. 2: No.5
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when there is a relative contraindication to 
CAPD (for example, when significant input 
from a partner or assistant is required).
Conclusions and implications
Policy implications
CCPD is a comparable alternative to CAPD in terms
of patient outcome but is more expensive. Provid-
ers of dialysis services require to make a judgement
about whether the extra cost is worth the extra
benefit that it may provide.
Future research needs
1. Further RCTs are required in which CCPD 
is compared with CAPD with particular refer-
ence to peritonitis, technique failure rates 
and patient preference. If these confirm the
reduced peritonitis rate of CCPD, it may need
to be considered as the preferred chronic
peritoneal dialysis option.
2. The more widespread use of CCPD may have
significant resource-use implications. Future
RCTs should include a thorough economic
evaluation to provide more information on
whether any additional benefits are worth the
additional resources that CCPD, relative to
CAPD, may require.
RCTs and economic evaluations are required 
that compare CCPD with haemodialysis to deter-
mine whether it is efficient to provide CCPD for
those patients who have a relative contraindication
to CAPD and would otherwise be treated 
by haemodialysis.
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Introduction
Patients with ESRD require either dialysis
(haemodialysis or peritoneal dialysis) or renal
transplantation to maintain life. A renal transplant
is normally considered to be the preferred choice
but there are insufficient donors to meet the
demand. Therefore, for those patients for whom
transplants are unavailable or who are not suitable
for transplantation, a decision has to be made on
which mode of dialysis should be used.
The objective of this review was to ascertain if 
there is clear evidence for the increased effective-
ness of haemodialysis compared with CAPD for all
patients with ESRD or for a particular sub-group.
Another objective was to ascertain the relative costs
of haemodialysis and CAPD, and to combine this
information with the information on effectiveness
to determine which method is the more efficient. 
The review is described in detail in chapter 2. In
addition, a systematic review of economic aspects
was undertaken to identify formal economic
evaluations that had tried to assess the relative
efficiency of CAPD and haemodialysis.
However, as no RCTs were identified that compared
CAPD with haemodialysis, only the review of
economic evaluations was possible.
Economic evaluation
Introduction
The principles of economic evaluation are
described in detail in chapter 3 (page 9) including,
in an economic framework, the manner in which
costs and outcome are related (see, in particular,
Table 2 and Figure 3).
Methods
Search for data on efficiency
The methods of data extraction and analysis 
used are described in detail in chapter 3 of the
main report.
The following data were extracted from the
economic evaluations identified; author, title, 
year of study, study question, country and setting,
study design of main data source, methodological
quality, (e.g. blinding, intention-to-treat) of the
main data source, sample size, measures used 
and main findings.
Results
Identification of data on resource use and cost
The systematic literature search for studies that
reported data on resource use for haemodialysis
and compared CAPD was intended to identify the
costs of the relative resource use of these two
modes of treatment. The intention was that this
information would be combined with data on
benefits obtained from the systematic review of
RCTs. However, since no RCTs were identified 
this was not possible.
It was possible, however, to systematically identify
reports of economic evaluations that approxi-
mately matched the study question. Studies that 
did not include at least a comparison of CAPD 
and haemodialysis were excluded. Economic
evaluation involves the formal analysis of the costs
(resources use) and effectiveness (health effects) 
of two or more courses of action. Hence studies
that only analysed the cost of these two modalities
were excluded because they did not contain 
a formal description of the relative benefits of 
CAPD or haemodialysis or implicitly assumed the
benefits of the two treatments were equal. When
information on relative costs are not combined
with benefits then there is insufficient evidence 
to assess the relative worth of alternative inter-
ventions under investigation. This situation is
depicted by row ‘D’ in Figure 3 (page 10), 
where the question marks indicate there is
insufficient evidence.
For the same reason, studies of the costs of illness
in which the global costs of the treatment of ESRD
were reported were also excluded because they 
did not provide information on patient costs 
and do not report information on the relative
Appendix 9
Systematic review 6:Comparison of 
haemodialysis with CAPD as treatment for 
patients with ESRDAppendix 9
136
effectiveness of CAPD and haemodialysis. A total 
of seven evaluations were identified (Tajima, et al.,
1987; Churchill, et al., 1984; Croxson & Ashton,
1990; Karlberg & Nyberg, 1995; Sesso, et al., 1990;
Huraib, et al., 1990; Smith, et al., 1989); a summary
of these articles is presented in Table 42.
All except two of the studies (Karlberg & Nyberg,
1995; Smith, et al., 1989) were based on retro-
spective unmatched cohort studies. Two studies
addressed the efficiency of CAPD relative to
hospital haemodialysis, (Karlberg & Nyberg, 1995;
Huraib, et al., 1990), two also looked at renal
transplantation (Tajima, et al., 1987; Sesso, et al.,
1990), two included both home haemodialysis and
renal transplantation (Croxson & Ashton, 1990;
Karlberg & Nyberg, 1995), and one looked at
CAPD, hospital haemodialysis, home haemodialysis
and subsidiary unit haemodialysis (Smith, et al.,
1989).The results are summarised in Table 43.
So far the work of Tajima and colleagues (1987)
has been considered in abstract form only because
the main text is in Japanese and is not yet available
in translation. This study, based on a retrospective
cohort of 27 patients, reported that renal trans-
plantation was cheaper than CAPD which, in turn,
was cheaper than hospital haemodialysis. Limited
information on benefits was given in the abstract,
reporting only that the quality of life of patients
with transplants was better than the quality of life 
of patients on hospital haemodialysis. No infor-
mation was provided in the abstract on the quality
of life of patients receiving CAPD relative to
hospital haemodialysis.
Churchill and colleagues’ (1984) paper is based
upon a retrospective cohort design comparing
CAPD and hospital haemodialysis. This type of
study design does not control for potential biases 
in patient selection. Separate data are not reported
on costs but the number of life-years gained was
reported to be greater for hospital haemodialysis
than for CAPD (see Table 43). The study reported
that the cost per life-year gained of CAPD versus 
no treatment was Canadian $33,400 and of hospital
haemodialysis was Canadian $48,700 in the finan-
cial year 1980/81. The cost estimates used in this
study are mostly based on fees and it is unclear how
well these correspond to the economic or oppor-
tunity cost of providing these treatments. A further
issue is that the calculation of costs and benefits is
based solely on data for the 32 patients on hospital
haemodialysis and 12 patients on CAPD for
1980/81. This is a small sample and the limited
follow-up for this chronic condition means that
important information may be missed. In parti-
cular, the complications of haemodialysis, such 
as access problems, and complications of CAPD
other than peritonitis, such as catheter infections,
are not considered. The short follow-up also 
means that changes in modality were also 
not considered.
The study by Croxson and Ashton (1990), based on
a retrospective non-randomised cohort, compared
four alternative modes of management of ESRD:
CAPD, hospital haemodialysis, home haemodialysis
and renal transplantation. This study developed a
mathematical Markov process (see Glossary) based
on the data from 280 patients on dialysis and on
TABLE 42  A summary of the study design and comparisons made in the identified economic evaluations comparing haemodialysis with
CAPD for treatment of patients with ESRD
Study Source of evidence Country of origin Comparison
Tajima,et al., Unmatched retrospective cohort Japan CAPD,hospital haemodialysis,
1987 (abstract only) transplantation.
Churchill,et al.,1984 Unmatched retrospective cohort Canada CAPD,hospital haemodialysis.
Croxson & Ashton, Unmatched retrospective cohort  New Zealand CAPD,hospital haemodialysis,
1990 and literature review home haemodialysis,transplantation
Karlberg & Nyberg, Survey of population of patients  Sweden CAPD,hospital haemodialysis,
1995 with ESRD outpatient haemodialysis,
transplantation
Sesso,et al.,1990 Unmatched cohort of non-diabetic  Brazil CAPD,hospital haemodialysis,
patients transplantation
Huraib,et al.,1990 Unmatched retrospective cohort Saudi Arabia CAPD and hospital haemodialysis
Smith,et al.,1989 Matched prospective cohort  Wales CAPD,hospital haemodialysis,home 
haemodialysis,subsidiary dialysis unitHealth Technology Assessment 1998; Vol. 2: No.5
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TABLE 43  A summary of the results of the identified economic evaluations comparing haemodialysis with CAPD for treatment of
patients with ESRD
Study Sample size Costs Benefits Cost per unit of benefit
Tajima, 27 patients Per patient  1st month 2nd month  Quality of life of transplant  No data reported in the abstract
et al., per month  760,000 onwards greater 
1987 (yen): 660,000 240,000
(abstract  CAPD 3,800,000 460,000   
only) Hospital 60,000
haemo-
dialysis
Transplant
Churchill, 44 patients  Not reported Survival on modality: Cost per life-year per patient (CAN $):
et al., followed-up  CAPD,12 patients each  CAPD,$33,400
1984 for 1 year; survived 8.52 years Hospital haemodialysis,$48,700
CAPD,12, Hospital haemodialysis,
Hospital  32 patients each survived 
haemodialysis 32 26.14 years
Croxson  280 patients  Present value per patient per life-year  Present value of life-years  Cost per life-year per patient (NZ $):
& Ashton, followed-up  (NZ $): per patient: CAPD,26,390
1990 for 5 years CAPD,60,125 CAPD,2.28 Hospital haemodialysis,35,270
Hospital haemodialysis,98,260 Hospital haemodialysis,2.78 Home haemodialysis,28,175
Home haemodialysis,80,245 Home haemodialysis,2.85 Transplant,18,483
Transplant,79,800 Transplant,4.29
Karlberg  Swedish ESRD  Per patient per year ($): All modes of treatment  Cost per life-year per patient ($):
& Nyberg, population –  CAPD,30,000 assumed to obtain the  CAPD,30,000
1995 approximately  Hospital haemodialysis,60,000 same survival Hospital haemodialysis,60,000
537–574 per  Outpatient haemodialysis,40,000 Outpatient haemodialysis,40,000
million Transplant,10,000 Transplant,10,000 
population
Sesso, 121 patients  Per cohort per year ($): CAPD,22.5 total years  Cost per life-year per patient ($):
et al., followed-up  CAPD,282,996 for 24 patients CAPD,12,578 
1990 for 1 year; Hospital haemodialysis,516,112 Hospital haemodialysis, Hospital haemodialysis,10,981 
CAPD 24, Transplant,208,159 47 total years for  Transplant,4657
Hospital 47  patients
haemodialysis 47, Transplant,44.7 total years 
Transplant 50 for 50 patients
Huraib, 58 patients, Per patient per month (Saudi Riyals): CAPD,2/19 died at a  Not calculated
et al., CAPD 19, CAPD,6534  mean of 14 months 
1990 Hospital  Hospital haemodialysis,8364  follow-up (range 
haemodialysis 39 3–31 months)
Hospital haemodialysis,
4/38 died at a mean of 
21 months follow-up 
(range 5.5–43 months)
Smith, 127 patients, Per patient per year (£): 100% survival assumed  Cost per QALY per patient (£):
et al., CAPD 20, CAPD,7109 per modality for 5 years. CAPD,6731
1989 Subsidiary renal  Subsidiary renal unit  Rosser matrix health  Subsidiary renal unit haemodialysis,
unit haemodialysis 40, haemodialysis,14,476 state utility: 15,594
Hospital  Hospital haemodialysis,15,702 CAPD,0.94 Hospital haemodialysis,15,702 
haemodialysis 22, Home haemodialysis,10,221 Subsidiary renal unit  Home haemodialysis,9292 
Home haemodialysis,0.93
haemodialysis 45 Hospital haemodialysis,0.90
Home haemodialysis,0.94Appendix 9
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data extracted from the literature. The costs per
patient per year of treatment were greatest for
hospital haemodialysis, followed by home haemo-
dialysis, renal transplantation and, finally, CAPD.
The study reported that the benefits to patients,
calculated from the Markov model based on the
retrospective cohort study, was greatest for renal
transplantation, followed by, in descending order,
home haemodialysis, hospital haemodialysis and
CAPD (see Table 43). The cost per life-year gained
relative to no treatment was least for renal trans-
plantation, followed by, in ascending order, CAPD,
home haemodialysis and hospital haemodialysis.
The methodology used to conduct the economic
evaluation was robust, since the Markov process
approach allowed the transfer of patients between
modalities and allowed the modelling of patient
survival using the data from the cohort study.
However, it only considered costs and benefits 
for 5 years. The authors also emphasised that 
there may be considerable selection bias due 
to the non-randomised nature of the study.
The study by Karlberg and Nyberg (1995)
compared hospital haemodialysis, outpatient
haemodialysis (haemodialysis under minimal super-
vision but still within the same hospital setting),
CAPD and renal transplantation. The study pur-
ports to be a cost-effectiveness analysis. However, 
it explicitly assumes that survival is the same for 
all patients and does not consider differences in
quality of life. The study is also based on unmatch-
ed cohort data and thus there may be substantial
selection biases. The study reported that the costs
per year was least for renal transplantation, then
CAPD, followed by outpatient haemodialysis and
hospital haemodialysis, respectively.
Sesso and colleagues (1990) from Brazil compared
CAPD, hospital haemodialysis and renal transplant-
ation. The benefits of treatment per patient were
reported to be greatest for hospital haemodialysis,
followed by CAPD and, finally, transplantation. 
The costs of treatment per patient were reported 
to be greatest for CAPD, then hospital haemo-
dialysis and least for renal transplantation (see
Table 43). It also found that the cost per life-year
gained was least for renal transplantation, then
hospital haemodialysis then CAPD. This study was
based on a retrospective cohort of patients but did
not allow for patients switching between modalities.
The cost-effectiveness of hospital haemodialysis 
was heavily influenced by the low wage rates of 
staff and the re-use of membranes. When correc-
tion is made for the re-use of consumables for
haemodialysis, it becomes more expensive per 
life-year than CAPD.
Huraib and colleagues (1990) from Saudi 
Arabia compared CAPD and hospital haemo-
dialysis. Approximately the same percentage of
patients in both arms of the study died during the
study period (13% of haemodialysis patients and
11% of CAPD patients). Of the patients initially
treated by CAPD, 43% transferred to another
modality of dialysis and patients treated with CAPD
spent more time in hospital for dialysis-related
reasons (e.g. access problems, peritonitis, fluid
overload) than did patients treated with haemo-
dialysis. CAPD was associated with a reduction in
the number of required transfusions and thus a
reduction in the chance of transfusion related
complications, such as hepatitis. The introduction
of recombinant human EPO to correct the anaemia
suffered by haemodialysis patients has reduced the
requirements for blood transfusions in haemo-
dialysis patients. Thus the benefits of CAPD are no
longer relevant in this respect. No attempt was
made to combine the alternative measures of
effectiveness and so no explicit judgement was
made as to whether haemodialysis was more
effective than CAPD. The study also reported that
CAPD was cheaper than haemodialysis; however,
the costing methodology was not described and 
it is unclear what costs were included and whether
the costing methodology made allowance of the
ability of patients to switch between modalities.
Furthermore, the study was based on a retro-
spective cohort of patients and there was differ-
ential follow-up of patients in the two groups
(haemodialysis patients were followed up for a
mean of 21 months and CAPD patients were
followed up for a mean of 15 months).
The report to the Welsh Office by Smith and
colleagues (1989) compared hospital haemo-
dialysis, home haemodialysis, CAPD and haemo-
dialysis at ‘subsidiary’ centres. This study explicitly
assumed that survival was the same for all modal-
ities. It found, however, using the Rosser matrix
(Kind, et al., 1982) – a method used to measure
quality of life – that the quality of life of patients 
was greatest for patients treated by CAPD or home
haemodialysis followed by, in descending order,
haemodialysis at a subsidiary unit and hospital
haemodialysis. The costs of treatment were least 
for CAPD and, in ascending order, home haemo-
dialysis, haemodialysis at a subsidiary unit and
hospital haemodialysis. The cost per quality
adjusted life-year was least for CAPD, followed by,
in ascending order, home haemodialysis, haemo-
dialysis at a subsidiary unit and hospital haemo-
dialysis. The study was based upon a prospective
matched cohort of patients, where patients were
matched for age, sex and risk factors. However, Health Technology Assessment 1998; Vol. 2: No.5
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the study did not allow the switching of patients
between modalities and 100% 5-year survival was
assumed. The Rosser matrix, used to assess quality
of life, has also been criticised as not being a valid
measure of this factor (Loomes & McKenzie, 1989).
These studies report that CAPD provides less
benefit to patients but at less cost than hospital
haemodialysis (see Table 43). However, in terms of
the framework described in Figure 3 (page 10), a
policy of starting on haemodialysis relative to one
of starting on CAPD is described by area D4, since
there are no reliable estimates of effectiveness and
poor estimates of cost (as the costs of treatment are
partly determined by survival, the probability of
switching modality and the probability that compli-
cations will occur which are also measures of effec-
tiveness). If the assumption is made that the avail-
able evidence is valid then, in terms of Figure 3, a
policy of starting on haemodialysis relative to one
of starting on CAPD is described by area A3. Here 
a judgement is required as to whether the more
expensive treatment (hospital haemodialysis) is
worth the extra benefit that it appears to provide.
Some estimate can be obtained by looking at the
ratios of cost-effectiveness for the two methods of
treatment. The average cost per life year saved of
CAPD is lower than that for hospital haemodialysis,
as can be seen from the last column of Table 43.
This suggests that that CAPD uses less resources
than hospital haemodialysis to obtain a given
output, such as a life-year saved. Additional infor-
mation can be obtained by looking at the incre-
mental cost per life-year saved for haemodialysis
relative to CAPD. The incremental cost per life-
year saved of haemodialysis is the ratio of the extra
cost of haemodialysis over CAPD divided by the
extra life expectancy of haemodialysis over CAPD.
Using data from Croxson and Ashton (1990) – the
strongest paper in terms of its economic method-
ology because of its approach to modelling the
costs and benefits of the modalities under consider-
ation – the extra cost per extra life-year saved on
haemodialysis relative to CAPD (the incremental
cost per life-year of haemodialysis relative to CAPD)
is NZ $76,270. The comparison of this result to the
average cost per life-year saved shows that the cost
of additional years of life saved by haemodialysis is
2.9 times the cost of the life-year saved by CAPD
relative to no treatment (NZ $26,390 per life-year).
This relative difference would persist if the costs
were converted into pounds and corrected 
for inflation.
Discussion
As no randomised controlled comparisons 
of haemodialysis with CAPD were found, we
concentrated on finding reports of economic
evaluations, recognising that these would incor-
porate assumptions about the relative clinical
effectiveness of the two modalities which may 
be unreliable.
In the event, only seven economic evaluations 
were identified that attempted to answer the study
question. The synthesis of these results, with the
caveats alluded to above, suggest that CAPD may be
more efficient than hospital haemodialysis despite
assuming that it is less effective than haemodialysis.
There are reasons for treating this conclusion 
with caution. The evaluations were conducted in a
variety of different countries and their applicability
to the UK situation may, therefore, be limited. 
This is a consequence of local variations in clinical
practice, differences in the characteristics of the
samples used and differences in the unit costs of
factor inputs. In the study by Sesso and colleagues
(1990), for example, the cost of haemodialysis was
considered to be heavily influenced by the low cost 
of labour and the reuse of dialysers. While reuse 
of dialysers is possible elsewhere, the effect of this
on overall cost is uncertain and will depend upon
the sterilisation process used. The use of labour 
is an integral and major part of hospital haemo-
dialysis, while comprising a comparatively minor
part of CAPD costs; hence, these analyses are
sensitive to variations in labour costs.
Another limitation is that, with the exception 
of the study by Karlberg & Nyberg (1995), all 
of the studies identified, were based on relatively
small sample sizes and the largest study explicitly
assumed that survival was the same for all treatment
modalities. This assumption does not correspond
with the data extracted from the four studies that
reported survival (Churchill, et al., 1984; Croxon 
& Ashton, 1990; Sesso, et al., 1990; Huraib, 
et al., 1990).
The relative cost-effectiveness 
of CAPD versus haemodialysis;
a Markov modelling approach
Since there are no RCTs that investigate the 
relative effectiveness of CAPD or haemodialysis,
and since there are also very few economic evalu-
ations that seek to address the question of which
method of dialysis is the most efficient, a more
sophisticated economic evaluation was attempted
to investigate the more appropriate modality on
which a patient should initiate treatment. This
economic evaluation was based on an attempt Appendix 9
140
to identify systematically observational studies that
addressed the study question.
Methods of analysis
The analysis was based on a Markov model; this, 
in simple terms, describes possible patient pathways
through a given process of card, in this case a
patient’s lifetime on dialysis, and can be used to
estimate a patient’s lifetime outcomes, such as sur-
vival and cost. The Markov model was populated 
by data obtained from a systematic review of obser-
vational studies (no RCT addressing this question
has ever been completed). It should be noted that
perfect strategies to identify observational studies
do not currently exist. However, this method has
the potential to allow the best model to be made
form the best evidence available.
The Markov model, shown in Figure 13, illustrates
the steps that a patient commencing treatment on
haemodialysis may go through. A similar model 
can be defined for a CAPD patient.
The states of health that a patient may go through
are denoted in each box. They were identified 
from the systematic review (Gokal, et al., 1987;
Charytan, et al., 1986; Burton & Walls, 1989). An
arrow indicates that movement from one state to
another is possible. The movement between each
state is determined by a probability (obtained 
from the systematic review) of the patient either
experiencing a complication, remaining on
haemodialysis or dying.
Because of the limited data available for this model,
it was not possible to model a patient who switched
straight to CAPD from haemodialysis without
experiencing a complication first. A patient also
cannot spend more than 1 month in the state 
of complication.
The length of each cycle was defined as 1 month to
make the model more detailed, although a patient
can remain on haemodialysis, for example, for sev-
eral months without experiencing a complication
or dying. The patient will continue ‘travelling’
through this model until, eventually, the state 
of ‘death’ is reached.
The probabilities for moving between each 
state of health were converted to matrix form for
analysis. The final analysis provided the length of
time a person commencing treatment on either
CAPD or haemodialysis would spend in each state
of health and, hence, the total expected survival 
of the patient.
Costs were calculated in 1996/97 pounds sterling
for each state of health within the Markov model.
They included all items of resource used (e.g.
labour, consumables, capital and overheads) 
and were based on local prices. For haemodialysis, 
costs were based on the patient undergoing three
dialysis sessions per week; for CAPD, costs were
based on four exchanges per day.
Costs were built up from one dialysis session or
exchange, then aggregated to a yearly cost and
divided by twelve to obtain the monthly cost. 
The cost of access surgery was also calculated 
and added to the final cost. Costs and survivals 
were not discounted as the Markov model does 
not allow for this.
Survival of patients with ESRD
Low and high estimates of survival of patients
initiating treatment either on CAPD or haemo-
dialysis are shown in Table 44. The high prob-
abilities refer to high probabilities of dying, having
a complication and switching modality. The low
probabilities refer to low probabilities of dying,
having a complication and switching modality.
Costs of patients with ESRD
The costs for each month were multiplied by the
number of months spent in that state of health to
obtain the cost of survival for each treatment modal-
ity (Table 44). The cost of each modality varies for
each scenario but the initial modality of treatment 
is responsible for most of the cost incurred.
Cost-effectiveness
The ratios of extra cost to extra effectiveness of
providing haemodialysis in preference to CAPD 
are shown in Figure 14. These ratios were calculated
Complication
Death
Haemodialysis CAPD
FIGURE 13  Markov modelHealth Technology Assessment 1998; Vol. 2: No.5
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using the data presented in Table 44. Haemodialysis
is more effective and less costly than CAPD for
those comparisons where no ratio is presented.
Quality of life
The impact of weighting survival by estimates of 
the quality of life for each health state is shown 
in Table 45. Adjusting the actual survival by the
quality-of-life weighting shows the expected period
of full health that would be considered to be equal
to the actual length of survival calculated by the
model. For example, a weighting of 0.5 means that
each month of survival predicted by the model is
equivalent to 0.5 months of full health.
Discussion
The analysis provides differing results using
different assumption of costs and effectiveness. 
For 11 of the 16 scenarios, haemodialysis would 
be the treatment of choice as it provides greater
survival time at a low cost than CAPD.
The ratio of extra cost of haemodialysis to its extra
effectiveness for the other five scenarios varies
between £396 and £1596 per additional month 
of survival. To allow for the extra survival, however,
additional funding would be required. If extra
funds could not be obtained, resources would have
to be obtained from elsewhere. The judgement
about whether to advocate haemodialysis over
CAPD in such situations would depend on what
benefits could be obtained from the use of these
extra resources elsewhere.
The weighting of survival by quality of life further
affects the results of the analysis. This indicates 
that the quality of life of patients while on dialysis 
is an important factor that should be taken into
consideration when deciding on the initial treat-
ment. The methodology used in this paper could, if
better raw data were available, be used by clinicians
to help to decide how best to treat their patients.
Although the raw data used in this study is rela-
tively poor, it is the best available. Given that judge-
ments have to be made on the best way of treating
patients with ESRD, this model could be used by
policy-makers to judge resource allocation for
treatment of dialysis patients.
TABLE 44  Survival and costs of treatment (rounded to 
nearest £)
Starting treatment  Total cost  Survival 
modality (£) (months)
Haemodialysis 1 63,370 71.51
Haemodialysis 2 73,797 78.94
Haemodialysis 3 79,478 78.94
Haemodialysis 4 68,267 71.51
CAPD A 65,061 69.1
CAPD B 67324 71.23
CAPD C 76,426 71.23
CAPD D 73,807 69.1
1 – low costs with high probabilities;cost per month:
haemodialysis £868.43,haemodialysis complication 
£884.95,CAPD £905.19.CAPD complication £1029.28.
2 – low costs and low probabilities;cost per month:haemo- 
dialysis £868.43,haemodialysis complication £884.95,
CAPD £905.19,CAPD complication £1029.28.
3 – high costs and low probabilities;cost per month:haemo-
dialysis £923.03,haemodialysis complication £1188.59,
CAPD £905.19,CAPD complication £1724.65.
4 – high costs and high probabilities;cost per month:haemo- 
dialysis £923.03,haemodialysis complication £1188.59,
CAPD £905.19,CAPD complication £1724.65.
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FIGURE 14  Sensitivity analysis of extra cost of haemodialysis to its extra effectiveness relative to CAPD (.........,CAPDA;– – –,CAPDB;
–––,CAPDC;–––,CAPDD)Appendix 9
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The results presented here are based on the 
best evidence available from a systematic review. 
It should be noted, however, that there were only
very limited data available to construct the model.
Hence, the results of this study are of limited value
in informing patient treatment modality. Future
research should concentrate on examining the
quality of life of patients on dialysis and on de-
veloping studies which provide stronger data 
on which a Markov model could be based.
Conclusions and implications
The issue facing the health services is not 
whether to have CAPD or haemodialysis but 
rather the balance of provision between the two
modalities. It is known from variations in uptake 
of these techniques in different countries that a
large proportion of patients requiring dialysis for
ESRD could be managed with either CAPD or
haemodialysis initially. What is required is infor-
mation about the relative costs, benefits and risks 
of policies of starting with one or other treatment
modality. In this respect it should be possible 
to develop a more detailed model based upon
observational data. Ideally, information on bene-
fits and risks should come from comparisons,
within a pragmatic RCT, of policies based on
starting with CAPD or haemodialysis, as used 
in the UK.
Data are not available to allow reliable 
conclusions to be drawn about the relative
effectiveness and efficiency of haemodialysis 
and CAPD.
If an assumption is made of equal effectiveness 
in terms of survival then the limited data available
favour CAPD.
Although some studies have assumed that a policy
of starting with haemodialysis is more effective than
a policy of starting with CAPD, it is not possible to
quantify this extra benefit reliably using current
data and, hence, it is not possible to determine
whether haemodialysis is worth any extra cost that
may be incurred. This issue would be resolved most
reliably by a pragmatic randomised trial that
included a formal economic evaluation comparing
the two policies. Currently, Baxter Ltd are attempt-
ing to undertake a RCT in this area (Personal
communication, 1998).
The implications of policies based on starting 
with haemodialysis rather than on CAPD are more
complex than described in previously reported
economic evaluations. 
The development of new methods of dialysis, such
as CCPD, and the advances in renal transplantation
techniques warrant additional evaluation to investi-
gate their place in the treatment of ESRD alongside
haemodialysis and CAPD.
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Form sent to all authors of articles where further details of randomisation 
were required
NHS (UK) Executive Systematic Review of the Management of End-Stage 
Renal Disease
RANDOMISATION
CITATION:
1.  Patients randomised to treatment groups or to order of 
treatment   YES/NO
2.  State method of randomisation used if known (e.g. day of week, 
date of birth, open or closed random number tables, telephone or 
third party involvement):
Please return to Dr Conal Daly, Department of Medicine & Therapeutics, 
Polwarth Building, Foresterhill, Aberdeen AB9 2ZD, Scotland.
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e
 
d
a
t
a
)
A
 
=
 
Y
e
s
B
 
=
 
P
o
s
s
i
b
l
y
,
 
b
u
t
 
n
o
t
 
c
l
e
a
r
C
 
=
 
N
o
P
o
t
e
n
t
i
a
l
 
f
o
r
 
b
i
a
s
 
a
r
o
u
n
d
 
t
i
m
e
 
o
f
 
t
r
e
a
t
m
e
n
t
 
o
r
 
d
u
r
i
n
g
 
o
u
t
c
o
m
e
a
s
s
e
s
s
m
e
n
t
 
(
b
l
i
n
d
i
n
g
)
1
.
 
W
e
r
e
 
p
a
t
i
e
n
t
s
 
‘
b
l
i
n
d
’
 
t
o
 
t
r
e
a
t
m
e
n
t
 
s
t
a
t
u
s
 
(
e
.
g
.
 
p
l
a
c
e
b
o
)
?
A
 
(
i
)
 
=
 
a
c
t
i
o
n
 
t
a
k
e
n
 
a
t
 
b
l
i
n
d
i
n
g
 
l
i
k
e
l
y
 
t
o
 
b
e
 
e
f
f
e
c
t
i
v
e
A
 
(
i
i
)
 
=
 
b
l
i
n
d
i
n
g
 
s
t
a
t
e
d
 
b
u
t
 
n
o
 
d
e
s
c
r
i
p
t
i
o
n
 
g
i
v
e
n
B
 
(
i
)
 
=
 
n
o
 
m
e
n
t
i
o
n
 
o
f
 
b
l
i
n
d
i
n
g
B
 
(
i
i
)
 
=
 
a
t
t
e
m
p
t
 
a
t
 
b
l
i
n
d
i
n
g
 
b
u
t
 
r
e
a
s
o
n
 
t
o
 
t
h
i
n
k
 
i
t
 
m
a
y
 
n
o
t
 
h
a
v
e
 
b
e
e
n
 
s
u
c
c
e
s
s
f
u
l
C
 
=
 
n
o
t
 
b
l
i
n
d
e
d
2
.
 
W
e
r
e
 
h
e
a
l
t
h
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
‘
b
l
i
n
d
’
 
t
o
 
t
r
e
a
t
m
e
n
t
 
s
t
a
t
u
s
 
(
e
.
g
.
 
p
l
a
c
e
b
o
)
?
A
 
(
i
)
 
=
 
a
c
t
i
o
n
 
t
a
k
e
n
 
a
t
 
b
l
i
n
d
i
n
g
 
l
i
k
e
l
y
 
t
o
 
b
e
 
e
f
f
e
c
t
i
v
e
A
 
(
i
i
)
 
=
 
b
l
i
n
d
i
n
g
 
s
t
a
t
e
d
 
b
u
t
 
n
o
 
d
e
s
c
r
i
p
t
i
o
n
 
g
i
v
e
n
B
 
(
i
)
 
=
 
n
o
 
m
e
n
t
i
o
n
 
o
f
 
b
l
i
n
d
i
n
g
B
 
(
i
i
)
 
=
 
a
t
t
e
m
p
t
 
a
t
 
b
l
i
n
d
i
n
g
 
b
u
t
 
r
e
a
s
o
n
 
t
o
 
t
h
i
n
k
 
i
t
 
m
a
y
 
n
o
t
 
h
a
v
e
 
b
e
e
n
 
s
u
c
c
e
s
s
f
u
l
C
 
=
 
n
o
t
 
b
l
i
n
d
e
d
3
.
 
W
e
r
e
 
o
u
t
c
o
m
e
 
a
s
s
e
s
s
o
r
s
 
b
l
i
n
d
 
t
o
 
t
r
e
a
t
m
e
n
t
 
s
t
a
t
u
s
?
A
 
(
i
)
 
=
 
a
c
t
i
o
n
 
t
a
k
e
n
 
a
t
 
b
l
i
n
d
i
n
g
 
l
i
k
e
l
y
 
t
o
 
b
e
 
e
f
f
e
c
t
i
v
e
A
 
(
i
i
)
 
=
 
b
l
i
n
d
i
n
g
 
s
t
a
t
e
d
 
b
u
t
 
n
o
 
d
e
s
c
r
i
p
t
i
o
n
 
g
i
v
e
n
B
 
(
i
)
 
=
 
n
o
 
m
e
n
t
i
o
n
 
o
f
 
b
l
i
n
d
i
n
g
B
 
(
i
i
)
 
=
 
a
t
t
e
m
p
t
 
a
t
 
b
l
i
n
d
i
n
g
 
b
u
t
 
r
e
a
s
o
n
 
t
o
 
t
h
i
n
k
 
i
t
 
m
a
y
 
n
o
t
 
h
a
v
e
 
b
e
e
n
s
u
c
c
e
s
s
f
u
l
C
 
=
 
n
o
t
 
b
l
i
n
d
e
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N
H
S
 
(
U
K
)
 
E
x
e
c
u
t
i
v
e
 
S
y
s
t
e
m
a
t
i
c
 
R
e
v
i
e
w
 
o
f
 
t
h
e
 
M
a
n
a
g
e
m
e
n
t
 
o
f
 
E
n
d
-
s
t
a
g
e
R
e
n
a
l
 
D
i
s
e
a
s
e
F
u
r
t
h
e
r
 
R
a
n
d
o
m
i
s
e
d
 
o
r
 
Q
u
a
s
i
-
r
a
n
d
o
m
i
s
e
d
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
I
f
 
a
n
y
 
t
r
i
a
l
s
 
k
n
o
w
n
,
 
p
l
e
a
s
e
 
f
i
l
l
 
i
n
 
a
n
y
 
d
e
t
a
i
l
s
 
a
v
a
i
l
a
b
l
e
 
t
o
 
y
o
u
 
b
e
l
o
w
.
P
l
e
a
s
e
 
r
e
t
u
r
n
 
t
o
:
 
D
r
 
C
o
n
a
l
 
D
a
l
y
,
 
D
e
p
a
r
t
m
e
n
t
 
o
f
 
M
e
d
i
c
i
n
e
 
&
 
T
h
e
r
a
p
e
u
t
i
c
s
,
P
o
l
w
a
r
t
h
 
B
u
i
l
d
i
n
g
,
 
F
o
r
e
s
t
e
r
h
i
l
l
,
 
A
b
e
r
d
e
e
n
 
A
B
9
 
2
Z
D
,
 
S
c
o
t
l
a
n
d
,
 
U
K
.
I
f
 
n
o
n
e
 
k
n
o
w
n
 
p
l
e
a
s
e
 
t
i
c
k
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
T
i
t
l
e
A
u
t
h
o
r
s
D
e
p
a
r
t
m
e
n
t
 
a
n
d
 
a
d
d
r
e
s
s
 
o
f
 
i
n
s
t
i
t
u
t
i
o
n
P
u
b
l
i
s
h
e
d
 
o
r
 
p
r
e
s
e
n
t
e
d
 
Y
E
S
/
N
O
 
(
p
l
e
a
s
e
 
c
i
r
c
l
e
 
o
n
e
)
J
o
u
r
n
a
l
 
o
r
 
C
o
n
f
e
r
e
n
c
e
V
o
l
u
m
e
/
N
u
m
b
e
r
/
P
a
g
e
s
T
i
t
l
e
A
u
t
h
o
r
s
D
e
p
a
r
t
m
e
n
t
 
a
n
d
 
a
d
d
r
e
s
s
 
o
f
 
i
n
s
t
i
t
u
t
i
o
n
P
u
b
l
i
s
h
e
d
 
o
r
 
p
r
e
s
e
n
t
e
d
 
Y
E
S
/
N
O
 
(
p
l
e
a
s
e
 
c
i
r
c
l
e
 
o
n
e
)
J
o
u
r
n
a
l
 
o
r
 
C
o
n
f
e
r
e
n
c
e
V
o
l
u
m
e
/
N
u
m
b
e
r
/
P
a
g
e
s
E
x
a
m
p
l
e
s
 
o
f
 
l
e
t
t
e
r
s
 
t
o
 
b
i
o
m
e
d
i
c
a
l
 
c
o
m
p
a
n
i
e
s
 
a
n
d
a
u
t
h
o
r
s
 
o
f
 
r
e
l
e
v
a
n
t
 
R
C
T
s
 
o
r
 
q
u
a
s
i
-
R
C
T
s
L
e
t
t
e
r
 
t
o
 
r
e
l
e
v
a
n
t
 
b
i
o
m
e
d
i
c
a
l
 
c
o
m
p
a
n
i
e
s
D
e
a
r
 
[
R
e
c
i
p
i
e
n
t
s
 
n
a
m
e
]
W
e
 
a
r
e
 
u
n
d
e
r
t
a
k
i
n
g
 
a
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
o
f
 
t
h
e
 
u
s
e
 
o
f
 
a
c
e
t
a
t
e
 
c
o
m
p
a
r
e
d
 
t
o
 
b
i
c
a
r
b
o
n
a
t
e
 
b
u
f
f
e
r
 
i
n
 
t
h
e
d
i
a
l
y
s
a
t
e
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
m
a
i
n
t
a
i
n
e
d
 
o
n
 
h
a
e
m
o
d
i
a
l
y
s
i
s
.
 
T
h
i
s
 
i
s
 
o
n
e
 
o
f
 
a
s
e
r
i
e
s
 
o
f
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
s
 
o
f
 
a
s
p
e
c
t
s
 
o
f
 
t
h
e
 
m
a
n
a
g
e
m
e
n
t
 
o
f
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
w
e
,
 
i
n
 
t
h
e
D
e
p
a
r
t
m
e
n
t
 
o
f
 
M
e
d
i
c
i
n
e
 
a
n
d
 
T
h
e
r
a
p
e
u
t
i
c
s
 
a
t
 
t
h
e
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
A
b
e
r
d
e
e
n
,
 
h
a
v
e
 
b
e
e
n
 
c
o
m
m
i
s
s
i
o
n
e
d
t
o
 
u
n
d
e
r
t
a
k
e
 
b
y
 
t
h
e
 
R
e
s
e
a
r
c
h
 
a
n
d
 
D
e
v
e
l
o
p
m
e
n
t
 
P
r
o
g
r
a
m
m
e
 
o
f
 
t
h
e
 
N
a
t
i
o
n
a
l
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
 
i
n
 
t
h
e
U
K
.
 
T
h
e
 
p
u
r
p
o
s
e
 
o
f
 
t
h
e
 
p
r
o
j
e
c
t
 
i
s
 
t
o
 
d
e
s
c
r
i
b
e
 
t
h
e
 
e
v
i
d
e
n
c
e
-
b
a
s
e
 
f
o
r
 
c
e
r
t
a
i
n
 
k
e
y
 
d
e
c
i
s
i
o
n
s
 
i
n
 
E
S
R
D
m
a
n
a
g
e
m
e
n
t
 
a
n
d
 
t
h
u
s
 
i
n
d
i
c
a
t
e
,
 
w
h
e
r
e
 
p
o
s
s
i
b
l
e
,
 
w
h
a
t
 
i
s
 
b
e
s
t
 
p
r
a
c
t
i
c
e
 
o
r
,
 
a
l
t
e
r
n
a
t
i
v
e
l
y
,
 
w
h
e
r
e
 
f
u
t
u
r
e
r
e
s
e
a
r
c
h
 
s
h
o
u
l
d
 
b
e
 
c
o
n
c
e
n
t
r
a
t
e
d
.
O
n
l
y
 
r
a
n
d
o
m
i
s
e
d
 
o
r
 
q
u
a
s
i
-
r
a
n
d
o
m
i
s
e
d
 
c
o
n
t
r
o
l
l
e
d
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
w
i
l
l
 
b
e
 
i
n
c
l
u
d
e
d
 
i
n
 
o
u
r
 
r
e
v
i
e
w
.
 
T
h
e
m
e
t
h
o
d
o
l
o
g
y
 
o
f
 
o
u
r
 
l
i
t
e
r
a
t
u
r
e
 
s
e
a
r
c
h
 
a
n
d
 
t
r
i
a
l
 
a
s
s
e
s
s
m
e
n
t
 
i
s
 
b
a
s
e
d
 
o
n
 
t
h
a
t
 
o
f
 
t
h
e
 
C
o
c
h
r
a
n
e
C
o
l
l
a
b
o
r
a
t
i
o
n
.
 
W
e
 
a
r
e
 
m
e
m
b
e
r
s
 
o
f
 
t
h
e
 
n
a
s
c
e
n
t
 
R
e
n
a
l
 
C
o
c
h
r
a
n
e
 
G
r
o
u
p
 
b
a
s
e
d
 
i
n
 
L
y
o
n
,
 
F
r
a
n
c
e
.
[
C
o
m
p
a
n
y
 
n
a
m
e
]
 
h
a
s
 
o
b
v
i
o
u
s
l
y
 
b
e
e
n
 
v
e
r
y
 
c
l
o
s
e
l
y
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
r
e
s
e
a
r
c
h
 
a
n
d
 
d
e
v
e
l
o
p
m
e
n
t
 
i
n
h
a
e
m
o
d
i
a
l
y
s
a
t
e
 
b
u
f
f
e
r
 
s
y
s
t
e
m
s
.
 
W
e
 
w
o
u
l
d
 
b
e
 
g
r
a
t
e
f
u
l
 
i
f
 
y
o
u
 
c
o
u
l
d
 
i
n
d
i
c
a
t
e
 
i
f
 
y
o
u
 
k
n
o
w
 
o
f
 
a
n
y
 
o
t
h
e
r
p
o
s
s
i
b
l
y
 
r
a
n
d
o
m
i
s
e
d
 
o
r
 
q
u
a
s
i
-
r
a
n
d
o
m
i
s
e
d
 
s
t
u
d
i
e
s
 
p
u
b
l
i
s
h
e
d
,
 
u
n
p
u
b
l
i
s
h
e
d
 
o
r
 
i
n
 
p
r
o
g
r
e
s
s
 
o
n
 
t
h
i
s
t
o
p
i
c
 
i
n
 
a
d
d
i
t
i
o
n
 
t
o
 
t
h
o
s
e
 
w
e
 
h
a
v
e
 
a
l
r
e
a
d
y
 
i
d
e
n
t
i
f
i
e
d
 
(
s
e
e
 
e
n
c
l
o
s
e
d
 
l
i
s
t
 
i
n
 
a
l
p
h
a
b
e
t
i
c
a
l
 
o
r
d
e
r
a
c
c
o
r
d
i
n
g
 
t
o
 
f
i
r
s
t
 
a
u
t
h
o
r
)
.
T
h
a
n
k
 
y
o
u
 
f
o
r
 
y
o
u
r
 
t
i
m
e
.
Y
o
u
r
s
 
s
i
n
c
e
r
e
l
y
C
o
n
a
l
 
D
a
l
y
C
l
i
n
i
c
a
l
 
R
e
s
e
a
r
c
h
 
F
e
l
l
o
w
 
i
n
 
N
e
p
h
r
o
l
o
g
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L
e
t
t
e
r
 
t
o
 
a
u
t
h
o
r
s
 
o
f
 
r
e
l
e
v
a
n
t
 
R
C
T
s
 
o
r
 
q
u
a
s
i
-
R
C
T
s
D
e
a
r
 
D
r
 
[
N
a
m
e
]
W
e
 
a
r
e
 
u
n
d
e
r
t
a
k
i
n
g
 
a
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
o
f
 
t
h
e
 
u
s
e
 
o
f
 
a
c
e
t
a
t
e
 
c
o
m
p
a
r
e
d
 
t
o
 
b
i
c
a
r
b
o
n
a
t
e
 
b
u
f
f
e
r
 
i
n
 
t
h
e
d
i
a
l
y
s
a
t
e
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
m
a
i
n
t
a
i
n
e
d
 
o
n
 
h
a
e
m
o
d
i
a
l
y
s
i
s
.
 
T
h
i
s
 
i
s
 
o
n
e
 
o
f
 
a
s
e
r
i
e
s
 
o
f
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
s
 
o
f
 
a
s
p
e
c
t
s
 
o
f
 
t
h
e
 
m
a
n
a
g
e
m
e
n
t
 
o
f
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
w
e
 
i
n
 
t
h
e
D
e
p
a
r
t
m
e
n
t
 
o
f
 
M
e
d
i
c
i
n
e
 
a
n
d
 
T
h
e
r
a
p
e
u
t
i
c
s
 
a
t
 
t
h
e
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
A
b
e
r
d
e
e
n
 
h
a
v
e
 
b
e
e
n
 
c
o
m
m
i
s
s
i
o
n
e
d
t
o
 
u
n
d
e
r
t
a
k
e
 
b
y
 
t
h
e
 
R
e
s
e
a
r
c
h
 
a
n
d
 
D
e
v
e
l
o
p
m
e
n
t
 
P
r
o
g
r
a
m
m
e
 
o
f
 
t
h
e
 
N
a
t
i
o
n
a
l
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
 
i
n
 
t
h
e
U
K
.
 
T
h
e
 
p
u
r
p
o
s
e
 
o
f
 
t
h
e
 
p
r
o
j
e
c
t
 
i
s
 
t
o
 
d
e
s
c
r
i
b
e
 
t
h
e
 
e
v
i
d
e
n
c
e
-
b
a
s
e
 
f
o
r
 
c
e
r
t
a
i
n
 
k
e
y
 
d
e
c
i
s
i
o
n
s
 
i
n
 
E
S
R
D
m
a
n
a
g
e
m
e
n
t
 
a
n
d
 
t
h
u
s
 
i
n
d
i
c
a
t
e
,
 
w
h
e
r
e
 
p
o
s
s
i
b
l
e
,
 
w
h
a
t
 
i
s
 
b
e
s
t
 
p
r
a
c
t
i
c
e
 
o
r
 
a
l
t
e
r
n
a
t
i
v
e
l
y
 
w
h
e
r
e
 
f
u
t
u
r
e
r
e
s
e
a
r
c
h
 
s
h
o
u
l
d
 
b
e
 
c
o
n
c
e
n
t
r
a
t
e
d
.
O
n
l
y
 
r
a
n
d
o
m
i
s
e
d
 
o
r
 
q
u
a
s
i
-
r
a
n
d
o
m
i
s
e
d
 
c
o
n
t
r
o
l
l
e
d
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
w
i
l
l
 
b
e
 
i
n
c
l
u
d
e
d
 
i
n
 
o
u
r
 
r
e
v
i
e
w
.
 
T
h
e
m
e
t
h
o
d
o
l
o
g
y
 
o
f
 
o
u
r
 
l
i
t
e
r
a
t
u
r
e
 
s
e
a
r
c
h
 
a
n
d
 
t
r
i
a
l
 
a
s
s
e
s
s
m
e
n
t
 
i
s
 
b
a
s
e
d
 
o
n
 
t
h
a
t
 
o
f
 
t
h
e
 
C
o
c
h
r
a
n
e
C
o
l
l
a
b
o
r
a
t
i
o
n
.
 
W
e
 
a
r
e
 
m
e
m
b
e
r
s
 
o
f
 
t
h
e
 
n
a
s
c
e
n
t
 
R
e
n
a
l
 
C
o
c
h
r
a
n
e
 
G
r
o
u
p
 
b
a
s
e
d
 
i
n
 
L
y
o
n
,
 
F
r
a
n
c
e
.
Y
o
u
r
 
s
t
u
d
y
:
 
[
i
n
s
e
r
t
 
f
u
l
l
 
r
e
f
e
r
e
n
c
e
 
i
n
c
l
u
d
i
n
g
 
t
i
t
l
e
,
 
a
u
t
h
o
r
s
,
 
j
o
u
r
n
a
l
,
 
y
e
a
r
,
 
v
o
l
u
m
e
,
 
n
u
m
b
e
r
,
 
p
a
g
e
s
]
 
w
i
l
l
b
e
 
i
n
c
l
u
d
e
d
 
i
n
 
o
u
r
 
r
e
v
i
e
w
.
 
W
e
 
w
o
u
l
d
 
b
e
 
g
r
a
t
e
f
u
l
 
i
f
 
y
o
u
 
c
o
u
l
d
 
i
n
d
i
c
a
t
e
 
o
n
 
t
h
e
 
e
n
c
l
o
s
e
d
 
f
o
r
m
 
i
f
 
y
o
u
k
n
o
w
 
o
f
 
a
n
y
 
o
t
h
e
r
 
p
o
s
s
i
b
l
y
 
r
a
n
d
o
m
i
s
e
d
 
o
r
 
q
u
a
s
i
-
r
a
n
d
o
m
i
s
e
d
 
s
t
u
d
i
e
s
 
p
u
b
l
i
s
h
e
d
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n
p
u
b
l
i
s
h
e
d
 
o
r
 
i
n
p
r
o
g
r
e
s
s
 
o
n
 
t
h
i
s
 
t
o
p
i
c
 
i
n
 
a
d
d
i
t
i
o
n
 
t
o
 
t
h
o
s
e
 
w
e
 
h
a
v
e
 
a
l
r
e
a
d
y
 
i
d
e
n
t
i
f
i
e
s
 
(
s
e
e
 
e
n
c
l
o
s
e
d
 
l
i
s
t
 
–
 
i
n
a
l
p
h
a
b
e
t
i
c
a
l
 
o
r
d
e
r
 
a
c
c
o
r
d
i
n
g
 
t
o
 
f
i
r
s
t
 
a
u
t
h
o
r
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a
n
d
 
r
e
t
u
r
n
 
i
t
 
t
o
 
m
e
 
i
n
 
t
h
e
 
a
c
c
o
m
p
a
n
y
i
n
g
 
e
n
v
e
l
o
p
e
.
T
h
a
n
k
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o
u
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o
r
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o
u
r
 
t
i
m
e
.
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c
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n
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n
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c
a
l
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e
s
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r
c
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o
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u
t
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r
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r
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a
l
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r
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c
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r
i
f
i
c
a
t
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n
 
o
f
m
e
t
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o
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o
l
o
g
y
 
r
e
q
u
i
r
e
d
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e
a
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a
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e
]
W
e
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r
e
 
u
n
d
e
r
t
a
k
i
n
g
 
a
 
s
y
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t
e
m
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t
i
c
 
r
e
v
i
e
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f
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h
e
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s
e
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f
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c
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e
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o
m
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r
e
d
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i
t
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i
c
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r
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n
a
t
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b
u
f
f
e
r
 
i
n
t
h
e
 
d
i
a
l
y
s
a
t
e
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
m
a
i
n
t
a
i
n
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d
 
o
n
 
h
a
e
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o
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.
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r
i
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y
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t
e
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t
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i
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s
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e
c
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n
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r
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a
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e
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h
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e
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r
t
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n
t
 
o
f
 
M
e
d
i
c
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r
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t
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t
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b
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r
c
h
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n
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e
v
e
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o
p
m
e
n
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r
o
g
r
a
m
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e
 
o
f
 
t
h
e
 
N
a
t
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o
n
a
l
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e
a
l
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h
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r
v
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c
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e
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f
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t
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o
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c
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e
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i
d
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n
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b
a
s
e
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c
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r
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a
i
n
 
k
e
y
 
d
e
c
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s
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o
n
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S
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n
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e
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c
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c
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t
u
r
e
r
e
s
e
a
r
c
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b
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c
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b
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b
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b
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b
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e
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u
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p
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p
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d
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t
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d
 
(
s
e
e
 
e
n
c
l
o
s
e
d
 
l
i
s
t
 
–
 
i
n
a
l
p
h
a
b
e
t
i
c
a
l
 
o
r
d
e
r
 
a
c
c
o
r
d
i
n
g
 
t
o
 
f
i
r
s
t
 
a
u
t
h
o
r
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p
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c
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c
e
l
l
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s
e
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o
t
e
s
S
t
u
d
y
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o
p
u
l
a
t
i
o
n
A
g
e
 
(
m
e
a
n
,
 
r
a
n
g
e
 
&
 
S
D
 
o
r
 
S
E
M
)
 
M
a
l
e
:
F
e
m
a
l
e
C
o
-
m
o
r
b
i
d
i
t
y
 
d
e
s
c
r
i
p
t
i
o
n
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n
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s
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n
 
c
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r
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x
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c
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r
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c
t
e
r
i
s
t
i
c
s
 
o
f
 
i
n
t
e
r
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o
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u
r
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f
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r
i
a
l
 
i
.
e
.
 
h
o
w
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o
n
g
 
w
i
t
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a
c
h
 
m
e
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e
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c
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c
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c
e
t
a
t
e
/
b
i
c
a
r
b
o
n
a
t
e
M
e
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p
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b
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.
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c
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c
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p
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r
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i
e
n
t
s
 
o
r
 
t
r
e
a
t
m
e
n
t
 
s
e
s
s
i
o
n
s
)
I
n
t
r
a
d
i
a
l
y
t
i
c
 
h
e
a
d
a
c
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i
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p
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p
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.
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p
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.
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Study design
1. RCT
2.  Non-RCT controlled trials
2.1 Controlled, interrupted time series
2.2  Controlled before and after
2.3 Well adjusted or matched cohort 
(rigorous attempts to adjust for 
prognostic variables)
3.   Other observational studies
3.1 Case  control
3.2  Inadequately adjusted or matched 
cohort studies
3.3 Uncontrolled before and after
3.4 Case series
3.5 Case studies
Description of withdrawal and drop-outs
A.  Numbers and reasons
B. Numbers  only
C. Not  mentioned
Numbers lost to follow-up
Numbers
Patients blinded to treatment
1.  Action taken likely to be effective
2.  No mention of blinding or action likely 
to be unsuccessful
3. Not  blinded
Healthcare providers blinded to treatment
1.  Action taken likely to be effective
2.  No mention of blinding or action likely 
to be unsuccessful
3. Not  blinded
Outcome assessors blinded to treatment
1.  Action taken likely to be effective
2.  No mention of blinding or action likely 
to be unsuccessful
3. Not  blinded
Economic evaluation
A. None
B. Cost  analysis
C. Cost  minimisation
D. Cost-effectiveness
E. Cost–utility
F. Cost–benefit
Quantities reported
Yes or No
Cost considered
1. Capital
2. Consumables
3. Staff
4. Overheads
Benefit measure
e.g. life-years, survival, Qalys, HYEs, WTP, 
human capital.
Notes
Reverse of methodological assessment form
Methodological assessment form
Topic number
Selection bias Treatment or assessment bias Economic
Paper First  Publication  Study  Description  Number  Analysis  on  Patient  Health- Outcome  Economic  Quantities Costs  Benefit 
(ref. no.) author date design or  of with- lost to  intention- blinded to  care  assessors  evaluation (yes/no) considered measure
design of  drawal  follow-up to-treat  treatment  providers  blinded
study for  and  basis status blinded
principle drop-out
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